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Obesity is a primary risk factor for vascular diseases because of adipose tissue accumulation. This 
accumulation can significantly aggravate any injury to the blood-brain barrier (BBB), leading to 
disruption in BBB integrity that may cause both; enhancement in production of amyloid-β (Aβ) 
peptides through the amyloidogenic pathway and, impairment of the clearance of the peptide. 
Subsequent senile plaque accumulation between neurons and impaired clearance of Aβ in addition 
to intracellularly localized neurofibrillary tangles have been shown to be one of the main causes of 
and a hallmark of Alzheimer’s disease, a progressive neurodegenerative disease. The 
amyloidogenic pathway consists of cleavage of a membrane protein which is amyloid precursor 
protein (APP) via β-secretase followed by γ-secretase, which then produces Aβ and the soluble 
amyloid precursor protein (sAPPβ). In the amyloidogenic pathway, sAPPβ translocates to the 
extracellular space and APP intracellular domain (AICD) to the nucleus, whereas the non-
amyloidogenic pathway involves sequential APP proteolysis by α-secretase and γ-secretase. We 
aimed to study factors influencing Aβ degradation in order to try to reduce its deteriorating effects 
on the ischemic brain. The brain is a cholesterol-rich organ, and in the ischemic brain, cholesterol 
balance is altered due to loss of the BBB integrity, leading to the accumulation of Aβ as previously 
described in earlier studies. Therefore, the influence of cholesterol on Aβ deposition and 
degradation have been studied in this thesis from different perspectives, including the many 
enzymes involved in Aβ degradation on the cell membrane and extracellular space. In order to 
detect the potent enzymes involved in Aβ peptide degradation, mouse Neuro 2a (N2a) cells were 
used to quantify Aβ degradation both intracellularly (by quantifying the remaining peptide using 
living N2a cells) and extracellularly (by detecting Aβ in culture medium of the same cell line with 
or without cholesterol). Results obtained from this study showed that a reduction of about 20% 
was detected for intracellular and extracellular Aβ due to the effects of degrading enzymes, 
including the insulin-degrading enzyme (IDE) and neprilysin. IDE, which is a primary Aβ peptide 
degradation-related enzyme, was taken into consideration exclusively in this study because other 
enzymes have already been previously studied. The elimination of IDE in N2a IDE knockdown 
cells resulted in a reduction in Aβ intracellular degradation up to 5%, while it reached 20% when 
IDE was functioning. Moreover, extracellular Aβ even increased to about 25% in N2a IDE 
knockdown cells, emphasizing the important role of IDE in Aβ degradation in addition to the 
influence of cholesterol as an IDE modulator. Furthermore, cholesterol effects on IDE were 
revealed from different experiments in which cholesterol influenced the activity of IDE by up-




AICD effects have been studied to determine the impact of these proteins on gene expressions of 
key regulators involved in the cholesterol biosynthetic pathway and because the transcriptional 
impact of these proteins on cholesterol biosynthesis have not been studied while, it need to be 
uncovered. Results obtained from gene expression analysis showed that deletion of APP and 
AICD by using mouse embryogenic fibroblasts MEF APP/APLP2 -/- and MEF ΔCT15, 
respectively, when compared with MEF WT, caused downregulation of cholesterol gene 
expression, whereas deletion of Aβ by using MEF PS1/2 -/- cells produced an upregulation of 
cholesterol gene expression. 
 As part of this thesis, the effects of selected substances or compounds on Aβ’s aggregation or 
deposition was conducted using circular dichroism spectrometry to determine the changes in Aβ’s 
secondary structure. Aggregation of this protein occurs once a decrease in its α-helix formation or 
an increase in the number of β-sheets within its structure occurs. These two secondary structural 
elements have been used as an indication of Aβ aggregation, in which the peptide in its native 
form, is folded and functioning properly (high α-helix) or when it is misfolded (less α-helix). β-
sheet formation and accumulation increases and finally, this accumulation forms plaques that 
deteriorate in adjacent neurons, leading to cell apoptosis. Detection of α-helices by CD 
spectrometry was done at wavelengths of 208, 222, and 193 nm, β-sheets were detected at 218 and 
192 nm, and random coils were detected at a wavelength of 205 nm. The influence of vitamins C 
and E, potassium, and sodium tellurite and sulfite have been observed at a concentration of 20 µM 
for each of them. Selenium compounds showed enhancement at 15 µM. Finally, sodium sulfide, 
lithium, sodium, copper, and zinc chlorides, Gallic, p-coumaric, sinapic, and vanillic acids, 
hesperidin, naringin, catechin, and flavones enhanced α-helix formation at a lower concentration 
of 5 µM as compared to a control mix of Aβ without additives. Finally, no effect from various 
compounds on AICD accumulation was observed. 
From another aspect, Aβ may play a role in the innate immune system as an antimicrobial peptide. 
This role is controversial and has been considered in this study by evaluation of its assumed effects 
on the Steinernema feltiae, Escherichia coli, Candida albicans, and Saccharomyces cerevisiae 
strains. Limited Aβ effects on these cells’ viability has been detected. This effect can be attributed 









Durch die Vermehrung von Fettgewebe ist Übergewicht ein Hauptrisikofaktor für 
Gefäßkrankheiten. Diese Vermehrung beeinträchtigt die Integrität der Blut-Hirn 
Schranke, was zur Steigerung der Produktion von Amyloid-β (Aβ) Peptiden in der 
amyloidogenen Prozessierung und zur Einschränkung Aβ-Clearance führt. Folglich 
sammeln sich senile Plaques zwischen den Neuronen, die zusammen mit einer gestörten 
Clearance von Aβ‚ und intrazellulären neurofibrillären Tangles als Hauptauslöser und 
Kennzeichen der neurodegenerativen Alzheimer-Krankheit ausgemacht wurden. Die 
amyloidogene Prozessierung besteht aus der Spaltung des Transmembranproteins 
Amyloid Precurser Protein (APP) zunächst durch die β-Sekretase gefolgt von der ɣ-
Sekretase, wobei Aβ und das lösliche Amyloid Precursor Protein (sAPP) entstehen. 
Hierbei transloziert das sAPP in den Extrazellulärraum und die APP intracellular 
domain (AICD) nach intrazellulär. Die nicht-amyloidogene Prozessierung umfasst die 
sequentielle Proteolyse durch ɑ-Sekretase und ɣ-Sekretase. Unser Ziel war es, 
Einflussfaktoren auf die Aβ-Degradation zu untersuchen, um die negative Aβ-Wirkung 
auf das ischämische Gehirn zu reduzieren. Das Gehirn ist ein cholesterolreiches Organ. 
Im ischämischen Zustand ist das Cholesterolgleichgewicht durch die eingeschränkte 
Integrität der Blut-Hirn-Schranke verändert. Dies führt zu Aβ-Ansammlung, wie 
bereits in früheren Untersuchungen beschrieben. Deswegen wird in der vorliegenden 
Dissertation der Einfluss des Cholesterols auf Aβ-Ablagerung und Degradation mit 
verschiedenen Herangehensweisen untersucht. Eingeschlossen sind dabei die vielen 
Enzyme, die Aβ in der Plasmamembran und im Extrazellulärraum degradieren. Um die 
Aβ-degradierenden Enzyme auszumachen, wurden Neuro 2a (N2a) - Mauszellen zur 
Quantifizierung der intrazellulären Aβ-Degradation (Messung des verbleibenden 
Peptids in lebenden N2a-Zellen) und der extrazellulären (Messung des Aβs in 
Zellkulturmedium derselben Zelllinie mit oder ohne Cholesterol) benutzt. Aus diesen 
Untersuchungen ergab sich eine Reduktion des intra- und extrazellulären Aβs um 20%, 
die von Aβ-degradierenden Enzymen, darunter Insulin-degrading enzyme (IDE) und 
Neprilysin, vermittelt wird. Da andere Enzyme bereits in vorangegangenen Studien 
untersucht wurden, wird hier ausschließlich das IDE als wichtiges Aβ-degradierendes 
Enzym berücksichtigt. Die Eliminierung von IDE in N2a-IDE-Knockdown-Zellen 
führte zu einer Verminderung intrazellulären Aβs um bis zu 5%, wohingegen es bei 




an, wodurch die wichtige Rolle des IDE in der Aβ-Degradation und den Einfluss des 
Cholesterols als IDE-Modulator unterstrichen wird. Darüberhinaus zeigten 
verschiedene Experimente, dass Cholesterol die IDE-Aktivität steigert durch 
Steigerung der Genexpression, Erhöhung der Spiegel und der Stabilität. Auf Grundlage 
früherer Ergebnisse wurden APP, Aβ und AICD untersucht, um deren Einfluss auf die 
Genexpression der regulatorischen Enzyme der Cholesterolbiosynthese zu ermitteln. 
Ergebnisse daraus stellten dar, dass eine Deletion von APP und AICD in embryogenen 
Maus-Fibroblasten MEF APP/APLPp2 -/- bzw. MEF ΔCT15 verglichen mit MEF WT 
zu einer Herunterregulation der Cholesterol-Genexpression führten, wohingegen die 
Deletion von Aβ in MEF PS1/2 -/- eine Hochregulation zur Folge hatte. 
Ein Teil dieser Doktorarbeit untersucht die Effekte ausgewählter Substanzen auf die 
Aβ-Aggregation und Ablagerung mittels Circulardichroismus-Spektroskopie (CD-
Spektroskopie), um Veränderungen der Sekundärstruktur festzustellen. Eine 
Aggregation dieses Proteins zeichnet sich durch eine verringerte Ausprägung der ɑ-
Helix-Konformation oder eine vermehrte Anzahl an β-Faltblättern in seiner Struktur 
aus. Diese beiden Elemente der Sekundärstruktur dienten als Indikatoren der Aβ-
Aggregation, in der das Peptid in seiner nativen Form vorliegt, gefaltet und 
funktionsfähig (hohe ɑ-Helix-Anteile) oder wenn es fehlgefaltet ist (geringere ɑ-Helix-
Anteile). β-Faltblatt-Bildung und Anhäufung führt letztendlich zur Plaquebildung, 
welche benachbarte Neurone beeinträchtigen und deren Apoptose herbeiführen. In der 
CD-Spektroskopie wurden ɑ-Helices bei den Wellenlängen 208, 222 und 193 nm, β-
Faltblätter bei 218 und 192 nm und Random coils bei 205 nm detektiert. Der Einfluss 
von Vitamin C und E, Kalium, Natriumtellurit und Natriumsulfit wurde je bei einer 
Konzentration von 20 μM beobachtet. Caesiumchlorid und Selen zeigten eine 
Verbesserung bei einer Konzentration von 15 μM. Letztendlich verbesserten 
Natriumsulfid, Lithium, Natrium, Kupfer und Zinkchlorid sowie Gallussäure, 
Ferulasäure, p-Cumarsäure, Sinapinsäure und Vanillinsäure, Hesperidin, Naringin, 
Catechin und Flavone die ɑ-Helix-Ausbildung bei Konzentrationen von 5μM 
verglichen mit einer Aβ-Kontrolle ohne Additive. Zudem wurde ein unerwarteter 
Effekt verschiedener Substanzen auf die AICD-Akkumulation beobachtet. 
Ein anderer Aspekt des Aβs ist die mögliche Rolle im angeborenen Immunsystem als 
antimikrobielles Peptid. Diese Rolle ist umstritten und wurde in meiner Untersuchung 
durch die Effekte auf Steinernema feltiae, Escherichia coli, Candida albicans und 




Zellüberleben konnten gezeigt werden. Diese Effekte sind jedoch eher auf die toxische 
Wirkung des Aβ zurückzuführen, als auf seine antimikrobiellen Eigenschaften. Dieser 






































Obesity is a primary risk factor for ischemic stroke because of the impairment in blood 
flow or even clotting due to the accumulation of adipose tissue in these patients. 
Additionally, ischemic stroke mediates the progressive neurodegenerative disease, 
Alzheimer’s disease (AD). Upon stroke due to obesity, a disruption occurs in the blood-
brain barrier (BBB), a barrier protecting the brain from harmful substances and 
controlling the intake of required substances for proper brain function, which underlies 
imbalance of cholesterol levels and homeostasis in the brain, main constitute of the 
brain (25% of total brain mass), and accumulation of amyloid β peptide, a hall mark of 
AD which is a product of the proteolytic cleavage of amyloid precursor protein (APP) 
along with APP intracellular domain (AICD). The aggregation of the insoluble form of 
the amyloid beta (Aβ) peptide is considered to play a significant role in 
neurodegeneration that leads to neuronal apoptosis and the main cause of senile plaques 
which have been considered toxic to surrounding neurons. The accumulation of 
amyloid β occurs primarily when the clearance of the peptide from the brain is 
obstructed due to reduced expression of lipoprotein receptor protein (LRP1), a key 
factor involved in the clearance of Aβ, as a consequence to the loss of BBB integrity.  
  
1.1 Problem statement 
Accumulation of Aβ is a primary risk factor in developing AD implications and hence, 
disaggregation or degradation of such peptide is a target of many investigations to 
minimize its burden on the nervous system. One of the approaches is by studying 
enzymes responsible for degrading Aβ such as neprilysin (nep), insulin degrading 
enzyme (IDE), and matrix metallopeptidase 9 (MMP9) because these enzymes are 
secreted inside the brain while drug resistance occurs due to the presence of efflux 
pumps, ATP-binding cassette subfamily b1 (ABCB1), on the surface of endothelium, 
cells that are connected tightly by tight junctions to form BBB. However, the impact of 
cholesterol on the enzymatic activity of IDE, as a therapeutic target of AD, in degrading 
Aβ is un-studied yet, which is the interest of this study as well as transcriptional impacts 
of APP, AICD and Aβ on cholesterol homeostasis. Transctiptional studies have been 




associated with the early onset of Alzheimer’s. However, transcriptional functions of 
APP, AICD, and Aβ in regulating cholesterol biosynthesis have not been studied which 
are one of the interests in the current investigation. Additionally, Aβ generation induced 
by microorganism’s infiltration to the brain have been suggested as a response of innate 
immune system in which Aβ plays the role of antimicrobial peptide (AMP). The latter 
hypothesis has been examined in the current study to determine the antimicrobial 
function potential of Aβ. Finally, nutrients from different sources which can help in 
maintaining Aβ in its monomer state, soluble form of the peptide that can be cleared 
out of the brain, have been studied in vitro to overcome the drug delivery implications 
due to the efflux pumps across BBB. These nutrients can cross BBB through channels 
or transporters to play a role in reducing the harmful aggregation of Aβ.  
           
1.2 Research aims 
- To examine the transcriptional impact of APP, AICD and Aβ on cholesterol de 
novo biosynthesis pathway. 
- To study the combined role of cholesterol and IDE in degrading Aβ. 
- To examine the antimicrobial activity of Aβ subsequent to microorganism’s 
inflammation. 
- To examine the influence of nutrients from different sources in suppressing 
Aβ deposition. 
 
1.3 Research objectives 
To achieve these aims, following research objectives would be utilized: 
- To study the impact of APP and its derivatives; Aβ, and AICD on the 
transcription of genes involved in cholesterol biosynthesis pathway by 
employing mouse embryonic fibroblasts cells (MEF) and qRT-PCR technique. 
MEF WT (wild type) as control, MEF APP/APLP2 -/- which are lacking APP 
and APLP2 (amyloid precursor like protein-2), MEF APPΔCTF15 (ΔΔ) lack to 
last 15 amino acids of APP C-terminal which do not express AICD, and MEF 
PS1/2 -/- that do not express Aβ, and MEF PS1res which express human Aβ 
only.  
- To study the impact of cholesterol on the enzymatic activity of IDE in degrading 




- To study the impact of cholesterol on IDE gene expression (qRT-PCR), level 
and stability (western blot). 
- To examine the antimicrobial activity of Aβ by measuring the impact of the 
peptide on the viability of bacteria and fungus strands and nematode utilizing 
Alamarblue assay.   
- To investigate the therapeutic potential or harmful impact of some nutrients and 
phytochemicals that can cross the blood brain barrier by channels or 
transporters, on the accumulation of Aβ by employing circular dichroism (CD) 
technique in studying the changes in secondary structure elements of the 
peptide, α-helix and β-sheet. These chemicals include: vitamins (ascorbic acid 
and α-tocotrienol), salts (lithium chloride, rubidium chloride, sodium chloride, 
cupric chloride, zinc chloride, sodium sulfide, sodium sulfite, sodium selenite, 
and sodium selenite), phytochemicals: Gallic acid, p-coumaric acid, sinapic 
acid, vanilic acid, hesperidin, naringin, and catechin hydrate,  and flavones and 
selenoflavones. 
 
This thesis is divided into five chapters. Chapter One contains an overview of the 
completed work and thesis structure. In Chapter Two, previous studies, which have 
been performed relevant to the interest of the study, are reviewed. Chapter Three 
contains a detailed presentation of the cell lines, materials and test methods which have 
been utilized during the experimental course of the study. Results of the experimental 
plan are illustrated in Chapter Four. This chapter contains the discussion of these results 
too. Finally, chapter Five, summarizes the main conclusions of the study as well as the 
recommendations for future work. 
Supporting literatures are listed in the Bibliography section of the thesis, and detailed 




































                                      










































Obesity is defined according to World Health Organization (WHO) as abnormal or 
excessive fat accumulation that impairs health and is measured by body mass index 
(BMI), a simple weight-for-height index that is used to classify overweight and obesity. 
It can be measured as a ratio of body weight (kg) to the squared body height in meters 
(kg/m2). Individuals with a BMI >25 are classified as overweight persons, while 
persons with >30 are considered obese (WHO, 2000). In Germany, around 30% of the 
elderly population (≥64 years) were obese in 2014 (Germany extended 2014 from 
worldobesity.org), while in Iraq it was around 23% in 2006 according to the same study. 
This rate is likely to increase and reach epidemic proportions. Obesity is a risk factor 
for ischemic stroke and vascular cognitive impairment (Andrew et al., 2015 and 
Seunghan et al., 2003) and increases AD progression (Gorelick et al., 2011) via 
aggravation of BBB injury (Tucsek et al., 2014). The capillary lengths in mouse is 0.6 
km while, in the human brains is 650 km, which represent >85% of total cerebral blood 
vessel length, that provides the largest surface area of endothelial cells (120 cm2/g of 
the brain) for solute transport exchange between blood and brain (Zlokovic, 2008). The 
estimated distance between the BBB and neurons is 8 µm on average, in which the 
diffusion of molecules from capillaries to neurons across the brain interstitial space 
occurs promptly (Montagne et al., 2017). 
 2.2 Blood brain barrier integrity  
As the name implies, this barrier is between the brain on one side and blood on the other 
one. The function of the BBB is to maintain the brain by stringent regulation of cell, 
molecular, and ion transport and xenobiotic efflux (Abbott et al., 2006; Tietz and 
Engelhardt, 2015). The adequate neuronal and synaptic peoformance is maintained by 
BBB through controlling the constitution of the internal neuronal milieu (Zhao et al., 
2015). This barrier consists of endothelial cells and blood vessel walls that are tightly 
connected through tight junctions (Daneman and Prat, 2015) as shown in Figure 2 
(Boonstra et al., 2015). As shown in the same figure the differences between blood 
vessels in the body and brain in which tight junctions are preventing free transport of 




specific polarized transport systems that mediate the transport of nutrients to the brain 
parenchyma, efflux of toxic metabolites from the brain, and regulation of the migration 
of circulating immune cells are displaying a unique phenotype BBB endothelial cells 








A tight junction consists of a complex combination of both transmembrane and 
cytoplasmic accessory proteins and is linked to the actin-based cytoskeleton, thus 
allowing it to form a seal with the cytoskeleton (Liu et al., 2012; Bauer et al., 2011). 
The first proteins that constitute a tight junction are occludin (molecular weight 60–65 
kDa) and claudin (molecular weight 20–24 kDa) followed by junctional adhesion 
molecules (molecular weight 40 kDa) in addition to cytoplasmic accessory proteins and 
the zonula occludens (ZO) protein family (molecular weight 160 kDa), (Sandoval and 
Witt, 2008). Figure 3 shows a schematic view of tight junction. This protein 




Figure 2: Composition of Blood brain barrier (BBB) (up), where endothelial cells are strictly 
connected by tight junction which prevent free transport of molecules, ions and xenobiotics 
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Figure 3: Schematic view of proteins that structuring tight junction, occludin, claudin, 




Additionally, in order to integrate the BBB’s full function, there is a group of ATP-
binding cassette (ABC) family of transporters (ABC-A1, -C1, and -G1) (Juan et al., 
2013). Obesity in aging increases BBB disruption, inflammation, and oxidative stress 
(Tucsek et al., 2014), and the influx of serum cholesterol through the BBB leads to 
accumulation of Alzheimer’s hall-mark peptide, Aβ (Gosselet, 2011). Cholesterol was 
taken into consideration in this study because it is the main lipid in the brain (O’Brien 
and Sampson, 1965). 
2.3 Cholesterol in the brain 
Cholesterol is an essential ingredient of cell membranes in mammalians. It is necessary 
for the cell membrane’s bilayer function and organization because of its structure, 
which consists of a fused rigid ring system, a polar hydroxyl group, and a hydrocarbon 
tail. Therefore, it can increase order within the membrane and thereby affect membrane 
fluidity, especially in lipid rafts (Grimm et al. 2013). Cholesterol is localized in sizable 
levels in the brain, where it comprises 25% of the total body cholesterol (Dietschy and 
Turkey, 2004; Dietschy, 2009; Bjorkhem, 2006) at a content of 15-30 mg/g tissue in 
the brain whereas in other tissues, the content is 2-3 mg/g tissue (Petrov et al, 2016). 




































































Figure 4: Chemical structure of cholesterol, C27H46O, molecular weight 386.664 g/mol 
(picture from https://pubchem.ncbi.nlm.nih.gov/cpmpound/cholesterol#section=Top 
with modifications). 
 
2.3.1 Cholesterol biosynthesis pathway 
Cholesterol homeostasis is maintained by sterol regulatory element-binding proteins 
(SREBPs), which are transcription factors involved in regulating cholesterol 
biosynthesis genes (Arenas et al, 2017 and Zhang and Liu, 2015). At low cholesterol 
concentrations, sterol sensing domains (SSDs) catalyzes SREBP cleavage activating 
protein (SCAP) to escort the in-active form of SREBP to the Golgi complex where, a 
sequential cleavage of SREBP by site-1 and site-2 proteases (S1P and S2P) occurs to 
form the mature SREBP (m-SREBP). The active form of SREBP (m-SREBP) is 
translocated to the nucleus to upregulate gene expression of cholesterol synthesis 
pathway by binding to sterol regulatory elements (SRE) in the promoter region of about 
30 genes (Petrov et al, 2016). At high cholesterol level, insulin-induced gene 1 and 2 
(INSIG-1 and INSIG-2), consolidated proteins in the endoplasmic reticulum (ER), 
inhibit SCAP from escorting SREBP to the Golgi complex and hence downregulating 
cholesterol biosynthesis.  
Cholesterol biosynthesis is a multi-step process which involves the formation of 
Acetoacetyl Co-A from two moles of Acetyl-Coenzyme-A then to form 3-hydroxy-3-
methylglutaryl-CoA by HMG-COA synthase (encoded by HMGCS1 gene) in the first 








(encoded by HMGCR gene) which is a rate-limit step in the cholesterol pathway. 
Isopentenyl pyrophosphate (IPP) is then produced after a series of enzymatic reaction 
of mevalonate pathway. Squalene is produced by condensation of six IPP molecules 
and regulated by many enzymes. Squalene cyclization to lanosterol and further steps 
(19-step process; Zhang and Liu, 2015) ends with production of cholesterol (Petrov et 
al, 2016; Zhang and Liu, 2015; Hung et al, 2013; and Ye and DeBose Boyd, 2011).   
2.4 Alzheimer’s Disease 
AD is defined as a neurodegenerative disorder of the central nervous system and is 
characterized by a progressive loss of short-term memory accompanied by a gradual 
loss of cognitive functions (Ross and Poirier, 2004). AD is the most common cause of 
dementia in the elderly, accounting for 60% to 70% of all dementia cases. It can be 
determined by a neuropathological diagnosis as a consequence of the presence of 
neurofibrillary tangles and senile plaques (Xu, et al., 2013). Furthermore, mostly the 
second element of dementia after AD is vascular dementia in aged pateints (Khan et al., 
2016). Definition of vascular dementia is the loss of cognitive function as a 
consequence of ischemic and hypoperfusive or haemorrhagic brain lesions because of 
cerebrovascular disease or cardiovascular pathology (Khan et al., 2016). Although 
extensive research has been conducted about AD and several outcomes have been 
disclosed, however there is a need to determine the accurate trigger factors of 
physiological changes which develop AD with exception of some genetic factors such 
as defined genetic mutations that leads to scarce and inherited forms of AD (Xu, et al., 
2013). Epidemiological studies predicted that 24.3 million people have dementia 
worldwide at present with an increase of 4.6 million new cases of dementia diagnosed 
every year (one new case every seven seconds). Moreover, some anticipations pointed 
out that the number of demented people will double every 20 years to 81.1 million by 
2040 (Ferri et al., 2010). 
 
2.4.1 Risk factors 
AD is a multifactorial disorder determined by the interaction of genetic and 
environmental factors. One of the genetic factors that may be responsible for the 
initiation of AD is mutations in the amyloid precursor protein (APP) and the presenilin-




common forms (ε2–4) in which the APOE ε4 allele mediates cholesterol metabolism 
by providing the characteristics for a protein that carries cholesterol in the bloodstream 
(Arbor et al., 2016). Individuals acquire one of the aforementioned forms of the APOE 
gene from parents (Kim et al., 2009). The risk of AD is increased in individuals who 
inherit one APOE ε4 gene as well as the early onset of the disease compared to those 
who inherit the ε2 or 3 form of the APOE gene. The risk is even higher when APOE- 
ε4 gene is inherited from both parents (Xu et al., 2013). Furthermore, the obesity-related 
alpha-ketoglutarate-dependent dioxygenase gene may increase the risk of developing 
AD due to the interaction with APOE-ε4 (Xu et al., 2013). Likewise, relatives of AD 
pateints of the first-degree (parent, brother, or sister) are candidate to develop the 
disease more than those who do not have such relative (Xu et al., 2013). Sporadic AD 
represents the majority of cases (95%) in which several studies have suggested a 
lifespan-dependent relationship of obesity with AD. Additionally, elevated cholesterol 
levels at midlife has also been reported to be associated with an increased risk of the 
AD at late-life (Xu et al., 2013).  
2.4.2 Amyloid precursor protein processing 
The principal pathological AD hallmarks are the formation and aggregation of senile 
plaques and neurofibrillary tangles at a higher rate in the brain of AD pateints when 
compared with healty individuals at identical ages (Saito et al., 2013). Amyloid-β (Aβ) 
peptide of the 39–43 amino-acid is the predominant constituent of senile plaques 
(Murphy and LeVine III, 2010). Aβ is generated as a final product of sequential 
proteolytic processing of amyloid protein precursor (APP). Aβ40 and Aβ42 peptides 
are popularly produced in human and murine brains (Younkin, 1998). In the 
amyloidogenic pathway, a sequential proteolytic cleavage of APP is mediated by β-
secretase (β-site APP cleaving enzyme 1 or BACE1) followed by the γ-secretase 
complex, which is consisted of four core subunits of presenilins PS1 or 2, anterior 
pharynx defective 1 (APH-1), presenilin enhancer 2 (PEN2), and nicastrin (Baranello 
et al., 2016). First cleavage event by β-secretase is occurred the luminal domain of APP 
which produces soluble APPβ (sAPPβ) and membrane-bound APP carboxyl-terminal 
fragment (CTFβ or C99; Grimm et al., 2008). C99 contains an intact Aβ sequence which 
is cleaved by γ-secretase to generate Aβ, which is released to the extracellular space at 
which point it accumulates to form senile plaques and APP intracellular domains 






























































Amyloidogenic pathway Non-amyloidogenic pathway 
microdomains (lipid rafts) are the locations in which amyloidogenic APP processing 
occurs (Saito et al., 2013; Rushworth and Hooper, 2011; Vetrivel and Thinakaran, 
2010; Kim et al. 2006). However, it is obscure how APP is translocated to lipid rafts 
and the molecular mechanism underlying such translocation. Membrane microdomains 
are rich in cholesterol and sphingolipids such as ceramide, gangliosides, 
glycerophospholipids, and sterols (Seghezza et al., 2014). The approximate diameter of 
lipid rafts has been determined to be roughly around 50 nm on average (Saito et al., 
2013). Golgi apparatus is forming lipid rafts and then transported to the plasma 
membrane at which point the main function is composing a floor for cell signaling, 
pathogen entry, cell adhesion, and protein sorting (Pike, 2003). The biochemical 
definition of lipid rafts is the detergent-resistant membrane (DRM) fraction (Saito et 















Figure 5: Amyloidogenic and non-amyloidogenic processing of APP. β-secretase and 
γ- secretase processing leading to producing Aβ and AICD. Accumulation of Aβ is the 
reason of senile plaques. While in non-amyloidogenic processing of APP, α-secretase 






The role of AICD in gene regulation is still controversial (Mett, 2017; Mueller et al., 
2008) since AICD, upon cleavage, is released to the nucleus. The cytosolic adaptor 
Fe65, a brain-enriched and member of family of multidomain adaptor proteins, interacts 
with AICD and translocate to the nucleus. Following the cleavage of APP, the Fe65 
adaptor protein rescues AICD from rapid degradation (Cao and Sudhof, 2001). 
Additionally, the translocation of AICD to the nucleus is showed to be mediated by 
Fe65 through studying mutated AICD protein which is lacking interaction site with 
Fe65. Such protein remained largely cytosolic indicating the essential role of Fe65 
(Kimberly et al., 2001). The supposed involvement of AICD in transcription has been 
investigated by employing a fusion protein consisting of the DNA-binding domain of 
the yeast Gal4 transcription factor and C-terminal APP domain, and it revealed that 
such a protein could activate transcription from the Ga14 dependent reporter plasmid 
only to a small extent (Cao and Sudhof, 2001; Slomnicki and Lesniak, 2008).   
2.4.3 Interaction between cholesterol and APP 
Several studies have shown that the transcriptional impact of APP on SREBP1/2, 
HMGCR, and HMGCS genes where, cholesterol biosynthesis process was inhibited as 
a result of increased expression of APP (Pierrot et al, 2013). APP-KO astrocytes have 
shown to up-regulate mRNA expression of HMGCR as compared to wild-type (Fong 
et al, 2018). However, the gene expression of HMGCR exhibited no changes in AD 
brains of human and mouse models (Mohamed et al, 2015). Furthermore, the role of 
Aβ was shown to down-regulate cholesterol biosynthesis due to the inhibited 
maturation of SREBP (Kant et al, 2019; Chang et al, 2017; Mohamed et al, 2015; and 
Grimm et al, 2007) and HMGCR (Beel et al, 2010). AICD has shown to down-regulate 
LRP-1 gene expression and thus reducing cellular cholesterol uptake (Zhang and Liu, 
2015; Hung et al, 2013; and Beel et al, 2010)      
2.5 Aβ degradation 
Participation of cholesterol in the process of Aβ clearance have been studied recently 
and shown that cholesterol may regulate Aβ degrading enzymes (Wong et al., 2014). 
One of such enzymes is IDE which transported (after synthesis) to the cell membrane 
by the secretory pathway and then, it either remains there or is secreted (Wong et al., 




a thiol zinc metalloendopeptidase (110 kDA) located in the cytosol, peroxisomes, 
endosomes, and on the cell surface (Saido and Leissring, 2012). Substrates of IDE 
comprise small proteins of diverse sequence such as insulin, Aβ, amylin, atrial 
natriuretic factor, and calcitonin, most of such substrates tend to form β-pleated sheet-
rich amyloid fibrils (Shen et al., 2006). Furthermore, degrading activity of several cell 
lines have been screened, results revealed that IDE participated as a mjor degrading 
enzyme of Aβ (Qiu et al., 1998). Additionally, IDE degrading activity has been 
compared with neprilysin (NEP) activity in degrading intracellular Aβ by transfecting 
cDNA of IDE and NEP into stable human cell line which expressing APP, results 
demonstrated that IDE significantly lowered the levels of soluble and insoluble Aβ, 
whereas NEP minimized only the insoluble levels of Aβ (Farris et al., 2004). In line 
with this result, it was proven in another study that IDE was principal protease capable 
of down-regulation the levels of secreted Aβ extracellularly (Qiu et al., 1998). NEP, an 
86 kDa protein, is also known as a neutral endopeptidase (Wang et al., 2006). NEP is 
expressed in both pre-post-synaptic brain neuronal plasma membranes (Barnes et al., 
1992) and is involved in Aβ degradation. Similarly, endothelin-converting enzyme 
(ECE), is a membrane-bound type II metalloprotease that degrades Aβ (Eckman et al., 
2000). There is evidence that angiotensin-converting enzyme (ACE), also known as 
dipeptidyl carboxypeptidase, can significantly inhibit Aβ aggregation, deposition, and 
cytotoxicity (Hu et al., 2001). A study with plasmin, tissue plasminogen activator (tPA), 
and urokinase-type plasminogen activator (uPA)-serine proteases have shown that tPA 
may be activated by Aβ in AD and enhance Aβ degradation (Ledesma et al., 2000). 
Matrix metalloproteinases (MMPs) belong to the family of zinc-dependent enzymes 
and are released into the extracellular space (Baranello et al., 2016). MMP-2 degrades 
Aβ1-40 and Aβ1-42 peptides in vitro (Roher et al., 1994). MMP-3 indirectly cleaves 
Aβ by activating MMP-9 (Baranello et al., 2016). MMP-9 degrades Aβ at important 
sites in order to facilitate β-sheet formation (Backstrom et al., 1996). 
A non-enzymatic pathway in Aβ clearance from the brain is also enrolled via different 
mechanisms. The BBB removes Aβ from the brain largely via the age-dependent, 
scavenger lipoprotein receptor-1 (LPR1) (Shibata et al., 2000). The main role of this 
receptor is cholesterol transport and metabolism. Another mechanism of Aβ removal 
from the brain was shown to be via activation of microglia by Aβ plaque formation 
(Frautschy et al., 1997) and clearance by phagocytosis. In addition to the 






















spaces until meeting the cerebrospinal fluid (CSF) and then drain into the cervical 
lymph nodes is another mechanism of Aβ clearance (Weller et al., 2000) where, at 
which point an accumulation of Aβ in ISF drainage pathway was found. Such 
aggregation is attributed to the increased Aβ generation, lowered solubility of Aβ, or 
impedance of Aβ drainage along periarterial interstitial fluid (ISF) drainage pathways 
resulting from aging factors in cerebral arteries (Weller et al., 2000). Figure 6 provides 













Figure 6: Schematic view of non-enzymatic mechanisms involved in Aβ clearance by 
lipoprotein receptor-1 (LRP-1), phagocytosis by microglia and drainage by ISF (Yoon 
et al., 2012 with modifications). 
 
2.6 Impact of metals on Aβ 
Metals have been shown to accumulate in the brains of AD patients. (Robinson and 
Bishop, 2001)). It has been revealed that when copper (Cu2+) has been implicated, a 
Cu2+-binding site on Aβ42 with a very-high-affinity of binding is mediating the 
precipitation of Aβ as well as increasing the the tendency of this peptide to self-
aggregate in aqueous solutions (Kitazawa et al., 2016). This affinity is less in Aβ1-40 
(Atwood et al., 2000). In contrast, another study demonstrated that Cu2+ prevented 
accumulation of Aβ1-42 in vitro (Mold et al., 2012). In line with this study, it was 
reported that zinc (Zn2+) caused a rapid precipitation of soluble Aβ1-40 into protease-




been shown to rise significantly with age in both humans and mice (Maynard et al., 
2005).   
 
2.7 Oxidative stress induced by Aβ 
Oxidative stress defined as the consequence increased reactive oxygen species (ROS) 
levels and impeded endogenous antioxidant mechanisms (Padurariu et al., 2013). It has 
been reported that Aβ impairs mitochondrial redox activity and increases reactive redox 
species (RRS) generation (Kadowaki et al., 2005), attacks cell membranes, initiates 
lipoperoxidation, and damages sensitive membrane proteins. The membrane barrier 
function and ion homeostasis are compromised (Henseley et al., 1994; Behl et al., 
1994). Several studies have also suggested that Aβ-induced oxidative stress leads to 
apoptotic-associated neuronal cell death (Cheignon et al., 2018). Soluble Aβ has been 
linked to an increase in hydrogen peroxide (H2O2) levels thus inducing the formation 

















Figure 7: Aβ plaques and oxidative stress, β- and γ- secretase cleave APPs and produce 
Aβ peptide. Outside cells, these proteins can lead to synapse loss and oxidative stress. 
Inside cells, Aβ accumulation can increase the generation of ROS, causing 

























2.8 Impact of phytochemicals 
2.8.1 Flavonoids 
Flavonoids are polyphenolic compounds possessing a C15 skeleton in which either two 
benzene rings are joined by a linear three carbon atoms chain or a chromane ring bears 
a secondary aromatic ring B at the second, third, or fourth position (Anand and Singh, 
2012) as shown in Figure 8. Over 4,000 different flavonoids have been described 
(Hollman and Katan, 1999). Flavonoids are classified into six categories: (1) flavones; 
(2) flavonols; (3) flavanones; (4) isoflavones; (5) flavanols; and (6) anthocyanins 
(Hollman and Katan, 1999). It was found that dietary flavonols could contribute 
significantly to the antioxidant defense systems present in blood plasma (Hollman and 
Katan, 1999). Furthermore, limiting Aβ production by inhibiting BACE1 activity (β-
secretase) was achieved by using isoliquiritigenin from Glycyrrhiza uralensis. Several 
processes of design, synthesis, and evaluation of hydroxy chalcones (simple chemical 
scaffold compound which is occurring naturally) to determine the inhibitory activities 
against BACE1 which was governed to a greater extent by the hydroxyl substituent on 
the chalcone’s A- and B-rings (Ma et al., 2011). Tau is a microtubule-binding protein 
that regulates the microtubule assembly and stability in neuronal cells. Aβ induces tau 
protein hyper-phosphorylation, which promotes microtubule instability and contributes 
to its neurotoxic effects by activating apoptotic pathways (Fath et al., 2002; Ballatore 
et al., 2007). Glycogen synthase kinase-3α and -β (GSK-α and GSK-β) are involved in 
tau protein hyperphosphorylation (Hanger et al., 1992). Inhibition of GSK-3β was 
achieved by different types of flavonoids (Anand and Singh, 2012; Ravishankar et al., 















2.8.2 Selenium and selenoproteins 
Selenocysteine is a naturally occurring amino acid in both eukaryotic and prokaryotic 
organisms (Wikipedia). Its chemical structure is shown in Figure 9. It can be found in 
bread, cereals, seafood, cruciferous vegetables (mainly broccoli), and especially Brazil 
nuts (Santos et al., 2014). Selenium and selenium compounds (sodium selenate 
[Na2SeO4], selenite [Na2SeO3], and selenoproteins) were shown to act as antioxidant 
compounds, which work in combination with the free radical scavenger enzyme 
glutathione peroxidase (GSH-Px) to catalyze the reduction of hydrogen peroxide and 
phospholipid hydroperoxides generated in vivo by ROS and hence protecting lipids 
(Santos et al., 2014; Rayman, 2000; Aaseth et al., 2016). Finally, in a different study, it 
was found that longtime supplementation of mice with Na2SeO4 were identified at one 
or more time points, especially iron and zinc, whose levels were significantly and 
persistently decreased after six-month Se supplementation. Untreated mice with 
Na2SeO4 supplementation showed deposition of Fe and Zn leading to increased Aβ 
production, elevated oxidative stress, and cell death (Zheng et al., 2016). Na2SeO3 can 
inhibit Aβ production by decreasing γ- secretase (Pillai et al., 2014). The recommended 
intake for men is 80 µg/day and women 57 µg/day to maintain selenium in equilibrium, 












2.8.3 Vitamin C and Vitamin E 
Ascorbic acid is a six-carbon compound related to glucose. It can be found in several 
natural resources such as citrus fruits and many vegetables. Vitamin C is the active 
form of ascorbic acid which plays a role as a reducing agent and coenzyme in several 




line which participate beneficially in several impacts on redox oxidative and 
mitochondrial pathways in the immune system, inflammatory pathways, endothelial 
integrity, and lipoprotein metabolism (Monacelli et al., 2017). Additionally, a line of 
evidence have demonstrated that ascorbic acid may maintain BBB integrity and hence 
prevent the onset of AD, in a stroke model (Monacelli et al., 2017).  Furthermore, BBB 
disruption was also impeded by ascorbic acid through upregulating the expression of 
the tight junction proteins, occludin and claudin-5 (Monacelli et al., 2017). Identical 
results have been reported for vitamin E’s effects as an antioxidant (Sung et al., 2003; 


































Different materials from various sources were used, and hence they are arranged in this 
section according to their type or use. 
 
3.1.1 Apparatus, reagents and solutions used in the study 
Apparatus and relevant accessories, chemical reagents, solutions, compounds, peptides, 
and disposable materials that were used in this study are listed in Appendix (A). 
 
3.1.2 Primers used in gene expression detection by RT-PCR 
Detection of gene expression have been carried out by quantitative real-time 
polymerase chain reaction (qRT-PCR), and primers needed for the detection of genes 
involved in the research plan are listed in Tables 1 and 2 for murine and human genes, 
respectively. The primer source was Eurofins Genomics. 
 
Table 1: Sequences of forward and reverse primers used in RT-PCR for murine genes 
Oligo-name Forward primer (5' ->3') Reverse Primer (5' ->3') 
Actb CCTAGGCACCAGGGTGTGAT TCTCCATGTCGTCCCAGTTG 
Fdft1 CTGGAAGACCAACAGGAAGG ACGGCCACATCTACGTTCTC 
Fdps TGAAGATCCTGATGGAGATGG CAGCTGCATTTGTTGTCCTG 
Hmgcr ATCGAGCCACGACCTAATGA TAAGCTGGGATATGCTTGGC 
Hmgcs1 GGCAGAAAGAGGGAAAGGAT GGCAGAAAGAGGGAAAGGAT 
Hmgcs2 GGTGGATGGGAAGCGTCTA GGTTGTTTCCAGCTTGCTTC 
IDE GCTACGTGCAGAAGGACCTC TGGACGTATAGCCTCGTGGT 
Lss CTGCAGAAGGCTCACGAGTT CAGTCCAGTGTGCTGAAGGA 






Table 2: Sequences of forward and reverse primers used in RT-PCR for human genes 
 
 
3.1.3 Cell lines   
Different cell lines were used for achieving research goals. Types of cell lines used in 
the study with brief descriptions of each are listed in Table 3. 
 
Table 3: Cell lines used as a part of the study 
Name Source 
MEF APP / APLP2 -/- Mouse fibroblastoma generated without expression of 
APP and APLP2 (Heber et al.,2000) 
MEF APPΔCTF15 (ΔΔ) Mouse fibroblastoma lack of the last 15 amino acids of 
APP C-terminal (Ring et al, 2007) 
MEF PS1/2 -/- Mouse fibroblastoma generated without expression of 
PS1 and PS2 (Herrmann et al.,2000) 
MEF PS1res Generated by Dr. Eva Hesser (Plasmid construct 
cloning by Dr. Marcus Grimm), Zeosin-resistant 
MEF WT Wild type mouse fibroblast cell line 
Mvk GGGACGATGTTCTTCCTTGAA TCTCAGGGAACTTGGTCAGC 
Pmvk GCGAGCACCTACAAGGAGAC CACTCACCAGCCAGATAGGC 
Polr2 AAGCGGATCACCACTCCTTA TGAGCAAAGGGTCTGTCTCC 
Sqle GTTGTTGCGGATGGACTCTT GGGTTGACCAGAACAAGCTC 
Oligo-
name 
Forward primer (5' ->3') Reverse Primer (5' ->3') 
ACTB CTTCCTGGGCATGGAGTC AGCACTGTGTTGGCGTACAG 
IDE AAGCAGGCTGCATTAGGAATTA CCTCTGTCAAGGGAGCTGAAC 




N2a IDE KD N2a mouse neuroblastoma, lack of sh-RNA function, 
generated by Janine Mett (Experimental neurology, 
University of Saarland) 
N2a WT Wild type, mouse neuroblastoma (Klebe et al., 1970) 
 
 
3.1.4 Lipids, Plasmids, Antibodies, and Kits 
Cholesterol (3β-hydroxy-5-chlesterol) was used in addition to PC 18:0 (1,2-distearoyl-
sn-glycero-3-phosphocholine), which was used for comparison purposes (Avanti). The 
plasmid pEZX-PG04-IDE-Gluc (GenCopoeia) was used for measuring IDE promoter 
activity. A primary monoclonal (not for IDE detection), ST1120, and secondary 
antibodies (polyclonal) used for the western blot are listed in Table 4. Table 5 contains 
a list of kits that were used in this thesis. 
 
Table 4: Primary and secondary antibodies 
Name Epitope / use Source 








P0260 Mouse IgG, HRP-coupled secondary 
antibody for western blot 
DAKO 
ST1120 N-terminus IDE for IDE 
immunoprecipitation, IDE activity and 
IDE western blot 
Merck Millipore 
W02 Human APP (5-10 amino acids of Aβ) 
for total Aβ immunoprecipitation and 
Aβ western blot 
Beyreuther 
(Heidelberg) 
W4011 Rabbit IgG, HRP- coupled secondary 








Table 5: list of kits used in the study 
Name Use Source 
High capacity cDNA RT cDNA synthesis Applied Biosystems 
Secrete-Pair Dual Luminescence 
Assay  
IDE promoter activity GenCopoeia 
 
 
3.1.5 Computer software utilized as a part of data analysis 
Data analyses obtained by different experiments were performed using the software 
listed in Table 6. 
 
Table 6: Computer programs used in data analysis 
Name Source 
Analyst 1.5 AB Sciex 
Excel Microsoft 
Image Gauge V3.45 Fuji Science lab 
Piko Real 2.1 Thermo Scientific 
 
3.2 Methods 
Preparation of cells, solutions, and compounds with corresponding protocols are 
described in the following sections. Description of testing methods, parameters, and 
test conditions are also presented. Unless otherwise indicated, all preparatory and 
testing protocols were performed according to Mett (Experimental Neurology 
Department, University of Saarland; Mett, 2017). 
 
3.2.1 Cell Cultures 
The cell culture protocol followed that of Doering, 2010. To avoid contamination, a 
laminar flow sterile workbench was used under sterile conditions. The culturing 





I. PBS solution:        137 mM NaCl 
       2.7 mM KCl 
                               8.1 mM Na2HPO4.2H2O 
                               1.5 mM KH2PO4             
pH adjusted to 7.5 with HCl. 
II. Cell cultivation in 10 ml cell culture medium, and cells were maintained at 37 
°C, 5% CO2, and 95% atmospheric humidity in 10 cm cell culture dishes.   
III. Cells were washed with 5 ml phosphate buffered saline (PBS) upon achieving 
about 90% to 100% confluency. 
IV. Incubation of cell cultures with 1.5 ml trypsin/ethylenediaminetetraacetic acid 
(EDTA) solution for 2 to 3 min to separate growing cells from the bottom of 
culture dish. 
V. Addition of 8.5 ml of fresh medium after trypsin/EDTA incubation. 
VI. According to the cell line undergoing cultivation, distribution of 0.5 to 3 ml 
according to cell line (Table 7) of the cell suspension on new culture dishes for 
further cultivation and brought to 10 ml final volume with fresh medium.  
VII. Seeding cells on new 10 cm dishes or 6, 12, 24, or 96 well plates according to 
the experiments of interest. 
 
Table 7: Cell culture media. 




N2a WT DMEM 
0.1 mM MEM amino acid solution 
10 % (v/v) FCS 
- - 
N2a IDE-KD 100U/ ml Penicillin 
0.1 mg/ml Streptomycin 
+ - 
 
Cells were stored long-term at –80 °C in liquid nitrogen according to the following 
protocol: 
I. preparation of freezing solution A:       




and freezing solution B:      
30% (v/v) FCS 
20% (v/v) DMSO in DMEM 
II. Washing of 60% to 80% confluent cells with 5 ml PBS. 
III. Separation from bed of 10 cm dish with 1.5 ml trypsin/EDTA solution. 
IV. Adding 4.5 ml culture medium and transferring to Falcon tube. 
V. Centrifugation at 355 g for 5 min.  
VI. Resuspension of cell pellets in 1.5 ml of freezing solution A. 
VII. Addition 1.5 ml of freezing solution B and aliquoting into two cryogenic 
vessels. 
VIII. Storage in a freezer box that contains isopropanol at –80 °C; this will lead to a 
gradual decrease in temperature at a rate of 1 °C/min. 
 
Re-cultivation of the cells can be carried out according to the following procedure: 
I. Thaw-freeze cycles of culture at room temperature. 
II. Dilution in 8.5 ml fresh, prewarmed culture medium. 
III. Centrifugation for 5 min. at 355 g. 
IV. Resuspension of cell pellets in 10 ml cell culture medium. 
V. Transfer to 10 cm cell culture dishes.  
 
3.2.2 Cell incubation with cholesterol 
Incubation of cells with cholesterol was carried out according to Grimm et al., 2013 in 
which N2a cells were incubated for 18 h + 6 h with Aβ40. Additionally, 6 h before 
incubation, the fetal calf serum in the culture medium was reduced to 0.1 %. 
Furthermore, to increase solubility of cholesterol in the aqueous culture medium, the 
ethanol-containing lipids and the medium in glass tubes were heated to 37 °C. The final 
concentration of cholesterol in the pre-warmed medium was 100 µM, and the batches 
were vortexed after removing old culture medium.      
                                       
3.2.3 Quantification of gene expression by qRT-PCR 
qRT-PCR is commonly applied in molecular biology in order to quantify the genes 
under consideration expressions. As a combined technique, it starts from isolation of 




and then amplification via PCR of gene sequences under consideration by using 
particular sets of primers designed for those genes. Furthermore, the fluorescent 
cyanine dye, SYBR green, was used to quantify the amplified gene products at the point 
at which they were bound to double-stranded DNA that emitted light upon excitation. 
Quantification can be accomplished by measuring the emitted light of the dye. Finally, 
the results were normalized and analyzed according to 2-ΔΔCT- method (Rao et al., 2013; 
Livak and Schmittgen, 2001).  
 
3.2.3.1 Total RNA Isolation 
The process of RNA isolation was conducted according to manufacturer’s instructions 
(Life Technologies, issue December 2012). 
Total ribonucleic acid (RNA) was isolated from cultured cells according to the 
following protocol: 
I. Complete removal of culture medium. 
II. Addition of 1ml TRIzol reagent per 6 well and scraping of cells with a rubber 
scraper from the bed of the cell culture dish. 
III. Addition of 200 µl chloroform, transfer to 1.5 ml Eppendorf reaction vessels, 
and incubation at room temperature for 5 min. 
IV. Shaking for 15 sec followed by incubation at room temperature for 3 min. 
V. Centrifugation for 15 min at 13,800 g and 4 °C. 
VI. After centrifugation, different layers can be seen: (1) the first layer in the 
bottom contains DNA and is red; (2) The middle layer contain proteins; and 
(3) the upper aqueous layer contains RNA. 
VII. Transfer of the upper layer into a new 1.5 ml Eppendorf. 
VIII. Mixing with 500 µl isopropanol and incubation for 10 min at room 
temperature. 
IX. Centrifugation at 13800 xg and 4 °C for 10 min in order to cause RNA pellet 
formation that was precipitated at the bottom of the vessel. 
X. Discard supernatant. Washing of pellets with 1 ml of 75% ethanol. 
XI. Centrifugation at 5400 xg for 5 min at 4 °C. 
XII. Discard the supernatant followed by air drying RNA for 5 min. 





After that, isolated RNA’s purity and concentration was determined using a Nano Drop 
spectrophotometer. Knowing that, the maximum absorbance of nucleic acids and 
proteins was read at 260 and 280 nm, respectively. Thus, the purity of the isolated RNA 
can be calculated as the ratio of absorbance for nucleic acids at 260 nm to the 
absorbance of proteins at 280 nm. As an indication of pure isolated RNA, the ratio 
should be is 2.2. Therefore, a ratio of >2 was used to indicate pure RNA in this study. 
Furthermore, the calculation of isolated RNA concentration depends on an absorbance 
at 260 nm in which an absorbance of 1 at this wavelength corresponds to a concentration 
of 40 µg/ml of pure RNA. For future use or long-term storage, isolated RNA can be 
kept at –80 °C.  
 
3.2.3.2 Reverse Transcription of Isolated RNA 
Synthesis of cDNA was carried out according to manufacturer’s instructions (Thermo 
Fisher Scientific, Issue March 2016).  
Isolated RNA from the previous step was used to synthesize complementary DNA. The 
synthesis process required the use of the High Capacity cDNA Reverse Transcription 
kit from Life Technologies according to manufacturer's instructions in a Primus 25 
Advanced PCR cycler as shown in Table 8. The cycler was operated according to the 
program shown in Table 9. 
 
Table 8: preparing solution for cDNA synthesis 
2 μg Isolated RNA 
2μl 10x RT buffer 
0,8μl  25x dNTP mix 
2μl 10x RT Random primer 
1μl MultiScribe reverse transcriptase 4,2μl 
4,2μl Nuclease-free water 












After those steps, the cDNA obtained was then diluted in nuclease-free water 1:10 and 
stored at -20 °C. 
 
3.2.3.3 Real-Time Polymerase Chain Reaction  
Amplification of cDNA obtained from previous step is performed by RT-PCR with 
gene-specific primers and SYBR green dye. The PikoReal PCR system, manufactured 
by Thermo Scientific, was used to measure gene expression in which batches prepared 
for RT-PCR were pipetted into 96-well plates, and fluorescence of emitted light from 
the SYBR green dye were measured. Every well contained the following: 
I. 2.5 μl cDNA 
II. μl nuclease water 
III. 0.25 μl forward primer 
IV. 0.25 μl reverse primer 
V. 5 μl SYBR Green master mix. 
The program of PCR is shown in Table 10. 
Table 10. Program for qRT-PCR 
Step  Process Duration, s Temperature, 
°C 
No. of cycles 
1 Denaturation 20 95 1 
2 Denaturation 3 95  
3 Attachment / elongation 30 60 40 
4 Melting curve analysis  60–95 1 
step duration Temperature cycles 
1 10min 25 °C 1 
2 120min 37 °C 1 
3 5min 85 °C 1 




Finally, the data was normalized to one or more housekeeping genes such as β-actin or 
the TATA binding box protein (TBP) by applying 2-ΔΔCT method (Rao et al., 2013; 
Livak and Schmittgen 2001).  
 
3.2.4 Western Blot method 
This technique is used extensively to detect specific proteins in a mixture of proteins 
from a sample by using sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) to separate proteins according to their size. After that, the separated 
proteins are transferred onto a nitrocellulose membrane and stained primary and 
secondary antibodies specific to their respective proteins. This technique consists of 
cell preparation (cell lysis) followed by gel electrophoresis, blotting, blocking, 
treatment with primary followed by secondary antibodies, and finally, treatment with 
reagents to visualize the enzyme and quantify the amount of protein. The subsequent 
paragraphs provide details for the cell preparation from tissue and protein extraction, 
including details of western blotting experiments.  
 
3.2.4.1 Determination of protein concentration  
In order to determine protein concentrations, the bicinchoninic acid (BCA) method, 
first described by Smith and co-workers in 1985 as a two steps reaction, was used. In 
the first step, the protein reduces Cu2+ to Cu1+ in an alkaline environment (Smith et al. 
1985). In the second step of the reaction, BCA reacts with the newly formed Cu1+ ions 
to form a purple colored BCA-Cu1+complex that has an absorbance at 560 nm. The 
BCA reaction solution consists of 4% (w/v) CuSO4.5H2O and BCA 1:39 (v/v). Samples 
were pipetted in triplicate into the wells of a 96-well plate, and 10 μl of lysates were 
used for protein determinations. Also, to prepare references for the calculations of 
protein concentration, serial dilutions of bovine serum albumin (BSA) prepared in 
water at 12 different concentrations (0.1 to 1.1 mg/ml) were used. Samples incubated 
at 37 °C for 15 min after 200 μl of BCA reaction solution. Samples were then shaken 
at 200 rpm at room temperature for an additional 15 min. Absorbances were then 
measured at 560 nm in a plate photometer, and the protein concentration in the samples 






     Figure 10: Protein concentration and linearity according to the BCA method. 
 
3.2.4.2 Protein separation by SDS-PAGE 
Protein electrophoresis via SDS-PAGE entails the separation of proteins according to 
their molecular weight within an electric field. The separation was carried out in 10%–
20% Tris-Tricine gradient gels by applying an electrical voltage. Proteins prepared in 
the previous step were used for this technique. Fifteen microliters of 3x protein sample 
buffer was added. Other samples were mixed with 1/3 volume 3x protein sample buffer. 
After that, samples were incubated for 5 min at 98 °C in a heating block in order to 
denature the proteins. The SDS contained in the protein sample buffer masks the 
intrinsic charges of the proteins with a negative charge, which in the electric field leads 
to the movement of the proteins towards the anode. The denatured samples were then 
centrifuged for a few seconds and loaded onto the gel pockets using a Hamilton 
capillary syringe. In addition, 5 μl of the protein size standard page ruler was applied 
to each gel, which allowed the subsequent estimation of the sample proteins’ molecular 
weights. The electrophoretic separation of the proteins took place in a chamber filled 
with running buffer by applying an electrical voltage of 120 V over a period of 60 to 
90 min. The composition of the running and protein sample buffers are described 
below: 
a. 1X running buffer for SDS-Page:  
I. 100 mM Tris/HCl pH 8.25 to 8.5 



























II. pH 6.8 100 mM tricine 
III. 0.1% (w/v) SDS in ddH2O 
 
b. 3X protein sample buffer: 
I. 187.5mM Tris/HCl pH 
II. 6% (w/v) SDS 
III. 30% (v/v) glycerin 
IV. 15% (v/v) β-mercaptoethanol 
V. 0.03% (w/v) Bromophenol in ddH2O 
 
3.2.4.3 Transfer of proteins 
In this step, proteins separated in the previous step were then transferred to a 
nitrocellulose membrane. This can be performed by applying an external electrical 
voltage, which enables the protein detection using specific antibodies. Tris-tricine gel 
was placed on a nitrocellulose membrane and wrapped on both sides with two layers of 
Whatman filter paper and a sponge. The whole assembly was suspended in a plastic 
tank filled with transfer buffer. Negatively charged proteins transfer by SDS occurred 
toward the anode at 38 0 mA and 4 °C. Depending on the molecular weight of the 
proteins to be transferred, the transfer time may vary from 1 to 2 h for small peptides 
such as Aβ. However, the default time was set to 3 h. The transfer buffer consisted of 
several ingredients: 
I. 25 mM Tris / HCl pH8,7 
II. 192 mm glycine 
III. 20% (v/v) methanol 
IV. 0.025% (w/v) SDS in ddH2O. 
 
3.2.4.4 Immunological detection of proteins  
In this step, proteins were detected using specific antibodies in which specific binding 
of the primary antibody to its epitope occurs. The primary antibody can then be 




peroxidase (HRP). An enzymatic reaction results in a light reaction that occurs upon 
contact of the ECL (enhanced chemiluminescence) reaction solution with the 
horseradish peroxidase. The light reaction will enable the preparation of labeled 
proteins on photosensitive films. Before the treatment with primary antibody, the 
membrane is incubated in blocking solution in order to reduce the amount of 
nonspecific protein binding during subsequent steps in the assay using inert protein or 
nonionic detergent. When using the anti-amyloid primary antibody, W02, the 
nitrocellulose membrane was heated prior to blocking for 5 min in PBS in a microwave 
oven at 700 W (Ida et al., 1996). This was followed by three washing steps and 
incubation of the membrane with the respective primary antibody. After washing again 
three times, the membrane was incubated for 1 h with the appropriate secondary 
antibody and then washed an additional three times after which the ECL reaction 
solution was pipetted onto the membrane, resulting in an HRP-catalyzed 
chemiluminescent reaction. The membrane was placed between two copy sheets 
without air bubbles and exposed in a darkroom on an ECL hypersensitive film. Finally, 
bands were evaluated using the computer software Image Gauge V3.45. 
 
3.2.5 Determination of Aβ degradation 
Western blotting was used to measure the remaining Aβ in living cells and culture 
medium. The cells were seeded in 24-well plates till confluency which correspond with 
a cell number of 0.24 × 106 cells / well and treated as previously described with and 
without the addition of cholesterol. Following that step, cells were incubated with 
cholesterol in combination with 0.5 µg/ml of human Aβ40. Also, total degradation was 
measured in cell lysates and in the conditioned medium from incubated cells. The 
localization of Aβ degrading proteases was also considered by measuring the activity 
of intracellular and extracellular degrading enzyme activities. In order to measure 
activities, Aβ40 was added to the sample material in a glass bottle and shaken at 37 °C 
and 300 rpm.  
Since the antibody W02 used in the western blot analysis exclusively detected human 
Aβ, only the supplemented human Aβ40 was detected with the use of murine cells. 
When using human cells, endogenous Aβ detection was experimentally excluded.  
 
3.2.6 Evaluation of the effects of cholesterol on IDE activity 




Internally quenched fluorogenic substrates are commonly used in this type of 
measurement. This particular method consisted of a fluorophore and a quencher linked 
by an amino acid sequence and mimicking a substrate of the respective enzyme, which 
contained the enzyme’s interface. Fluorescence resonance energy transfer (FRET) 
between the quenching moiety and the fluorophore prevents fluorescence emission. 
After hydrolysis of the substrate, a fluorophore is excited at a certain wavelength due 
to the spatial separation of the two groups. The resulting fluorescence can be measured 
using a suitable detector in real time. Prior to the start of experiment, it is essential to 
determine the optimum measurement parameters by scanning the excitation and 
emission first for the substrate Mca-RPPGFSAFK (Dnp)-OH. Fluorescence was 
measured using an incremental 5 nm excitation wavelength increase for each step.  
 
To study the direct influences of cholesterol on the IDE-enzyme activity, the 
recombinant human IDE was analyzed after in vitro incubation with the cholesterol. 
Assay buffer B for IDE used in this experiment consists of:  
I. 100 mM Tris/HCl, pH 7.5 
II. 50 mM NaCl 
III. 10 µM ZnCl2 in ddH2O without inhibitors 
 
The experimental procedure is described below: 
I. Addition of recombinant human IDE 50 ng/200 µl of assay buffer IDE-B 
in small glass bottles with 100 µM of cholesterol. 
II. Shaking at 37 °C and 300 U/min for 15 min. 
III. Pipetting triplicate 50 µl aliquots of the mixture into black 96-well 
plates. 
IV. Adding the substrate Mca-RPPGFSAFK (Dnp)-OH at a final 
concentration of 5 µM. 
V. Continuous recording of the emitted fluorescence at excitation and 
emission wavelengths of 320 and 405 nm, respectively, in a Safire2 
fluorimeter.  
 
3.2.7 Impact of cholesterol on IDE promoter activity 
(According to the manufacturer’s instructions, secreted-pair dual luminescence assay 




IDE promoter activity was measured using a luciferase activity. This can be conducted 
by measuring a reporter enzyme’s activity; therefore, the promoter activity is measured 
indirectly, and cases in which the promoter under study (IDE in this case) is regulating 
the transcription of the reporter can be measured. Thus, cells need to be first transfected 
by the reporter enzyme. The transfection process may include variations that can affect 
transfection efficiency; therefore, a second reporter gene under the control of active 
promoter is used. Co-transfection of the second promoter is needed in addition to 
normalization of data obtained from measuring activity of second reporter gene’s 
activity to the standard reporter enzyme’s activity. Measuring IDE promoter activity 
was preceded by a step in which cells were transfected using Lipofectamine 
transfection 2000 and plasmid pEZX-PG04-IDE-Gluc according to the following 
protocol: 
 
I. Incubation of OptiMEM (7.5 ml) with plasmid DNA (16 µg) for 5 min at room 
temperature in a 1.5 ml Eppendorf reaction tube. 
II. Incubation of OptiMEM with Lipofectamine 2000 (36µl) in another 1.5 ml 
Eppendorf tube. 
III. Combining the two mixtures for 20 min at room temperature. 
IV. Washing cells of 70%–80% confluency with OptiMEM and presenting 
OptiMEM to cells being transfected. 
V. Reducing OptiMEM to about 50% according to manufacturer’s instruction 
(Invitrogen, version July 2005) for achieving increased transfection efficiency. 
VI. Addition of the plasmid DNA, Lipofection 2000, and OptiMEM mixture to 
cells and incubating the cells and mixture for 4 to 6 h at 37 °C. 
VII. Replacing transfection medium with new culture medium. 
VIII. Transfected cells were used for an expression period of 48 to72 h for 
subsequent experiments.  
 
After this step, the IDE promoter controls the reporter gene, which encodes the secreted 
Gaussia luciferase. Furthermore, the constitutively active cytomegalovirus (CMV) 
promoter controls the secretion of the standard reporter enzyme alkaline phosphatase 
(SEAP) gene that is contained in the same plasmid. After 24 h of transfection, cells 
were seeded in 24-well plates, and after an additional 24 h, incubation with substrate 




reporter activities were measured using the culture medium and were done using a 
Secrete-Pair Dual Luminescence Assay kit according to the manufacturer’s instructions 
with white 96-well plates. Signal detection was performed in an Infinite M1000 pro-
fluorometer / luminometer. Normalization of signals was carried out as the ratio of 
Gaussia luciferase signals to SEAP signals for the respective sample.  
 
3.2.8 Evaluation the impact of cholesterol on IDE stability 
The experimental protocol was based on the thesis of Haupenthal (Haupenthal, 
2016). 
Determination of IDE protein stability with and without cholesterol was achieved by 
inhibiting IDE protein biosynthesis with cycloheximide and then quantified by western 
blotting. A comparison between the results obtained for the control and cholesterol 
treated samples was established in order to determine whether protein stability 
increased or decreased. Thus, the test was carried out using confluent N2a cells on a 
6-well plate according to the following procedure: 
I. After cells reached confluency on 6-well plate, they were washed once with 1% 
FCS and then FCS concentration in the media was reduced to 0.1%. 
II. Incubation with 20 µg/ml cycloheximide for 8 h. 
III. Removal of culture medium and cell incubation for an additional 16 h with 
cycloheximide and cholesterol. 
IV. Centrifugation of the collected media at 13,000 rpm for 5 min. 
V. Collection of the supernatant for extracellular IDE testing after removal of dead 
cells, storage at –80 °C. 
VI. Washing wells once with PBS on ice. 
VII. Adding 200 µl lysis buffer containing 10% protease inhibitors. 
VIII. Leaving on ice for 30 min followed by scraping cells and pipetting the scraped 
cells several times. 
IX. Collecting in Eppendorf tubes followed by centrifugation at 13,000 for 5 min. 
X. Using the supernatant for the BCA assay standard after removing pellets. 
XI. Applying western blotting and blocking using 10% skimmed milk in TBS with 







3.2.9 Preparation of monomeric Aβ 
The protocol of producing monomerized peptide was according to Stine (Stine et al., 
2011). Homogeneous unaggregated Aβ40 peptide was produced by using strong 
solvent to prevent any structural changes prior to incubation with additives. 
Monomerization was carried out according the following protocol: 
I. Prepare a 1 mM Aβ solution by adding 2.217 ml of hexafluoro-2-propanpl 
(HFIP) directly to the vial containing 10 mg lyophilized powder of peptide 
through the rubber septum using a 2.5 mL glass Hamilton syringe with a Teflon 
plunger and sharp (not blunt-end) needle.  
II. After the peptide is completely dissolved, pierce the septum with a syringe 
needle to release the vacuum. 
III. Incubate the Aβ–HFIP solution at room temperature (RT) for at least 30 min. 
IV. Uncap the glass vial (pliers work well), and remove the rubber septum being 
careful not to allow the HFIP to come in contact with the septum. Have a rack 
of 0.5 mL or 1.7 mL micro-centrifuge tubes ready. 
V. Using a positive-displacement repeating pipette, aliquot the solution into 10 μL 
(0.045 mg for Aβ40) or 100 μL (0.45 mg for Aβ40) aliquots in either 0.5 mL or 
1.7 mL microcentrifuge tubes. 
VI. Allow HFIP to evaporate in the open tubes overnight in the fume hood. 
VII. Transfer tubes to a SpeedVac and dry down for 1 h without heating to remove 
any remaining traces of HFIP and moisture. 
The previous steps should be carried out in a fume hood, then: 
 
VIII. Remove tubes from SpeedVac. The resulting peptide should be a thin clear film 
at the bottom of the tubes. 
IX. Store dried peptide films over desiccant in glass jars at −20 °C. 
X. Prior to use, remove peptide film from −20 °C freezer and allow sample to thaw 
till RT. 
XI. Prepare a 5 mM Aβ DMSO stock by adding 20 μL fresh dry dimethyl sulfoxide 
(DMSO) to 0.45 mg Aβ40 peptide (2 μl to 0.045 mg Aβ40). Pipette thoroughly, 
scraping down the sides of the tube near the bottom to ensure complete 
resuspension of peptide film. 
XII. Vortex well (~30 sec) and pulse in a microcentrifuge to collect solution at the 




XIII. Sonicate 5 mM Aβ DMSO solution for 10 min in a bath sonicator. 
XIV. To this Aβ aliquot, add ice-cold H2O to a final concentration of 100 μM Aβ. 
XV. Vortex for 15 sec and use immediately. 
 
3.2.10 Viability of nematodes  
A homogeneous mixture of Steinernema feltiae was prepared by suspending 200 mg of 
powder in 50 mL of distilled water at 27 ºC to restore the nematodes. The suspension 
was then kept at RT for 30 min. Subsequently, viable nematodes were counted under 
the microscope (0 h) at a 4-fold magnification (TR 200, VWR International, Belgium). 
After that, previously prepared Aβ was added to well plates at a concentration of 1, 1.5, 
and 2 µM and incubated in the dark at RT for 24 h. Thereafter live and dead nematodes 
were counted under the microscope (24 h). Each concentration was replicated three 
times per experiment, and each experiment was conducted three times. 
The viability of the nematodes was assessed then according to the following formula:  
 




            V24h = number of live nematodes after 24 h  
            V0h = number of live nematodes at 0 h. 
 
 
3.2.11 Cell viability test using AlamarBlue 
The AlamarBlue test has been used frequently for the determination of cell viability 
and cytotoxicity in a wide spectrum of cell lines, including bacteria, yeast, fungi, 
protozoa and cultured mammalian and piscine cells (Rampersad, 2012). Detection of 
cell viability for selected strands of bacteria by AlamarBlue to test the antimicrobial 
activity of Aβ have been carried out by using resazurin dye (7-Hydroxy3H-phenoxazin-
3-one 10-oxide). The process is explained in the publication of G-biosciences 
“AlamarBlue dye in its oxidized form is blue in color and non-fluorescent. In 
AlamarBlue assay reagent, the growing cells cause a chemical reduction of the 
AlamarBlue dye from non-fluorescent blue to fluorescent red. The continued growth of 
viable cells maintains a reducing environment (fluorescent, red) and inhibition of 
growth maintains an oxidized environment (non-fluorescent, blue), which can be 






Rampersad stated: “In addition to mitochondrial reductases, other enzymes (such as the 
diaphorase (EC 1.8.1.4, dihydrolipoamine dehydrogenase), NAD(P)H: quinone 
oxidoreductase (EC 1.6.99.2) and flavin reductase (EC 1.6.99.1) located in the 
cytoplasm and the mitochondria may be able to reduce AlamarBlue” (Rampersad, 
2012). 
 
3.2.11.1 Preparation of inoculum 
The preparation of inoculum is done by using a direct broth suspension of isolated 
colonies selected from 18 to 24-h agar plates. After that, the turbidity of the suspension 
can be adjusted to be equivalent to a 0.5 McFarland turbidity standard. Approximately, 
1.5 x 108 CFU/mL (colony forming unit), is expected according to this standard for 
Escherichia coli. After adjustment of suspension, inoculums were diluted in broth to a 
final concentration according to the cell types. Finally, mixing with the antimicrobial 
agent (Aβ) for the concentrations under consideration was done. Furthermore, a tube 
with broth only without bacteria and another tube with growth control without the 
antimicrobial agent were used as a control. After that, incubation of tubes for 16 to 20 
h at 35 ±2 ͦ C in an ambient air incubator was done (M. Balouiri et al, 2016).  
 
3.2.11.2 Preparation of AlamarBlue  
The preparation of AlamarBlue was achieved by dissolving high purity resazurin in 
PBS (pH 7.4) to 0.15 mg/mL. The solution was filtered through a 0.2 µm filter into a 
sterile, light protected container. The resazurin solution can be stored at 4 °C for 
immediate use or at –20 °C for long-term storage, protected from light (G-Biosciences, 
2016). 
 
3.2.11.3 Detection of viable cells 
The quantification of viable cells was performed by preparing pre-adjusted tubes of 
cells and antimicrobial agent (Aβ), in opaque-welled 96-well plates of a final volume 
of 100 µl per well. After that, 20 µl resazurin solution to each well has been added. 
After incubation for 1 hour at 37 °C, the absorbance was recorded using microplate 
reader EL 800 Bioscience instrumentation and 570 nm and 630 nm filters. The percent 






% reduction = 
(𝑂2 𝑥 𝐴1)−(𝑂1 𝑥 𝐴2)
(𝑂2 𝑥 𝑃1)−(𝑂1 𝑥 𝑃2)
 𝑥 100                                                           eq.2 
 
In which: 
O1 = molar extinction coefficient (E) of oxidized AlamarBlue at 570 nm. = 80586 
O2 = E of oxidized AlamarBlue at 630 nm. = 34798 
A1 = absorbance of test wells at 570 nm 
A2 = absorbance of test wells at 630 nm.  
P1 = absorbance of positive growth control well (cells + AlamarBlue, without Aβ) at 
570 nm 
P2 = absorbance of positive growth control well (cells + AlamarBlue, without Aβ) at 
630 nm. 
 
3.2.12 Evaluation of Aβ aggregation by circular dichroism spectrometry 
Circular dichroism (CD) spectrometry measures the differences in absorption between 
right- and left-handed circularly polarized light over a range of wavelengths. The 
differences occur due to the protein and peptide chirality. Thus, conformational changes 
of Aβ40 can be detected using this technique. CD has been applied extensively to the 
structural characterization of peptides because it is not the sum of the CD spectra of the 
individual residues or bases but is greatly influenced by the three-dimensional 
structure of the peptide itself. Likewise, each peptide has a specific CD signature, and 
this has the advantage of detecting elements of a specific peptide’s structure and 
determining changes in the peptide’s structure. Peptide aggregation then can be 
determined by monitoring changes in the peptide’s secondary structure elements such 
as the α-helix (wavelength –208, –222, and +193 nm), β-sheet (wavelength –218 and 
+195 nm), and random coil (wavelength –205 nm). Highly aggregated peptides show 
an increase in the secondary structure’s β-sheet element. The CD spectra in the far‐UV 
range (190–260 nm) can be used to predict the formation of each secondary structural 
element in protein’s structure. This method was used to assess changes in Aβ’s 
secondary structure, which is incubated with selected compounds, and their impact on 
the peptide’s accumulation. 
 
3.2.12.1 Preparation of compounds 




Chemical compounds were dissolved in Tris to a concentration of 1 mM as a stock 
solution. Afterward, different concentrations of compounds were added to the peptide. 
The concentrations used in this study were 10, 15, and 20 μM as final concentrations. 
Three-hundred milliliters of solution was then loaded in the CD spectrometer cuvette, 
and the spectrum measured at different time intervals to monitor changes in the 
secondary structure of the peptide upon incubation with compounds. Unless stated 
otherwise, three replicates were examined for every compound, and a spectrum for the 
monomerized peptide without the compound was used as the control. Analysis of data 
obtained from the CD spectrum was carried out according to Wiedemann et, al., 2013 
and Micsonai et al., 2015. The experiments were carried out in the Laboratory of the 
Institute of Bioorganic Chemistry in Saarbruecken. 
 
3.2.12.2 Data analysis and plotting 
Acquired data by CD spectrometry was analysed and plotted by a web server-based 
called CD analysis and Plotting tool (CAPITO; https://capito.nmr.leibniz-fli.de//). It is 
assumed that for a given protein, the CD spectrum is the resultant of linear combination 
of basis spectra and, elements of the secondary structure for the given protein increases 
characteristcs of bands in wavelengh and intensity (Wiedemann et al, 2013) as shown 
in the following equation: 
 
[θ]λ= ∑ 𝑓𝑛 + 𝑆𝜆𝑛 + 𝑛𝑜𝑖𝑠𝑒                                                                        eq.3 
Where: 
λ: wavelength in nm 
[θ]: molar ellipticity   
𝑓𝑛: fraction of each secondary structure, n and, 
𝑆𝜆𝑛: ellipticity at each wavelength of each n
th  secondary structure. 
The sum of all fractions is 1. 
The result of the predicted secondary structure is compared with the 3D structure 
database of known proteins provided in proteins CD data bank (PCDDB) for more 
reliable results. Input data of CAPITO server is either; millidegrees (mdeg); mean 
residue extinction coeffiecient (∆ϵ in M-1 cm-1) or; mean residue ellipticity ([θ] in deg 
cm2 dmol-1). In the current study the default input has been used (mdeg). Furthermore, 




µM, 15 µM, and 20 µM). After that, the server runs Chou-Fasman-algorithm to predict 
the secodary structure of the peptide. Results are shown in a graph represents the 
spectral data into ∆ϵ or [θ] as a function of wavelength. Figure 11 shows a sample of 
secondary structure elements prediction of 100% α-helix, 100% β-sheet, and 100% 
Random coil (irregular). 
                        
    
Figure 11: Sample of pure secondary structure elements (α-helix, β-sheet, or random 
coil) of a protein. 
 
Besides the prediction of secondary structure elements, folding state of the protein 
being tested is estimated as a plot of spectral values at 200 nm versus 222 nm and 
according to PCDDB entries as shown in Figure 12. 
 






Figure 12: Estimation of folding state of sample protein. Uncolored squares represent 
entries by PCCDB whereas, colored circles represent the results obtained during 
experiment at different concentrations (for example). 
 
3.2.13 Statistical analysis 
All results were presented as boxplots and followed by table containing statistical 
parameters, average, confidence interval (CI), standard deviation and standard error of 
the mean (SEM). Statistical significance was analyzed using the Student’s two-tailed t-
test for normally distributed data and non-parametric test which is Mann-Whitney U 
test for not normally distributed data. Test of normal distribution of the data was 
performed by Shapiro-Wilk test, while Leven’s test was conducted to examine the 
equality of variances. Analyses of results and statistical tests were performed with SPSS 
software (IBM SPSS statistics data editor) version 25. Statistical significance was 
























Results and Discussion 
4.1 Results 
4.1.1 Influence of APP, AICD, and Aβ on cholesterol homeostasis 
Transcriptional effects of APP and its proteolytic fragments on the expression of 
cholesterol bio-synthesis genes and sterol regulatory binding protein (SREBP-1) and 
related genes, which are summarized in Table 11, were determined by employing qRT-
PCR in quantifying the gene expression as the first interest of the study. Cholesterol 
bio-synthesis process was reviewed in section 2.3.1 whereas, the impact of full length 
APP and its proteolytic fragments on cholesterol homeostasis was studied previously 
as shown in section 2.4.3. However, information regarding the direct impact of APP on 
gene expression of enzymes involved in cholesterol bio-synthesis process is still 
needed.         
 
Table 11: Detailed names of genes involved in the study. 
Gene Name 
HMGCS1 3-Hydroxy-3-MethylGlutaryl-CoA Synthase 1 
HMGCS2 3-Hydroxy-3-MethylGlutaryl-CoA Synthase 2 
HMGCR 3-Hydroxy-3-MethylGlutaryl-CoA Reductase 
MVK MeValonate Kinase 
PMVK PhosphoMeValonate Kinase 
MVD MeValonate (diphospho) Decarboxylase 
FDPS Farnesyl DiphosPhate Synthase 
FDFT Farnesyl-Diphoshate FarnesylTransferase  
SQLE SQuaLene Epoxidase 
LSS LanoSterol Synthase (2,3-oxidosqualene-lanosterol cyclase) 
SREBF1 Sterol Regulatory Element Binding transcription Factor 1 
SREBF2 Sterol Regulatory Element Binding transcription Factor 2 
SCAP 
Sterol regulatory element-binding protein Cleavage-Activating 
Protein 
INSIG Insulin Induced Gene 1 





4.1.1.1 Impact of APP 
Mouse embryonic fibroblasts-wild type (MEF-WT) was used as a control and compared 
with the results of MEF cells which are lacking amyloid precursor protein APP and 
APP homologues, APLP2 (MEF APP/APLP2-/-) as samples of the test. Results are 
shown in Figure 13 and statistics are summarized in Table 12.  
 
 
Figure 13: Quantitative determination of gene expression for genes involved in 
cholesterol biosynthesis pathway by using the real-time reverse transcriptase 
polymerase chain reaction (qRT-PCR) technique (n=13-16). β-actin was used as a 
housekeeping gene. Results were normalized to the housekeeping gene, and control and 
quantitative detection of gene expressions were calculated by employing the 2-ΔΔ 
method. Mouse embryonic fibroblasts- wild type cells MEF WT (control) and mouse 
embryonic fibroblasts lacking APP and APLP2, MEF APP/APLP2 -/- (sample). 
Boxplots represent; minimum, first quartile, median, third quartile, and maximum. 
Outliers represent 1.5 (circle) and 2 (star) times’ interquartile range. Horizontal line 
represent mean of controls. Statistical significance was determined using Student’s 
unpaired two-sided t-test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, and n.s., not 
significant).    
 








Table 12: Descriptive statistics of quantified MEF-WT (control) and MEF 
APP/APLP2 -/- (sample) genes. 
Gene Mean 




SEM p n 
Lower Upper 
Hmgcs1 
Control 1.0098 0.9276 1.0919 0.15420 0.03855 
0.007 
16 
Sample 0.7735 0.6256 0.9214 0.27761 0.06940 16 
Hmgcs2 
Control 0.9567 0.7543 1.1590 0.33483 0.09286 
0.044 
13 
Sample 1.2653 1.0231 1.5075 0.40082 0.11117 13 
Hmgcr 
Control 1.0105 0.9277 1.0934 0.15546 0.03886 
0.000109 
16 
Sample 0.6937 0.5667 0.8207 0.23838 0.05960 16 
Mvk 
Control 1.0206 0.9253 1.1158 0.16500 0.04410 
0.000195 
14 
Sample 0.7457 0.6473 0.8442 0.17052 0.04557 14 
Pmvk 
Control 1.0559 0.8751 1.2368 0.29925 0.08300 
0.000060 
13 
Sample 0.5041 0.3352 0.6731 0.27964 0.07756 13 
Mvd 
Control 1.0134 0.9228 1.1040 0.17003 0.04251 
7.239E-7 
16 
Sample 0.4797 03214 0.6381 0.29717 0.07429 16 
Fdps 
Control 1.0188 0.9121 1.1254 0.19255 0.04972 
0.085 
15 
Sample 0.7936 0.5500 1.0372 0.43994 0.11359 15 
Fdft 
Control 1.0255 0.8964 1.1546 0.21363 0.05925 
0.303 
13 
Sample 0.9112 0.7127 1.1097 0.32848 0.09110 13 
Sqle 
Control 1.0693 0.9413 1.1972 0.21168 0.05871 
0.702 
13 
Sample 1.1495 0.7214 1.5776 0.70842 0.19648 13 
Lss 
Control 1.0131 0.9314 1.0949 0.14162 0.03785 
0.490 
14 
Sample 0.9049 0.5846 1.2251 0.55467 0.14824 14 
 
Similarly, gene expression of sterol regulatory element binding protein (SREBP-1) 
genes are shown in Figure 14, while Table 13 summarizes the statistics of these genes.   
 
Figure 14: Quantitative determination of gene expression for genes involved in SREBP-
1 and related genes by using the real-time reverse transcriptase polymerase chain 
reaction (qRT-PCR) technique (n=6). β-actin was used as a housekeeping gene. Results 




were normalized to the housekeeping gene, and control and quantitative detection of 
gene expressions were calculated by employing the 2-ΔΔ method. Mouse embryonic 
fibroblasts- wild type cells MEF WT (control) and mouse embryonic fibroblasts lacking 
APP and APLP2, MEF APP/APLP2 -/- (sample). Boxplots represent; minimum, first 
quartile, median, third quartile, and maximum. Outliers represent 1.5 (circle) and 2 
(star) times’ interquartile range. Horizontal line represents mean of controls. Statistical 
significance was determined using Student’s unpaired two-sided t-test (* p ≤ 0.05, ** 
p ≤ 0.01, *** p ≤ 0.001, and n.s., not significant).    
 
 
Table 13: Descriptive statistics of quantified MEF-WT (control) and MEF APP/APLP2 
-/- (sample) genes. 
Gene Mean 




SEM p n 
Lower Upper 
Srebf1 
Control 1.0148 0.8001 1.2295 0.20460 0.08353 
0.029 
6 
Sample 1.5453 1.0538 2.0368 0.46830 0.19118 6 
Srebf2 
Control 1.0327 0.7074 1.3580 0.30997 0.12654 
0.205 
6 
Sample 0.8076 0.5321 1.0831 0.26256 0.10719 6 
Scap 
Control 1.0039 0.9010 1.1069 0.09806 0.04003 
0.014 
6 
Sample 0.8159 0.6911 0.9406 0.11887 0.04853 6 
Insig1 
Control 1.0077 0.8632 1.1522 0.13771 0.05622 
0.000356 
6 
Sample 0.5633 0.5280 0.5987 0.03370 0.01376 6 
S1p 
Control 1.0126 0.8270 1.1982 0.17689 0.07221 
0.243 
6 
Sample 0.8432 0.5453 1.1412 0.28395 0.11592 6 
 
Results in the figures above shows downregulation in the transcription of cholesterol 
bio-synthesis genes, but not for HMGCS2 and SREBF1, in case of APP absence. More 
results are shown in Table B-27 and B-40 – B-42 in the appendix. 
 
4.1.1.2 Impact of AICD 
In the same manner, the effect of AICD absence was investigated by mediating MEF 
APPΔCT15 that is lacking the last 15 amino acids of the APP C-terminus Figure 15 for 
cholesterol biosynthesis and Table 14 for relevant statistics. Details associated with this 






Figure 15: Quantitative determination of gene expression for genes involved in 
cholesterol biosynthesis pathway by using the real-time reverse transcriptase 
polymerase chain reaction (qRT-PCR) technique (n=13-15). β-actin was used as a 
housekeeping gene. Results were normalized to the housekeeping gene and control, and 
quantitative detection of gene expressions were calculated by employing the 2-ΔΔ 
method. Mouse embryonic fibroblasts- wild type cells MEF WT (control) and MEF 
APPΔCT15 that is lacking the last 15 amino acids of the APP C-terminus (sample). 
Boxplots represent; minimum, first quartile, median, third quartile, and maximum. 
Outliers represent 1.5 (circle) and 2 (star) times’ interquartile range. Horizontal line 
represents mean of controls. Statistical significance was determined using Student’s 
unpaired two-sided t-test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, and n.s., not 
significant).    
 
Table 14: Descriptive statistics of quantified MEF-WT (control) and MEF APPΔCT15 
(sample) genes. 
Gene Mean 




SEM p n 
Lower Upper 
Hmgcs1 
Control 0.9761 0.9286 1.0236 0.08223 0.02198 
0.374 
14 
Sample 1.0484 0.8847 1.2121 0.28347 0.07576 14 
Hmgcs2 
Control 1.0697 0.8025 1.3370 0.46288 0.12371 
0.000231 
14 
Sample 4.3969 2.9603 5.8336 2.48826 0.66501 14 
Hmgcr 
Control 1.0138 0.9188 1.1088 0.17147 0.04427 
0.001 
15 
Sample 0.6629 0.4746 0.8512 0.34005 0.08780 15 
Mvk 
Control 1.0043 0.9442 1.0644 0.10408 0.02782 
0.054 
14 













Control 1.0478 0.8527 1.2429 0.33791 0.09031 
0.001 
14 
Sample 0.6567 0.5281 0.7852 0.22262 0.05950 14 
Mvd 
Control 1.0090 0.9131 1.1049 0.16611 0.04439 
0.009 
14 
Sample 0.7450 0.5726 0.9173 0.29845 0.07976 14 
Fdps 
Control 1.0228 0.9018 1.1439 0.2163 0.05645 
0.000056 
15 
Sample 0.6782 0.5825 0.7739 0.17282 0.04462 15 
Fdft 
Control 0.9939 0.8643 1.1235 0.21445 0.05948 
0.033 
13 
Sample 1.2477 1.0400 1.4555 0.34377 0.09534 13 
Sqle 
Control 1.0185 0.8590 1.1780 0.26397 0.07321 
0.069 
13 
Sample 1.2996 1.0209 1.5783 0.46116 0.12790 13 
Lss 
Control 1.0196 0.9072 1.1320 0.19464 0.05202 
0.869 
14 
Sample 0.999 0.7709 1.2288 0.39656 0.10598 14 
 
The impact of AICD on SREBP-1 and related genes are shown in Figure 16 and Table 
15 for relevant statistics. Details shown in Tables B-26, B-38 and B-39 in the appendix. 
 
Figure 16: Quantitative determination of gene expression for genes involved in SREBP-
1 and related genes by using the real-time reverse transcriptase polymerase chain 
reaction (qRT-PCR) technique (n=5). β-actin was used as a housekeeping gene. Results 
were normalized to the housekeeping gene, and control and quantitative detection of 
gene expressions were calculated by employing the 2-ΔΔ method. Mouse embryonic 
fibroblasts- wild type cells MEF WT (control) and MEF APPΔCT15 that is lacking the 
last 15 amino acids of the APP C-terminus (sample). Boxplots represent; minimum, 
first quartile, median, third quartile, and maximum. Outliers represent 1.5 (circle) and 
2 (star) times’ interquartile range. Horizontal line represents mean of controls. 
Statistical significance was determined using Student’s unpaired two-sided t-test (* p ≤ 








Table 15: Descriptive statistics of quantified MEF-WT (control) and MEF APPΔCT15 
(sample) genes. 
Gene Mean 
95% CI for mean Std. 
deviation 
SEM p n 
Lower Upper 
Srebf1 
Control 1.0131 0.7834 1.2428 0.18502 0.08274 
0.112 
5 
Sample 1.3297 0.8946 1.7648 0.35041 0.15671 5 
Srebf2 
Control 1.0100 0.8097 1.2103 0.16132 0.07214 
0.700 
5 
Sample 1.0595 0.7791 1.3399 0.22584 0.10100 5 
Scap 
Control 1.0010 0.9379 1.0641 0.05083 0.02273 
0.037 
5 
Sample 1.4203 1.0397 1.8009 0.30650 0.13707 5 
Insig1 
Control 1.0188 0.7462 1.2913 0.21948 0.09816 
0.594 
5 
Sample 0.9465 0.7096 1.1835 0.19082 0.08534 5 
S1p 
Control 1.0031 0.8939 1.1123 0.08794 0.03933 
0.010 
5 
Sample 1.4381 1.1561 1.7200 0.22708 0.10155 5 
 
Significant decrease in the expression of rate-limit enzyme, HMGCR, was detected 
with a non-significant increase of SREBP-1 and related genes. 
4.1.1.3 Impact of Aβ 
Finally, the transcriptional regulation of Aβ was studied in MEF PS1res cells (control), 
which are lacking mouse PS1 and PS2 but expressing human PS1 and MEF PS1/PS2 -
/- that are lacking mouse PS1 and PS2 (sample), as shown in Figure 17, statistical 
analysis of the obtained results are summarized in Table 16. More details shown in 
Tables B-14 – B-22, B-25 and B-35 – B-37 in the appendix. 
 
 
Figure 17: Quantitative determination of gene expression for genes involved in 










polymerase chain reaction (qRT-PCR) technique (n=10-14). β-actin was used as a 
housekeeping gene. Results were normalized to the housekeeping gene, and control and 
quantitative detection of gene expressions were calculated by employing the 2-ΔΔ 
method. Mouse embryonic fibroblasts cells which are lacking mouse PS1 / PS2 and 
expressing human PS1 MEF PS1res (control) and MEF PS1/PS2 -/- which are lacking 
mouse PS1 and PS2 (sample). Boxplots represent; minimum, first quartile, median, 
third quartile, and maximum. Outliers represent 1.5 (circle) and 2 (star) times’ 
interquartile range. Horizontal line represent mean of controls. Statistical significance 
was determined using Student’s unpaired two-sided t-test (* p ≤ 0.05, *** p ≤ 0.001, 
and n.s., not significant).    
 
Table 16: Descriptive statistics of quantified MEF PS1res. (control) and MEF PS1/PS2 
-/- (sample) genes. 
Gene Mean 




SEM T.Test n 
Lower Upper 
Hmgcs1 
Control 1.0888 0.8836 1.2940 0.35539 0.09498 
0.000059 
14 
Sample 2.3597 1.8780 2.8414 0.83434 0.22299 14 
Hmgcs2 
Control 0.9613 0.8143 1.1084 0.23144 0.06681 
0.593 
12 
Sample 1.0355 0.7724 1.2986 0.41406 0.11953 12 
Hmgcr 
Control 1.0371 0.8701 1.2040 0.28912 0.07727 
0.000080 
14 
Sample 1.6571 1.4238 1.8904 0.40407 0.10799 14 
Mvk 
Control 1.0893 0.9093 1.2693 0.29780 0.08260 
0.234 
13 
Sample 0.9640 0.8311 1.0969 0.21991 0.06099 13 
Pmvk 
Control 1.0434 0.7795 1.3072 0.43658 0.12109 
0.407 
13 
Sample 1.2397 0.8065 1.6729 0.71686 0.19882 13 
Mvd 
Control 1.0029 0.8647 1.1412 0.22885 0.06347 
0.726 
13 
Sample 0.9714 0.8357 1.1071 0.22455 0.06228 13 
Fdps 
Control 0.9538 0.7939 1.1137 0.27693 0.07401 
0.000038 
14 
Sample 1.4861 1.3177 1.6545 0.29161 0.07793 14 
Fdft 
Control 1.0055 0.8748 1.1362 0.22640 0.06051 
0.037 
14 
Sample 1.2538 1.0471 1.4604 0.35796 0.09567 14 
Sqle 
Control 1.1540 0.9326 1.3754 0.32953 0.09936 
0.122 
11 
Sample 1.6495 1.0225 2.2765 0.93324 0.28138 11 
Lss 
Control 1.0435 0.8035 1.2834 0.33541 0.10607 
0.467 
10 
Sample 1.1700 0.8684 1.4717 0.42172 0.13336 10 
 
Rate-limit enzyme, HMGCR, showed a statisticly significant upregulation induced by 
the absence of Aβ. Likewise, the impact of Aβ on SREBP-1 and relevant genes are 
elucidated in Figure 18, while statistical analysis results are detailed in Table 17. More 





Figure 18: Quantitative determination of gene expression for genes involved in SREBP-
1 and related genes by using the real-time reverse transcriptase polymerase chain 
reaction (qRT-PCR) technique (n=5). β-actin was used as a housekeeping gene. Results 
were normalized to the housekeeping gene, and control and quantitative detection of 
gene expressions were calculated by employing the 2-ΔΔ method. Mouse embryonic 
fibroblasts cells which are lacking mouse PS1 / PS2 and expressing human PS1 MEF 
PS1res (control) and MEF PS1/PS2 -/- which are lacking mouse PS1 and PS2 (sample). 
Boxplots represent; minimum, first quartile, median, third quartile, and maximum. 
Outliers represent 1.5 (circle) and 2 (star) times’ interquartile range. Horizontal line 
represents mean of controls. Statistical significance was determined using Student’s 
unpaired two-sided t-test (* p ≤ 0.05, *** p ≤ 0.001, and n.s., not significant).    
 
Table 17: Descriptive statistics of quantified MEF PS1res. (control) and MEF PS1/PS2 
-/- (sample) genes. 
Gene Mean 
95% CI for mean Std. 
deviation 
SEM p n 
Lower Upper 
Srebf1 
Control 1.0132 0.7982 1.2282 0.17317 0.07744 
0.001 
5 
Sample 0.5709 0.4749 0.6669 0.07733 0.03458 5 
Srebf2 
Control 1.0192 0.7448 1.2936 0.22100 0.09883 
0.094 
5 
Sample 1.2349 1.1957 1.2740 0.03152 0.01409 5 
Scap 
Control 1.0380 0.6615 1.4145 0.30323 0.13561 
0.904 
5 
Sample 1.0683 0.5072 1.6294 0.45188 0.20209 5 
Insig1 
Control 1.0125 0.7975 1.2275 0.17314 0.07743 
0.030 
5 
Sample 2.3509 1.8696 2.8322 1.31266 0.58704 5 
S1p 
Control 1.0021 0.9102 1.0941 0.07409 0.03313 
0.596 
5 







4.1.2 Influence of cholesterol on Aβ degradation 
In the second phase of the study, the proposed function of cholesterol as a triggering 
factor for the enzymes involved in the process of Aβ degradation was examined. This 
was achieved by using neuroblastoma 2a cells (N2a) with the emphasis on the 
enzymatic activity of IDE. The reason of studying IDE is because this enzyme can 
degrade Aβ in the trans-membrane and the secreted IDE can degrade Aβ in the cytosol. 
Due to the fact that Aβ can be found on cell membrane and between cells (extracellular 
space), the impact of cholesterol was then studied in living N2a cells and culture 
medium, respectively, by quantifying the Aβ remaining after incubation with 
cholesterol on western blots.  
 
4.1.2.1 Impact of cholesterol on Aβ degradation in living N2a cells 
Determination of total Aβ degradation in living neuroblastoma 2a WT cells was 
measured by western blot technique as previously described in the methods section 
(3.2.4). The human sequence of synthetic peptide was incubated for 6 h with N2a cells 
at a concentration of 0.5 µg/ml with and without cholesterol (100 µM) in reduced 
culture medium (cholesterol in culture medium is neglected) to study its impact on Aβ 
degradation. Results of this experiment are shown in Figure 19, while Table 18 
contains statistical analysis outcomes. 
 
Figure 19: Impact of cholesterol on Aβ40 degradation in living N2a cells. Confluent 
mouse neuroblastoma N2a cells were incubated with reduced culture medium (DMEM 
/ 0.1% FCS) for 6 h. Culture medium is reduced to control cell number. After that cells 
             Aβ      





were then incubated with ethanol (control) or with cholesterol and ethanol (sample) at 
a concentration of 100 µM for 18 h. The human Aβ40 peptide sequence at a 
concentration of 0.5 µg/ml was added to control and sample and incubated for 6 h 
before quantification. Western blot analysis was used to quantify the remaining Aβ40 
peptides using the W02 antibody (n=16). 
Boxplots represent; minimum, first quartile, median, third quartile, and maximum. 
Horizontal line represents mean of control. Statistical significance was determined 
using Student’s unpaired two-sided t-test (*** p ≤ 0.001).    
 
More details are shown if Figures C-1 – C-3 and Tables C-1 – C-6 in the appendix. 
 
Table 18: Descriptive statistics of the remaining Aβ in N2a living cells. 
 Control Cholesterol 
Mean 100.0175 79.2825 
95% CI for 
mean 
Lower 96.3137 75.5786 
Upper 103.7214 82.9863 
Std. deviation 6.95080 6.95080 
SEM 1.73770 1.73770 
p 2.0426E-9 
n 16 16 
 
Degraded Aβ was increased to around 20% with statisticaly significant result as shown 
by the reduction of recombinant human Aβ due to the presence of cholesterol. 
 
4.1.2.2 Impact of cholesterol on Aβ degradation in N2a cells’ culture medium 
Quantification of the non-degraded amyloid peptide was carried out by Western Blot 
using the W02 antibody to detect the human synthetic peptide in the culture medium of 
N2a WT cells as already described. Different incubation times were first examined to 
choose the best incubation time for future experiments. Moreover, the human amyloid 
peptide concentration was set at 0.5 µg/ml as shown in Figure 20. Because this 
procedure had been already established (Mett, 2017) therefore, the experiment was 
carried out once. According to these results, incubation time was set to 24 h. Detailed 








                 
 
Figure 20: Effect of incubation time on Aβ40 degradation in culture media of N2a WT 
cells. Confluent mouse neuroblastoma N2a cells were incubated with reduced culture 
medium (DMEM / 0.1 % FCS) for 24 h. The human Aβ40 peptides sequence were 
incubated with the cells at a concentration of 0.5 µg/ml. The cells were tested at 
different times. Western blot analysis with the W02 antibody was used to quantify the 
remaining Aβ peptides. 
Error bars represent the standard deviation (±2.6, 0.85, 0.4, and 3.7 %) for incubation 
times of 8, 12, 24, and 30 h, respectively. 
 
The influence of cholesterol at a concentration of 100 µM on Aβ40 in the culture 
medium on N2a WT cells was measured as shown in Figure 21 and summarized 


























Figure 21: Influence of cholesterol on Aβ40 degradation in culture media of N2a WT 
cells. Confluent mouse neuroblastoma N2a cells were incubated with reduced culture 
medium (DMEM / 0.1 % FCS) for 24 h. The human Aβ40 peptides sequence at a 
concentration of 0.5 µg/ml were incubated with the reduced culture medium only for 
24 h with the addition of ethanol (control) or cholesterol and ethanol (sample) at a 
concentration of 100 µM. Western blot analysis with the W02 antibody was used to 
quantify the remaining Aβ peptides (n=13). 
Boxplots represent; minimum, first quartile, median, third quartile, and maximum. 
Horizontal line represent mean of control. Statistical significance was determined 
using Student’s unpaired two-sided t-test (*** p ≤ 0.001).    
 
Table 19: Statistics of the remaining Aβ40 in N2a culture medium. 
 Control Cholesterol 
Mean 100.0302 80.5698 
95% CI for 
mean 
Lower 94.0189 74.5585 
Upper 106.0415 86.5811 
Std. deviation 9.94759 9.94759 
SEM 2.75896 2.75896 
p 0.000043 




 Obviously, the impact of secreted IDE on the degradation of Aβ is shown in the 
extracellular space in the previous figure. However, in order to confirm the hypothesis 
that IDE is the main Aβ degrading enzyme in the extracellular space, the same 
*** 
             Aβ      




experiment was repeated but with the introduction of IDE knockdown N2a cells. 
Experiments were carried out with living cells and with culture medium to compare 
the results as shown in Figure 22 and relevant statistics in Table 20 (Detailed results 
are shown in Figures C-8 – C-10 and Tables C-15 – C-20 in the appendix), and Figure 
23 and pertinent statistics in Table 21 (Detailed of results are presented in Figures C-
11 – C-13 and Tables C-21 – C-26 in the appendix), respectively.  
  
 
Figure 22: Impact of cholesterol on Aβ40 degradation in living N2a IDE knockdown 
cells. Confluent mouse neuroblastoma N2a IDE knockdown cells were incubated with 
reduced culture medium (DMEM / 0.1% FCS) for 6 h to control cell number, then 
incubated with ethanol (control) or with cholesterol and ethanol at a concentration of 
100 µM (sample) for 18 h. The human Aβ40 peptide sequence at a concentration of 
0.5 µg/ml was added to control and sample and incubated for 6 h before quantification. 
Western blot analysis was used to quantify the remaining Aβ40 peptides using the 
W02 antibody (n=16). 
Boxplots represent; minimum, first quartile, median, third quartile, and maximum. 
Horizontal line represent mean of control. Statistical significance was determined 
using Student’s unpaired two-sided t-test (* p ≤ 0.05).    
 
Impeded activity of IDE resulted in a limited degradation potential of Aβ to only 5% 
intracellularly. 
               Aβ 





Table 20: Statistics of the remaining Aβ40 in living N2a IDE knockdown cells. 
 
 Control Cholesterol 
Mean 100.0911 94.7089 
95% CI for 
mean 
Lower 96.8235 91.4414 
Upper 103.3586 97.9765 
Std. deviation 6.13206 6.13206 
SEM 1.53302 1.53302 
p 0.019 





Figure 23: Influence of cholesterol on Aβ40 degradation in culture media of N2a IDE 
knock down (KD) cells. Confluent mouse neuroblastoma N2a KD cells were incubated 
with reduced culture medium (DMEM / 0.1 % FCS) for 24 h. The human Aβ40 
peptides sequence at a concentration of 0.5 µg/ml were incubated with the reduced 
culture medium only, for 24 h with the addition of ethanol (control) or cholesterol 
(sample) at a concentration of 100 µM. Western blot analysis with the W02 antibody 
was used to quantify the remaining Aβ peptides (n=13). 
Boxplots represent; minimum, first quartile, median, third quartile, and maximum. 
Horizontal line represent mean of control. Statistical significance was determined 
using Student’s unpaired two-sided t-test (*** p ≤ 0.001).    
 
 
               Aβ 





Significant increase in the accumulation of Aβ (29%) is achieved due to the absence 
of IDE. 
 
Table 21: Statistics of the remaining Aβ40 in culture medium of N2a IDE knockdown 
cells. 
 Control Cholesterol 
Mean 100.0199 129.7801 
95% CI for 
mean 
Lower 95.8446 125.6048 
Upper 104.1952 133.9554 
Std. deviation 6.90937 9.94759 
SEM 1.91631 2.75896 
P 7.6624E-11 
N 13 13 
 
 
4.1.2.3 Effects of cholesterol on IDE gene expression 
According to the results obtained in the previous section, cholesterol exhibited an 
obvious role in up-regulating IDE enzymatic activity. In order to investigate whether 
cholesterol influences IDE at the transcriptional level, IDE gene expressions (IDE59) 
were analyzed in the presence of cholesterol using qRT-PCR. The investigation was 
carried out using N2a-WT cells which are incubated cholesterol at a concentration of 
100 µM, for 18 h, then total RNA and subsequent cDNA was isolated as described 
previously. Two housekeeping genes were employed in the investigation: (1) β-actin 
and (2) Polr2 (Figure 24 and Table 22 for relevant statistics). More details are shown 
in Tables B-46 – B-52 in the appendix. 
 
 
Figure 24: Effects of cholesterol on IDE gene expression as compared with β-actin and 





neuroblastoma cells were incubated with cholesterol at a concentration of 100 µM. 
RT-PCR analysis was used to quantify IDE gene expression (n=12). Results were 
normalized to the housekeeping gene and control (no cholesterol) and quantitative 
detection of gene expression was calculated using the 2-ΔΔ method. Significance level, 
** p ≤0.01, n.s = not significant. 
 
Table 22: Statistics of IDE gene expression test. 
 
Upregulation of IDE gene expression was statisticaly significant with β-actin and non-
significant with Polr2 housekeeping genes due to the influence of cholesterol. 
 
4.1.2.3.1 Effects of cholesterol on IDE promoter activity 
Cholesterol’s effects on increased IDE gene expression were demonstrated by 
measuring IDE promoter activity using N2a WT cells incubated with and without 
cholesterol (control). The process included transient transfection with a reporter 
plasmid that contained the gene encoding Gaussia luciferase controlled by the IDE 
promoter, whereas the gene encoding SEAP was controlled by the active promoter as 
previously described in the methods section. Gaussia luciferase and SEAP signals were 
determined for the incubated cells’ culture medium, and the resulting data were 
normalized as a ratio of the measurement of Gaussia luciferase for each sample to that 
of SEAP activity. Figure 25 summarizes normalized results of cholesterol’s effects on 





95% CI for mean Std. 
deviation 




Control 1.0040 0.9527 1.0554 0.09267 0.02393 
0.004 
15 
Sample 1.1722 1.0673 1.2771 0.18941 0.049891 15 
Polr2 
Control 1.0358 0.9368 1.1347 0.16378 0.04542 
0.115 
13 





Figure 25: Influence of cholesterol on IDE59 promoter activity in N2a WT cells. 
Confluent mouse neuroblastoma wild type cells were incubated with Opti-MEM 
medium, lipofectamine (transfection reagent), and vector solution for 6 h, then 
incubated with reduced medium (DMEM / 0.1 % FCS) to control cell number and 
ethanol (control) or ethanol and cholesterol (sample) at a concentration of 100 µM, for 
16 h. Incubation media then collected and the assay solution was prepared according to 
the manufacturer’s instructions (n=12). 
Boxplots represent; minimum, first quartile, median, third quartile, and maximum. 
Horizontal line represents mean of control. Statistical significance was determined 
using Student’s unpaired two-sided t-test (*** p ≤ 0.001).  
   
Table 23: Statistics of IDE59 promoter activity in N2a WT cells. 
 Control Cholesterol 
Mean 100.0350 123.7650 
95% CI for 
mean 
Lower 92.7980 116.7650 
Upper 107.2718 131.0018 
Std. deviation 11.38992 11.38992 
SEM 3.28799 3.28799 
p 0.000041 
n 12 12 
 
Obvious enhancement in the transcriotion of IDE gene is shown (24%) as a 
consequence of cholesterol’s impact. 
 
 




4.1.2.4 Effects of cholesterol on IDE protein levels 
In order to measure cholesterol’s effects on IDE membrane and extracellular protein 
levels, western blots technique was employed to quantify IDE protein in N2a WT cells 
as shown in Figure 26 and statistics in Table 24 for intracellular IDE protein level, 
whereas Figure 27 and dependent statistics in Table 25, demonstrates the influence of 
cholesterol on extracellular IDE protein level. 
 
Figure 26: Influence of cholesterol on IDE protein level in N2a WT cells lysate. 
Confluent mouse neuroblastoma cells were cultured in reduced culture medium 
(DMEM / 0.1 FCS) for 6 h, then incubated with ethanol (control) or cholesterol and 
ethanol (sample) at a concentration of 100 µM, for 18 h, in reduced culture medium. 
Cell lysate were quantified by western blot using ST1120 secondary antibody (n=15).  
Boxplots represent; minimum, first quartile, median, third quartile, and maximum. 
Horizontal line represent mean of control. Statistical significance was determined 
using Student’s unpaired two-sided t-test (*** p ≤ 0.001).    
 
Table 24: Statistics of IDE protein level in N2a WT cells lysate. 
 Control Cholesterol 
Mean 100.0278 117.9722 
95% CI for 
mean 
Lower 93.3877 111.3321 
Upper 106.6679 124.6123 
Std. deviation 11.99049 11.99049 
SEM 3.09593 3.09593 
p 0.000323 
N 15 15 
Details are shown in Figures C-14, 16, 17 and Tables C-27, 29, 31, 33-35 in the 
appendix. 
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Cholesterol has induced the increase of IDE level to about 18% in the cytosol of N2a 




Figure 27: Influence of cholesterol on IDE protein level in N2a WT cells culture 
medium. Confluent mouse neuroblastoma cells were cultured in reduced culture 
medium (DMEM / 0.1 FCS) for 6 h, then incubated with ethanol (control) or cholesterol 
(sample) at a concentration of 100 µM, for 18 h, in reduced culture medium. Culture 
medium was quantified by western blot using ST1120 secondary antibody (n=14).  
Boxplots represent; minimum, first quartile, median, third quartile, and maximum. 
Horizontal line represent mean of control. Statistical significance was determined 
using Student’s unpaired two-sided t-test (* p ≤ 0.05).    
 
Table 25: Statistics of IDE protein level in N2a WT cells culture medium. 
 Control Cholesterol 
Mean 100.0029 115.4971 
95% CI for 
mean 
Lower 89.6251 105.1194 
Upper 110.3806 125.8749 
Std. deviation 17.97381 17.97381 
SEM 4.80370 4.80370 
P 0.031 
N 14 14 
Details are shown in Figure C-15-17 and Tables C-28, 30, 32, 36-38 in the appendix. 
Protein level of IDE is increased at a rate of around 15% due to the presence of 
cholesterol in the extracellular space of N2a cells. 
          IDE 





4.1.2.5 Effects of cholesterol on IDE protein stability  
Maintaining the folded (stable) state of IDE proteins in the presence of cholesterol was 
investigated to study cholesterol’s effects on IDE protein conformation by using 
cycloheximide (inhibitor of protein biosynthesis). Western blotting was used to quantify 
intracellular (Figure 28 and statistics in Table 26) and extracellular (Figure 29 and 
statistics in Table 27) IDE proteins in the presence of cholesterol.  
 
 
Figure 28: Effect of cholesterol on IDE protein stability in N2a WT cells lysate (n=15). 
Confluent N2a WT cells were cultured in reduced culture medium (DMEM / 0.1 % 
FCS), then with cycloheximide at a concentration of 20 µg/ml, for 8 h. After that cells 
were incubated with cycloheximide and with ethanol (control) or with ethanol and 
cholesterol at a concentration of 100 µM (sample), for 16 h in reduced culture medium. 
Detection by western blot analysis was used to quantify IDE level in lysate. Asterisks 
show statistical significance compared to control (*** p ≤0.001). 
 
Table 26: Statistics of IDE protein stability in N2a WT cells lysate. 
 Control Cholesterol 
Mean 100.0040 129.1960 
95% CI for 
mean 
Lower 88.4172 117.6092 
Upper 111.5908 140.7828 
Std. deviation 20.92303 20.92303 
SEM 5.40230 5.40230 
p 0.001 
n 15 15 
*** 
                  IDE 
      Cholesterol         -        + 







Figure 29: Effect of cholesterol on IDE protein stability in N2a WT cells culture 
medium. Confluent N2a WT cells were cultured in reduced culture medium (DMEM 
/ 0.1 % FCS), then with cycloheximide at a concentration of 20 µg/ml, for 8 h. After 
that cells were incubated with cycloheximide and with ethanol (control) or with ethanol 
and cholesterol at a concentration of 100 µM (sample), for 16 h in reduced culture 
medium. Detection by western blot analysis was used to quantify IDE level in culture 
medium (extracellular) (n=15). Asterisks show statistical significance compared to 
control (** p ≤0.01). 
 
Table 27: Statistics of IDE protein stability in N2a WT cells culture medium. 
 Control Cholesterol 
Mean 100.0318 130.3682 
95% CI for 
mean 
Lower 85.0444 115.3808 
Upper 115.0192 145.3556 
Std. deviation 27.06376 27.06376 
SEM 6.98783 6.98784 
p 0.005 
n 15 15 
 
Results showed that cholesterol participated in enhancing the resistance of IDE to 
cycloheximide and hence increasing its stability at a rate of around 29% and 30% in 
intracellular and exracellular space of N2a cells, respectively. Detailed results of 
intracellular IDE are presented in Figures C-18 – C-20 and Tables C-39 – C- 44, while 
extracellular IDE details are shown in Figures C-21 – C-23 and Tables C-45 C-50 in 
the appendix. 
** 
                  IDE 
      Cholesterol         -        + 





4.1.2.6 Effects of cholesterol on IDE activity 
The direct effects of cholesterol on IDE activity were measured for the purpose of 
studying the role of cholesterol on IDE from different aspects. Enzymatic activity of 
recombinant human IDE in the presence of cholesterol was evaluated after incubation 
for 15 min. After that period, the Mca-RPPGFSAFK (Dnp)-OH substrate was added 
and the enzymatic activity was measured. Furthermore, PC 18:0 was utilized to 
confirm the role of lipids on IDE activity. Figure 30 shows the results of cholesterol, 
and cholesterol and PC 18:0. Activation of IDE occurs in the presence of PC 18:0 with 
higher fluorescence intensity (starting at around 1000 AU) and by cholesterol with less 
extent (around 400 AU) while, ethanol (control) showed no impact on IDE activity. 

























































Figure 30: Effect of cholesterol on IDE protein activity. Recombinant human IDE 
enzyme was pre-incubated with ethanol (control) or ethanol and cholesterol at a 
concentration of 100 µM (sample) for 15 min. in vitro, then substrate Mca-
RPPGFSAFK (Dnp) -OH was added and fluorescence was measured (a.) and slope 
(b.), and (c) with the addition of PC18:0 at a concentration of 150 µM to the control 
and sample and the slope (d.). The vast difference in fluorescence intensity in (b) and 
(d) is due to the use of PC 18:0. Error bars represent the standard deviation of the mean 
(n = 3). n.s. = not significant. 
 
Obvious increase in IDE activity is observed due to the impact of cholesterol and 
PC18:0 lipid.  
 
4.1.3 Antimicrobial activity of Aβ 
As the third aim of the study, viability of nematode in the presence of Aβ are shown in 
Figure 31 at different Aβ concentrations in addition to negative and positive (ethanol) 
controls for comparison purposes. Obviously, it can be seen in Figure 31 that the 
peptide has not affected viability of S. feltiae regardless of the peptide concentration. 


















































Figure 31: Antimicrobial activity of Aβ against S. feltiae. Three concentrations of Aβ 
(1000, 1500, and 2000 nM) were incubated with nematodes in addition to the control 
sample (0 Aβ). Three independent experiments (n=9) were carried out at every 
concentration.  
Boxplots represent; minimum, first quartile, median, third quartile, and maximum. 
Horizontal line represents mean of control. n.s. = not significant. 
 
Table 28: Statistics of S. feltiae viability test. 
 
Aβ concentration, nM 0 1000 1500 2000 
Mean 100.0013 101.1786 101.1161 100.7040 
95% CI for 
mean 
Lower 97.83 99.3965 97.2274 97.5793 
Upper 102.18 102.9607 105.0048 103.8287 
Std. deviation 2.82787 2.31846 5.05902 4.06508 
SEM 0.94262 0.77282 1.68634 1.35503 
T.Test  0.348 0.574 0.676 
n 9 9 9 9 
 
Similarly, results from bacteria strands and fungus are shown in Figure 32 a., b. and c. 
for Escherichia coli, Candida albicans, and Saccharomyces cerevisiae respectively. 
Five concentrations of Aβ were used using sequential dilution method, these 









were normalized to the control sample in which there was no added recombinant Aβ 






0 187 375 750 1500 3000 
Mean 102.9292 78.1608 61.5008 57.2950 51.4975 50.7442 
95% CI 
for mean 
Lower 95.4633 71.8063 49.5002 48.8441 38.8846 34.7015 
Upper 110.3951 84.5153 73.5015 65.7459 64.1104 66.7868 
Std. deviation 6.01285 10.00125 18.88761 13.30083 19.85126 25.24928 
SEM 2.68903 2.88711 5.45238 3.83962 5.730565 7.28884 
p  0.000129 0.000007 0.000003 0.002* 0.000433 
n 5 12 12 12 12 12 
















0 187 375 750 1500 3000 
Mean 99.7840 87.2408 104.1708 64.3667 86.3508 57.1833 
95% CI 
for mean 
Lower 86.5305 69.0147 91.4171 46.4137 75.1576 39.4122 
Upper 113.0375 105.4670 116.9245 82.3196 97.5440 74.9545 
Std. deviation 18.52706 28.68589 20.07289 28.25588 17.61682 27.96983 
SEM 5.85877 8.28090 5.79454 8.15677 5.08554 8.07419 
p  0.248 0.603 0.003 0.097 0.001 







0 187 375 750 1500 3000 
Mean 99.9782 111.8676 106.1550 105.5400 103.9416 103.3108 
95% CI 
of mean 
Lower 87.4803 106.2109 98.4696 98.0413 98.3170 93.7119 
Upper 112.4760 117.5243 113.8404 105.9783 109.5662 112.9097 
Std. deviation 18.60329 12.42705 10.74348 11.80218 12.68588 15.88450 
SEM 5.60910 2.71181 3.397387 3.40700 2.704639 4.40557 
P  0.076 0.944* 0.409 0.703* 0.640 
N 11 21 10 12 22 13 
*) Mann-Whitney U test was used because the data were not normally distributed. 
 
Figure 32: Antimicrobial activity of Aβ against (a) E. coli at 0.5 x 106 cells per well, 
(b) C. albicans at 2.5 x 103 cells per well, and (c) S. cerevisiae at 0.5 x 106 cells per 
well. Five concentrations of Aβ (3000, 1500, 750, 375, and 187 nM) were incubated 
with these strands in addition to the negative and positive controls (mixture of 10,000 
units penicillin, 10 mg streptomycin and 25 µg amphotericin). Three individual 
experiments for every concentration were investigated. Boxplots represent; minimum, 












first quartile, median, third quartile, and maximum. Outliers represent 1.5 (circle) and 
2 (star) times’ interquartile range. Horizontal line represents mean of controls. 
Statistical significance was determined using Student’s unpaired two-sided t-test (* p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.001, and n.s., not significant).    
 
Results with E. coli indicated a dose-dependent effects on cell viability. While, it can 
be noted that the standard deviation is high in the results of C. albicans, this can be 
attributed to biological or technical variability. Finally, results with S. cerevisiae 
revealed no inhibition on cell growth except for a slight enhancement. 
 
4.1.4 Nutrients as a therapeutic target against Aβ  
In the previous sections, Aβ has been investigated to determine factors affecting its 
degradation and clearance from cells and hence prevent the early onset of AD. It has 
been examined as an AMP. In this section, in vitro studies have been considered which 
comprise the use of chemical compounds that can assist in preventing Aβ accumulation. 
Organic and inorganic substances have been used to study their impact on Aβ 
aggregation. CD spectrometry has been employed for this purpose where recombinant 
human Aβ40 has been monomerized (details in section 3.2.9) for further using as 
control or to incubate with a specific compound. Changes in Aβ’s secondary structure 
have been used as an indicator of accumulation as previously described in section 
3.2.12.2. Conformational switching from α-helix or random coil to a β-sheet is 
considered an indicator of peptide misfolding and aggregation (Serpell, 1999; Adessi 
and Soto, 2002; Funke and Willbold, 2012; Nie et al., 2011). The compound that 
maintains Aβ in a monomerized state or impairs β-sheet accumulation has been 
suggested as a therapeutic compound or supplement for curing AD. Spectra at 222 nm 
are an indication of the α-helical secondary structure, while spectra at 212 and 205 nm 
are an indication of β-sheet and random coils, respectively (Birthwhistle, 2012). 
Various groups of compounds representing humans’ daily dietary intake has been 
selected in order to examine their impact on Aβ accumulation as shown in the next sub-
sections. 
 
4.1.4.1 Impact of Vitamin C and Vitamin E 
Ascorbic acid (CAS no. 50-81-7; molecular weight 176.12 g/mol; Figure 33 a.) and α-




b.) was incubated with 10 µM of Aβ for 24 h, and changes in the secondary structure 
are shown in Figure 34 a and b, respectively. 
 
a.     
                                           
                                                    
                b.                             
 
 
             
 
             Figure 33: Chemical structure of (a.) L-ascorbic acid and (b.) α-tocotrienol. 
 
Every CD signal data set was analyzed and presented in two panels in the same figure; 
the first panel (upper panel) represents CD signals distributed along the far UV range 
(190–260 nM), and the second panel (lower panel) shows the peptide’s predicted state 
at these wavelengths. The peptide in its native state is folded and unfolded when 
conformational changes, including stacking or accumulation of β-sheets, occur. 
Generaly, higher doses of ascorbic acid or α-tocotrienol has reduced the accumulation 



































Figure 34: Changes in Aβ‘s secondary structure resulting from the effects of (a) L-
Ascorbic acid and (b) C29H44O2 (both at 15 and 20 µM as shown above) CD spectrum 
and (lower panel) prediction of peptide state. Spectra at 222 or 208 nm indicate α-helix, 
while spectra at 212 nm indicate β-sheet, and at 205 nm indicates a random coil.   
 
4.1.4.2 Effects of tellurite compounds 
Potassium tellurate hydrate (K2TeO4.H2O, Cas No. 314041-10-6, molecular weight, 
269.79 g/mol) and sodium tellurite (Na2TeO3, Cas no. 10102-20-2, molecular weight 
221.577 g/mol) were used in the study of Aβ accumulation. CD signals are shown in 
Figure 35 a and b, respectively. 






























Figure 35: Effects of (a) K2TeO4.H2O and (b) Na2TeO3, on Aβ aggregation. Ten 
micromolar of Aβ was incubated with each compound at concentrations of 10, 15, and 
20 µM. Control represents Aβ alone. 
 
Higher concentrations of potassium tellurate hydrate and sodium tellurite have reduced 
the accumulation of Aβ. 
 
4.1.4.3 Effect of chloride compounds 
A series of selected chloride compounds were used in the experiments, in which these 
compounds’ characteristics are presented in Table 29. 
 
Table 29: Properties of chloride compounds. 
Compound name Molecular formula CAS no. Molecular weight, g/mol 
Lithium Chloride LiCl 7447-41-8 42.39 
Rubidium Chloride RbCl 7791-11-9 120.918 
Sodium Chloride NaCl 7647-14-5 58.44 
Cupric Chloride CuCl2 7447-39-4 134.446 





The results show an enhancement in α-helix at the lower concentration (5 µM) of each 
compound as shown in Figure 36 a–e, while an increase in chloride concentration (>5 






























Figure 36: Effects of (a) LiCl, (b) RbCl, (c) NaCl, (d) CuCl2, and (e) ZnCl2 on Aβ 
aggregation. Ten micromolar Aβ was incubated with each compound used at 
concentrations of 5, 10, 15, and 20 µM. Control represents Aβ alone. 
 
Results showed that the accumulation of Aβ is reduced at low concentrations excep 
for lithium and rubidium chlorides. 
 
4.1.4.4 Effects of sulfur compounds 
Sodium sulfide (Na2S, CAS no. 1313-82-2, Molecular weight 79.048 g/mol), sodium 
sulfite (Na2SO3, CAS no. 7757-83-7, Molecular weight 126.037 g/mol), and sodium 
sulfate (Na2SO4, CAS no. 7757-82-6, molecular weight 142.036 g/mol) were 
introduced to the study of Aβ aggregation. Different effects caused by each one of these 
chemicals were noticed when added at different concentrations to Aβ as shown in 


































































Figure 37: Effects of (a) Na2S, (b) Na2SO3, and (c) Na2SO4, on Aβ aggregation. Ten 
micromolar Aβ was incubated with each compound that were used at concentrations of 
5, 10, 15, and 20 µM. Control represents Aβ alone. 
 
Accumulation of Aβ has been reduced at low concentrations of sulfur compounds. 
 
4.1.4.5 Selenium compounds  
Sodium selenite (Na2SeO3, CAS no. 10102-18-8, molecular weight 172.94 g/mol) and 
sodium selenate (Na2SeO4, CAS no. 10102-23-5, molecular weight 188.95 g/mol) 
















Figure 38: Effects of (a) Na2SeO3 and (b) Na2SeO4 on Aβ aggregation. Ten micromolar 
Aβ was incubated with each compound that were used at concentrations of 5, 10, 15, 
and 20 µM. Control represents Aβ alone. 
 





4.1.4.6 Effects of organic compounds 
Organic acids have also been used to measure their effects on the characteristics of Aβ’s 
secondary structure. Figure 39 displays chemical structure of the selected compounds, 
and Table 30 lists these compounds’ properties.  
 
 
      
 









































Gallic acid p-coumaric acid Sinapic acid 
Hespiridin  
Vanillic acid 




Table 30: Properties of organic acids. 
Compound 
name 













501-98-4 C9H8O3 164.16 
Sinapic acid 3,5-Dimethoxy-4-
hydroxycinnamic acid 
530-59-6 C11H12O5 224.212 
Vanilic acid 4-Hydroxy-3-
methoxybenzoic acid 
121-34-6 C8H8O4 168.148 











Figure 40 a–g shows CD signals at different concentration of each of the compounds 
used in the study.  
 
 





























b. p-Coumaric acid 
 
 
                                         












































































































Figure 40: Effects of (a) gallic acid (b) p-coumaric acid, (c) sinapinic acid, (d) vanillic 
acid (e) hespiridin, (f) naringin and (g.) catechin on Aβ’s aggregation. Ten micromolar 
Aβ was incubated with each compound that were used at concentrations of 5, 10, 15, 






Aggregation of Aβ is achieved at only low concentrations, but not for vanilic acid and 
naringin, of these phytochemicals 
 
4.1.4.7 Flavones and selenoflavones 
Several flavones have been chosen and evaluated to study their impact on the secondary 
structure elements of Aβ (Figure 41)  
 
                             
 
               
                         
 
Figure 41: Chemical structure and molecular weight of the employed flavones in this 
study. 
(a) (b) 







Analysis by circular dichroism spectrometry for these compounds in combination with 
Aβ at different concentrations showed limited effects on Aβ’s secondary structural 
elements (α-helix, β-sheet, and random coil; Figure 42 a–f). Despite the role of 
flavonoids in protecting the brain from Aβ’s toxicity, results showed that all flavonoids 
used in the analysis at all concentrations (5, 10, 15, and 20 µM) exhibited the same 
effects by preventing progressive Aβ accumulation rather than via changing secondary 
Aβ structural elements. 
 
 


























































Figure 42: Effects of flavones and selenoflavones on Aβ aggregation. Ten micromolar 
Aβ was incubated with each compound that were used at concentrations of 5, 10, 15, 
and 20 µM. Control represents Aβ alone. 
 
Negligible or no effect was detected for the flavones used in the study. 
 
4.1.4.8 Effects of organic and inorganic compounds on AICD 
Intracellular AICD accumulation was described as a regulator of γ-secretase 
transcription, hence increasing the production of Aβ by APP cleavage. Therefore, the 
effects of chemicals and phytochemicals were investigated for the first time in the 




































g. Gallic acid 
 




















i. Sinapinic acid 
 
j. Vanillic acid 
 
Figure 43: Effects of (a) C29H44O2, (b) RbCl, (c) NaCl, (d) CuCl2, (e) Na2SO3, (f) 
Na2SO4, (g) gallic acid, (h) p-coumaric acid, (i) sinapinic acid, and (j) vanillic acid on 
the aggregation of AICD. Ten micromolar AICD was incubated with each compound 





Obviously, the investigated compounds at different concentrations produced minimal 
effects on AICD’s secondary structural elements. Furthermore, there are undetected 




4.2.1 Transcriptional regulation of cholesterol by APP 
Although the impact of cholesterol homeostasis on the progression of AD due to the 
accumuleation of Aβ peptides in the amyloidogenic processing of APP and its 
deleterious impact has been investigated by several lines of studies. However, the 
influence of APP or its intracellular domain (AICD) or Aβ have not been studied which 
are targeted in the current study. Physiological role of APP, AICD and Aβ on lipids 
homeostasis and alterations has been investigated in AD brains (Grimm et al, 2017) 
while, the transcriptional function of these proteins was the one of the interests of this 
investigation. Moreover, some transcriptional and physiological studies reported the 
bidirectional influences of APP and its fragments, AICD and Aβ, on APOE ε4 allele, 
cholesterol and other lipids transporter in the central nervous system (CNS), because it 
has been suggested as a causative factor in AD (Grimm et al, 2017; Lee et al, 2017; Liu 
et al, 2013). 
Cholesterol undergoes de novo biosynthesis in the astrocytes (Orth and Bellosta, 2012) 
because BBB impermeability does not allow its transport into the brain. De novo 
biosynthesis of cholesterol is a multistage process (Liscum, 2002) in which 
transcriptional regulation of the cholesterol pathway is mediated by the sterol-
regulatory element binding protein type-2 (SREBP-2) (Horton et al., 2002; Ferris et al., 
2017). This isoform of the protein and other isoforms (SREBP-1a and SREBP-1c) are 
a family of transcription factors that regulate cholesterol and fatty acid homeostasis 
(Accad and Frresse Jr, 1998). After synthesis, precursor (P)SREBP-2, is introduced into 
the endoplasmic reticulum (ER) as inactive protein (Ye et al., 2011). Precursor protein 
contains two transmembrane helices with N- and C- terminals facing the cytosol 
(Waterham, 2006). An interaction is occurring betwee C-terminus of (P)SREBP-2 with 




protein regulated by sterol level. Detection of sterol level is achieved by sterol sensing 
domains (SSD) in five transmembrane helices (2-6) of the eight transmembrane helices 
of SCAP (Okamoto et al., 2006). The combination of (P)SREBP-2/SCAP is localized 
into coat protein complex II (COPII) which are vesicles bud from ER, and transport to 
the Golgi complex by budding process (Horton et al., 2002; Camargo et al., 2009). 
Precursor protein is cleaved sequentially at the Golgi by two proteases, site-1-protease 
(S1P) and site-2- protease (S2P). The result of sequential proteolytic processing is the 
release of the N-terminal of SREBP-2 to form the mature protein ((M)SREBP-2) which 
enters the nucleus to regulate gene transcription (Mohamed, et al., 2015). The process 
of cholesterol synthesis starts by forming acetoacetyl Co-A from two moles of acetyl 
Co-A in the presence of acetoacetyl Co-A thiolase (Zhang and Liu, 2014). 3-hydroxy-
3-methylglutaryl (HMG) Co-A is formed from one mole of acetyl Co-A and acetoacetyl 
Co-A in the presence of (HMG) Co-A synthase (HMGS) (Sapir et al., 2014). HMGCR 
converts HMG Co-A to mevalonic acid. The product of HMGCR, mevalonic acid, is 
sequentially phosphorylated to 5-phosphomevalonate by the enzyme mevalonate kinase 
(MK) and to 5-pyrophosphomevalonate by phosphomevalonate kinase (PMK). 5-
pyrophosphomevalonate is converted to isopentenylpyrophosphate (IPP) by 
mevalonate diphosphate decarboxylase (Nes, 2011). IPP is isomerized to dimethylallyl 
pyrophosphate (DMPP) in the presence of IPP isomerase (IPPI). IPP combines with 
DMPP to form geranyl pyrophosphate (GPP) after which GPP is condensed with 
another molecule of IPP to yield farnesylpyrophosphate (FPP) (Nes, 2011). GPP and 
FPP syntheses are both catalyzed by farnesylpyrophosphate synthase (FPPS), a 
prenyltranferase. FPP initiates the branches of the pathway that generates cholesterol 
and non-cholesterol isoprenoids (Mohamed et al., 2015; Lu et al., 2010; Song et al., 












Cholesterol is essential for cell growth and function and a key constituent in maintaining 
functioning cell membrane (Hussain et. al., 2019 and Yeagle, 1991). However, 
hypercholesterolemia is proposed as a risk factor in developing AD (Pan et. al., 2018 
and Howland et. al., 1998). Cholesterol levels has been proven to be associated with 
enhanced amyloid precursor protein (APP) level (Wood et. al., 2014). Aβ peptide, a 
hallmark of AD, which produced in the amyloidogenic pathway of APP by β- and γ-
secretases sequential cleavage, has been shown to obstruct the activity of 
Hydroxymethylglutaryl-CoA reductase HMGCR, a rate-limit enzyme in cholesterol 
bio-synthesis, and subsequently diminishing cholesterol de novo bio-synthesis from a 
side and cholesterol levels regulate Aβ’s production rate (Grimm et. al., 2005 and 
Bodovitz and Klein, 1996) from the other side. Amyloid intracellular domain (AICD), 
a product of γ-secretase cleavage of transmembrane terminal of APP (C99), is likely 
 
 
Figure 44: Cholesterol synthesis in the mevalonate pathway. The precursor acetyl Co 
A is converted first to 3-hydroxy-3- methylglutaryl-CoA (HMG-CoA) and then to 
mevalonate. The rate-limiting step of cholesterol biosynthesis is the conversion of 
HMG-CoA to mevalonate catalyzed by the HMG-CoA reductase (HMGCR), which is 




participate in transcriptional events that reducing cholesterol bio-synthesis (Beel et. al., 
2010). Epidemiological surveys in patients taking statin, cholesterol lowering drug, 
demonstrated a reduction in AD popularity (Wood et. al., 2014). Nonetheless, some 
studies demonstrated that enhancing dietary cholesterol of mouse models that 
expressing Swedish familial AD mutations and human Aβ has lowered Aβ40 and Aβ42 
significantly but with no impact on C-terminal APP products (Goldman et al., 2018; 
Wood et. al, 2014; and Halford and Russel, 2008). Such controversial results suggesting 
that cholesterol homeostasis or distribution within the brain may have a role in APP 
processing and/or Aβ accumulation (Wood et. al., 2014) because brain is a cholesterol-
rich organ which produces its own cholesterol and, blood brain barrier (BBB) maintains 
this homeostasis. Dysfunction of BBB because of ischemic stroke, for example, may 
affect this homeostasis due to the cholesterol gradient between the brain and the blood 
resulting in a turbulence in the brain cholesterol (Nation et al., 2019; Montagne et al., 
2017; Roh et al., 2017, and Li et al., 2015).  
In the current study, genes involved in the de novo cholesterol biosynthetic pathway 
have been studied in order to detect the influence of APP or one of its fragments (AICD 
and Aβ) on the expression of these genes by utilizing mouse embryonic fibroblasts 
lacking APP/APLP2 (MEF APP/APLP2-/-). Furthermore, MEF WT cells were used as 
the control for comparison and normalization purposes because such cells are 
expressing APP (Figure 13). Quantitative detection of relevant genes showed that all 
gene expressions, except the 3-hydroxy-3-methylglutaryl-CoA synthase-2 (HMGCS2) 
gene, were reduced in the absence of APP. As it is shown by the results, the rate-limit 
enzyme (HMGCR) is down-regulated significantly (p ≤0.001) in MEF cells which are 
devoid of APP referring to a possible association to some extent between the expression 
of APP and cholesterol de novo bio-synthesis. These results are consistent with the 
results obtained some researches (Grimm et al, 2017; Mohamed et al, 2015 and, Pierrot 
et al, 2013). Likewise, mevalonate pathway genes; mevalonate kinase (MVK), 
phosphomevalonate kinase (PMVK), and mevalonate (diphospho) decarboxylase 
(MVD) exhibited a reduced expression and this is likely attributed to the impact of 
reduced upstream enzyme (HMGCR) or direct regulation by APP which is supported 
by findings of other researchers (Mohamed et al, 2015). This achievement is analogous 
to the results obtained when differentiating APP-knockout (APP KO) human induced 
pluripotent stem cells (hiPSCs) into human astrocytes where, a reduction in HMGCR 




genes (genes of proteins involved in escorting and delivering SREBP-1 from the 
endoplasmic reticulum [ER] to the nucleus) were studied by using the same cells for 
control and sample because this protein is responsible for transcription regulation of 
cholesterol biosynthesis as described in chapter II of this study. Results showed a 
reduction in SREBP-1 gene expression, except for the Sterol Regulatory Element 
Binding transcription Factor 1 (SREBF1) gene. Correspondingly, an identical 
achievements were obtained but by utilizing SREBP-2 protien (Mohamed et al, 2015). 
These results indicate that APP may participate in transcriptional regulation of 
cholesterol and there is a possibility of a link between higher cholesterol levels and 
increased APP expression. However, limited studies considered the transcriptional 
impact of APP on cholesterol biosynthesis while it has been studied thoroughly in this 
study. 
Additionally, in order to study AICD’s transcriptional role in cholesterol homeostasis, 
MEF APPΔCT15 was used. This cell line does not have functional AICD, which was 
achieved by deletion of last 15 amino acids of the APP C-terminal, MEF WT was used 
as control cells. Results showed a significant reduction in gene expression of HMGCR 
(p ≤ 0.001) in cases in which the AICD function is eliminated when compared with 
control cells that have normal AICD expression. Identical impact is observed of APP 
and AICD in regulating cholesterol homeostasis (Wood et al, 2014). While, results of 
SREBP-1 gene expression revealed a marginal impact of AICD in regulating target 
genes compared to control cells. The impact of AICD on cholesterol bio-synthesis was 
first studied because no or little is known about its role in controlling cholesterol 
biosynthesis. 
Finally, the influence of Aβ on gene expression of the cholesterol biosynthetic pathway 
was accomplished using MEF PS1res as a control cell line in which these cells were 
stably transfected with human PS1, but not human PS2, and deficient mouse PS1 and 
PS2. PS1 and PS2 proteins are the catalytic site of γ-secretase in which, in the 
amyloidogenic pathway, the product of γ-secretase is Aβ and AICD. MEF PS1/2-/- cells 
were used as sample cells. These cells were deficient in mouse PS1 and PS2 proteins 
by double knockdown genes of these proteins so as to prevent the production of 
endogenous Aβ. Results from the gene expression test showed an obvious increase in 
the cholesterol synthesis gene expressions in addition to SREBP-1 genes in the absence 




and HMGCR was significantly upregulated (p ≤0.001), HMGCS2 exhibited 
insignificant increase illustrating that the difference between control and sample may 
occurred by chance. Most studies were investigated the impact of cholesterol or 
HMGCR inhibitors on the progression of AD (Zou et al, 2019; Mohamed et al, 2015 
and, Wood et al, 2014) while in this novel study, the impact of Aβ on cholesterol 
biosynthesis pathway was studies. Aβ down-regulation was associated with an increase 
in cholesterol gene transcription, indicating that the amyloidogenic APP processing 
pathway is not the preferred pathway for maintaining cell functionality and may 
demonstrate the toxic impact of such peptide. Aβ’s role in cell apoptosis in AD patients 
that is due to the loss of cell integrity may be explained as a result of Aβ over-expression 
and a lower rate of cholesterol production.  
 
4.2.2 Influence of cholesterol in Aβ degradation 
Cholesterol’s effects on total Aβ degradation by enzymes involved in this process were 
examined. A reduction in Aβ of about 20% was determined for aggregated β amyloid 
peptides (Figure 19). Identical findings have been obtained elsewhere (Mett, 2017). 
The decrease in amyloid aggregation may result from the multiple proteases that have 
been shown to degrade the Aβ peptide, including IDE, NEP, endothelin-converting 
enzymes, and plasmin in the cytosol or cell membrane, and IDE in the extracellular 
(Weller et al., 2000). As is shown in Figure 20, a reduction in the remaining β-amyloid 
peptide of about 52%, 58%, 65% and 69% for incubation time intervals 8, 12, 24, and 
30 h, respectively can be seen in the extracellular Aβ because of the enzymatic activity 
of IDE, which is secreted through unconventional pathway (Zhao et al., 2009) or 
because of the loss of cell integrity (Song et al., 2018). Results shown in Figure 21 
support an important physiological role for extracellular IDE in Aβ catabolism and 
homeostasis in the presence of cholesterol, in which a decrease of about 20% was 
determined as can be seen in the same figure. According to the latter achievement, 
reduced cholesterol levels is likely to cause a decrease in the amount of IDE in 
detergent-resistant membranes (DRMs) the point in which co-localization of IDE and 
Aβ was shown to occur (Bulloj et al., 2008). This change in lipid compositions also 
has an impact on secreted IDE, leaving extracellular Aβ in a non-degraded form. For 
this reason, IDE considered as a therapeutic target for AD and type 2 diabetes mellitus 
(T2DM) because it degrades insulin and Aβ. In addition to these targets, IDE degrades 




IDE arises some concerns about its role as a therapeutic target and needs to be studied 
thoroughly. To confirm the hypothesis that IDE is the major Aβ degrading enzyme in 
the extracellular space, the same experiment was then repeated but with the use of N2a 
IDE knockdown cells. Tests were carried out with living cells and with culture medium 
to compare the results as shown in Figure 22 and 23, respectively. Both graphs are 
showing the important role of IDE as a degrading enzyme of the Aβ peptide. In living 
cells as presented in Figure 22, only 5% of the added synthetic human sequence Aβ 
was catabolized by multiple membrane proteases such as NEP, endothelin converting 
enzyme-1, plasmin, and matrix metalloproteinases (MMP9) in the absence of IDE. 
Thus, it can be concluded that IDE is responsible for degrading 15% of Aβ, whereas 
in N2a WT cells, the degradation was around 20% as shown previously in Figure 19. 
While in N2a IDE knockdown cells, the degradation was reduced to 5%. On the other 
hand, deleting the effects of IDE in the extracellular space resulted in an increase in 
Aβ aggregation. This increase proved the importance of IDE in the process of 
extracellular catabolism of Aβ.  The increase in quantified Aβ is likely to the 
interaction with murine Aβ peptide (Steffen et. al, 2017; Bright et. al, 2014; and Fung 
et. al, 2004) 
Two mechanisms have been developed to explain the secretion of IDE from the 
cytosol, one of which is by unconventional pathway, where IDE still secreted although 
secretion inhibitor had been used (Zhao et al., 2009), while in the second mechanism, 
IDE secreted due to the loss of cell integrity, and verified by the release of cytosolic 
enzymes (Song et al., 2018). Results obtained in this investigation supports the first 
mechanism because, cholesterol presence maintains cell membrane integrity thus the 
hypothesis of IDE secretion by the loss of cell integrity is eliminated (Dios et. al, 2019). 
However, the second secretion pathway can be explained when Aβ accumulation 
increases, due to impaired clearance or catabolism, and hence diminish cholesterol 
homeostasis and leading to the loss of cell integrity which releases the cell content 
including IDE. 
Results in Figure 24 show that high cholesterol levels caused an increase in IDE gene 
expression of about 18% and 13% as compared with control (housekeeping) genes, β-
actin and Polr2, respectively, which reflects cholesterol’s impact on IDE transcription. 
Figure 25 summarizes the normalized results of cholesterol’s impact on the IDE 
promoter in which results of cholesterol’s influence on IDE gene expression was 




was obtained for the IDE promoter as compared to control sample. Cholesterol’s effects 
on IDE levels in the membrane and extracellular space was considered and evaluated 
by quantifying IDE protein with western blotting and N2a cells. Obviously, as shown 
in Figure 26, there was an effect of cholesterol on IDE protein demonstrated as an 
enhancement in the protein level by 22% for both intracellular and extracellular IDE. 
Results of IDE gene expression detection, promoter assays, and protein levels 
confirmed cholesterol’s role on IDE at both transcription and regulatory levels, and the 
dual impact of high cholesterol levels on increasing Aβ deposits via APP processing 
from one side and up-regulation of IDE that degrades Aβ from the opposite side. Protein 
stability is a measure of a protein’s capability to remain in its natural state (folded) 
because it is important to keep a protein’s function. Therefore, the stability of the IDE 
protein has been measured in the presence of cholesterol in order to study the effects of 
high cholesterol levels on IDE protein stability. The results obtained from this 
experiment showed that there was an increase of about 47% in intracellular IDE and 
around 50% in extracellular IDE. 
With respect to IDE activity, Figure 30b shows that there is no activity for IDE without 
cholesterol, whereas incubation with 100 µM cholesterol resulted in a steep increase in 
the first 400 s of the test followed by a gradual increase between the intervals of 400 to 
1000 sec. After 1000 sec, there was no detected increase. In order to verify the role of 
phospholipids on the IDE activity, 150 µM of PC 18:0 was incubated with both control 
and sample wells in which fluorescence intensity was measured as shown in Figure 30d. 
The effects of PC 18:0 on the enzyme activity is obvious by the increase in both the 
control sample and cholesterol-containing sample curves. Identical impact was 
investigated for cholesterol, phospholipids. The rate of the increase was different, in 
which in the first 400 sec of the test, it was steep for cholesterol and phospholipid, while 
steepness was limited for the extracted lipid at the same time interval. The final steady 
state rate of fluorescence (after 1000 s from the beginning of the test) showed that the 
increase in activity was double compared to the starting point of the test; this finding 
confirmed the role of lipids in IDE’s enzymatic activity. 
 
4.2.3 Anti-microbial activity of Aβ peptide 
Despite the deleterious impact of Aβ accumulation as shown previously and its 




peptide in the innate immune system as an AMP (Kumar et al, 2016; Soscia et al. 2010). 
The mechanism of Aβ activity as an antimicrobial peptide can be explained by the 
interaction between the heparin-binding domains of soluble Aβ oligomers with 
microbial cell wall carbohydrates. Adhesion of pathogen to infected cells is inhibited 
thanks to protofibrils developed in such interaction. Propagation of Aβ fibrils mediates 
agglutination and eventual entrapment of unattached microbes (Washicosky et al. 
2016). It is unclear yet whether Aβ production and accumulation could increase a 
response of the innate immune system to infections (Aryal et al., 2014; Spitzer et al., 
2016, Regitz and Wenzel, 2014). Antimicrobial peptides or host defense peptides are 
targeting a broad spectrum of microorganisms (viruses, bacteria, fungus, and parasites) 
and can be found in prokaryotes and eukaryotes (Bahar and Ren, 2013). The role of Aβ 
in the innate immune system has been presented by some researchers (Cosztyla et. al, 
2018; Kumar et al, 2016; and Soscia et al. 2010). Its effects have been proposed to be 
due to Aβ’s agglutination characteristic that is considered to trap microbes (Cosztyla 
et. al., 2018 and Washicosky et al., 2016) and explained according to pathogen 
hypothesis for AD, in which bacterial infection mediates the aggregation of Aβ 
(Cosztyla et. al., 2018). In this study, although higher and toxic doses of Aβ have been 
utilized, the obtained results of the nematode viability test showed that the impact of 
Aβ as AMP is negligible at all doses of peptide that were used. Correspondingly, results 
with E. coli showed the same impact in which the density of viable cells at a higher 
dose of Aβ were >50 % as shown in Figure 32 a., and the growth increased in a dose-
dependent manner to reach 80% as Aβ concentration decreased, indicating a marginal 
inhibitory effect of the peptide on E. coli growth. Similarly, the AlamarBlue assay 
demonstrated that there was a limited effect of Aβ as an antimicrobial peptide in 
inhibiting the growth of C. albicans at different Aβ concentrations. Interestingly, S. 
cerevisiae results revealed a slight enhancement in cell proliferation depending on the 
Aβ concentration as shown in Figure 32 c. Results obtained in this study revealed that 
there was no or only limited impact of Aβ on nematodal, fungal, and bacterial viability. 
Therefore, its role is still controversial, and more research is required in order to 
determine whether Aβ behaves as an AMP or a mere extrinsic influence due may be to 
the interaction of Aβ with cholesterol in lipopolysaccharide (LPS) molecules in the 






4.2.4 Regulation of Aβ aggregation by phytochemicals 
It is well-accepted that the consumption of sufficient amounts of phytochemicals on a 
regular basis is as essential as the use of synthesized medications with respect to 
people’s state of health or perhaps they provide an alternative solution to conventional 
medications in some cases. For example, omega 3 has been proven to enhance Aβ 
degradation and clearance through up-regulation of IDE enzymatic activity (Grimm et 
al, 2016). Additionally, brain is protected by blood brain barrier which strictly regulate 
the uptake of medications by efflux pumps. For these reasons, a broad array of 
phytochemicals has been studied here in vitro and applied at different doses in order to 
recognize and differentiate their influences regarding inhibition of Aβ aggregation 
through studying changes in its secondary structure. 
 
4.2.4.1 Vitamins  
Ascorbic acid (AA) or vitamin C which is a water soluble vitamin available in citrus 
fruits such as orange or grapefruit in addition to kiwi, mango, watermelon, strawberries, 
pineapple, and papaya as well as in vegetables such as green pepper, spinach, leafy 
greens, tomato, broccoli, and cabbage. It is known for its antioxidant features, reducing 
the free radicals induced damage, by reducing oxidative stress cytokine release due to 
deposited Aβ in hippocampus of rats (Harrison and May, 2009) and diminished cell 
apoptosis induced by the accumulation of Aβ in SH-SY5Y human neuroblastoma cells 
(Harrison and May, 2009) and suppressing fibrillogenesis of Aβ (Monacelli et. al., 
2017). In the same context of the obtained results by previous studies, the role of 
ascorbic acid is shown in Figure 34a (first panel), where an increase in the ⍺-helix 
secondary structural element can be noted at 222 nm (Greenfield, 2006), and in (second 
panel) the direction to native form of peptide can be seen as concentration of L-ascorbic 
acid increases. These results support the importance of ascorbic acid supplementation 
in maintaining the brain functionality (Hagel et. al., 2018). Vitamin E is known for its 
antioxidant characteristics as well as strengthen the immune system and supports cell 
functions. Main sources of this vitamin is, vegetable oils, nuts, and seeds. Some studies 
showed that α-tocopherol and α-tocotrienol participated in events related to Aβ 
disaggregation and clearance from the brain including enhancing the expression of IDE 
and LRP1 (Desrumaux et. al., 2018; La Fata et. al., 2014; and Nishida et. al, 2009). In 
line with these findings, results of the current study showed that CD spectrum 




and random coil, respectively (Greenfield, 2006), enhanced in a dose dependent rate of 
the compound concentrations, which indicates that α-tocotrienol was capable of 
maintaining Aβ in its native state. This finding is shown in Figure 34b for the CD 
spectra and peptide conformation prediction in which the shift was obvious from pre-
molten globules to native peptides (folded), indicating a reduction in Aβ toxicity. 
 
4.2.4.2 Tellurite 
Similar observations of tellurite compounds were detected in which it was shown that 
at increasing K2O4Te hydrate concentrations, the α-helix was enhanced slightly at 200 
nm, and the β-sheet at 195 nm increased more as shown in Figure 35a. The impact of 
increasing Na2TeO3 concentrations on the peptide’s aggregation can be seen in Figure 
35b as indicated by the α-helix spectra increase at 222 nm, which indicates that the 
peptide is conserved in its folded state. Moreover, in the same figure, there is a distinct 
shift in the peptide’s pre-molten to native state. 
  
4.2.4.3 Chlorides, sulfur, and selenium compounds 
Lithium chloride salt can be found in grains and vegetables as well as in some sources 
of tap water. Dietary intake of Li has been determined in a range of 610-3100 µg of 
daily intake and prescribed for patients with bipolar disorder (Schrauzer et. al., 2002). 
Epidemiological studies evidenced the impact of lithium chloride in attenuating Aβ 
levels and around 31% enhancement in the clearance of the toxic peptide by increasing 
the expression of LRP-1 which is correlated with the clearance across BBB (Forlenza 
et. al., 2014). Contrarily, results from CD show that lithium chloride is considered an 
agent that may increase Aβ production (Feyt, et al., 2005). Along with this result, the 
CD spectrum of lithium chloride showed a limited effect on Aβ aggregation as shown 
in Figure 36a in which an increase in its concentration had limited effects at a 
wavelength of 222 nm, indicating that the α-helix secondary structure unaltered even 
with an increase in lithium chloride concentrations. There is an increasing in spectral 
signal around 215 nm wavelength, indicating an increase in β-sheet formation. Such 
increase in the β-sheet is unfavorable because it leads plaque formation. Analogous 
results have been obtained by treating Aβ with rubidium chloride (Figure 36b). Also, 
sodium chloride was found to have a role in Aβ accumulation in cultured cells resulting 
from abolished peptide clearance (Cheng et al., 2015). CD analysis of different 




222 nm as shown in Figure 36c. Although all concentrations had a similar effect, the 
minimum concentration is preferred in order to avoid the side-effects caused by the 
higher doses of this salt. Oxidative stress induced by CuCl2 has been characterized in 
AD via the interaction between copper and Aβ (Atwood et al., 2000 and Hu et al., 2016). 
Figure 36d shows the CD spectrum of CuCl2 at different concentrations in which a 
considerable increase in the α-helix secondary structure was detected at a wavelength 
of 222 nm for all concentrations. Identical results were obtained with ZnCl2 as shown 
in Figure 36e. The destructive impact of these two compounds in inducing oxidative 
stress is during metabolism due to releasing of free radicals. This effect can be 
minimized through reducing the intake to the minimum rate. 
Sodium sulfite is one of the preservatives used in canned vegetables, potato chips, soup 
mixes, and vegetable juices. Acceptable daily intake (ADI) of 0.7 mg / kg of body 
weight / day was considered as a safe dose of sulfite (Lien et. al., 2016, and Zhang et 
al., 2004) to prevent the increase in reactive oxygen species (ROS) in the brain which 
is induced by increasing intake of such salt (Zhang et. al, 2004). Na2SO3 exhibited a 
significant effect in maintaining Aβ in its native conformation as shown in Figure 37b 
with a huge increase in the α-helix spectrum at 222 nm at the four concentrations used 
for the analysis. Correspondingly, Na2SO3 affected Aβ aggregation at a concentration 
of 5 µM as shown in Figure 37b, in which the highest increase in the α-helix secondary 
structural element spectra was obtained. This effect decreased as the concentration of 
Na2SO3 was increased. While, Na2SO4 which is used as a source of sodium in 
supplemented nutrients at a maximum of 200 mg sodium / day for adults (EFSA, 2010). 
The current results showed less impact on Aβ accumulation at 5 µM and 222 nm, but 
random coils increased at this concentration (Figure 37c) in the spectrum at 205 nm. 
For concentrations >5 µM, a large increase in the α-helix spectra was detected. These 
results suggest that the optimum Na2SO3 and Na2SO4 concentrations are 5 and 20 µM, 
respectively, for preservation of the Aβ secondary structural elements within the native 
or folded state. Otherwise, β-sheets may be formed and then form stacks that lead to 
insoluble senile plaques. Sulfites are used in packaged foods as preservatives to 
improve flavor or appearance, therefore AD patients should avoid processed food or 
minimize the intake of such foods to avoid burden of these compounds.   
European medicines agency has determined the total food and supplementation) intake 
of sodium selenite and sodium selenite to a maximum of 300 µg / person / day 




signal at 193 nm, which corresponds to the α-helix. Na2SeO3’s effects are dose-
dependent as shown in Figure 38a. Na2SeO4’s effects were characterized by a large 
increase in the CD spectra at 208 and 222 nm, both of which indicate an increase in the 
α-helix component of the Aβ secondary structure, except at higher concentration of 
Na2SeO4 (20 µM) in which no effects were detected as shown in Figure 38b. The 
detected role of selenium compounds supports the evidenced role of these compounds 
as antioxidants. Diets-enriched with selenium are essential for the clearance of Aβ 
because it is shown to prevent the accumulation in vitro, in this study, and in vivo as 
shown in section 2.8.2 of chapter two. However, to avoid the toxic impact and 
sensitivity by higher doses of selenium, ≥ 20 µM (EPMAR, 2015), it is highly 
recommended to use selenite and selenite at lower concentrations. 
 
4.2.4.4 Organic acids 
Gallic acid is the most active component of grape seed extract, which inhibits Aβ 
aggregation by stabilizing kappa-casein (a milk protein that forms amyloid fibrils 
immediately under physiological conditions) to prevent its aggregation (Liu et al., 
2013). In line with this, gallic acid showed inhibition of Aβ deposition at lower 
concentrations (5 µM) as shown in Figure 40a, in which the CD signal increased at a 
wavelength of 222 nm. Nonetheless, higher concentrations had an adverse effect by 
decreasing α-helix formation. Besides that, p-coumaric acid has been shown to 
attenuate Aβ (25-35)-induced toxicity by regulating nuclear factor (NF)-κB signaling 
pathway. NF-κB is a transcription factor that plays a key role in the gene regulation 
associated with inflammation and its activation is one of the signaling pathways through 
which Aβ exerts its neurotoxicity (Yoon et al., 2014). Analysis of CD spectra of p-
coumaric acid-treated Aβ at different concentrations emphasized that at concentrations 
<15 µM, α-helix formation increased significantly, while an adverse effect was 
obtained at 20 µM as shown in Figure 40b, indicating a limitation in the use of this 
compound in human diet. Sinapinic acid is a phenolic antioxidant and free radical 
scavenger (Chen, 2016) and has been suggested as a source of nutraceuticals in brain 
disorders such as AD (Bais et al., 2017). Analysis of the CD spectra of this compound 
displayed a role in α-helix formation at a concentration of 5 µM in which the signal at 
a wavelength of 222 nm increased at this concentration. A higher concentration of 
sinapinic acid had a negative role on Aβ deposition as shown by reduced spectra at a 




42-induced oxidative stress and cognitive impairment in mice (Ul-Amin. et al., 2017). 
However, CD spectra of Aβ with different concentrations of vanillic acid showed 
limited effects on the secondary structural elements of Aβ at low concentrations (5 µM 
and 10 µM), there was no enhancement in α-helix formation, whereas at higher vanillic 
acid concentrations (15 and 20 µM), there were negative effects suggesting that an 
increase in concentration is not preferable (Figure 40d). Hesperidin produced 
downregulatory autophagy characteristics that controlled the impairment of energy 
metabolism which leading to neuronal injury in AD (Huang et al, 2012; Cho, 2006, and 
Wang et al., 2013). Only at lower concentration (5 µM) did hesperidin cause an 
enhancement in α-helix formation (Figure 40e), whereas, higher concentrations 
produced random responses. Naringin has been shown to have a role in improving the 
long-term memory of AD patients by inhibition of calcium/calmodulin-dependent 
protein kinase II (CaMKII) auto-phosphorylation (an enzyme that plays an important 
role in long-term memory (Wang et al., 2013). Limited enhancement in α-helix 
formation at a wavelength of 222 nm accompanied by the formation of β-sheets at a 
wavelength 218 nm (Figure 40f), at lower concentrations (5 µM). Other concentrations 
had no or opposite effects. Catechin hydrate has been shown to prevent Aβ-induced 
neurotoxicity (Heo and Lee, 2005). The CD spectrum of catechin hydrate showed that 
at a lower concentration of 5 µM, an enhanced signal obtained at wavelength 222 nm 
indicating the formation of an α-helix (Figure 40g), while higher concentrations had 
less effects on α-helix formation. 
Flavonoids (Figure 42) are potent antioxidants and metal chelators. However, the used 
flavonoids are not suggested to act as impairment factors of Aβ deposition due to the 
weak signals obtained for ⍺-helix formation at all concentrations of compounds that 
were used in the experiments. The unanticipated results can be explained as 
polyphenols cross blood-brain barrier and inhibit amyloidogenic pathway (Teles et al., 
2018) rather than preventing the accumulation of Aβ. 
Secondary structure elements of AICD seems unaffected by chemicals used in the CD 
study as shown in Figure 43, indicating that the aggregation could be attributed to other 
factors such as Fe65 which translocate this fragment to the nucleus. 
Despite that CD investigation is a fast and accurate method for studying the state of 
specific protein or peptide. However, such method is an in vitro study, and this type of 




multifactorial process which involves various signaling pathways that’s still need to be 
studied.  
Table 31 summarizes the effect of each compound on Aβ aggregation according to its 
concentration in the solution. 
 
Table 31: Detected impact of phytochemicals and inorganic compounds on the 
resistance of Aβ to aggregation. 
Compound 
Concentration of compound, µM 
5 10 15 20 
L-ascorbic acid  - + ++ 
α-tocotrienol  + ++ ++ 
K2TeO4.H2O   + ++ ++ 
Na2TeO3  + ++ ++ 
LiCl - - - - 
RbCl - - - - 
NaCl + + + + 
CuCl2 + + + + 
ZnCl2 + + + + 
Na2S ++ ++ ++ ++ 
Na2SO3 + + + - 
Na2SO4 - + + ++ 
Na2SeO3 - + + + 
Na2SeO4  + + - 
Gallic acid + + - - 
p-coumaric acid + + - - 
Sinapic acid + + - - 
Vanilic acid - - - - - - 
Hesperidin + - - - 
Naringin - - - - 
Catechin hydrate + - - - 
++: High impact  
+: moderate impact 
-:  low impact  















According to the results obtained, tests performed, materials used, equipment 
employed, literature cited and laboratory conditions, the following can be 
concluded: 
 
1) APP and its fragment (AICD) deletion from MEF cells down-regulated 
gene expression of cholesterol, SREBP-1, and related gene expressions, 
indicating a role for these proteins in cholesterol homeostasis in the lipid 
raft microdomain of a cell membrane. 
 
2) Aβ peptide affected the cholesterol bio-synthetic pathway at a 
transcriptional level in mouse embryogenic fibroblasts by up-regulating 
cholesterol gene expression significantly, and in the absence of Aβ affected 
genes involved in the cholesterol synthetic pathway, SREBP-1 and related 
genes. These effects may be related to cell apoptosis in AD patients due to 
the loss of cell wall integrity upon the reduced levels of cholesterol. 
 
3) The presence of cholesterol in N2a living cells (intracellular) and in culture 
medium (extracellular) caused a reduction in recombinant human Aβ to 
(81%) in both compartments, possibly due to the effects of degrading 
enzymes such as IDE, NEP, ECE-1, and MMP.  
 
4) Mouse neuroblastoma cells that do not express insulin-degrading enzyme 
(N2a IDE kd) showed significant degradation of Aβ after incubation with 
cholesterol in living cells (95%), whereas an enhancement in Aβ 
aggregation occurred in these cells’ culture medium (130%). Both results 
indicate that IDE is the most important enzyme involved in Aβ peptide 
degradation in addition to its activity not only at the cell membrane but also 
in the extracellular space as a result of exosomal secretion. These results 
support the mechanism of un-conventional secretion pathway of IDE. 
However, the mechanism of IDE secretion due to the loss of cell integrity 




on cholesterol bio-synthesis, which is essential to the cell membrane and 
integrity.   
 
5) Cholesterol’s effects on IDE appear to be up-regulation of IDE gene 
expression as compared to housekeeping genes β-actin (118%) and Pol2 
(113%). IDE gene promoter activity also increased in the presence of 
cholesterol (124%), indicating that cholesterol has an impact on IDE 
transcription and thus increasing IDE synthesis and association 
intracellularly (122%) and secretion extracellularly (123%). In line with 
these findings, the enzymatic activity of IDE significantly increased three 
times (for example, a three time increase in activity when incubated with 
cholesterol in N2a cells was observed). Furthermore, cholesterol caused an 
increase in IDE stability (maintaining the folded state of protein) in the 
cytosol (147%) and extracellular space (150%). Due to these effects, the 
interaction between cholesterol and the enzyme needs to be studied to 
determine whether such effects occurred of this interaction or because of 
other factors related to the increased proportion of cholesterol. 
 
6) There may be no specific role for Aβ in the innate immune system as an 
AMP in nematodes. Also, according to the limited effects of Aβ in 
inhibiting the growth of different fungi and bacteria used in the study, its 
role as an AMP may not be a substantially characteristic but could be an 
extrinsic effect due to Aβ‘s agglutination features. 
 
7) A study of L-ascorbic acid and α-tocotrienol effects showed a reduction in 
Aβ accumulation at a concentration of 20 µM for both agents as evaluated 
using the CD technique to detect changes in this peptide’s secondary 
structural elements. This concentration for both vitamins is recommended 
as it relates to prevention of Aβ peptides aggregation. 
 
8) K2TeO4.H2O and Na2TeO3 caused an increase in α-helix formation at a 
wavelength of 222 nm when its concentration was increased to 20 µM in 





9) Chlorides, which have been used in this study, affected Aβ’s secondary 
structure in which LiCl, NaCl, CuCl2, and ZnCl2 enhanced formation of α-
helices at a lower concentration of 5 µM, indicating that the use of chlorides 
should be used at minimum doses in the human diet or as supplements to 
suppress the undesirable impact of these compounds. 
 
10) Na2S at a concentration of 5 µM, affected Aβ’s α-helix formation as 
indicated by the intense spectra at a wavelength of 222 nm, whereas Na2SO3 
and Na2SO4 had the same effects at concentrations of 20 µM and 15 µM, 
respectively.  
 
11) Nutrients containing Na2SeO3, and Na2SeO4 are recommended because 
both of these compounds produced an increase in α-helix formation at 
concentrations of 20 µM and 10 µM, respectively. 
 
12) Organic compounds at different concentrations that have been employed in 
this study showed an increase in maintenance of Aβ in its folded form and 
thus prevents the peptide aggregation. Gallic, p-coumaric, sinapinic, and 
vanillic acids, hesperidin, naringenin, catechin, and the group of flavones at 
a concentration of 5 µM for every one of the above-mentioned compounds 
that were used in the study produced an improvement regarding Aβ 
secondary structure by maintaining the peptide in its native form (folded) 
and preventing formation of β-sheets  
 
13) CD spectrometry is a method that has been used for in vitro structural 
element detection of peptides. However, utilizing this method in the study 
of aggregation of Aβ peptide can be regarded as a one-dimensional study 
because the impact of a specified compound was studied on the peptide’s 
secondary structural elements regardless of the effects caused by other 
factors (such as proteins and enzymes). Peptide accumulation is a complex 
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List of apparatus, chemicals and disposables 
 
Table A-1: Apparatus and related accessories 
Name Manufacturer 
Analytical balance Multiple 
CanoScan LiDE 50 Canon 
Centrifuges Multiple 
Electronic pipette, 8-channel Eppendorf 
Fluorometer / Luminometer Infinite M1000 pro Tecan 
Fluorometer Safire II Tecan 
Freezer -20 ͦ C Premium Liebherr 
Freezer -80 ͦ C Hera Freeze Thermo Electron 
Freezer box Cryo container Nalgene 
Gel chamber Novex Mini-cell Life Technologies 
Hamilton capillary Hamilton 
Heating block thermo shaker Universal Laboratory 
Incubator Different 
Incubator Heracell 150 Heraeus 
Incubator, 37 ͦ C Heraeus 
Light microscope Nikon Nikon 
Magnetic heating stirrer Heidolph instruments 
Mass Spectrometer 4000 QTRAP AB Sciex 
Microwaves Multiple 
MINILYS homogenizer Peqlab 
NanoDrop 8000 UV -Vis spectrophotometer Thermo Scientific 
Nitrogen tank -196 ͦ C Air Liquide 
PCR cycler PRIMUS  25 Advanced Peqlab 
pH meter 766 Calimatic kink 





Pipette boy Comfort Integra Biosciences AG 
Pipette set Eppendorf 
Potter tube B. brown 
Precision balance Different 
Precision balance EW Core 
Rotor TLA-55 Beckman Coulter 
Single multi pipette M4 Eppendorf 
Trans blot gel holder + sponge BioRad 
Transfer chamber BioRad 
Ultracentrifuge Optima LE-80K Beckman Coulter 
Vortex Genie2 Bender & Hobein 
Water bath Multiple 
Wheaton shaker multi reax Heidolph instrument 
 
Table A-2: List of chemical materials used in the study 
Name Supplier 
1-Step PNPP Thermo Scientific 
3’-(p-aminophenyl) fluorescein (APF) Invitrogen 
3’-(p-hydrophenyl) fluorescein (HPF) Invitrogen 
Ampicillin Roth 
Aβ1-40 peptide GenScript 
Aβ1-42 peptide GenScript 
Aβ1-42 peptide Innovagen 
Bicinchoninic acid Sigma Aldrich 
BSA Roth 
BSA fatty acid free Sigma Aldrich 
CaCl2 .2H2O Merck Millipore 
Chloroform, HPLC grade Merck Millipore 
Complete protease inhibitor cocktail EDTA Roche 





CuSo4 .5H2O Roth 
Cycloheximide from Streptomyces Sigma Aldrich 
DMEM Sigma Aldrich 
DMSO Roth 
ECL hyper film Amersham 
ECL solutions  Perkin Elmer 
EDTA Roth 
Ethanol HPLC grade Sigma Aldrich 
Fast SYBR green master mix Life technologies 
FCS PAN Biotech 
Fixer Kodak 
GBX developer solutions Kodak 
Glycerin Roth 
HBS buffer Synvolux theraputics 
HEPES Sigma Aldrich 
Isopropanol HPLC grade VWR 
KCl Merck Millipore 
Lipofectamine 2000 Life technologies 
MEM amino acid solution Sigma Aldrich 
Methanol HPLC grade VWR 
MgCl2 Roth 
Milk powder blotting grade Roth 
NaCl Applichem 
NaCl Sigma Aldrich 
NEM Santa Cruz technologies 
Opti-MEM Life technologies 
Penicillin / Streptomycin solution  Sigma Aldrich 
Protein G Sepharose Sigma Aldrich 
Recombinant human IDE R&D Systems 
SDS Sigma Aldrich 





Sucrose Sigma Aldrich 
Tricine Biomol 
Tris Sigma Aldrich 
Triton X-100 Merch Millipore 
TRIzol  Life technologies 
Trypsin / EDTA solution Sigma Aldrich 
Tween-20 Sigma Aldrich 
Water HPLC grade VWR 
Water RNase-free Qiagen 
ZnCl2 Sigma Aldrich 
β-mercapto ethanol Sigma Aldrich 
β-secretase inhibitor II Calbiochem 
β-secretase inhibitor IV Calbiochem 
β-secretase inhibitor X Calbiochem 
γ-secretase substrate Calbiochem 
 
Table A-3: Disposable materials used in the research 
Name Supplier 
10 cm dishes for cell culture Sarstedt 
12-well plate for cell culture Falcon 
24-well plate for cell culture Falcon 
6-well plate for cell culture Falcon 
96 well Maxi-sorp plate, black VWR 
96 well plate for cell culture Falcon 
96 well plate for RT-PCR Thermo Scientific 
96 well plate, black Costar 
96 well plate, transparent Greiner 
96 well plate, white Nunc 
96-deep well plate Nunc 





Filter paper Whatman 
Freezing tubes 1.8 ml Nunc 
Glass beads for MINILYS homogenizer 0.55 mm Peqlab 
Glass bottles, 2 ml Neolab 
Glass pipette Neolab 
Glass tubes Wheaton 
Needels 23G x1”, 0.6 mm x 25 mm Becton Dickinson & Co. 
Needels 24G x 1”, 0.55 mm x 25 mm Becton Dickinson & Co. 
Nitrocellulose membrane, 0.2 µm pore size Whatman 
Nitrocellulose membrane, 0.45 µm pore size Whatman 
Pasteur pipette VWR 
Petri dishes Sarstedt 
Photo copying films Xerox 
Reaction tubes, 1.5 ml Eppendorf 
Reaction tubes. 2 ml Eppendorf 
Rubber scraper  Hartenstein 
Sealing film for 96 well plate Peqlab 
Sealing film for RT-PCR plate Thermo scientific 
Silicon mat  Nunc 
Syringe, 1 ml Becton Dickinson & Co. 
Tris-Tricine gel, 10-20 % Anamed gel elctrophoresis 











qRT-PCR results of cholesterol, SREBP-1, and IDE genes 
 
 
Table B-1: Quantification of gene expression for MEF WT, MEF APP ∆ CT 15 (MEF 
dd), and MEF APP/APLP2 -/- (MEF 10.6), first experiment, part one. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 1731.05 
Baseline range start: 3    




Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty mef wt 13 Actin Beta 16.14 
A02-Ch5 SYBR Empty mef wt 15 Actin Beta 18.93 
A03-Ch5 SYBR Empty mef wt 16 Actin Beta 15.64 
A04-Ch5 SYBR Empty mef wt 17 Actin Beta 15.64 
A05-Ch5 SYBR Empty mef wt 18 Actin Beta 15.66 
A06-Ch5 SYBR Empty mef dd 19 Actin Beta 16.22 
A07-Ch5 SYBR Empty mef dd 20 Actin Beta 16.19 
A08-Ch5 SYBR Empty mef dd 22 Actin Beta 16.28 
A09-Ch5 SYBR Empty mef dd 23 Actin Beta 16.19 
A10-Ch5 SYBR Empty mef dd24 Actin Beta 16.27 
A11-Ch5 SYBR Empty mef 10.6 26 Actin Beta 15.67 




A13-Ch5 SYBR Empty mef 10.6 28 Actin Beta 15.8 
A14-Ch5 SYBR Empty mef 10.6 29 Actin Beta 15.25 
A15-Ch5 SYBR Empty mef 10.6 30 Actin Beta 15.82 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty mef wt 13 hmgcs_1 20.32 
B02-Ch5 SYBR Empty mef wt 15 hmgcs_1 23.98 
B03-Ch5 SYBR Empty mef wt 16 hmgcs_1 20.46 
B04-Ch5 SYBR Empty mef wt 17 hmgcs_1 20.45 
B05-Ch5 SYBR Empty mef wt 18 hmgcs_1 20.49 
B06-Ch5 SYBR Empty mef dd 19 hmgcs_1 20.84 
B07-Ch5 SYBR Empty mef dd 20 hmgcs_1 20.62 
B08-Ch5 SYBR Empty mef dd 22 hmgcs_1 20.54 
B09-Ch5 SYBR Empty mef dd 23 hmgcs_1 20.55 
B10-Ch5 SYBR Empty mef dd24 hmgcs_1 20.85 
B11-Ch5 SYBR Empty mef 10.6 26 hmgcs_1 20.65 
B12-Ch5 SYBR Empty mef 10.6 27 hmgcs_1 20.72 
B13-Ch5 SYBR Empty mef 10.6 28 hmgcs_1 20.2 
B14-Ch5 SYBR Empty mef 10.6 29 hmgcs_1 20.84 
B15-Ch5 SYBR Empty mef 10.6 30 hmgcs_1 20.29 
B16-Ch5 [none] [none]   n. def. 
C01-Ch5 SYBR Empty mef wt 13 hmgcs_2 34.4 
C02-Ch5 SYBR Empty mef wt 15 hmgcs_2 36.07 
C03-Ch5 SYBR Empty mef wt 16 hmgcs_2 34.93 
C04-Ch5 SYBR Empty mef wt 17 hmgcs_2 34.64 
C05-Ch5 SYBR Empty mef wt 18 hmgcs_2 34.39 
C06-Ch5 SYBR Empty mef dd 19 hmgcs_2 32.63 
C07-Ch5 SYBR Empty mef dd 20 hmgcs_2 32.34 
C08-Ch5 SYBR Empty mef dd 22 hmgcs_2 33.22 
C09-Ch5 SYBR Empty mef dd 23 hmgcs_2 32.89 
C10-Ch5 SYBR Empty mef dd24 hmgcs_2 32.92 
C11-Ch5 SYBR Empty mef 10.6 26 hmgcs_2 33.93 
C12-Ch5 SYBR Empty mef 10.6 27 hmgcs_2 33.88 
C13-Ch5 SYBR Empty mef 10.6 28 hmgcs_2 35.15 
C14-Ch5 SYBR Empty mef 10.6 29 hmgcs_2 34.36 
C15-Ch5 SYBR Empty mef 10.6 30 hmgcs_2 34.9 
C16-Ch5 [none] [none]   n. def. 
D01-Ch5 SYBR Empty mef wt 13 hmgcr 20.65 
D02-Ch5 SYBR Empty mef wt 15 hmgcr 24.19 
D03-Ch5 SYBR Empty mef wt 16 hmgcr 20.79 
D04-Ch5 SYBR Empty mef wt 17 hmgcr 20.52 
D05-Ch5 SYBR Empty mef wt 18 hmgcr 20.74 
D06-Ch5 SYBR Empty mef dd 19 hmgcr 22 
D07-Ch5 SYBR Empty mef dd 20 hmgcr 21.73 




D09-Ch5 SYBR Empty mef dd 23 hmgcr 22.1 
D10-Ch5 SYBR Empty mef dd24 hmgcr 21.93 
D11-Ch5 SYBR Empty mef 10.6 26 hmgcr 20.98 
D12-Ch5 SYBR Empty mef 10.6 27 hmgcr 21.01 
D13-Ch5 SYBR Empty mef 10.6 28 hmgcr 20.54 
D14-Ch5 SYBR Empty mef 10.6 29 hmgcr 20.7 
D15-Ch5 SYBR Empty mef 10.6 30 hmgcr 20.64 
D16-Ch5 [none] [none]   n. def. 
E01-Ch5 SYBR Empty mef wt 13 mvk 23.49 
E02-Ch5 SYBR Empty mef wt 15 mvk 26.54 
E03-Ch5 SYBR Empty mef wt 16 mvk 23.56 
E04-Ch5 SYBR Empty mef wt 17 mvk 23.18 
E05-Ch5 SYBR Empty mef wt 18 mvk 23.26 
E06-Ch5 SYBR Empty mef dd 19 mvk 23.74 
E07-Ch5 SYBR Empty mef dd 20 mvk 24.1 
E08-Ch5 SYBR Empty mef dd 22 mvk 23.98 
E09-Ch5 SYBR Empty mef dd 23 mvk 23.66 
E10-Ch5 SYBR Empty mef dd24 mvk 23.94 
E11-Ch5 SYBR Empty mef 10.6 26 mvk 23.51 
E12-Ch5 SYBR Empty mef 10.6 27 mvk 23.55 
E13-Ch5 SYBR Empty mef 10.6 28 mvk 23.54 
E14-Ch5 SYBR Empty mef 10.6 29 mvk 23.44 
E15-Ch5 SYBR Empty mef 10.6 30 mvk 23.63 
E16-Ch5 [none] [none]   n. def. 
F01-Ch5 SYBR Empty mef wt 13 pmvk 32.97 
F02-Ch5 SYBR Empty mef wt 15 pmvk 36.5 
F03-Ch5 SYBR Empty mef wt 16 pmvk 33.7 
F04-Ch5 SYBR Empty mef wt 17 pmvk 32.64 
F05-Ch5 SYBR Empty mef wt 18 pmvk 34.35 
F06-Ch5 SYBR Empty mef dd 19 pmvk 34.42 
F07-Ch5 SYBR Empty mef dd 20 pmvk 33.94 
F08-Ch5 SYBR Empty mef dd 22 pmvk 34.49 
F09-Ch5 SYBR Empty mef dd 23 pmvk 35.6 
F10-Ch5 SYBR Empty mef dd24 pmvk 35.38 
F11-Ch5 SYBR Empty mef 10.6 26 pmvk 35.93 
F12-Ch5 SYBR Empty mef 10.6 27 pmvk 34.28 
F13-Ch5 SYBR Empty mef 10.6 28 pmvk 33.61 
F14-Ch5 SYBR Empty mef 10.6 29 pmvk 32.39 
F15-Ch5 SYBR Empty mef 10.6 30 pmvk 33.17 






Table B-2 Quantification of gene expression for MEF WT, MEF APP ∆ CT 15 (MEF 
dd), and MEF APP/APLP2 -/- (MEF 10.6), first experiment, part two. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 2403.18 
Baseline range start: 3    




Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty mef wt 13 Actin Beta 16.11 
A02-Ch5 SYBR Empty mef wt 15 Actin Beta 19.41 
A03-Ch5 SYBR Empty mef wt 16 Actin Beta 16.38 
A04-Ch5 SYBR Empty mef wt 17 Actin Beta 16.09 
A05-Ch5 SYBR Empty mef wt 18 Actin Beta 16.53 
A06-Ch5 SYBR Empty mef dd 19 Actin Beta 16.78 
A07-Ch5 SYBR Empty mef dd 20 Actin Beta 16.84 
A08-Ch5 SYBR Empty mef dd 22 Actin Beta 16.88 
A09-Ch5 SYBR Empty mef dd 23 Actin Beta 17.04 
A10-Ch5 SYBR Empty mef dd 24 Actin Beta 16.56 
A11-Ch5 SYBR Empty mef 10.6 26 Actin Beta 16.33 
A12-Ch5 SYBR Empty mef 10.6 27 Actin Beta 17.74 
A13-Ch5 SYBR Empty mef 10.6 28 Actin Beta 16.08 
A14-Ch5 SYBR Empty mef 10.6 29 Actin Beta 16.79 
A15-Ch5 SYBR Empty mef 10.6 30 Actin Beta 16.14 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty mef wt 13 mvd 23.45 
B02-Ch5 SYBR Empty mef wt 15 mvd 26.74 




B04-Ch5 SYBR Empty mef wt 17 mvd 23.18 
B05-Ch5 SYBR Empty mef wt 18 mvd 23.31 
B06-Ch5 SYBR Empty mef dd 19 mvd 24.46 
B07-Ch5 SYBR Empty mef dd 20 mvd 24.29 
B08-Ch5 SYBR Empty mef dd 22 mvd 24.19 
B09-Ch5 SYBR Empty mef dd 23 mvd 24.13 
B10-Ch5 SYBR Empty mef dd 24 mvd 24.53 
B11-Ch5 SYBR Empty mef 10.6 26 mvd 24.3 
B12-Ch5 SYBR Empty mef 10.6 27 mvd 24.51 
B13-Ch5 SYBR Empty mef 10.6 28 mvd 24.19 
B14-Ch5 SYBR Empty mef 10.6 29 mvd 24.44 
B15-Ch5 SYBR Empty mef 10.6 30 mvd 24.23 
B16-Ch5 [none] [none]   n. def. 
C01-Ch5 SYBR Empty mef wt 13 fdps 20.72 
C02-Ch5 SYBR Empty mef wt 15 fdps 23.78 
C03-Ch5 SYBR Empty mef wt 16 fdps 20.59 
C04-Ch5 SYBR Empty mef wt 17 fdps 20.46 
C05-Ch5 SYBR Empty mef wt 18 fdps 20.64 
C06-Ch5 SYBR Empty mef dd 19 fdps 22 
C07-Ch5 SYBR Empty mef dd 20 fdps 21.48 
C08-Ch5 SYBR Empty mef dd 22 fdps 21.28 
C09-Ch5 SYBR Empty mef dd 23 fdps 21.32 
C10-Ch5 SYBR Empty mef dd 24 fdps 21.47 
C11-Ch5 SYBR Empty mef 10.6 26 fdps 20.28 
C12-Ch5 SYBR Empty mef 10.6 27 fdps 20.35 
C13-Ch5 SYBR Empty mef 10.6 28 fdps 19.98 
C14-Ch5 SYBR Empty mef 10.6 29 fdps 20.13 
C15-Ch5 SYBR Empty mef 10.6 30 fdps 20.63 
C16-Ch5 [none] [none]   n. def. 
D01-Ch5 SYBR Empty mef wt 13 fdtf1 21.66 
D02-Ch5 SYBR Empty mef wt 15 fdtf1 24.39 
D03-Ch5 SYBR Empty mef wt 16 fdtf1 21.12 
D04-Ch5 SYBR Empty mef wt 17 fdtf1 21.36 
D05-Ch5 SYBR Empty mef wt 18 fdtf1 21.13 
D06-Ch5 SYBR Empty mef dd 19 fdtf1 21.36 
D07-Ch5 SYBR Empty mef dd 20 fdtf1 21.33 
D08-Ch5 SYBR Empty mef dd 22 fdtf1 21.23 
D09-Ch5 SYBR Empty mef dd 23 fdtf1 21.12 
D10-Ch5 SYBR Empty mef dd 24 fdtf1 21.34 
D11-Ch5 SYBR Empty mef 10.6 26 fdtf1 21 
D12-Ch5 SYBR Empty mef 10.6 27 fdtf1 21.17 
D13-Ch5 SYBR Empty mef 10.6 28 fdtf1 20.82 
D14-Ch5 SYBR Empty mef 10.6 29 fdtf1 21.21 




D16-Ch5 [none] [none]   n. def. 
E01-Ch5 SYBR Empty mef wt 13 sqle 21.6 
E02-Ch5 SYBR Empty mef wt 15 sqle 24.41 
E03-Ch5 SYBR Empty mef wt 16 sqle 21.68 
E04-Ch5 SYBR Empty mef wt 17 sqle 21.2 
E05-Ch5 SYBR Empty mef wt 18 sqle 21.41 
E06-Ch5 SYBR Empty mef dd 19 sqle 21.57 
E07-Ch5 SYBR Empty mef dd 20 sqle 21.59 
E08-Ch5 SYBR Empty mef dd 22 sqle 21.66 
E09-Ch5 SYBR Empty mef dd 23 sqle 21.52 
E10-Ch5 SYBR Empty mef dd 24 sqle 21.95 
E11-Ch5 SYBR Empty mef 10.6 26 sqle 21.56 
E12-Ch5 SYBR Empty mef 10.6 27 sqle 21.64 
E13-Ch5 SYBR Empty mef 10.6 28 sqle 21.62 
E14-Ch5 SYBR Empty mef 10.6 29 sqle 21.44 
E15-Ch5 SYBR Empty mef 10.6 30 sqle 21.61 
E16-Ch5 [none] [none]   n. def. 
F01-Ch5 SYBR Empty mef wt 13 lss 23.43 
F02-Ch5 SYBR Empty mef wt 15 lss 27.35 
F03-Ch5 SYBR Empty mef wt 16 lss 23.43 
F04-Ch5 SYBR Empty mef wt 17 lss 23.39 
F05-Ch5 SYBR Empty mef wt 18 lss 23.65 
F06-Ch5 SYBR Empty mef dd 19 lss 24.37 
F07-Ch5 SYBR Empty mef dd 20 lss 24.27 
F08-Ch5 SYBR Empty mef dd 22 lss 24.13 
F09-Ch5 SYBR Empty mef dd 23 lss 23.76 
F10-Ch5 SYBR Empty mef dd 24 lss 24.46 
F11-Ch5 SYBR Empty mef 10.6 26 lss 24.32 
F12-Ch5 SYBR Empty mef 10.6 27 lss 24.1 
F13-Ch5 SYBR Empty mef 10.6 28 lss 23.57 
F14-Ch5 SYBR Empty mef 10.6 29 lss 23.3 
F15-Ch5 SYBR Empty mef 10.6 30 lss 23.44 
F16-Ch5 [none] [none]   n. def. 
 
 
Table B-3: Quantification of gene expression for MEF WT, MEF APP ∆ CT 15 (MEF 
dd), and MEF APP/APLP2 -/- (MEF 10.6), second experiment, part one. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  




Baseline: Trend Ch 5 Yes 727.05 
Baseline range start: 3    





Well Fluorophore Sample Type 
Sample 
Name Target Cq 
A01-Ch5 SYBR Empty wT actin beta 15.06 
A02-Ch5 SYBR Empty wT actin beta 14.51 
A03-Ch5 SYBR Empty wT actin beta 14.77 
A04-Ch5 SYBR Empty wT actin beta 14.42 
A05-Ch5 SYBR Empty wT actin beta 14.7 
A06-Ch5 SYBR Empty DD actin beta 15.98 
A07-Ch5 SYBR Empty DD actin beta 14.65 
A08-Ch5 SYBR Empty DD actin beta 24.03 
A09-Ch5 SYBR Empty DD actin beta 14.1 
A10-Ch5 SYBR Empty DD actin beta 14.34 
A11-Ch5 SYBR Empty 10.6 actin beta 14.72 
A12-Ch5 SYBR Empty 10.6 actin beta 14.53 
A13-Ch5 SYBR Empty 10.6 actin beta 14.49 
A14-Ch5 SYBR Empty 10.6 actin beta 14.39 
A15-Ch5 SYBR Empty 10.6 actin beta 14.24 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty wT polr2 20.69 
B02-Ch5 SYBR Empty wT polr2 20.84 
B03-Ch5 SYBR Empty wT polr2 20.9 
B04-Ch5 SYBR Empty wT polr2 20.52 
B05-Ch5 SYBR Empty wT polr2 20.6 
B06-Ch5 SYBR Empty DD polr2 22.11 
B07-Ch5 SYBR Empty DD polr2 21.14 
B08-Ch5 SYBR Empty DD polr2 34.95 




B10-Ch5 SYBR Empty DD polr2 21.16 
B11-Ch5 SYBR Empty 10.6 polr2 21.39 
B12-Ch5 SYBR Empty 10.6 polr2 20.87 
B13-Ch5 SYBR Empty 10.6 polr2 20.59 
B14-Ch5 SYBR Empty 10.6 polr2 20.61 
B15-Ch5 SYBR Empty 10.6 polr2 20.8 
B16-Ch5 [none] [none]   n. def. 
C01-Ch5 SYBR Empty wT hmcs1 19.5 
C02-Ch5 SYBR Empty wT hmcs1 19.06 
C03-Ch5 SYBR Empty wT hmcs1 19.25 
C04-Ch5 SYBR Empty wT hmcs1 19.17 
C05-Ch5 SYBR Empty wT hmcs1 19.1 
C06-Ch5 SYBR Empty DD hmcs1 20.11 
C07-Ch5 SYBR Empty DD hmcs1 19.03 
C08-Ch5 SYBR Empty DD hmcs1 28.05 
C09-Ch5 SYBR Empty DD hmcs1 19.01 
C10-Ch5 SYBR Empty DD hmcs1 19.01 
C11-Ch5 SYBR Empty 10.6 hmcs1 19.13 
C12-Ch5 SYBR Empty 10.6 hmcs1 19.34 
C13-Ch5 SYBR Empty 10.6 hmcs1 18.82 
C14-Ch5 SYBR Empty 10.6 hmcs1 19.19 
C15-Ch5 SYBR Empty 10.6 hmcs1 19.28 
C16-Ch5 [none] [none]   n. def. 
D01-Ch5 SYBR Empty wT hmgcs2 32.94 
D02-Ch5 SYBR Empty wT hmgcs2 32.34 
D03-Ch5 SYBR Empty wT hmgcs2 32.81 
D04-Ch5 SYBR Empty wT hmgcs2 32.75 
D05-Ch5 SYBR Empty wT hmgcs2 32.27 
D06-Ch5 SYBR Empty DD hmgcs2 31.45 
D07-Ch5 SYBR Empty DD hmgcs2 32.13 
D08-Ch5 SYBR Empty DD hmgcs2 34.24 
D09-Ch5 SYBR Empty DD hmgcs2 32.3 
D10-Ch5 SYBR Empty DD hmgcs2 31.8 
D11-Ch5 SYBR Empty 10.6 hmgcs2 32.96 
D12-Ch5 SYBR Empty 10.6 hmgcs2 31.96 
D13-Ch5 SYBR Empty 10.6 hmgcs2 31.53 
D14-Ch5 SYBR Empty 10.6 hmgcs2 32.02 
D15-Ch5 SYBR Empty 10.6 hmgcs2 31.75 
D16-Ch5 [none] [none]   n. def. 
E01-Ch5 SYBR Empty wT hmgcr 20.44 
E02-Ch5 SYBR Empty wT hmgcr 19.6 
E03-Ch5 SYBR Empty wT hmgcr 19.84 
E04-Ch5 SYBR Empty wT hmgcr 19.78 




E06-Ch5 SYBR Empty DD hmgcr 21.56 
E07-Ch5 SYBR Empty DD hmgcr 20.37 
E08-Ch5 SYBR Empty DD hmgcr 28.34 
E09-Ch5 SYBR Empty DD hmgcr 20.64 
E10-Ch5 SYBR Empty DD hmgcr 20.41 
E11-Ch5 SYBR Empty 10.6 hmgcr 20.58 
E12-Ch5 SYBR Empty 10.6 hmgcr 20.19 
E13-Ch5 SYBR Empty 10.6 hmgcr 19.87 
E14-Ch5 SYBR Empty 10.6 hmgcr 19.77 
E15-Ch5 SYBR Empty 10.6 hmgcr 19.73 
 
 
Table B-4: Quantification of gene expression for MEF WT, MEF APP ∆ CT 15 (MEF 
dd), and MEF APP/APLP2 -/- (MEF 10.6), second experiment, part two. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 764.99 
Baseline range start: 3    





Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty WT actin beta 14.94 
A02-Ch5 SYBR Empty WT actin beta 14.78 
A03-Ch5 SYBR Empty WT actin beta 14.69 
A04-Ch5 SYBR Empty WT actin beta 14.56 




A06-Ch5 SYBR Empty DD actin beta 15.38 
A07-Ch5 SYBR Empty DD actin beta 14.57 
A08-Ch5 SYBR Empty DD actin beta 24.15 
A09-Ch5 SYBR Empty DD actin beta 14.84 
A10-Ch5 SYBR Empty DD actin beta 14.99 
A11-Ch5 SYBR Empty 10.6 actin beta 14.74 
A12-Ch5 SYBR Empty 10.6 actin beta 14.62 
A13-Ch5 SYBR Empty 10.6 actin beta 14.27 
A14-Ch5 SYBR Empty 10.6 actin beta 14.22 
A15-Ch5 SYBR Empty 10.6 actin beta 14.38 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty WT polr2 20.87 
B02-Ch5 SYBR Empty WT polr2 21.1 
B03-Ch5 SYBR Empty WT polr2 20.88 
B04-Ch5 SYBR Empty WT polr2 20.63 
B05-Ch5 SYBR Empty WT polr2 20.8 
B06-Ch5 SYBR Empty DD polr2 22.24 
B07-Ch5 SYBR Empty DD polr2 21.3 
B08-Ch5 SYBR Empty DD polr2 33.85 
B09-Ch5 SYBR Empty DD polr2 21.33 
B10-Ch5 SYBR Empty DD polr2 21.59 
B11-Ch5 SYBR Empty 10.6 polr2 21.39 
B12-Ch5 SYBR Empty 10.6 polr2 20.83 
B13-Ch5 SYBR Empty 10.6 polr2 21.01 
B14-Ch5 SYBR Empty 10.6 polr2 20.64 
B15-Ch5 SYBR Empty 10.6 polr2 21 
B16-Ch5 [none] [none]   n. def. 
C01-Ch5 SYBR Empty WT mvk 22.88 
C02-Ch5 SYBR Empty WT mvk 22.43 
C03-Ch5 SYBR Empty WT mvk 22.44 
C04-Ch5 SYBR Empty WT mvk 22.34 
C05-Ch5 SYBR Empty WT mvk 22.4 
C06-Ch5 SYBR Empty DD mvk 23.03 
C07-Ch5 SYBR Empty DD mvk 22.03 
C08-Ch5 SYBR Empty DD mvk 34.19 
C09-Ch5 SYBR Empty DD mvk 22.12 
C10-Ch5 SYBR Empty DD mvk 21.87 
C11-Ch5 SYBR Empty 10.6 mvk 22.02 
C12-Ch5 SYBR Empty 10.6 mvk 22.27 
C13-Ch5 SYBR Empty 10.6 mvk 22.3 
C14-Ch5 SYBR Empty 10.6 mvk 22.47 
C15-Ch5 SYBR Empty 10.6 mvk 22.48 
C16-Ch5 [none] [none]   n. def. 




D02-Ch5 SYBR Empty WT pmvk 29.85 
D03-Ch5 SYBR Empty WT pmvk 29.85 
D04-Ch5 SYBR Empty WT pmvk 30.44 
D05-Ch5 SYBR Empty WT pmvk 29.75 
D06-Ch5 SYBR Empty DD pmvk 32.05 
D07-Ch5 SYBR Empty DD pmvk 30.06 
D08-Ch5 SYBR Empty DD pmvk n. def. 
D09-Ch5 SYBR Empty DD pmvk 31 
D10-Ch5 SYBR Empty DD pmvk 30.09 
D11-Ch5 SYBR Empty 10.6 pmvk 30.74 
D12-Ch5 SYBR Empty 10.6 pmvk 31.68 
D13-Ch5 SYBR Empty 10.6 pmvk 31.15 
D14-Ch5 SYBR Empty 10.6 pmvk n. def. 
D15-Ch5 SYBR Empty 10.6 pmvk 31.24 
D16-Ch5 [none] [none]   n. def. 
E01-Ch5 SYBR Empty WT mvd 22.55 
E02-Ch5 SYBR Empty WT mvd 22.21 
E03-Ch5 SYBR Empty WT mvd 22.13 
E04-Ch5 SYBR Empty WT mvd 22.45 
E05-Ch5 SYBR Empty WT mvd 21.9 
E06-Ch5 SYBR Empty DD mvd 22.64 
E07-Ch5 SYBR Empty DD mvd 22.37 
E08-Ch5 SYBR Empty DD mvd 30 
E09-Ch5 SYBR Empty DD mvd 22.28 
E10-Ch5 SYBR Empty DD mvd 22.16 
E11-Ch5 SYBR Empty 10.6 mvd 22.15 
E12-Ch5 SYBR Empty 10.6 mvd 23.04 
E13-Ch5 SYBR Empty 10.6 mvd 23.48 
E14-Ch5 SYBR Empty 10.6 mvd 23.87 
E15-Ch5 SYBR Empty 10.6 mvd 23.13 
E16-Ch5 [none] [none]   n. def. 
F01-Ch5 SYBR Empty WT fdps 19.12 
F02-Ch5 SYBR Empty WT fdps 19.08 
F03-Ch5 SYBR Empty WT fdps 18.82 
F04-Ch5 SYBR Empty WT fdps 19.03 
F05-Ch5 SYBR Empty WT fdps 19.06 
F06-Ch5 SYBR Empty DD fdps 20.52 
F07-Ch5 SYBR Empty DD fdps 19.65 
F08-Ch5 SYBR Empty DD fdps 29.7 
F09-Ch5 SYBR Empty DD fdps 19.97 
F10-Ch5 SYBR Empty DD fdps 19.65 
F11-Ch5 SYBR Empty 10.6 fdps 19.52 
F12-Ch5 SYBR Empty 10.6 fdps 19.73 




F14-Ch5 SYBR Empty 10.6 fdps 19.16 
F15-Ch5 SYBR Empty 10.6 fdps 19.12 
F16-Ch5 [none] [none]   n. def. 
 
 
Table B-5: Quantification of gene expression for MEF WT, MEF APP ∆ CT 15 (MEF 
dd), and MEF APP/APLP2 -/- (MEF 10.6), second experiment, part three. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 1026.33 
Baseline range start: 3    




Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty WT actin beta 15.3 
A02-Ch5 SYBR Empty WT actin beta 14.83 
A03-Ch5 SYBR Empty WT actin beta 14.93 
A04-Ch5 SYBR Empty WT actin beta 14.55 
A05-Ch5 SYBR Empty WT actin beta 14.86 
A06-Ch5 SYBR Empty DD actin beta 15.6 
A07-Ch5 SYBR Empty DD actin beta 14.96 
A08-Ch5 SYBR Empty DD actin beta 24.55 
A09-Ch5 SYBR Empty DD actin beta 15.42 
A10-Ch5 SYBR Empty DD actin beta 14.78 
A11-Ch5 SYBR Empty 10.6 actin beta 15.41 
A12-Ch5 SYBR Empty 10.6 actin beta n. def. 
A13-Ch5 SYBR Empty 10.6 actin beta 15.46 




A15-Ch5 SYBR Empty 10.6 actin beta 14.56 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty WT polr2 21.67 
B02-Ch5 SYBR Empty WT polr2 21.86 
B03-Ch5 SYBR Empty WT polr2 21.83 
B04-Ch5 SYBR Empty WT polr2 21.17 
B05-Ch5 SYBR Empty WT polr2 21.54 
B06-Ch5 SYBR Empty DD polr2 22.9 
B07-Ch5 SYBR Empty DD polr2 21.73 
B08-Ch5 SYBR Empty DD polr2 37.39 
B09-Ch5 SYBR Empty DD polr2 21.8 
B10-Ch5 SYBR Empty DD polr2 21.64 
B11-Ch5 SYBR Empty 10.6 polr2 21.45 
B12-Ch5 SYBR Empty 10.6 polr2 21.2 
B13-Ch5 SYBR Empty 10.6 polr2 21.02 
B14-Ch5 SYBR Empty 10.6 polr2 21.24 
B15-Ch5 SYBR Empty 10.6 polr2 21.16 
B16-Ch5 [none] [none]   n. def. 
C01-Ch5 SYBR Empty WT fdft 19.88 
C02-Ch5 SYBR Empty WT fdft 19.33 
C03-Ch5 SYBR Empty WT fdft n. def. 
C04-Ch5 SYBR Empty WT fdft 18.4 
C05-Ch5 SYBR Empty WT fdft 19.33 
C06-Ch5 SYBR Empty DD fdft 20.05 
C07-Ch5 SYBR Empty DD fdft 19.59 
C08-Ch5 SYBR Empty DD fdft 27.32 
C09-Ch5 SYBR Empty DD fdft 19.86 
C10-Ch5 SYBR Empty DD fdft 19.45 
C11-Ch5 SYBR Empty 10.6 fdft 19.41 
C12-Ch5 SYBR Empty 10.6 fdft 19.48 
C13-Ch5 SYBR Empty 10.6 fdft 19.22 
C14-Ch5 SYBR Empty 10.6 fdft 19.19 
C15-Ch5 SYBR Empty 10.6 fdft 19.31 
C16-Ch5 [none] [none]   n. def. 
D01-Ch5 SYBR Empty WT sqle 23.68 
D02-Ch5 SYBR Empty WT sqle 21.43 
D03-Ch5 SYBR Empty WT sqle 22.38 
D04-Ch5 SYBR Empty WT sqle 21.43 
D05-Ch5 SYBR Empty WT sqle 21.37 
D06-Ch5 SYBR Empty DD sqle 22.01 
D07-Ch5 SYBR Empty DD sqle 20.98 
D08-Ch5 SYBR Empty DD sqle 32.56 
D09-Ch5 SYBR Empty DD sqle 21.63 




D11-Ch5 SYBR Empty 10.6 sqle 20.52 
D12-Ch5 SYBR Empty 10.6 sqle 20.84 
D13-Ch5 SYBR Empty 10.6 sqle 20.59 
D14-Ch5 SYBR Empty 10.6 sqle 20.62 
D15-Ch5 SYBR Empty 10.6 sqle 20.47 
D16-Ch5 [none] [none]   n. def. 
E01-Ch5 SYBR Empty WT lss 23.31 
E02-Ch5 SYBR Empty WT lss 22.93 
E03-Ch5 SYBR Empty WT lss 23.01 
E04-Ch5 SYBR Empty WT lss 22.63 
E05-Ch5 SYBR Empty WT lss 22.72 
E06-Ch5 SYBR Empty DD lss 23.76 
E07-Ch5 SYBR Empty DD lss 22.24 
E08-Ch5 SYBR Empty DD lss 34.11 
E09-Ch5 SYBR Empty DD lss n. def. 
E10-Ch5 SYBR Empty DD lss 22.01 
E11-Ch5 SYBR Empty 10.6 lss 22.38 
E12-Ch5 SYBR Empty 10.6 lss 23.15 
E13-Ch5 SYBR Empty 10.6 lss 22.63 
E14-Ch5 SYBR Empty 10.6 lss 22.78 
E15-Ch5 SYBR Empty 10.6 lss 22.93 
 
 
Table B-6: Quantification of gene expression for MEF WT and MEF APP ∆ CT 15 
(MEF dd), third experiment, part one. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 1501,66 
Baseline range start: 3    







Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty wT actin beta 15,77 
A02-Ch5 SYBR Empty wT actin beta 15,26 
A03-Ch5 SYBR Empty wT actin beta 15,36 
A04-Ch5 SYBR Empty wT actin beta 15,46 
A05-Ch5 SYBR Empty wT actin beta 15,44 
A06-Ch5 SYBR Empty wT actin beta 15,65 
A07-Ch5 [none] [none]   n. def. 
A08-Ch5 SYBR Empty wt 3 actin beta 16,54 
A09-Ch5 SYBR Empty DD actin beta 15,85 
A10-Ch5 SYBR Empty DD actin beta 16,31 
A11-Ch5 SYBR Empty DD actin beta 16,28 
A12-Ch5 SYBR Empty DD actin beta 16,01 
A13-Ch5 [none] [none]   n. def. 
A14-Ch5 [none] [none]   n. def. 
A15-Ch5 [none] [none]   n. def. 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty wT polr2 22 
B02-Ch5 SYBR Empty wT polr2 21,91 
B03-Ch5 SYBR Empty wT polr2 21,71 
B04-Ch5 SYBR Empty wT polr2 21,58 
B05-Ch5 SYBR Empty wT polr2 21,57 
B06-Ch5 SYBR Empty wT polr2 21,73 
B07-Ch5 [none] [none]   n. def. 
B08-Ch5 SYBR Empty DD polr2 22,75 
B09-Ch5 SYBR Empty DD polr2 22,18 
B10-Ch5 SYBR Empty DD polr2 22,31 
B11-Ch5 SYBR Empty DD polr2 21,99 
B12-Ch5 SYBR Empty DD polr2 21,98 
B13-Ch5 [none] [none]   n. def. 
B14-Ch5 [none] [none]   n. def. 
B15-Ch5 [none] [none]   n. def. 




C01-Ch5 SYBR Empty wT hmgcr 20,62 
C02-Ch5 SYBR Empty wT hmgcr 20,28 
C03-Ch5 SYBR Empty wT hmgcr 20,91 
C04-Ch5 SYBR Empty wT hmgcr 20,24 
C05-Ch5 SYBR Empty wT hmgcr 20,28 
C06-Ch5 SYBR Empty wT hmgcr 20,19 
C07-Ch5 [none] [none]   n. def. 
C08-Ch5 SYBR Empty DD hmgcr 22,59 
C09-Ch5 SYBR Empty DD hmgcr 22,11 
C10-Ch5 SYBR Empty DD hmgcr 22,28 
C11-Ch5 SYBR Empty DD hmgcr 22,15 
C12-Ch5 SYBR Empty DD hmgcr 21,68 
C13-Ch5 SYBR Empty wt 3 hmgcr 20,17 
 
Table B-7: Quantification of gene expression for MEF WT and MEF APP ∆ CT 15 
(DD), third experiment, part two. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 1696,96 
Baseline range start: 3    




Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty wt actin beta 16,01 
A02-Ch5 SYBR Empty wt actin beta 15,7 
A03-Ch5 SYBR Empty wt actin beta 15,82 
A04-Ch5 SYBR Empty wt actin beta 15,61 




A06-Ch5 SYBR Empty wt actin beta 15,5 
A07-Ch5 [none] [none]   n. def. 
A08-Ch5 SYBR Empty DD actin beta 16,61 
A09-Ch5 SYBR Empty DD actin beta 16,1 
A10-Ch5 SYBR Empty DD actin beta 16,52 
A11-Ch5 SYBR Empty DD actin beta 16,37 
A12-Ch5 SYBR Empty DD actin beta 16,81 
A13-Ch5 [none] [none]   n. def. 
A14-Ch5 [none] [none]   n. def. 
A15-Ch5 [none] [none]   n. def. 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty wt polr2 22,08 
B02-Ch5 SYBR Empty wt polr2 22 
B03-Ch5 SYBR Empty wt polr2 21,95 
B04-Ch5 SYBR Empty wt polr2 21,52 
B05-Ch5 SYBR Empty wt polr2 21,73 
B06-Ch5 SYBR Empty wt polr2 21,59 
B07-Ch5 [none] [none]   n. def. 
B08-Ch5 SYBR Empty DD polr2 22,81 
B09-Ch5 SYBR Empty DD polr2 22,07 
B10-Ch5 SYBR Empty DD polr2 22,65 
B11-Ch5 SYBR Empty DD polr2 22,34 
B12-Ch5 SYBR Empty DD polr2 22,14 
B13-Ch5 [none] [none]   n. def. 
B14-Ch5 [none] [none]   n. def. 
B15-Ch5 [none] [none]   n. def. 
B16-Ch5 [none] [none]   n. def. 
C01-Ch5 SYBR Empty wt hmgcs1 20,43 
C02-Ch5 SYBR Empty wt hmgcs1 20,18 
C03-Ch5 SYBR Empty wt hmgcs1 20,26 
C04-Ch5 SYBR Empty wt hmgcs1 20,26 
C05-Ch5 SYBR Empty wt hmgcs1 20,05 
C06-Ch5 SYBR Empty wt hmgcs1 19,91 
C07-Ch5 [none] [none]   n. def. 
C08-Ch5 SYBR Empty DD hmgcs1 21,72 
C09-Ch5 SYBR Empty DD hmgcs1 21,19 
C10-Ch5 SYBR Empty DD hmgcs1 21,42 
C11-Ch5 SYBR Empty DD hmgcs1 21,22 
C12-Ch5 SYBR Empty DD hmgcs1 20,96 
C13-Ch5 [none] [none]   n. def. 
C14-Ch5 [none] [none]   n. def. 
C15-Ch5 [none] [none]   n. def. 
C16-Ch5 [none] [none]   n. def. 




D02-Ch5 SYBR Empty wt hmgcs2 34,9 
D03-Ch5 SYBR Empty wt hmgcs2 35,1 
D04-Ch5 SYBR Empty wt hmgcs2 34,68 
D05-Ch5 SYBR Empty wt hmgcs2 34,83 
D06-Ch5 SYBR Empty wt hmgcs2 35,03 
D07-Ch5 [none] [none]   n. def. 
D08-Ch5 SYBR Empty DD hmgcs2 33,06 
D09-Ch5 SYBR Empty DD hmgcs2 33,06 
D10-Ch5 SYBR Empty DD hmgcs2 32,69 
D11-Ch5 SYBR Empty DD hmgcs2 32,37 
D12-Ch5 SYBR Empty DD hmgcs2 33,91 
D13-Ch5 SYBR Empty wt hmgcs2 35,13 
D14-Ch5 SYBR Empty wt hmgcs2 35,24 
D15-Ch5 [none] [none]   n. def. 
D16-Ch5 [none] [none]   n. def. 
E01-Ch5 SYBR Empty wt mvk 23,7 
E02-Ch5 SYBR Empty wt mvk 23,41 
E03-Ch5 SYBR Empty wt mvk 23,47 
E04-Ch5 SYBR Empty wt mvk 23,64 
E05-Ch5 SYBR Empty wt mvk 23,39 
E06-Ch5 SYBR Empty wt mvk 23,3 
E07-Ch5 [none] [none]   n. def. 
E08-Ch5 SYBR Empty DD mvk 24,39 
E09-Ch5 SYBR Empty DD mvk 23,53 
E10-Ch5 SYBR Empty DD mvk 24,47 
E11-Ch5 SYBR Empty DD mvk 23,85 
E12-Ch5 SYBR Empty DD mvk 23,83 
E13-Ch5 SYBR Empty wt mvk 23,62 
E14-Ch5 SYBR Empty wt mvk 23,31 
 
 
Table B-8: Quantification of gene expression for MEF WT and MEF APP ∆ CT 15 
(DD), third experiment, part three. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 2069,06 
Baseline range start: 3    







Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty wt actin beta 16,36 
A02-Ch5 SYBR Empty wt actin beta 16,53 
A03-Ch5 SYBR Empty wt actin beta 16,37 
A04-Ch5 SYBR Empty wt actin beta 16,08 
A05-Ch5 SYBR Empty wt actin beta 15,95 
A06-Ch5 SYBR Empty wt actin beta 15,83 
A07-Ch5 [none] [none]   n. def. 
A08-Ch5 SYBR Empty DD actin beta 16,93 
A09-Ch5 SYBR Empty DD actin beta 16,49 
A10-Ch5 SYBR Empty DD actin beta 16,9 
A11-Ch5 SYBR Empty DD actin beta 16,66 
A12-Ch5 SYBR Empty DD actin beta 16,66 
A13-Ch5 [none] [none]   n. def. 
A14-Ch5 [none] [none]   n. def. 
A15-Ch5 [none] [none]   n. def. 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty wt polr2 22,5 
B02-Ch5 SYBR Empty wt polr2 22,5 
B03-Ch5 SYBR Empty wt polr2 22,5 
B04-Ch5 SYBR Empty wt polr2 22,28 
B05-Ch5 SYBR Empty wt polr2 22,28 
B06-Ch5 SYBR Empty wt polr2 22,07 
B07-Ch5 [none] [none]   n. def. 
B08-Ch5 SYBR Empty DD polr2 23,25 
B09-Ch5 SYBR Empty DD polr2 22,55 
B10-Ch5 SYBR Empty DD polr2 23,11 
B11-Ch5 SYBR Empty DD polr2 22,73 
B12-Ch5 SYBR Empty DD polr2 22,55 
B13-Ch5 [none] [none]   n. def. 
B14-Ch5 [none] [none]   n. def. 
B15-Ch5 [none] [none]   n. def. 




C01-Ch5 SYBR Empty wt pmvk 23,91 
C02-Ch5 SYBR Empty wt pmvk 23,66 
C03-Ch5 SYBR Empty wt pmvk 23,71 
C04-Ch5 SYBR Empty wt pmvk 23,89 
C05-Ch5 SYBR Empty wt pmvk 23,62 
C06-Ch5 SYBR Empty wt pmvk 23,65 
C07-Ch5 [none] [none]   n. def. 
C08-Ch5 SYBR Empty DD pmvk 25,16 
C09-Ch5 SYBR Empty DD pmvk 24,57 
C10-Ch5 SYBR Empty DD pmvk 24,93 
C11-Ch5 SYBR Empty DD pmvk 24,58 
C12-Ch5 SYBR Empty DD pmvk 24,66 
C13-Ch5 [none] [none]   n. def. 
C14-Ch5 [none] [none]   n. def. 
C15-Ch5 [none] [none]   n. def. 
C16-Ch5 [none] [none]   n. def. 
D01-Ch5 SYBR Empty wt mvd 23,31 
D02-Ch5 SYBR Empty wt mvd 23,28 
D03-Ch5 SYBR Empty wt mvd 23,51 
D04-Ch5 SYBR Empty wt mvd 23,47 
D05-Ch5 SYBR Empty wt mvd 22,9 
D06-Ch5 SYBR Empty wt mvd 23,09 
D07-Ch5 [none] [none]   n. def. 
D08-Ch5 SYBR Empty DD mvd 25,38 
D09-Ch5 SYBR Empty DD mvd 24,43 
D10-Ch5 SYBR Empty DD mvd 24,99 
D11-Ch5 SYBR Empty DD mvd 25,24 
D12-Ch5 SYBR Empty DD mvd 24,57 
D13-Ch5 [none] [none]   n. def. 
D14-Ch5 [none] [none]   n. def. 
D15-Ch5 [none] [none]   n. def. 
D16-Ch5 [none] [none]   n. def. 
E01-Ch5 SYBR Empty wt fdps 20,29 
E02-Ch5 SYBR Empty wt fdps 20,12 
E03-Ch5 SYBR Empty wt fdps 20,27 
E04-Ch5 SYBR Empty wt fdps 20,61 
E05-Ch5 SYBR Empty wt fdps 20,43 
E06-Ch5 SYBR Empty wt fdps 20,57 
E07-Ch5 [none] [none]   n. def. 
E08-Ch5 SYBR Empty DD fdps 21,83 
E09-Ch5 SYBR Empty DD fdps 21,59 
E10-Ch5 SYBR Empty DD fdps 21,68 
E11-Ch5 SYBR Empty DD fdps 21,54 





Table B-9: Quantification of gene expression for MEF WT and MEF APP ∆ CT 15 
(DD), third experiment, part four. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 2081,28 
Baseline range start: 3    




Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty WT actin beta 16,88 
A02-Ch5 SYBR Empty WT actin beta 15,97 
A03-Ch5 SYBR Empty WT actin beta 16,09 
A04-Ch5 SYBR Empty WT actin beta 16,02 
A05-Ch5 SYBR Empty WT actin beta 15,84 
A06-Ch5 SYBR Empty WT actin beta 15,78 
A07-Ch5 [none] [none]   n. def. 
A08-Ch5 SYBR Empty DD actin beta 17,51 
A09-Ch5 SYBR Empty DD actin beta 16,34 
A10-Ch5 SYBR Empty DD actin beta 16,92 
A11-Ch5 SYBR Empty DD actin beta 16,57 
A12-Ch5 SYBR Empty DD actin beta 16,64 
A13-Ch5 [none] [none]   n. def. 
A14-Ch5 [none] [none]   n. def. 
A15-Ch5 [none] [none]   n. def. 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty WT polr2 22,65 
B02-Ch5 SYBR Empty WT polr2 22,7 
B03-Ch5 SYBR Empty WT polr2 22,57 




B05-Ch5 SYBR Empty WT polr2 22,32 
B06-Ch5 SYBR Empty WT polr2 22,17 
B07-Ch5 [none] [none]   n. def. 
B08-Ch5 SYBR Empty DD polr2 23,29 
B09-Ch5 SYBR Empty DD polr2 22,66 
B10-Ch5 SYBR Empty DD polr2 23,17 
B11-Ch5 SYBR Empty DD polr2 23,03 
B12-Ch5 SYBR Empty DD polr2 22,51 
B13-Ch5 [none] [none]   n. def. 
B14-Ch5 [none] [none]   n. def. 
B15-Ch5 [none] [none]   n. def. 
B16-Ch5 [none] [none]   n. def. 
C01-Ch5 SYBR Empty WT fdft 21,39 
C02-Ch5 SYBR Empty WT fdft 21,32 
C03-Ch5 SYBR Empty WT fdft 20,91 
C04-Ch5 SYBR Empty WT fdft 21,17 
C05-Ch5 SYBR Empty WT fdft 20,91 
C06-Ch5 SYBR Empty WT fdft 21,16 
C07-Ch5 [none] [none]   n. def. 
C08-Ch5 SYBR Empty DD fdft 22,08 
C09-Ch5 SYBR Empty DD fdft 21,6 
C10-Ch5 SYBR Empty DD fdft 21,91 
C11-Ch5 SYBR Empty DD fdft 21,51 
C12-Ch5 SYBR Empty DD fdft 21,44 
C13-Ch5 [none] [none]   n. def. 
C14-Ch5 [none] [none]   n. def. 
C15-Ch5 [none] [none]   n. def. 
C16-Ch5 [none] [none]   n. def. 
D01-Ch5 SYBR Empty WT sqle 21,63 
D02-Ch5 SYBR Empty WT sqle 21,36 
D03-Ch5 SYBR Empty WT sqle 21,25 
D04-Ch5 SYBR Empty WT sqle 21,16 
D05-Ch5 SYBR Empty WT sqle 21,11 
D06-Ch5 SYBR Empty WT sqle 21,13 
D07-Ch5 [none] [none]   n. def. 
D08-Ch5 SYBR Empty DD sqle 22,31 
D09-Ch5 SYBR Empty DD sqle 21,85 
D10-Ch5 SYBR Empty DD sqle 22,24 
D11-Ch5 SYBR Empty DD sqle 22,27 
D12-Ch5 SYBR Empty DD sqle 21,65 
D13-Ch5 [none] [none]   n. def. 
D14-Ch5 [none] [none]   n. def. 
D15-Ch5 [none] [none]   n. def. 




E01-Ch5 SYBR Empty WT lss 23,3 
E02-Ch5 SYBR Empty WT lss 23,03 
E03-Ch5 SYBR Empty WT lss 23,08 
E04-Ch5 SYBR Empty WT lss 23,2 
E05-Ch5 SYBR Empty WT lss 23,12 
E06-Ch5 SYBR Empty WT lss 23,16 
E07-Ch5 [none] [none]   n. def. 
E08-Ch5 SYBR Empty DD lss 24,63 
E09-Ch5 SYBR Empty DD lss 23,8 
E10-Ch5 SYBR Empty DD lss 24,28 
E11-Ch5 SYBR Empty DD lss 23,87 
E12-Ch5 SYBR Empty DD lss 23,57 
 
 
Table B-10: Quantification of gene expression for MEF WT and MEF APP/APLP2 -/- 
(MEF 10.6), third experiment, part one. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 1868,34 
Baseline range start: 3    





Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty WT actin beta 15,36 
A02-Ch5 SYBR Empty WT actin beta 15,59 




A04-Ch5 SYBR Empty WT actin beta 15,1 
A05-Ch5 SYBR Empty WT actin beta 15,37 
A06-Ch5 SYBR Empty WT actin beta 15,37 
A07-Ch5 [none] [none]   n. def. 
A08-Ch5 SYBR Empty 10,6 actin beta 15,35 
A09-Ch5 SYBR Empty 10,6 actin beta 15,23 
A10-Ch5 SYBR Empty 10,6 actin beta 15,74 
A11-Ch5 SYBR Empty 10,6 actin beta 15,47 
A12-Ch5 SYBR Empty 10,6 (11) actin beta 15,49 
A13-Ch5 SYBR Empty WT actin beta 15,42 
A14-Ch5 SYBR Empty 10,6 (12) actin beta 15,44 
A15-Ch5 [none] [none]   n. def. 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty WT polr2 21,77 
B02-Ch5 SYBR Empty WT polr2 21,88 
B03-Ch5 SYBR Empty WT polr2 22,08 
B04-Ch5 SYBR Empty WT polr2 21,43 
B05-Ch5 SYBR Empty WT polr2 21,59 
B06-Ch5 SYBR Empty WT polr2 21,79 
B07-Ch5 [none] [none]   n. def. 
B08-Ch5 SYBR Empty 10,6 polr2 21,61 
B09-Ch5 SYBR Empty 10,6 polr2 21,27 
B10-Ch5 SYBR Empty 10,6 polr2 21,55 
B11-Ch5 SYBR Empty 10,6 polr2 21,31 
B12-Ch5 SYBR Empty 10,6 (10) polr2 21,55 
B13-Ch5 SYBR Empty 10,6 polr2 n. def. 
B14-Ch5 SYBR Empty 10,6 (12) polr2 23,15 
B15-Ch5 [none] [none]   n. def. 
B16-Ch5 [none] [none]   n. def. 
C01-Ch5 SYBR Empty WT hmgcr 20,27 
C02-Ch5 SYBR Empty WT hmgcr 20,46 
C03-Ch5 SYBR Empty WT hmgcr 20,39 
C04-Ch5 SYBR Empty WT hmgcr 20,2 
C05-Ch5 SYBR Empty WT hmgcr 20,25 
C06-Ch5 SYBR Empty WT hmgcr 20,33 
C07-Ch5 [none] [none]   n. def. 
C08-Ch5 SYBR Empty 10,6 hmgcr 21,31 
C09-Ch5 SYBR Empty 10,6 hmgcr 21,25 
C10-Ch5 SYBR Empty 10,6 hmgcr 21,37 
C11-Ch5 SYBR Empty 10,6 hmgcr 21,22 
C12-Ch5 SYBR Empty 10,6 (11) hmgcr 21,27 
C13-Ch5 SYBR Empty 10,6 hmgcr n. def. 






Table B-11: Quantification of gene expression for MEF WT and MEF APP/APLP2 -/- 
(MEF clone 10.6), third experiment, part two. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 1717,82 
Baseline range start: 3    





Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty WT actin beta 15,55 
A02-Ch5 SYBR Empty WT actin beta 15,83 
A03-Ch5 SYBR Empty WT actin beta 15,59 
A04-Ch5 SYBR Empty WT actin beta 15,31 
A05-Ch5 SYBR Empty WT actin beta 15,13 
A06-Ch5 SYBR Empty WT actin beta 15,33 
A07-Ch5 [none] [none]   n. def. 
A08-Ch5 SYBR Empty 10,6 actin beta 15,14 
A09-Ch5 SYBR Empty 10,6 actin beta 15,16 
A10-Ch5 SYBR Empty 10,6 actin beta 15,32 
A11-Ch5 SYBR Empty 10,6 actin beta 15,39 
A12-Ch5 SYBR Empty 10,6 actin beta 15,28 
A13-Ch5 SYBR Empty 10,6 actin beta 15,25 
A14-Ch5 [none] [none]   n. def. 
A15-Ch5 [none] [none]   n. def. 
A16-Ch5 [none] [none]   n. def. 




B02-Ch5 SYBR Empty WT polr2 21,85 
B03-Ch5 SYBR Empty WT polr2 21,99 
B04-Ch5 SYBR Empty WT polr2 21,64 
B05-Ch5 SYBR Empty WT polr2 21,6 
B06-Ch5 SYBR Empty WT polr2 21,68 
B07-Ch5 [none] [none]   n. def. 
B08-Ch5 SYBR Empty 10,6 polr2 21,42 
B09-Ch5 SYBR Empty 10,6 polr2 21,24 
B10-Ch5 SYBR Empty 10,6 polr2 22,16 
B11-Ch5 SYBR Empty 10,6 polr2 21,36 
B12-Ch5 SYBR Empty 10,6 polr2 21,36 
B13-Ch5 SYBR Empty 10,6 polr2 21,18 
B14-Ch5 [none] [none]   n. def. 
B15-Ch5 [none] [none]   n. def. 
B16-Ch5 [none] [none]   n. def. 
C01-Ch5 SYBR Empty WT hmgcs1 20,06 
C02-Ch5 SYBR Empty WT hmgcs1 20,32 
C03-Ch5 SYBR Empty WT hmgcs1 20,33 
C04-Ch5 SYBR Empty WT hmgcs1 19,97 
C05-Ch5 SYBR Empty WT hmgcs1 19,98 
C06-Ch5 SYBR Empty WT hmgcs1 20,12 
C07-Ch5 [none] [none]   n. def. 
C08-Ch5 SYBR Empty 10,6 hmgcs1 20,83 
C09-Ch5 SYBR Empty 10,6 hmgcs1 20,9 
C10-Ch5 SYBR Empty 10,6 hmgcs1 21,01 
C11-Ch5 SYBR Empty 10,6 hmgcs1 21,01 
C12-Ch5 SYBR Empty 10,6 hmgcs1 20,86 
C13-Ch5 SYBR Empty 10,6 hmgcs1 20,82 
C14-Ch5 [none] [none]   n. def. 
C15-Ch5 [none] [none]   n. def. 
C16-Ch5 [none] [none]   n. def. 
D01-Ch5 SYBR Empty WT hmgcs2 34,4 
D02-Ch5 SYBR Empty WT hmgcs2 35,25 
D03-Ch5 SYBR Empty WT hmgcs2 36,72 
D04-Ch5 SYBR Empty WT hmgcs2 35,92 
D05-Ch5 SYBR Empty WT hmgcs2 35,12 
D06-Ch5 SYBR Empty WT hmgcs2 36,53 
D07-Ch5 [none] [none]   n. def. 
D08-Ch5 SYBR Empty 10,6 hmgcs2 35,69 
D09-Ch5 SYBR Empty 10,6 hmgcs2 34,51 
D10-Ch5 SYBR Empty 10,6 hmgcs2 34,67 
D11-Ch5 SYBR Empty 10,6 hmgcs2 34,82 
D12-Ch5 SYBR Empty 10,6 hmgcs2 35,08 




D14-Ch5 [none] [none]   n. def. 
D15-Ch5 [none] [none]   n. def. 
D16-Ch5 [none] [none]   n. def. 
E01-Ch5 SYBR Empty WT hmgcr 20,32 
E02-Ch5 SYBR Empty WT hmgcr 20,41 
E03-Ch5 SYBR Empty WT hmgcr 20,49 
E04-Ch5 SYBR Empty WT hmgcr 20,3 
E05-Ch5 SYBR Empty WT hmgcr 20,13 
E06-Ch5 SYBR Empty WT hmgcr 20,49 
E07-Ch5 [none] [none]   n. def. 
E08-Ch5 SYBR Empty 10,6 hmgcr 21,42 
E09-Ch5 SYBR Empty 10,6 hmgcr 21,13 
E10-Ch5 SYBR Empty 10,6 hmgcr 21,23 
E11-Ch5 SYBR Empty 10,6 hmgcr 21,27 
E12-Ch5 SYBR Empty 10,6 hmgcr 21,26 
E13-Ch5 SYBR Empty 10,6 hmgcr 21,29 
E14-Ch5 [none] [none]   n. def. 
E15-Ch5 [none] [none]   n. def. 
E16-Ch5 [none] [none]   n. def. 
F01-Ch5 SYBR Empty WT mvk 22,86 
F02-Ch5 SYBR Empty WT mvk 23,14 
F03-Ch5 SYBR Empty WT mvk 23,21 
F04-Ch5 SYBR Empty WT mvk 23,56 
F05-Ch5 SYBR Empty WT mvk 22,95 
F06-Ch5 SYBR Empty WT mvk 22,96 
F07-Ch5 [none] [none]   n. def. 
F08-Ch5 SYBR Empty 10,6 mvk 23,68 
F09-Ch5 SYBR Empty 10,6 mvk 23,67 
F10-Ch5 SYBR Empty 10,6 mvk 23,75 
F11-Ch5 SYBR Empty 10,6 mvk 23,86 
F12-Ch5 SYBR Empty 10,6 mvk 23,76 
F13-Ch5 SYBR Empty 10,6 mvk 23,92 
 
Table B-12: Quantification of gene expression for MEF WT and MEF APP/APLP2 -/- 
(MEF clone 10.6), third experiment, part three. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 1739,97 
Baseline range start: 3    







Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty WT actin beta 15,96 
A02-Ch5 SYBR Empty WT actin beta 14,88 
A03-Ch5 SYBR Empty WT actin beta 15,62 
A04-Ch5 SYBR Empty WT actin beta 15,32 
A05-Ch5 SYBR Empty WT actin beta 15,53 
A06-Ch5 SYBR Empty WT actin beta 15,4 
A07-Ch5 [none] [none]   n. def. 
A08-Ch5 SYBR Empty 10,6 actin beta 15,76 
A09-Ch5 SYBR Empty 10,6 actin beta 15,17 
A10-Ch5 SYBR Empty 10,6 actin beta 16,1 
A11-Ch5 SYBR Empty 10,6 actin beta 15,41 
A12-Ch5 SYBR Empty 10,6 actin beta 15,6 
A13-Ch5 SYBR Empty 10,6 actin beta 15,61 
A14-Ch5 [none] [none]   n. def. 
A15-Ch5 [none] [none]   n. def. 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty WT polr2 21,6 
B02-Ch5 SYBR Empty WT polr2 21,76 
B03-Ch5 SYBR Empty WT polr2 22,21 
B04-Ch5 SYBR Empty WT polr2 21,58 
B05-Ch5 SYBR Empty WT polr2 21,75 
B06-Ch5 SYBR Empty WT polr2 21,67 
B07-Ch5 [none] [none]   n. def. 
B08-Ch5 SYBR Empty 10,6 polr2 21,48 
B09-Ch5 SYBR Empty 10,6 polr2 21,21 
B10-Ch5 SYBR Empty 10,6 polr2 21,52 
B11-Ch5 SYBR Empty 10,6 polr2 21,42 
B12-Ch5 SYBR Empty 10,6 polr2 21,53 
B13-Ch5 SYBR Empty 10,6 polr2 21,67 
B14-Ch5 [none] [none]   n. def. 




B16-Ch5 [none] [none]   n. def. 
C01-Ch5 SYBR Empty WT pmvk 23,08 
C02-Ch5 SYBR Empty WT pmvk 23,37 
C03-Ch5 SYBR Empty WT pmvk 23,34 
C04-Ch5 SYBR Empty WT pmvk 23,5 
C05-Ch5 SYBR Empty WT pmvk 23,01 
C06-Ch5 SYBR Empty WT pmvk 23,31 
C07-Ch5 [none] [none]   n. def. 
C08-Ch5 SYBR Empty 10,6 pmvk 24,49 
C09-Ch5 SYBR Empty 10,6 pmvk 24,66 
C10-Ch5 SYBR Empty 10,6 pmvk 24,67 
C11-Ch5 SYBR Empty 10,6 pmvk 24,57 
C12-Ch5 SYBR Empty 10,6 pmvk 24,49 
C13-Ch5 SYBR Empty 10,6 pmvk 24,14 
C14-Ch5 [none] [none]   n. def. 
C15-Ch5 [none] [none]   n. def. 
C16-Ch5 [none] [none]   n. def. 
D01-Ch5 SYBR Empty WT mvd 22,46 
D02-Ch5 SYBR Empty WT mvd 21,96 
D03-Ch5 SYBR Empty WT mvd 22,56 
D04-Ch5 SYBR Empty WT mvd 22,78 
D05-Ch5 SYBR Empty WT mvd 22,38 
D06-Ch5 SYBR Empty WT mvd 22,96 
D07-Ch5 [none] [none]   n. def. 
D08-Ch5 SYBR Empty 10,6 mvd 24,51 
D09-Ch5 SYBR Empty 10,6 mvd 24,21 
D10-Ch5 SYBR Empty 10,6 mvd 24,51 
D11-Ch5 SYBR Empty 10,6 mvd 24,36 
D12-Ch5 SYBR Empty 10,6 mvd 24,48 
D13-Ch5 SYBR Empty 10,6 mvd 24,14 
D14-Ch5 [none] [none]   n. def. 
D15-Ch5 [none] [none]   n. def. 
D16-Ch5 [none] [none]   n. def. 
E01-Ch5 SYBR Empty WT fdps 19,89 
E02-Ch5 SYBR Empty WT fdps 19,65 
E03-Ch5 SYBR Empty WT fdps 20,29 
E04-Ch5 SYBR Empty WT fdps 20,01 
E05-Ch5 SYBR Empty WT fdps 19,63 
E06-Ch5 SYBR Empty WT fdps 19,55 
E07-Ch5 [none] [none]   n. def. 
E08-Ch5 SYBR Empty 10,6 fdps 20,83 
E09-Ch5 SYBR Empty 10,6 fdps 39,04 
E10-Ch5 SYBR Empty 10,6 fdps 20,7 




E12-Ch5 SYBR Empty 10,6 fdps 19,87 
E13-Ch5 SYBR Empty 10,6 fdps 20,53 
 
Table B-13: Quantification of gene expression for MEF WT and MEF APP/APLP2 -/- 
(MEF clone 10.6), third experiment, part four. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 1907,14 
Baseline range start: 3    




Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty WT actin beta 15,58 
A02-Ch5 SYBR Empty WT actin beta 15,82 
A03-Ch5 SYBR Empty WT actin beta 15,94 
A04-Ch5 SYBR Empty WT actin beta 15,46 
A05-Ch5 SYBR Empty WT actin beta 15,54 
A06-Ch5 SYBR Empty WT actin beta 15,57 
A07-Ch5 [none] [none]   n. def. 
A08-Ch5 SYBR Empty 10,6 actin beta 15,98 
A09-Ch5 SYBR Empty 10,6 actin beta 15,37 
A10-Ch5 SYBR Empty 10,6 actin beta 15,56 
A11-Ch5 SYBR Empty 10,6 actin beta 15,59 
A12-Ch5 SYBR Empty 10,6 actin beta 15,56 
A13-Ch5 SYBR Empty 10,6 actin beta 15,59 
A14-Ch5 [none] [none]   n. def. 
A15-Ch5 [none] [none]   n. def. 




B01-Ch5 SYBR Empty WT polr2 22,12 
B02-Ch5 SYBR Empty WT polr2 22,21 
B03-Ch5 SYBR Empty WT polr2 22,29 
B04-Ch5 SYBR Empty WT polr2 21,84 
B05-Ch5 SYBR Empty WT polr2 21,78 
B06-Ch5 SYBR Empty WT polr2 21,98 
B07-Ch5 [none] [none]   n. def. 
B08-Ch5 SYBR Empty 10,6 polr2 22,29 
B09-Ch5 SYBR Empty 10,6 polr2 21,35 
B10-Ch5 SYBR Empty 10,6 polr2 21,71 
B11-Ch5 SYBR Empty 10,6 polr2 21,68 
B12-Ch5 SYBR Empty 10,6 polr2 21,48 
B13-Ch5 SYBR Empty 10,6 polr2 21,63 
B14-Ch5 [none] [none]   n. def. 
B15-Ch5 [none] [none]   n. def. 
B16-Ch5 [none] [none]   n. def. 
C01-Ch5 SYBR Empty WT fdft 20,43 
C02-Ch5 SYBR Empty WT fdft 21,06 
C03-Ch5 SYBR Empty WT fdft 20,88 
C04-Ch5 SYBR Empty WT fdft 20,61 
C05-Ch5 SYBR Empty WT fdft 20,43 
C06-Ch5 SYBR Empty WT fdft 20,78 
C07-Ch5 [none] [none]   n. def. 
C08-Ch5 SYBR Empty 10,6 fdft 21,02 
C09-Ch5 SYBR Empty 10,6 fdft 21,3 
C10-Ch5 SYBR Empty 10,6 fdft 21,43 
C11-Ch5 SYBR Empty 10,6 fdft 21,4 
C12-Ch5 SYBR Empty 10,6 fdft 21,28 
C13-Ch5 SYBR Empty 10,6 fdft 21,28 
C14-Ch5 [none] [none]   n. def. 
C15-Ch5 [none] [none]   n. def. 
C16-Ch5 [none] [none]   n. def. 
D01-Ch5 SYBR Empty WT sqle 20,85 
D02-Ch5 SYBR Empty WT sqle 21,35 
D03-Ch5 SYBR Empty WT sqle 21,07 
D04-Ch5 SYBR Empty WT sqle 21,15 
D05-Ch5 SYBR Empty WT sqle 21,03 
D06-Ch5 SYBR Empty WT sqle 21,15 
D07-Ch5 [none] [none]   n. def. 
D08-Ch5 SYBR Empty 10,6 sqle 21,57 
D09-Ch5 SYBR Empty 10,6 sqle 21,49 
D10-Ch5 SYBR Empty 10,6 sqle 21,88 
D11-Ch5 SYBR Empty 10,6 sqle 21,76 




D13-Ch5 SYBR Empty 10,6 sqle 21,62 
D14-Ch5 [none] [none]   n. def. 
D15-Ch5 [none] [none]   n. def. 
D16-Ch5 [none] [none]   n. def. 
E01-Ch5 SYBR Empty WT lss 22,68 
E02-Ch5 SYBR Empty WT lss 22,88 
E03-Ch5 SYBR Empty WT lss 22,87 
E04-Ch5 SYBR Empty WT lss 22,76 
E05-Ch5 SYBR Empty WT lss 22,45 
E06-Ch5 SYBR Empty WT lss 22,72 
E07-Ch5 [none] [none]   n. def. 
E08-Ch5 SYBR Empty 10,6 lss 23,96 
E09-Ch5 SYBR Empty 10,6 lss 23,43 
E10-Ch5 SYBR Empty 10,6 lss 23,57 
E11-Ch5 SYBR Empty 10,6 lss 24,04 
E12-Ch5 SYBR Empty 10,6 lss 23,96 
E13-Ch5 SYBR Empty 10,6 lss 23,72 
 
 
Table B-14: Quantification of gene expression for MEF PS1 rescue (MEF 26), and 
MEF PS1/2 -/- (MEF DK), first experiment, part one. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 1281.52 
Baseline range start: 3    








Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty #26 1 actin beta 15.09 
A02-Ch5 SYBR Empty #26 2 actin beta 15.29 
A03-Ch5 SYBR Empty #26 3 actin beta 15.27 
A04-Ch5 SYBR Empty #26 4 actin beta 15.19 
A05-Ch5 SYBR Empty #26 5 actin beta 15.31 
A06-Ch5 SYBR Empty #26 6 actin beta 15.99 
A07-Ch5 SYBR Empty DK 1 actin beta 14.79 
A08-Ch5 SYBR Empty DK 2 actin beta 27.41 
A09-Ch5 SYBR Empty DK 3 actin beta 15.06 
A10-Ch5 SYBR Empty DK 4 actin beta 15.05 
A11-Ch5 SYBR Empty DK 5 actin beta 15.88 
A12-Ch5 SYBR Empty DK 6 actin beta 15.14 
A13-Ch5 SYBR Empty #26 1 actin beta 15.06 
A14-Ch5 SYBR Empty #26 2 actin beta 15.15 
A15-Ch5 SYBR Empty #26 3 actin beta 14.98 
A16-Ch5 SYBR Empty #26 4 actin beta 14.93 
B01-Ch5 SYBR Empty #26 1 ATP 18.54 
B02-Ch5 SYBR Empty #26 2 ATP 18.88 
B03-Ch5 SYBR Empty #26 3 ATP 18.51 
B04-Ch5 SYBR Empty #26 4 ATP 18.21 
B05-Ch5 SYBR Empty #26 5 ATP 18.73 
B06-Ch5 SYBR Empty #26 6 ATP 18.42 
B07-Ch5 SYBR Empty DK 1 ATP 17.5 
B08-Ch5 SYBR Empty DK 2 ATP 17.64 
B09-Ch5 SYBR Empty DK 3 ATP 17.92 
B10-Ch5 SYBR Empty DK 4 ATP 17.64 
B11-Ch5 SYBR Empty DK 5 ATP 18.77 
B12-Ch5 SYBR Empty DK 6 ATP 18 
B13-Ch5 SYBR Empty #26 1 ATP 18.8 
B14-Ch5 SYBR Empty #26 2 ATP 18.67 
B15-Ch5 SYBR Empty #26 3 ATP 18.66 
B16-Ch5 SYBR Empty #26 4 ATP 18.48 
C01-Ch5 SYBR Empty #26 1 hmgcs_1 21.34 
C02-Ch5 SYBR Empty #26 2 hmgcs_1 21.59 
C03-Ch5 SYBR Empty #26 3 hmgcs_1 21.59 
C04-Ch5 SYBR Empty #26 4 hmgcs_1 20.63 
C05-Ch5 SYBR Empty #26 5 hmgcs_1 21.39 
C06-Ch5 SYBR Empty #26 6 hmgcs_1 21.27 
C07-Ch5 SYBR Empty DK 1 hmgcs_1 19.99 
C08-Ch5 SYBR Empty DK 2 hmgcs_1 20.04 
C09-Ch5 SYBR Empty DK 3 hmgcs_1 20.42 
C10-Ch5 SYBR Empty DK 4 hmgcs_1 20.19 




C12-Ch5 SYBR Empty DK 6 hmgcs_1 20.24 
C13-Ch5 SYBR Empty #26 1 pmvk 33.6 
C14-Ch5 SYBR Empty #26 2 pmvk n. def. 
C15-Ch5 SYBR Empty #26 3 pmvk 33.12 
C16-Ch5 SYBR Empty #26 4 pmvk 34.27 
D01-Ch5 SYBR Empty #26 1 hmgcs_2 34.54 
D02-Ch5 SYBR Empty #26 2 hmgcs_2 33.65 
D03-Ch5 SYBR Empty #26 3 hmgcs_2 34.75 
D04-Ch5 SYBR Empty #26 4 hmgcs_2 34.06 
D05-Ch5 SYBR Empty #26 5 hmgcs_2 34.33 
D06-Ch5 SYBR Empty #26 6 hmgcs_2 34.05 
D07-Ch5 SYBR Empty DK 1 hmgcs_2 34.12 
D08-Ch5 SYBR Empty DK 2 hmgcs_2 34.15 
D09-Ch5 SYBR Empty DK 3 hmgcs_2 34.26 
D10-Ch5 SYBR Empty DK 4 hmgcs_2 34.27 
D11-Ch5 SYBR Empty DK 5 hmgcs_2 34.22 
D12-Ch5 SYBR Empty DK 6 hmgcs_2 34.12 
D13-Ch5 SYBR Empty #26 1 mvd 22.87 
D14-Ch5 SYBR Empty #26 2 mvd 23.17 
D15-Ch5 SYBR Empty #26 3 mvd 23.24 
D16-Ch5 SYBR Empty #26 4 mvd 23.08 
E01-Ch5 SYBR Empty #26 1 hmgcr 22.04 
E02-Ch5 SYBR Empty #26 2 hmgcr 21.81 
E03-Ch5 SYBR Empty #26 3 hmgcr 22 
E04-Ch5 SYBR Empty #26 4 hmgcr 21.48 
E05-Ch5 SYBR Empty #26 5 hmgcr 21.92 
E06-Ch5 SYBR Empty #26 6 hmgcr 21.81 
E07-Ch5 SYBR Empty DK 1 hmgcr 20.81 
E08-Ch5 SYBR Empty DK 2 hmgcr 20.83 
E09-Ch5 SYBR Empty DK 3 hmgcr 21.09 
E10-Ch5 SYBR Empty DK 4 hmgcr 20.81 
E11-Ch5 SYBR Empty DK 5 hmgcr 22.32 
E12-Ch5 SYBR Empty DK 6 hmgcr 21.09 
E13-Ch5 SYBR Empty #26 5 actin beta 15.04 
E14-Ch5 SYBR Empty #26 6 actin beta 15.04 
E15-Ch5 SYBR Empty DK 7 actin beta 14.64 
E16-Ch5 SYBR Empty DK 8 actin beta 15.18 
F01-Ch5 SYBR Empty #26 1 mvk 23.4 
F02-Ch5 SYBR Empty #26 2 mvk 23.86 
F03-Ch5 SYBR Empty #26 3 mvk 23.58 
F04-Ch5 SYBR Empty #26 4 mvk 23.44 
F05-Ch5 SYBR Empty #26 5 mvk 23.52 
F06-Ch5 SYBR Empty #26 6 mvk 23.63 




F08-Ch5 SYBR Empty DK 2 mvk 22.87 
F09-Ch5 SYBR Empty DK 3 mvk 23.43 
F10-Ch5 SYBR Empty DK 4 mvk 22.9 
F11-Ch5 SYBR Empty DK 5 mvk 24.27 
F12-Ch5 SYBR Empty DK 6 mvk 22.93 
F13-Ch5 SYBR Empty #26 5 ATP 18.43 
F14-Ch5 SYBR Empty #26 6 ATP 18.93 
F15-Ch5 SYBR Empty DK 7 ATP 17.74 
F16-Ch5 SYBR Empty DK 8 ATP 17.94 
 
 
Table B-15: Quantification of gene expression for MEF PS1 rescue (MEF 26), and 
MEF PS1/2 -/- (MEF DK), first experiment, part two. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 1201.06 
Baseline range start: 3    




Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty #26 1 actin beta 15.37 
A02-Ch5 SYBR Empty #26 2 actin beta 15.25 
A03-Ch5 SYBR Empty #26 3 actin beta 15.16 
A04-Ch5 SYBR Empty #26 4 actin beta 15.52 
A05-Ch5 SYBR Empty #26 5 actin beta 15.14 
A06-Ch5 SYBR Empty #26 6 actin beta 15.17 
A07-Ch5 SYBR Empty DK 1 actin beta 14.64 




A09-Ch5 SYBR Empty DK 3 actin beta 14.86 
A10-Ch5 SYBR Empty Dk 4 actin beta 15.06 
A11-Ch5 SYBR Empty Dk 5 actin beta 15.98 
A12-Ch5 SYBR Empty Dk 6 actin beta 15.26 
A13-Ch5 SYBR Empty #26 5 pmvk 33.3 
A14-Ch5 SYBR Empty #26 6 pmvk 32.68 
A15-Ch5 SYBR Empty DK 7 pmvk 31.76 
A16-Ch5 SYBR Empty DK 8 pmvk 33.23 
B01-Ch5 SYBR Empty #26 1 ATP 18.83 
B02-Ch5 SYBR Empty #26 2 ATP 18.94 
B03-Ch5 SYBR Empty #26 3 ATP 18.96 
B04-Ch5 SYBR Empty #26 4 ATP 18.44 
B05-Ch5 SYBR Empty #26 5 ATP 18.5 
B06-Ch5 SYBR Empty #26 6 ATP 18.44 
B07-Ch5 SYBR Empty DK 1 ATP 17.69 
B08-Ch5 SYBR Empty DK 2 ATP 17.71 
B09-Ch5 SYBR Empty DK 3 ATP 18.05 
B10-Ch5 SYBR Empty Dk 4 ATP 17.72 
B11-Ch5 SYBR Empty Dk 5 ATP 18.83 
B12-Ch5 SYBR Empty Dk 6 ATP 18.09 
B13-Ch5 SYBR Empty #26 5 mvd 22.77 
B14-Ch5 SYBR Empty #26 6 mvd 22.94 
B15-Ch5 SYBR Empty DK 7 mvd 22.8 
B16-Ch5 SYBR Empty DK 8 mvd 22.77 
C01-Ch5 SYBR Empty #26 1 fdps 21.41 
C02-Ch5 SYBR Empty #26 2 fdps 21.66 
C03-Ch5 SYBR Empty #26 3 fdps 21.2 
C04-Ch5 SYBR Empty #26 4 fdps 20.64 
C05-Ch5 SYBR Empty #26 5 fdps 21.09 
C06-Ch5 SYBR Empty #26 6 fdps 20.95 
C07-Ch5 SYBR Empty DK 1 fdps 20.16 
C08-Ch5 SYBR Empty DK 2 fdps 20.2 
C09-Ch5 SYBR Empty DK 3 fdps 20.67 
C10-Ch5 SYBR Empty Dk 4 fdps 20.14 
C11-Ch5 SYBR Empty Dk 5 fdps 21.51 
C12-Ch5 SYBR Empty Dk 6 fdps 20.33 
C13-Ch5 SYBR Empty DK 9 actin beta 15.28 
C14-Ch5 SYBR Empty DK 10 actin beta 14.94 
C15-Ch5 SYBR Empty DK 11 actin beta 15.98 
C16-Ch5 SYBR Empty DK 12 actin beta 15.13 
D01-Ch5 SYBR Empty #26 1 fdft1 21.14 
D02-Ch5 SYBR Empty #26 2 fdft1 21.92 
D03-Ch5 SYBR Empty #26 3 fdft1 21.1 




D05-Ch5 SYBR Empty #26 5 fdft1 20.76 
D06-Ch5 SYBR Empty #26 6 fdft1 20.98 
D07-Ch5 SYBR Empty DK 1 fdft1 20.46 
D08-Ch5 SYBR Empty DK 2 fdft1 20.51 
D09-Ch5 SYBR Empty DK 3 fdft1 20.7 
D10-Ch5 SYBR Empty Dk 4 fdft1 20.28 
D11-Ch5 SYBR Empty Dk 5 fdft1 21.3 
D12-Ch5 SYBR Empty Dk 6 fdft1 20.67 
D13-Ch5 SYBR Empty DK 9 ATP 18.19 
D14-Ch5 SYBR Empty DK 10 ATP 18.11 
D15-Ch5 SYBR Empty DK 11 ATP 19.27 
D16-Ch5 SYBR Empty DK 12 ATP 18.17 
E01-Ch5 SYBR Empty #26 1 fdft1 21.6 
E02-Ch5 SYBR Empty #26 2 fdft1 21.73 
E03-Ch5 SYBR Empty #26 3 fdft1 21.71 
E04-Ch5 SYBR Empty #26 4 fdft1 21.15 
E05-Ch5 SYBR Empty #26 5 fdft1 21.34 
E06-Ch5 SYBR Empty #26 6 fdft1 21.41 
E07-Ch5 SYBR Empty DK 1 fdft1 20.51 
E08-Ch5 SYBR Empty DK 2 fdft1 20.74 
E09-Ch5 SYBR Empty DK 3 fdft1 21.06 
E10-Ch5 SYBR Empty Dk 4 fdft1 20.76 
E11-Ch5 SYBR Empty Dk 5 fdft1 22.19 
E12-Ch5 SYBR Empty Dk 6 fdft1 21.11 
E13-Ch5 SYBR Empty DK 9 pmvk 33.46 
E14-Ch5 SYBR Empty DK 10 pmvk 32.9 
E15-Ch5 SYBR Empty DK 11 pmvk 35.42 
E16-Ch5 SYBR Empty DK 12 pmvk 34.04 
F01-Ch5 SYBR Empty #26 1 fdft1 23.16 
F02-Ch5 SYBR Empty #26 2 fdft1 23.77 
F03-Ch5 SYBR Empty #26 3 fdft1 23.09 
F04-Ch5 SYBR Empty #26 4 fdft1 23.01 
F05-Ch5 SYBR Empty #26 5 fdft1 23.37 
F06-Ch5 SYBR Empty #26 6 fdft1 23.24 
F07-Ch5 SYBR Empty DK 1 fdft1 22.19 
F08-Ch5 SYBR Empty DK 2 fdft1 22.6 
F09-Ch5 SYBR Empty DK 3 fdft1 22.65 
F10-Ch5 SYBR Empty Dk 4 fdft1 22.51 
F11-Ch5 SYBR Empty Dk 5 fdft1 24.15 
F12-Ch5 SYBR Empty Dk 6 fdft1 23.13 
F13-Ch5 SYBR Empty DK 9 mvd 23.43 
F14-Ch5 SYBR Empty DK 10 mvd 23.21 
F15-Ch5 SYBR Empty DK 11 mvd 23.81 





Table B-16: Quantification of gene expression for MEF PS1 rescue (MEF 26), and 
MEF PS1/2 -/- (MEF DK), first experiment, part three. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 1201,06 
Baseline range start: 3    




Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty 1 Actin 15,37 
A02-Ch5 SYBR Empty 2 Actin 15,25 
A03-Ch5 SYBR Empty 3 Actin 15,16 
A04-Ch5 SYBR Empty 4 Actin 15,52 
A05-Ch5 SYBR Empty 5 Actin 15,14 
A06-Ch5 SYBR Empty 6 Actin 15,17 
A07-Ch5 SYBR Empty 7 Actin 14,64 
A08-Ch5 SYBR Empty 8 Actin 14,69 
A09-Ch5 SYBR Empty 9 Actin 14,86 
A10-Ch5 SYBR Empty 10 Actin 15,06 
A11-Ch5 SYBR Empty 11 Actin 15,98 
A12-Ch5 SYBR Empty 12 Actin 15,26 
A13-Ch5 SYBR Empty 5 pmvk 33,3 
A14-Ch5 SYBR Empty 6 pmvk 32,68 
A15-Ch5 SYBR Empty 7 pmvk 31,76 
A16-Ch5 SYBR Empty 8 pmvk 33,23 
B01-Ch5 SYBR Empty 1 ATP 18,83 
B02-Ch5 SYBR Empty 2 ATP 18,94 
B03-Ch5 SYBR Empty 3 ATP 18,96 




B05-Ch5 SYBR Empty 5 ATP 18,5 
B06-Ch5 SYBR Empty 6 ATP 18,44 
B07-Ch5 SYBR Empty 7 ATP 17,69 
B08-Ch5 SYBR Empty 8 ATP 17,71 
B09-Ch5 SYBR Empty 9 ATP 18,05 
B10-Ch5 SYBR Empty 10 ATP 17,72 
B11-Ch5 SYBR Empty 11 ATP 18,83 
B12-Ch5 SYBR Empty 12 ATP 18,09 
B13-Ch5 SYBR Empty 5 mvd 22,77 
B14-Ch5 SYBR Empty 6 mvd 22,94 
B15-Ch5 SYBR Empty 7 mvd 22,8 
B16-Ch5 SYBR Empty 8 mvd 22,77 
C01-Ch5 SYBR Empty 1 fdps 21,41 
C02-Ch5 SYBR Empty 2 fdps 21,66 
C03-Ch5 SYBR Empty 3 fdps 21,2 
C04-Ch5 SYBR Empty 4 fdps 20,64 
C05-Ch5 SYBR Empty 5 fdps 21,09 
C06-Ch5 SYBR Empty 6 fdps 20,95 
C07-Ch5 SYBR Empty 7 fdps 20,16 
C08-Ch5 SYBR Empty 8 fdps 20,2 
C09-Ch5 SYBR Empty 9 fdps 20,67 
C10-Ch5 SYBR Empty 10 fdps 20,14 
C11-Ch5 SYBR Empty 11 fdps 21,51 
C12-Ch5 SYBR Empty 12 fdps 20,33 
C13-Ch5 SYBR Empty 9 act 15,28 
C14-Ch5 SYBR Empty 10 act 14,94 
C15-Ch5 SYBR Empty 11 act 15,98 
C16-Ch5 SYBR Empty  act 15,13 
D01-Ch5 SYBR Empty 1 fdft1 21,14 
D02-Ch5 SYBR Empty 2 fdft1 21,92 
D03-Ch5 SYBR Empty 3 fdft1 21,1 
D04-Ch5 SYBR Empty 4 fdft1 20,6 
D05-Ch5 SYBR Empty 5 fdft1 20,76 
D06-Ch5 SYBR Empty 6 fdft1 20,98 
D07-Ch5 SYBR Empty 7 fdft1 20,46 
D08-Ch5 SYBR Empty 8 fdft1 20,51 
D09-Ch5 SYBR Empty 9 fdft1 20,7 
D10-Ch5 SYBR Empty 10 fdft1 20,28 
D11-Ch5 SYBR Empty 11 fdft1 21,3 
D12-Ch5 SYBR Empty 12 fdft1 20,67 
D13-Ch5 SYBR Empty 9 Atp 18,19 
D14-Ch5 SYBR Empty 10 Atp 18,11 
D15-Ch5 SYBR Empty 11 Atp 19,27 




E01-Ch5 SYBR Empty 1 sqle 21,6 
E02-Ch5 SYBR Empty 2 sqle 21,73 
E03-Ch5 SYBR Empty 3 sqle 21,71 
E04-Ch5 SYBR Empty 4 sqle 21,15 
E05-Ch5 SYBR Empty 5 sqle 21,34 
E06-Ch5 SYBR Empty 6 sqle 21,41 
E07-Ch5 SYBR Empty 7 sqle 20,51 
E08-Ch5 SYBR Empty 8 sqle 20,74 
E09-Ch5 SYBR Empty 9 sqle 21,06 
E10-Ch5 SYBR Empty 10 sqle 20,76 
E11-Ch5 SYBR Empty 11 sqle 22,19 
E12-Ch5 SYBR Empty 12 sqle 21,11 
E13-Ch5 SYBR Empty 9 pmvk 33,46 
E14-Ch5 SYBR Empty 10 pmvk 32,9 
E15-Ch5 SYBR Empty 11 pmvk 35,42 
E16-Ch5 SYBR Empty  pmvk 34,04 
F01-Ch5 SYBR Empty 1 lss 23,16 
F02-Ch5 SYBR Empty 2 lss 23,77 
F03-Ch5 SYBR Empty 3 lss 23,09 
F04-Ch5 SYBR Empty 4 lss 23,01 
F05-Ch5 SYBR Empty 5 lss 23,37 
F06-Ch5 SYBR Empty 6 lss 23,24 
F07-Ch5 SYBR Empty 7 lss 22,19 
F08-Ch5 SYBR Empty 8 lss 22,6 
F09-Ch5 SYBR Empty 9 lss 22,65 
F10-Ch5 SYBR Empty 10 lss 22,51 
F11-Ch5 SYBR Empty 11 lss 24,15 
F12-Ch5 SYBR Empty 12 lss 23,13 
F13-Ch5 SYBR Empty 9 mvd 23,43 
F14-Ch5 SYBR Empty 10 mvd 23,21 
F15-Ch5 SYBR Empty 11 mvd 23,81 
F16-Ch5 SYBR Empty  mvd 23,48 
 
 
Table B-17: Quantification of gene expression for MEF PS1 rescue (MEF 26), and 
MEF PS1/2 -/- (MEF DK), second experiment, part one. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  




Baseline range start: 3    




Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty #26 1 actin beta 15,26 
A02-Ch5 SYBR Empty #26 2 actin beta 15,5 
A03-Ch5 SYBR Empty #26 3 actin beta 15,27 
A04-Ch5 SYBR Empty #26 4 actin beta 15,11 
A05-Ch5 SYBR Empty #26 5 actin beta 15,01 
A06-Ch5 [none] [none]   n. def. 
A07-Ch5 [none] [none]   n. def. 
A08-Ch5 [none] [none]   n. def. 
A09-Ch5 [none] [none]   n. def. 
A10-Ch5 SYBR Empty DK 8 actin beta 15,16 
A11-Ch5 SYBR Empty DK 9 actin beta 14,96 
A12-Ch5 SYBR Empty DK10 actin beta 15,22 
A13-Ch5 SYBR Empty DK 11 actin beta 14,88 
A14-Ch5 SYBR Empty DK  12 actin beta 15,42 
A15-Ch5 [none] [none]   n. def. 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty #1 ATP 18,44 
B02-Ch5 SYBR Empty  ATP 19,02 
B03-Ch5 SYBR Empty  ATP 18,79 
B04-Ch5 SYBR Empty  ATP 18,38 
B05-Ch5 SYBR Empty  ATP 18,18 
B06-Ch5 [none] [none]   n. def. 
B07-Ch5 [none] [none]   n. def. 
B08-Ch5 [none] [none]   n. def. 
B09-Ch5 [none] [none]   n. def. 
B10-Ch5 SYBR Empty  ATP 18,06 
B11-Ch5 SYBR Empty  ATP 17,87 
B12-Ch5 SYBR Empty  ATP 18,04 




B14-Ch5 SYBR Empty  ATP 18,32 
B15-Ch5 [none] [none]   n. def. 
B16-Ch5 [none] [none]   n. def. 
C01-Ch5 SYBR Empty #1 hmgcs1 21,16 
C02-Ch5 SYBR Empty  hmgcs1 21,45 
C03-Ch5 SYBR Empty  hmgcs1 21,16 
C04-Ch5 SYBR Empty  hmgcs1 20,9 
C05-Ch5 SYBR Empty  hmgcs1 20,54 
C06-Ch5 [none] [none]   n. def. 
C07-Ch5 [none] [none]   n. def. 
C08-Ch5 [none] [none]   n. def. 
C09-Ch5 [none] [none]   n. def. 
C10-Ch5 SYBR Empty  hmgcs1 19,88 
C11-Ch5 SYBR Empty  hmgcs1 19,88 
C12-Ch5 SYBR Empty  hmgcs1 19,69 
C13-Ch5 SYBR Empty  hmgcs1 19,58 
C14-Ch5 SYBR Empty  hmgcs1 20,15 
C15-Ch5 [none] [none]   n. def. 
C16-Ch5 [none] [none]   n. def. 
D01-Ch5 SYBR Empty #1 hmgcs2 33,84 
D02-Ch5 SYBR Empty  hmgcs2 34,42 
D03-Ch5 SYBR Empty  hmgcs2 34,04 
D04-Ch5 SYBR Empty  hmgcs2 33,67 
D05-Ch5 SYBR Empty  hmgcs2 33,33 
D06-Ch5 [none] [none]   n. def. 
D07-Ch5 [none] [none]   n. def. 
D08-Ch5 [none] [none]   n. def. 
D09-Ch5 [none] [none]   n. def. 
D10-Ch5 SYBR Empty  hmgcs2 33,32 
D11-Ch5 SYBR Empty  hmgcs2 33,68 
D12-Ch5 SYBR Empty  hmgcs2 34,13 
D13-Ch5 SYBR Empty  hmgcs2 33,64 
D14-Ch5 SYBR Empty  hmgcs2 34,04 
D15-Ch5 [none] [none]   n. def. 
D16-Ch5 [none] [none]   n. def. 
E01-Ch5 SYBR Empty #1 hmgcr 21,47 
E02-Ch5 SYBR Empty  hmgcr 21,82 
E03-Ch5 SYBR Empty  hmgcr 21,49 
E04-Ch5 SYBR Empty  hmgcr 21,18 
E05-Ch5 SYBR Empty  hmgcr 20,81 
E06-Ch5 [none] [none]   n. def. 
E07-Ch5 [none] [none]   n. def. 
E08-Ch5 [none] [none]   n. def. 




E10-Ch5 SYBR Empty  hmgcr 20,52 
E11-Ch5 SYBR Empty  hmgcr n. def. 
E12-Ch5 SYBR Empty  hmgcr 20,25 
E13-Ch5 SYBR Empty  hmgcr 20,43 
E14-Ch5 SYBR Empty  hmgcr 20,8 
E15-Ch5 [none] [none]   n. def. 
E16-Ch5 [none] [none]   n. def. 
F01-Ch5 SYBR Empty #1 MVK 23,13 
F02-Ch5 SYBR Empty  MVK 23,25 
F03-Ch5 SYBR Empty  MVK 23,05 
F04-Ch5 SYBR Empty  MVK 22,74 
F05-Ch5 SYBR Empty  MVK 22,52 
F06-Ch5 [none] [none]   n. def. 
F07-Ch5 [none] [none]   n. def. 
F08-Ch5 [none] [none]   n. def. 
F09-Ch5 [none] [none]   n. def. 
F10-Ch5 SYBR Empty  MVK 22,86 
F11-Ch5 SYBR Empty  MVK 23,33 
F12-Ch5 SYBR Empty  MVK 23,55 
F13-Ch5 SYBR Empty  MVK 23,05 






Table B-18: Quantification of gene expression for MEF PS1 rescue (MEF 26), and 
MEF PS1/2 -/- (MEF DK), second experiment, part two. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 1330.82 
Baseline range start: 3    








Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty #26 1 actin beta 16.41 
A02-Ch5 SYBR Empty #26 2 actin beta 15.71 
A03-Ch5 SYBR Empty #26 3 actin beta 15.41 
A04-Ch5 SYBR Empty #26 4 actin beta 15.4 
A05-Ch5 SYBR Empty #26 5 actin beta 15.02 
A06-Ch5 [none] [none]   n. def. 
A07-Ch5 [none] [none]   n. def. 
A08-Ch5 [none] [none]   n. def. 
A09-Ch5 [none] [none]   n. def. 
A10-Ch5 SYBR Empty DK 8 actin beta 15.57 
A11-Ch5 SYBR Empty DK 9 actin beta 15.39 
A12-Ch5 SYBR Empty Dk 10 actin beta 15.37 
A13-Ch5 SYBR Empty Dk 11 actin beta 15.04 
A14-Ch5 SYBR Empty Dk 12 actin beta 16.12 
A15-Ch5 [none] [none]   n. def. 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty #26 1 ATP 19.1 
B02-Ch5 SYBR Empty #26 2 ATP 18.9 
B03-Ch5 SYBR Empty #26 3 ATP 18.5 
B04-Ch5 SYBR Empty #26 4 ATP 18.44 
B05-Ch5 SYBR Empty #26 5 ATP 18.23 
B06-Ch5 [none] [none]   n. def. 
B07-Ch5 [none] [none]   n. def. 
B08-Ch5 [none] [none]   n. def. 
B09-Ch5 [none] [none]   n. def. 
B10-Ch5 SYBR Empty DK 8 ATP 18.08 
B11-Ch5 SYBR Empty DK 9 ATP 18.12 
B12-Ch5 SYBR Empty Dk 10 ATP 18.23 
B13-Ch5 SYBR Empty Dk 11 ATP 18.1 
B14-Ch5 SYBR Empty Dk 12 ATP 18.43 




B16-Ch5 [none] [none]   n. def. 
C01-Ch5 SYBR Empty #26 1 PMVK 33.25 
C02-Ch5 SYBR Empty #26 2 PMVK 35.05 
C03-Ch5 SYBR Empty #26 3 PMVK 33.99 
C04-Ch5 SYBR Empty #26 4 PMVK 34.94 
C05-Ch5 SYBR Empty #26 5 PMVK 32.97 
C06-Ch5 [none] [none]   n. def. 
C07-Ch5 [none] [none]   n. def. 
C08-Ch5 [none] [none]   n. def. 
C09-Ch5 [none] [none]   n. def. 
C10-Ch5 SYBR Empty DK 8 PMVK 32.47 
C11-Ch5 SYBR Empty DK 9 PMVK 31.99 
C12-Ch5 SYBR Empty Dk 10 PMVK 32.4 
C13-Ch5 SYBR Empty Dk 11 PMVK 32.56 
C14-Ch5 SYBR Empty Dk 12 PMVK 33.95 
C15-Ch5 [none] [none]   n. def. 
C16-Ch5 [none] [none]   n. def. 
D01-Ch5 SYBR Empty #26 1 MVD 23.34 
D02-Ch5 SYBR Empty #26 2 MVD 23.49 
D03-Ch5 SYBR Empty #26 3 MVD 23.23 
D04-Ch5 SYBR Empty #26 4 MVD 23.02 
D05-Ch5 SYBR Empty #26 5 MVD 22.92 
D06-Ch5 [none] [none]   n. def. 
D07-Ch5 [none] [none]   n. def. 
D08-Ch5 [none] [none]   n. def. 
D09-Ch5 [none] [none]   n. def. 
D10-Ch5 SYBR Empty DK 8 MVD 23.41 
D11-Ch5 SYBR Empty DK 9 MVD 23.51 
D12-Ch5 SYBR Empty Dk 10 MVD 23.32 
D13-Ch5 SYBR Empty Dk 11 MVD 23.04 
D14-Ch5 SYBR Empty Dk 12 MVD 23.72 
D15-Ch5 [none] [none]   n. def. 
D16-Ch5 [none] [none]   n. def. 
E01-Ch5 SYBR Empty #26 1 Fdps 21.4 
E02-Ch5 SYBR Empty #26 2 Fdps 21.42 
E03-Ch5 SYBR Empty #26 3 Fdps 21.24 
E04-Ch5 SYBR Empty #26 4 Fdps 21.11 
E05-Ch5 SYBR Empty #26 5 Fdps 20.88 
E06-Ch5 [none] [none]   n. def. 
E07-Ch5 [none] [none]   n. def. 
E08-Ch5 [none] [none]   n. def. 
E09-Ch5 [none] [none]   n. def. 
E10-Ch5 SYBR Empty DK 8 Fdps 20.16 




E12-Ch5 SYBR Empty Dk 10 Fdps 20.23 
E13-Ch5 SYBR Empty Dk 11 Fdps 20.19 
E14-Ch5 SYBR Empty Dk 12 Fdps 20.36 
 
 
Table B-19: Quantification of gene expression for MEF PS1 rescue (MEF 26), and 
MEF PS1/2 -/- (MEF DK), second experiment, part three. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 0 
Baseline range start: 3    




Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty #26 1 actin beta 11.3 
A02-Ch5 SYBR Empty #26 2 actin beta 10.87 
A03-Ch5 SYBR Empty #26 3 actin beta 10.95 
A04-Ch5 SYBR Empty #26 4 actin beta 11.23 
A05-Ch5 SYBR Empty #26 5 actin beta 5.46 
A06-Ch5 [none] [none]   n. def. 
A07-Ch5 [none] [none]   n. def. 
A08-Ch5 [none] [none]   n. def. 
A09-Ch5 [none] [none]   n. def. 
A10-Ch5 SYBR Empty DK 1 actin beta 6.32 
A11-Ch5 SYBR Empty Dk 2 actin beta 9.42 
A12-Ch5 SYBR Empty Dk 3 actin beta 10.9 
A13-Ch5 SYBR Empty Dk 4 actin beta 11.01 




A15-Ch5 [none] [none]   n. def. 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty #26 1 ATP 14.14 
B02-Ch5 SYBR Empty #26 2 ATP 14.87 
B03-Ch5 SYBR Empty #26 3 ATP 14.08 
B04-Ch5 SYBR Empty #26 4 ATP 14.02 
B05-Ch5 SYBR Empty #26 5 ATP 14.01 
B06-Ch5 [none] [none]   n. def. 
B07-Ch5 [none] [none]   n. def. 
B08-Ch5 [none] [none]   n. def. 
B09-Ch5 [none] [none]   n. def. 
B10-Ch5 SYBR Empty DK 1 ATP 13.88 
B11-Ch5 SYBR Empty Dk 2 ATP 14.03 
B12-Ch5 SYBR Empty Dk 3 actin beta 12.03 
B13-Ch5 SYBR Empty Dk 4 ATP 13.21 
B14-Ch5 SYBR Empty Dk 5 ATP 13.93 
B15-Ch5 SYBR Empty DK 3 ATP 13.93 
B16-Ch5 [none] [none]   n. def. 
C01-Ch5 SYBR Empty #26 1 sqle 17.79 
C02-Ch5 SYBR Empty #26 2 sqle 17.13 
C03-Ch5 SYBR Empty #26 3 sqle 17.25 
C04-Ch5 SYBR Empty #26 4 sqle 17.22 
C05-Ch5 SYBR Empty #26 5 sqle 17.05 
C06-Ch5 [none] [none]   5.06 
C07-Ch5 [none] [none]   n. def. 
C08-Ch5 [none] [none]   n. def. 
C09-Ch5 [none] [none]   19.49 
C10-Ch5 SYBR Empty DK 1 sqle 16.73 
C11-Ch5 SYBR Empty Dk 2 sqle 16.51 
C12-Ch5 SYBR Empty Dk 3 sqle 16.2 
C13-Ch5 SYBR Empty Dk 4 sqle 16.23 
C14-Ch5 SYBR Empty Dk 5 sqle 16.48 
C15-Ch5 [none] [none]   15.63 
C16-Ch5 [none] [none]   n. def. 
D01-Ch5 SYBR Empty #26 1 lss 19.18 
D02-Ch5 SYBR Empty #26 2 lss 19.1 
D03-Ch5 SYBR Empty #26 3 lss 19.12 
D04-Ch5 SYBR Empty #26 4 lss 18.27 
D05-Ch5 SYBR Empty #26 5 lss 19 
D06-Ch5 [none] [none]   n. def. 
D07-Ch5 [none] [none]   n. def. 
D08-Ch5 [none] [none]   n. def. 
D09-Ch5 [none] [none]   n. def. 




D11-Ch5 SYBR Empty Dk 2 lss 17.76 
D12-Ch5 SYBR Empty Dk 3 lss 19.49 
D13-Ch5 SYBR Empty Dk 4 lss 17.84 
D14-Ch5 SYBR Empty Dk 5 lss 17.68 




Table B-20: Quantification of gene expression for MEF PS1 rescue (MEF 26), and 
MEF PS1/2 -/- (MEF DK), three experiment, part one. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 1269,81 
Baseline range start: 3    




Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty #26 actin beta 15.45 
A02-Ch5 SYBR Empty #26 actin beta 15.59 
A03-Ch5 SYBR Empty #26 actin beta 15.48 
A04-Ch5 SYBR Empty #26 actin beta 15.35 
A05-Ch5 SYBR Empty #26 actin beta 15.22 
A06-Ch5 SYBR Empty #26 actin beta 15.19 
A07-Ch5 [none] [none]   n. def. 
A08-Ch5 SYBR Empty DK actin beta 14.86 
A09-Ch5 SYBR Empty DK actin beta 16.34 




A11-Ch5 SYBR Empty DK actin beta 14.87 
A12-Ch5 SYBR Empty DK actin beta 14.96 
A13-Ch5 [none] [none]   n. def. 
A14-Ch5 [none] [none]   n. def. 
A15-Ch5 [none] [none]   n. def. 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty #26 polr2 21.35 
B02-Ch5 SYBR Empty #26 polr2 21.25 
B03-Ch5 SYBR Empty #26 polr2 21.27 
B04-Ch5 SYBR Empty #26 polr2 21.31 
B05-Ch5 SYBR Empty #26 polr2 21.16 
B06-Ch5 SYBR Empty #26 polr2 20.8 
B07-Ch5 [none] [none]   n. def. 
B08-Ch5 SYBR Empty DK polr2 20.65 
B09-Ch5 SYBR Empty DK polr2 22 
B10-Ch5 SYBR Empty DK polr2 20.68 
B11-Ch5 SYBR Empty DK polr2 20.66 
B12-Ch5 SYBR Empty DK polr2 20.88 
B13-Ch5 [none] [none]   n. def. 
B14-Ch5 [none] [none]   n. def. 
B15-Ch5 [none] [none]   n. def. 
B16-Ch5 [none] [none]   n. def. 
C01-Ch5 SYBR Empty #26 hmgcs2 36.09 
C02-Ch5 SYBR Empty #26 hmgcs2 35.25 
C03-Ch5 SYBR Empty #26 hmgcs2 35.66 
C04-Ch5 SYBR Empty #26 hmgcs2 35.82 
C05-Ch5 SYBR Empty #26 hmgcs2 36.01 
C06-Ch5 SYBR Empty #26 hmgcs2 36.44 
C07-Ch5 [none] [none]   n. def. 
C08-Ch5 SYBR Empty DK hmgcs2 35.01 
C09-Ch5 SYBR Empty DK hmgcs2 35.33 
C10-Ch5 SYBR Empty DK hmgcs2 35.63 
C11-Ch5 SYBR Empty DK hmgcs2 35.81 
C12-Ch5 SYBR Empty DK hmgcs2 35.16 
C13-Ch5 [none] [none]   n. def. 
C14-Ch5 [none] [none]   n. def. 
C15-Ch5 [none] [none]   n. def. 
C16-Ch5 [none] [none]   n. def. 
D01-Ch5 SYBR Empty #26 hmgcr 22.5 
D02-Ch5 SYBR Empty #26 hmgcr 22.55 
D03-Ch5 SYBR Empty #26 hmgcr 22.23 
D04-Ch5 SYBR Empty #26 hmgcr 22.33 
D05-Ch5 SYBR Empty #26 hmgcr 21.3 




D07-Ch5 [none] [none]   n. def. 
D08-Ch5 SYBR Empty DK hmgcr 20.86 
D09-Ch5 SYBR Empty DK hmgcr 21.65 
D10-Ch5 SYBR Empty DK hmgcr 21.09 
D11-Ch5 SYBR Empty DK hmgcr 20.77 
D12-Ch5 SYBR Empty DK hmgcr 20.98 
D13-Ch5 [none] [none]   n. def. 
D14-Ch5 [none] [none]   n. def. 
D15-Ch5 [none] [none]   n. def. 
D16-Ch5 [none] [none]   n. def. 
E01-Ch5 SYBR Empty #26 Mvk 24.29 
E02-Ch5 SYBR Empty #26 Mvk 23.78 
E03-Ch5 SYBR Empty #26 Mvk 24.24 
E04-Ch5 SYBR Empty #26 Mvk 24.39 
E05-Ch5 SYBR Empty #26 Mvk 23.86 
E06-Ch5 SYBR Empty #26 Mvk 23.65 
E07-Ch5 [none] [none]   n. def. 
E08-Ch5 SYBR Empty DK Mvk n. def. 
E09-Ch5 SYBR Empty DK Mvk 23 
E10-Ch5 SYBR Empty DK Mvk 23.34 
E11-Ch5 SYBR Empty DK Mvk 23.05 




Table B-21: Quantification of gene expression for MEF PS1 rescue (MEF 26), and 
MEF PS1/2 -/- (MEF DK), third experiment, part two. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 1819.42 
Baseline range start: 3    







Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty #26 actin beta 18.19 
A02-Ch5 SYBR Empty #26 actin beta 16.96 
A03-Ch5 SYBR Empty #26 actin beta 17.1 
A04-Ch5 SYBR Empty #26 actin beta 16.57 
A05-Ch5 SYBR Empty #26 actin beta 16.62 
A06-Ch5 SYBR Empty #26 actin beta 16.14 
A07-Ch5 [none] [none]   n. def. 
A08-Ch5 SYBR Empty DK actin beta 15.34 
A09-Ch5 SYBR Empty DK actin beta 16.75 
A10-Ch5 SYBR Empty DK actin beta 16.08 
A11-Ch5 SYBR Empty DK actin beta 15.41 
A12-Ch5 SYBR Empty DK actin beta 16.12 
A13-Ch5 [none] [none]   n. def. 
A14-Ch5 [none] [none]   n. def. 
A15-Ch5 [none] [none]   n. def. 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty #26 polr2 22.55 
B02-Ch5 SYBR Empty #26 polr2 22.35 
B03-Ch5 SYBR Empty #26 polr2 22.7 
B04-Ch5 SYBR Empty #26 polr2 21.57 
B05-Ch5 SYBR Empty #26 polr2 21.41 
B06-Ch5 SYBR Empty #26 polr2 21.46 
B07-Ch5 [none] [none]   n. def. 
B08-Ch5 SYBR Empty DK polr2 21.37 
B09-Ch5 SYBR Empty DK polr2 23.01 
B10-Ch5 SYBR Empty DK polr2 21.6 
B11-Ch5 SYBR Empty DK polr2 21.12 
B12-Ch5 SYBR Empty DK polr2 21.33 
B13-Ch5 [none] [none]   n. def. 
B14-Ch5 [none] [none]   n. def. 
B15-Ch5 [none] [none]   n. def. 




C01-Ch5 SYBR Empty #26 pmvk 25.25 
C02-Ch5 SYBR Empty #26 pmvk 25.17 
C03-Ch5 SYBR Empty #26 pmvk 25 
C04-Ch5 SYBR Empty #26 pmvk 25.25 
C05-Ch5 SYBR Empty #26 pmvk 24.93 
C06-Ch5 SYBR Empty #26 pmvk 25.03 
C07-Ch5 [none] [none]   n. def. 
C08-Ch5 SYBR Empty DK pmvk 24.17 
C09-Ch5 SYBR Empty DK pmvk 25.58 
C10-Ch5 SYBR Empty DK pmvk 24.03 
C11-Ch5 SYBR Empty DK pmvk 24.16 
C12-Ch5 SYBR Empty DK pmvk 24 
C13-Ch5 [none] [none]   n. def. 
C14-Ch5 [none] [none]   n. def. 
C15-Ch5 [none] [none]   n. def. 
C16-Ch5 [none] [none]   n. def. 
D01-Ch5 SYBR Empty #26 mvd 24.26 
D02-Ch5 SYBR Empty #26 mvd 24.2 
D03-Ch5 SYBR Empty #26 mvd 24.28 
D04-Ch5 SYBR Empty #26 mvd 24.39 
D05-Ch5 SYBR Empty #26 mvd 24.23 
D06-Ch5 SYBR Empty #26 mvd 24.37 
D07-Ch5 [none] [none]   n. def. 
D08-Ch5 SYBR Empty DK mvd 23.34 
D09-Ch5 SYBR Empty DK mvd 24.08 
D10-Ch5 SYBR Empty DK mvd 22.93 
D11-Ch5 SYBR Empty DK mvd 22.96 
D12-Ch5 SYBR Empty DK mvd 23.08 
D13-Ch5 [none] [none]   n. def. 
D14-Ch5 [none] [none]   n. def. 
D15-Ch5 [none] [none]   n. def. 
D16-Ch5 [none] [none]   n. def. 
E01-Ch5 SYBR Empty #26 fdps 22.4 
E02-Ch5 SYBR Empty #26 fdps 22.01 
E03-Ch5 SYBR Empty #26 fdps 21.97 
E04-Ch5 SYBR Empty #26 fdps 22.15 
E05-Ch5 SYBR Empty #26 fdps 22.31 
E06-Ch5 SYBR Empty #26 fdps 22.08 
E07-Ch5 [none] [none]   n. def. 
E08-Ch5 SYBR Empty DK fdps 21.01 
E09-Ch5 SYBR Empty DK fdps 21.67 
E10-Ch5 SYBR Empty DK fdps 20.58 
E11-Ch5 SYBR Empty DK fdps 20.51 





Table B-22: Quantification of gene expression for MEF PS1 rescue (MEF 26), and 
MEF PS1/2 -/- (MEF DK), third experiment, part three. 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 1993,26 
Baseline range start: 3    




Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty #26 actin beta 16.4 
A02-Ch5 SYBR Empty #26 actin beta 16.57 
A03-Ch5 [none] [none]   16.89 
A04-Ch5 SYBR Empty #26 actin beta 16.25 
A05-Ch5 SYBR Empty #26 actin beta 16.27 
A06-Ch5 SYBR Empty #26 actin beta 16.6 
A07-Ch5 [none] [none]   n. def. 
A08-Ch5 SYBR Empty DK actin beta 15.79 
A09-Ch5 SYBR Empty DK actin beta 17.26 
A10-Ch5 SYBR Empty DK actin beta 15.72 
A11-Ch5 SYBR Empty DK actin beta 18.31 
A12-Ch5 SYBR Empty DK actin beta 16.26 
A13-Ch5 SYBR Empty #26 3 actin beta 15.9 
A14-Ch5 [none] [none]   n. def. 
A15-Ch5 [none] [none]   n. def. 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty #26 polr2 21.78 
B02-Ch5 SYBR Empty #26 polr2 21.8 
B03-Ch5 SYBR Empty #26 polr2 21.65 




B05-Ch5 SYBR Empty #26 polr2 21.65 
B06-Ch5 SYBR Empty #26 polr2 21.59 
B07-Ch5 [none] [none]   n. def. 
B08-Ch5 SYBR Empty DK polr2 21.43 
B09-Ch5 SYBR Empty DK polr2 23.02 
B10-Ch5 SYBR Empty DK polr2 21.43 
B11-Ch5 SYBR Empty DK polr2 21.29 
B12-Ch5 SYBR Empty DK polr2 21.43 
B13-Ch5 [none] [none]   n. def. 
B14-Ch5 [none] [none]   n. def. 
B15-Ch5 [none] [none]   n. def. 
B16-Ch5 [none] [none]   n. def. 
C01-Ch5 SYBR Empty #26 hmgcs1 23.24 
C02-Ch5 SYBR Empty #26 hmgcs1 23.02 
C03-Ch5 SYBR Empty #26 hmgcs1 23.26 
C04-Ch5 SYBR Empty #26 hmgcs1 23.51 
C05-Ch5 SYBR Empty #26 hmgcs1 23.22 
C06-Ch5 SYBR Empty #26 hmgcs1 23.18 
C07-Ch5 [none] [none]   n. def. 
C08-Ch5 SYBR Empty DK hmgcs1 21.05 
C09-Ch5 SYBR Empty DK hmgcs1 21.9 
C10-Ch5 SYBR Empty DK hmgcs1 20.83 
C11-Ch5 SYBR Empty DK hmgcs1 20.76 
C12-Ch5 SYBR Empty DK hmgcs1 20.9 
C13-Ch5 [none] [none]   n. def. 
C14-Ch5 [none] [none]   n. def. 
C15-Ch5 [none] [none]   n. def. 
C16-Ch5 [none] [none]   n. def. 
D01-Ch5 SYBR Empty #26 fdft 22.48 
D02-Ch5 SYBR Empty #26 fdft 22.52 
D03-Ch5 SYBR Empty #26 fdft 22.54 
D04-Ch5 SYBR Empty #26 fdft 22.55 
D05-Ch5 SYBR Empty #26 fdft 22.47 
D06-Ch5 SYBR Empty #26 fdft 22.85 
D07-Ch5 [none] [none]   n. def. 
D08-Ch5 SYBR Empty DK fdft 21.52 
D09-Ch5 SYBR Empty DK fdft 23.07 
D10-Ch5 SYBR Empty DK fdft 21.46 
D11-Ch5 SYBR Empty DK fdft 21.36 
D12-Ch5 SYBR Empty DK fdft 21.25 
D13-Ch5 [none] [none]   n. def. 
D14-Ch5 [none] [none]   n. def. 
D15-Ch5 [none] [none]   n. def. 




E01-Ch5 SYBR Empty #26 sqle 22.86 
E02-Ch5 SYBR Empty #26 sqle 22.74 
E03-Ch5 SYBR Empty #26 sqle 22.57 
E04-Ch5 SYBR Empty #26 sqle 22.72 
E05-Ch5 SYBR Empty #26 sqle 22.51 
E06-Ch5 SYBR Empty #26 sqle 22.56 
E07-Ch5 [none] [none]   n. def. 
E08-Ch5 SYBR Empty DK sqle 21.57 
E09-Ch5 SYBR Empty DK sqle 22.35 
E10-Ch5 SYBR Empty DK sqle 21.35 
E11-Ch5 SYBR Empty DK sqle 21.38 
E12-Ch5 SYBR Empty DK sqle 21.39 
E13-Ch5 [none] [none]   n. def. 
E14-Ch5 [none] [none]   n. def. 
E15-Ch5 [none] [none]   n. def. 
E16-Ch5 [none] [none]   n. def. 
F01-Ch5 SYBR Empty #26 lss 26.03 
F02-Ch5 SYBR Empty #26 lss 24.94 
F03-Ch5 SYBR Empty #26 lss 24.96 
F04-Ch5 SYBR Empty #26 lss 25.4 
F05-Ch5 SYBR Empty #26 lss 25.46 
F06-Ch5 SYBR Empty #26 lss 25.16 
F07-Ch5 [none] [none]   n. def. 
F08-Ch5 SYBR Empty DK lss 22.93 
F09-Ch5 SYBR Empty DK lss 24.72 
F10-Ch5 SYBR Empty DK lss 22.84 
F11-Ch5 SYBR Empty DK lss 23.6 
F12-Ch5 SYBR Empty DK lss 23.48 
 
 
Table B-23: Quantification of qRT-PCR test by 2-∆∆ method for MEF WT (control) 













1 5.05 4.43  0.312 -0.308 0.8055243 1.23799 
2 4.82 4.26  0.082 -0.478 0.944747 1.392811 
3 4.81 4.36  0.072 -0.378 0.9513183 1.299539 
4 4.83 4.58 4.738 0.092 -0.158 0.9382212 1.115739 
1 4.44 4.13  -0.084 -0.394 1.0599528 1.314032 
2 4.55 4.38  0.026 -0.144 0.9821396 1.104964 
3 4.48 4.02  -0.044 -0.504 1.0309683 1.41814 
4 4.75 4.91  0.226 0.386 0.8550022 0.765248 




1 4.42 5.11  -0.076 0.614 1.0540914 0.653383 
2 4.48 5.09  -0.016 0.594 1.0111521 0.662504 
3 4.44 4.9  -0.056 0.404 1.0395794 0.75576 
4 4.65 4.85  0.154 0.354 0.8987551 0.782412 
5 4.49 4.15 4.496 -0.006 -0.346 1.0041675 1.271032 
        
     Average 0.976098 1.048379 
     SD 0.082228 0.283473 













1 18.26 16.42  -0.224 -2.064 1.1679674 4.18144 
2 17.14 16.15  -1.344 -2.334 2.5385418 5.042014 
3 19.29 16.94  0.806 -1.544 0.5719655 2.916019 
4 19 16.7  0.516 -1.784 0.699308 3.443797 
5 18.73 16.65 18.484 0.246 -1.834 0.8432311 3.565242 
1 17.88 15.47  -0.05 -2.46 1.0352649 5.502167 
2 17.83 17.48  -0.1 -0.45 1.0717735 1.36604 
3 18.33 18.2  0.4 0.27 0.7578583 0.82932 
4 17.57 17.46 17.93 -0.36 -0.47 1.2834259 1.385109 
1 19.23 16.45  0.02 -2.76 0.9862327 6.773962 
2 19.2 16.96  -0.01 -2.25 1.0069556 4.756828 
3 19.28 16.17  0.07 -3.04 0.952638 8.224911 
4 19.07 16  -0.14 -3.21 1.1019051 9.253505 
5 19.27 17.1 19.21 0.06 -2.11 0.9592641 4.316913 
        
     Average 1.069738 4.396948 
     SD 0.4628777 2.488258 













1 4.51 5.78  -0.466 0.804 1.3812744 0.572759 
2 5.26 5.54  0.284 0.564 0.8213107 0.676424 
3 5.15 5.4  0.174 0.424 0.8863817 0.745355 
4 4.88 5.91  -0.096 0.934 1.068806 0.523405 
5 5.08 5.66 4.976 0.104 0.684 0.9304497 0.622437 
1 5.38 5.58  0.2 0.4 0.8705506 0.757858 
2 5.09 5.72  -0.09 0.54 1.0643702 0.687771 
3 5.07 4.31  -0.11 -0.87 1.0792282 1.827663 
4 5.36 6.54  0.18 1.36 0.882703 0.389582 
5 5 6.07 5.18 -0.18 0.89 1.1328839 0.539614 
1 4.85 6.05  -0.158 1.042 1.1157393 0.485654 
2 5.02 6.26  0.012 1.252 0.9917167 0.419866 
3 5.55 5.97  0.542 0.962 0.6868181 0.513345 




5 4.84 5.67 5.008 -0.168 0.662 1.1234999 0.632002 
        
     Average 1.0137962 0.662928 
     SD 0.171471 0.340055 













1 7.35 7.52  -0.254 -0.084 1.1925089 1.059953 
2 7.61 7.91  0.006 0.306 0.9958498 0.808881 
3 7.92 7.7  0.316 0.096 0.803294 0.935623 
4 7.54 7.47  -0.064 -0.134 1.0453601 1.097332 
5 7.6 7.67 7.604 -0.004 0.066 1.0027764 0.955283 
1 7.94 7.65  0.172 -0.118 0.8876113 1.085229 
2 7.65 7.46  -0.118 -0.308 1.0852294 1.23799 
3 7.78 7.28  0.012 -0.488 0.9917167 1.402499 
4 7.72 6.88 7.768 -0.048 -0.888 1.0338307 1.850609 
1 7.69 7.78  -0.092 -0.002 1.0658467 1.001387 
2 7.71 7.43  -0.072 -0.352 1.0511729 1.276329 
3 7.65 7.95  -0.132 0.168 1.0958118 0.890076 
4 8.03 7.48  0.248 -0.302 0.842063 1.232852 
5 7.83 7.02 7.782 0.048 -0.762 0.9672763 1.69584 
        
     Average 1.0043106 1.180706 
     SD 0.1040832 0.300624 













1 16.83 18.2  -0.8 0.57 1.7411011 0.673617 
2 17.57 17.75  -0.06 0.12 1.0424658 0.920188 
3 18.06 18.21  0.43 0.58 0.7422618 0.668964 
4 17 19.41  -0.63 1.78 1.547565 0.291183 
5 18.69 19.11 17.63 1.06 1.48 0.4796321 0.358489 
1 15.07 16.67  -0.18 1.42 1.1328839 0.373712 
2 15.07 15.49  -0.18 0.24 1.1328839 0.846745 
3 15.88 16.16  0.63 0.91 0.6461764 0.532185 
4 15.07 15.1 15.25 -0.18 -0.15 1.1328839 1.109569 
1 7.55 8.23  0.05 0.73 0.9659363 0.602904 
2 7.13 8.08  -0.37 0.58 1.2923528 0.668964 
3 7.34 8.03  -0.16 0.53 1.1172871 0.692555 
4 7.81 7.92  0.31 0.42 0.8066418 0.747425 
5 7.67 8 7.5 0.17 0.5 0.8888427 0.707107 
        
     Average 1.0477796 0.656686 
     SD 0.3379131 0.222623 
















1 7.34 7.68  0.266 0.606 0.8316221 0.657016 
2 7.33 7.45  0.256 0.376 0.8374065 0.770571 
3 6.83 7.31  -0.244 0.236 1.1842716 0.849096 
4 7.09 7.09  0.016 0.016 0.9889709 0.988971 
5 6.78 7.97 7.074 -0.294 0.896 1.2260349 0.537375 
1 7.61 7.26  0.092 -0.258 0.9382212 1.19582 
2 7.43 7.8  -0.088 0.282 1.0628957 0.82245 
3 7.89 7.44  0.372 -0.078 0.7727105 1.055554 
4 7.22 7.17 7.518 -0.298 -0.348 1.2294389 1.272795 
1 6.95 8.45  -0.086 1.414 1.0614232 0.37527 
2 6.75 7.94  -0.286 0.904 1.2192551 0.534403 
3 7.14 8.09  0.104 1.054 0.9304497 0.481631 
4 7.39 8.58  0.354 1.544 0.7824118 0.342933 
5 6.95 7.91 7.036 -0.086 0.874 1.0614232 0.545632 
        
     Average 1.0090382 0.744965 
     SD 0.1661068 0.298448 













1 4.61 5.22  0.276 0.886 0.8258777 0.541112 
2 4.37 4.64  0.036 0.306 0.9753555 0.808881 
3 4.21 4.4  -0.124 0.066 1.0897521 0.955283 
4 4.37 4.28  0.036 -0.054 0.9753555 1.038139 
5 4.11 4.91 4.334 -0.224 0.576 1.1679674 0.670821 
1 4.18 5.14  -0.112 0.848 1.0807254 0.555554 
2 4.3 5.08  0.008 0.788 0.9944702 0.579146 
3 4.13 5.55  -0.162 1.258 1.1188371 0.418123 
4 4.47 5.13  0.178 0.838 0.8839275 0.559419 
5 4.38 4.66 4.292 0.088 0.368 0.9408261 0.774856 
1 3.93 4.9  -0.256 0.714 1.1941632 0.609628 
2 3.59 5.1  -0.596 0.914 1.5115199 0.530712 
3 3.9 4.78  -0.286 0.594 1.2192551 0.662504 
4 4.53 4.88  0.344 0.694 0.7878539 0.618138 
5 4.98 4.42 4.186 0.794 0.234 0.5767428 0.850274 
        
     Average 1.022842 0.678173 
     SD 0.2186316 0.172817 










∆∆Ct fdft control fdft 
1 5.55 4.58  0.522 -0.448 0.6964057 1.364148 




3 4.74 4.35  -0.288 -0.678 1.2209465 1.59992 
4 5.27 4.08  0.242 -0.948 0.8455723 1.929196 
5 4.6 4.78 5.028 -0.428 -0.248 1.3453672 1.18756 
1 4.58 4.45  0.23 0.1 0.8526349 0.933033 
2 4.5 3.63  0.15 -0.72 0.9012505 1.647182 
3 4.47 4.67 4.35 0.12 0.32 0.9201877 0.80107 
1 4.51 4.57  -0.47 -0.41 1.3851095 1.328686 
2 5.35 5.26  0.37 0.28 0.7737825 0.823591 
3 4.82 4.99  -0.16 0.01 1.1172871 0.993092 
4 5.15 4.94  0.17 -0.04 0.8888427 1.028114 
5 5.07 4.8 4.98 0.09 -0.18 0.9395227 1.132884 
        
     Average 0.9939031 1.247726 
     SD 0.21445 0.343769 













1 5.49 4.79  0.334 -0.366 0.7933338 1.288775 
2 5 4.75  -0.156 -0.406 1.1141937 1.325007 
3 5.3 4.78  0.144 -0.376 0.9050065 1.297739 
4 5.11 4.48  -0.046 -0.676 1.0323985 1.597704 
5 4.88 5.39 5.156 -0.276 0.234 1.2108331 0.850274 
1 8.38 6.41  1.216 -0.754 0.4304746 1.686462 
2 6.6 6.02  -0.564 -1.144 1.4783624 2.209929 
3 6.88 6.21  -0.284 -0.954 1.217566 1.937236 
1 4.75 4.8  -0.392 -0.342 1.3122113 1.267513 
2 5.39 5.51  0.248 0.368 0.842063 0.774856 
3 5.16 5.32  0.018 0.178 0.9876009 0.883928 
4 5.14 5.7  -0.002 0.558 1.0013873 0.679243 
5 5.27 5.01 5.142 0.128 -0.132 0.9150992 1.095812 
        
     Average 1.0185023 1.299575 
     SD 0.2639655 0.461159 









∆∆Ct lss control lss 
1 7.32 7.59  -0.026 0.244 1.0181852 0.844401 
2 7.94 7.43  0.594 0.084 0.6625035 0.943438 
3 7.05 7.25  -0.296 -0.096 1.2277357 1.068806 
4 7.3 6.72  -0.046 -0.626 1.0323985 1.54328 
5 7.12 7.9 7.346 -0.226 0.554 1.1695877 0.681129 
1 8.01 8.16  -0.016 0.134 1.0111521 0.911301 
2 8.1 7.28  0.074 -0.746 0.9500004 1.677136 
3 8.08 9.56  0.054 1.534 0.9632619 0.345319 




1 6.42 7.12  -0.566 0.134 1.4804133 0.911301 
2 7.06 7.46  0.074 0.474 0.9500004 0.719966 
3 6.99 7.36  0.004 0.374 0.9972313 0.77164 
4 7.18 7.3  0.194 0.314 0.8741786 0.804408 
5 7.28 6.93 6.986 0.294 -0.056 0.8156375 1.039579 
        
     Average 1.0195878 0.999856 
     SD 0.1946408 0.396556 




Table B-24: Quantification of qRT-PCR test by 2-∆∆ method for MEF WT (control) 













1 4.18 4.98  -0.558 0.242 1.4722269 0.845572 
2 5.05 4.92  0.312 0.182 0.8055243 0.88148 
3 4.82 4.4  0.082 -0.338 0.944747 1.264003 
4 4.81 5.59  0.072 0.852 0.9513183 0.554016 
5 4.83 4.47 4.738 0.092 -0.268 0.9382212 1.204137 
1 4.44 4.41  -0.084 -0.114 1.0599528 1.082225 
2 4.55 4.81  0.026 0.286 0.9821396 0.820173 
3 4.48 4.33  -0.044 -0.194 1.0309683 1.143931 
4 4.75 4.8  0.226 0.276 0.8550022 0.825878 
5 4.4 5.04 4.524 -0.124 0.516 1.0897521 0.699308 
1 4.51 5.69  -0.1633333 1.016666667 1.1198716 0.494257 
2 4.49 5.74  -0.1833333 1.066666667 1.1355044 0.477421 
3 4.74 5.69  0.06666667 1.016666667 0.9548416 0.494257 
4 4.66 5.62  -0.0133333 0.946666667 1.0092848 0.51883 
5 4.85 5.58 4.673333 0.17666667 0.906666667 0.8847448 0.533416 
6 4.79 5.57  0.11666667 0.896666667 0.9223162 0.537126 
        
     Average 1.009776 0.773502 
     SD 0.1541982 0.27761 













1 18.26 18.26  -0.224 -0.224 1.1679674 1.167967 
2 19 19.11  0.516 0.626 0.699308 0.64797 
3 18.73 19.08 18.484 0.246 0.596 0.8432311 0.661586 




2 17.83 17.43  -0.1 -0.5 1.0717735 1.414214 
3 18.04 17.04  0.11 -0.89 0.9265881 1.853176 
4 18.33 17.63  0.4 -0.3 0.7578583 1.231144 
5 17.57 17.51 17.93 -0.36 -0.42 1.2834259 1.337928 
1 19.42 19.35  -0.78 -0.85 1.7171309 1.802501 
2 21.13 19.35  0.93 -0.85 0.5248583 1.802501 
3 20.61 19.93  0.41 -0.27 0.7526234 1.205808 
4 19.99 19.8 20.2 -0.21 -0.4 1.1566882 1.319508 
5 21.2 19.94  1 -0.26 0.5 1.197479 
        
     Average 0.9566706 1.265263 
     SD 0.3348294 0.400819 










∆∆Ct hmgcr control hmgcr 
1 4.51 5.31  -0.466 0.334 1.3812744 0.793334 
2 5.26 5.21  0.284 0.234 0.8213107 0.850274 
3 5.15 4.74  0.174 -0.236 0.8863817 1.177723 
4 4.88 5.45  -0.096 0.474 1.068806 0.719966 
5 5.08 4.82 4.976 0.104 -0.156 0.9304497 1.114194 
1 5.38 5.86  0.2 0.68 0.8705506 0.624165 
2 5.09 5.66  -0.09 0.48 1.0643702 0.716978 
3 5.07 5.38  -0.11 0.2 1.0792282 0.870551 
4 5.36 5.38  0.18 0.2 0.882703 0.870551 
5 5 5.99 5.18 -0.18 0.81 1.1328839 0.570382 
1 4.77 6.28  -0.13 1.38 1.0942937 0.384219 
2 4.58 5.97  -0.32 1.07 1.2483305 0.476319 
3 4.9 5.91  0 1.01 1 0.496546 
4 4.99 5.88  0.09 0.98 0.9395227 0.50698 
5 5 5.98 4.9 0.1 1.08 0.933033 0.473029 
 5.16 6.04  0.26 1.14 0.8350879 0.45376 
        
     Average 1.0105141 0.693686 
     SD 0.1554572 0.238383 









∆∆Ct mvk control mvk 
1 7.35 7.84  -0.254 0.236 1.1925089 0.849096 
2 7.61 7.75  0.006 0.146 0.9958498 0.903753 
3 7.92 7.74  0.316 0.136 0.803294 0.910039 
4 7.54 8.19  -0.064 0.586 1.0453601 0.666187 
5 7.6 7.81 7.604 -0.004 0.206 1.0027764 0.866938 
1 7.65 7.65  -0.118 -0.118 1.0852294 1.085229 
2 7.75 8.03  -0.018 0.262 1.0125548 0.833931 




4 7.72 8.1 7.768 -0.048 0.332 1.0338307 0.794434 
1 7.31 8.54  -0.3466667 0.883333333 1.2716192 0.542113 
2 7.31 8.51  -0.3466667 0.853333333 1.2716192 0.553504 
3 7.62 8.43  -0.0366667 0.773333333 1.0257411 0.585064 
4 8.25 8.47  0.59333333 0.813333333 0.6628097 0.569066 
5 7.82 8.48 7.656667 0.16333333 0.823333333 0.8929595 0.565135 
        
     Average 1.0205621 0.745748 
     SD 0.1649994 0.170523 










∆∆Ct pmvk control pmvk 
1 16.83 20.26  -0.8 2.63 1.7411011 0.161544 
2 17.57 18.48  -0.06 0.85 1.0424658 0.554785 
3 18.06 17.81  0.43 0.18 0.7422618 0.882703 
4 18.69 17.35 17.63 1.06 -0.28 0.4796321 1.214195 
1 15.07 16  -0.18 0.75 1.1328839 0.594604 
2 15.07 17.06  -0.18 1.81 1.1328839 0.285191 
3 15.16 16.88  -0.09 1.63 1.0643702 0.323088 
4 15.07 16.88 15.25 -0.18 1.63 1.1328839 0.323088 
1 7.72 8.91  0.19333333 1.383333333 0.8745827 0.383332 
2 7.5 8.96  -0.0266667 1.433333333 1.0186558 0.370274 
3 7.13 8.76  -0.3966667 1.233333333 1.3164627 0.425334 
4 7.74 8.69 7.526667 0.21333333 1.163333333 0.862542 0.44648 
5 7.28 8.29  -0.2466667 0.763333333 1.1864626 0.589134 
        
     Average 1.0559376 0.504135 
     SD 0.2992457 0.27964 









∆∆Ct mvd control mvd 
1 7.34 7.97  0.266 0.896 0.8316221 0.537375 
2 7.33 6.77  0.256 -0.304 0.8374065 1.234563 
3 6.83 8.11  -0.244 1.036 1.1842716 0.487678 
4 7.09 7.65  0.016 0.576 0.9889709 0.670821 
5 6.78 8.09 7.074 -0.294 1.016 1.2260349 0.494485 
1 7.61 7.41  0.092 -0.108 0.9382212 1.077733 
2 7.43 8.42  -0.088 0.902 1.0628957 0.535144 
3 7.44 9.21  -0.078 1.692 1.0555537 0.309498 
4 7.89 9.65  0.372 2.132 0.7727105 0.228141 
5 7.22 8.75 7.518 -0.298 1.232 1.2294389 0.425727 
1 6.87 8.82  -0.0466667 1.903333333 1.0328757 0.267325 
2 7.25 9.1  0.33333333 2.183333333 0.7937005 0.220166 
3 6.64 8.89  -0.2766667 1.973333333 1.2113927 0.254664 




5 7.12 8.74 6.916667 0.20333333 1.823333333 0.8685415 0.282567 
6 6.58 8.27  -0.3366667 1.353333333 1.2628355 0.391387 
        
     Average 1.0134085 0.479718 
     SD 0.1700287 0.29717 









∆∆Ct fdps control fdps 
1 4.61 3.95  0.276 -0.384 0.8258777 1.304955 
2 4.37 2.61  0.036 -1.724   
3 4.21 3.9  -0.124 -0.434 1.0897521 1.350974 
4 4.37 3.34  0.036 -0.994 0.9753555 1.9917 
5 4.11 4.49 4.334 -0.224 0.156 1.1679674 0.89751 
1 4.18 4.78  -0.112 0.488 1.0807254 0.713013 
2 4.3 5.11  0.008 0.818 0.9944702 0.567228 
3 4.13 4.84  -0.162 0.548 1.1188371 0.683968 
4 4.47 4.94  0.178 0.648 0.8839275 0.638164 
5 4.38 4.74 4.292 0.088 0.448 0.9408261 0.733058 
1 4.2 5.5  0.03333333 1.333333333 0.97716 0.39685 
2 4.17 5.3  0.00333333 1.133333333 0.9976922 0.455861 
3 3.68 5.77  -0.4866667 1.603333333 1.4012037 0.329116 
4 4.78 4.92  0.61333333 0.753333333 0.6536846 0.593231 
5 4.42 5.01 4.166667 0.25333333 0.843333333 0.8389558 0.557354 
6 3.75 4.7  -0.4166667 0.533333333 1.3348399 0.690956 
        
     Average 1.0187517 0.793596 
     SD 0.1925473 0.439943 









∆∆Ct fdft control fdft 
1 5.55 4.67  0.522 -0.358 0.6964057 1.281648 
2 4.74 4.74  -0.288 -0.288 1.2209465 1.220947 
3 5.27 4.42  0.242 -0.608 0.8455723 1.524145 
4 4.6 5.07 5.028 -0.428 0.042 1.3453672 0.971307 
1 4.58 4  0.23 -0.35 0.8526349 1.274561 
2 3.85 4.59  -0.5 0.24 1.4142136 0.846745 
3 4.47 4.75 4.35 0.12 0.4 0.9201877 0.757858 
1 4.85 5.04  -0.1966667 -0.00666667 1.1460474 1.004632 
2 5.24 5.93  0.19333333 0.883333333 0.8745827 0.542113 
3 4.94 5.87  -0.1066667 0.823333333 1.0767376 0.565135 
4 5.15 5.81  0.10333333 0.763333333 0.9308797 0.589134 
5 4.89 5.72 5.046667 -0.1566667 0.673333333 1.1147086 0.627056 
6 5.21 5.69  0.16333333 0.643333333 0.8929595 0.640232 
        




     SD 0.213634 0.32848 









∆∆Ct sqle control sqle 
1 5.49 5.23  0.334 0.074 0.7933338 0.95 
2 5 3.9  -0.156 -1.256 1.1141937 2.388326 
3 5.3 5.54  0.144 0.384 0.9050065 0.76631 
4 5.11 4.65  -0.046 -0.506 1.0323985 1.420107 
5 4.88 5.47 5.156 -0.276 0.314 1.2108331 0.804408 
1 6.88 6.02  -0.284 -1.144 1.217566 2.209929 
2 6.51 5.91 7.164 -0.654 -1.254 1.5735249 2.385018 
1 5.27 5.59  -0.1783333 0.141666667 1.1315759 0.906471 
2 5.53 6.12  0.08166667 0.671666667 0.9449653 0.627781 
3 5.13 6.32  -0.3183333 0.871666667 1.2468893 0.546515 
4 5.69 6.17  0.24166667 0.721666667 0.8457677 0.606397 
5 5.49 6.04 5.448333 0.04166667 0.591666667 0.9715319 0.663576 
6 5.58 6.03  0.13166667 0.581666667 0.9127764 0.668191 
        
     Average 1.0692587 1.149464 
     SD 0.2116767 0.708416 









∆∆Ct lss control lss 
1 7.32 7.99  -0.026 0.644 1.0181852 0.639936 
2 7.94 6.36  0.594 -0.986 0.6625035 1.980686 
3 7.05 7.49  -0.296 0.144 1.2277357 0.905006 
4 7.3 6.51  -0.046 -0.836 1.0323985 1.785094 
5 7.12 7.3 7.346 -0.226 -0.046 1.1695877 1.032399 
1 8.08 7.17  0.054 -0.856 0.9632619 1.810013 
2 8.08 8.18  0.054 0.154 0.9632619 0.898755 
3 7.86 8.37 8.026 -0.166 0.344 1.1219435 0.787854 
1 7.1 7.98  0.025 0.905 0.9828206 0.534033 
2 7.06 8.06  -0.015 0.985 1.0104514 0.505226 
3 6.93 8.01  -0.145 0.935 1.1057307 0.523042 
4 7.3 8.45  0.225 1.375 0.855595 0.385553 
5 6.91 8.4 7.075 -0.165 1.325 1.1211661 0.399149 
6 7.15 8.13  0.075 1.055 0.9493421 0.481297 
        
     Average 1.0131417 0.90486 
     SD 0.1416233 0.554667 






Table B-25: Quantification of qRT-PCR test by 2-∆∆ method for MEF PS1 rescue 













1 6.25 5.2  0.172 -0.878 0.8876113 1.837826 
2 6.32 5.36  0.242 -0.718 0.8455723 1.6449 
3 5.44 5.14  -0.638 -0.938 1.5561704 1.91587 
4 6.08 5.73 6.078 0.002 -0.348 0.9986147 1.272795 
1 5.28 5.1  -0.482 -0.662 1.3966785 1.582275 
2 5.9 4.72  0.138 -1.042 0.9087781 2.05908 
3 5.95 4.92  0.188 -0.842 0.8778218 1.792533 
4 5.89 4.47  0.128 -1.292 0.9150992 2.448673 
5 5.79 4.7 5.762 0.028 -1.062 0.980779 2.087824 
1 5.53 4.73  -1.0366667 -1.83666667 2.0514822 3.571838 
2 6.84 5.26  0.27333333 -1.30666667 0.8274056 2.473693 
3 6.45 4.64  -0.1166667 -1.92666667 1.0842269 3.801758 
4 6.37 5.11  -0.1966667 -1.45666667 1.1460474 2.744735 
5 6.95 4.64  0.38333333 -1.92666667 0.7666642 3.801758 
        
     Average 1.0887823 2.359683 
     SD 0.3570909 0.753323 













1 19.45 19.33  0.414 0.294 0.7505395 0.815637 
2 19.48 19.2  0.444 0.164 0.7350937 0.892547 
3 18.87 19.22  -0.166 0.184 1.1219435 0.880259 
4 19.02 18.34 19.036 -0.016 -0.696 1.0111521 1.620007 
1 18.06 18.98  -0.518 0.402 1.4319687 0.756808 
2 18.58 18.16  0.002 -0.418 0.9986147 1.336074 
3 18.92 18.72  0.342 0.142 0.7889468 0.906262 
4 18.77 18.91  0.192 0.332 0.8753913 0.794434 
5 18.56 18.76 18.578 -0.018 0.182 1.0125548 0.88148 
1 20.64 20.15  0.63 0.14 0.6461764 0.907519 
2 19.66 18.99  -0.35 -1.02 1.2745606 2.027919 
3 20.18 20.73  0.17 0.72 0.8888427 0.607097 
        
     Average 0.9613154 1.035504 
     SD 0.2314383 0.414057 










∆∆Ct hmgcr control hmgcr 
1 6.95 6.02  0.33 -0.6 0.7955365 1.515717 
2 6.73 6.03  0.11 -0.59 0.9265881 1.505247 




4 6.61 6.44 6.62 -0.01 -0.18 1.0069556 1.132884 
1 5.82 5.95  -0.308 -0.178 1.2379903 1.131314 
2 6.21 5.36  0.082 -0.768 0.944747 1.702907 
3 6.22 5.03  0.092 -1.098 0.9382212 2.140577 
4 6.07 5.55 6.128 -0.058 -0.578 1.0410216 1.492778 
1 5.8 5.38  -0.8033333 -1.22333333 1.7451286 2.334856 
2 7.05 6  0.44666667 -0.60333333 0.7337362 1.519223 
3 6.96 5.31  0.35666667 -1.29333333 0.7809669 2.450937 
4 6.75 6.19  0.14666667 -0.41333333 0.9033352 1.331759 
5 6.98 5.9 6.603333 0.37666667 -0.70333333 0.7702151 1.628263 
6 6.08 6.02  -0.5233333 -0.58333333 1.4372722 1.498307 
        
     Average 1.037052 1.657129 
     SD 0.2760154 0.417868 









∆∆Ct mvk control mvk 
1 8.31 8.1  -0.02 -0.23 1.0139595 1.172835 
2 8.31 8.37  -0.02 0.04 1.0139595 0.972655 
3 8.25 7.85  -0.08 -0.48 1.057018 1.394744 
4 8.21 8.39 8.33 -0.12 0.06 1.0867349 0.959264 
1 7.64 7.79  -0.094 0.056 1.0673253 0.961927 
2 7.87 7.7  0.136 -0.034 0.9100388 1.023847 
3 7.75 8.37  0.016 0.636 0.9889709 0.643495 
4 7.78 8.33  0.046 0.596 0.9686182 0.661586 
5 7.63 8.17 7.734 -0.104 0.436 1.0747492 0.739181 
1 7.51 8.47  -0.9866667 -0.02666667 1.9816012 1.018656 
2 8.76 8.44  0.26333333 -0.05666667 0.8331607 1.04006 
3 9.04 8.18 8.496667 0.54333333 -0.31666667 0.6861837 1.24545 
4 8.64 8.15  0.14333333 -0.34666667 0.9054248 1.271619 
     Average 1.0452111 1.008101 
     SD 0.3135636 0.225562 










∆∆Ct pmvk control pmvk 
1 18.54 17.12  0.156 -1.264 0.8975101 2.401607 
2 18.14 18.18  -0.244 -0.204 1.1842716 1.151888 
3 19.34 17.96  0.956 -0.424 0.5154842 1.341642 
4 18.26 19.44  -0.124 1.056 1.0897521 0.480964 
5 17.64 18.91 18.384 -0.744 0.526 1.674813 0.694478 
1 18.58 17.03  0.13 -1.42 0.9138315 2.675855 
2 19.54 17.52  1.09 -0.93 0.4697614 1.905276 
3 17.95 17.83 18.45 -0.5 -0.62 1.4142136 1.536875 
1 7.06 8.83  -0.972 0.798 1.961558 0.575146 




3 7.9 7.95  -0.132 -0.082 1.0958118 1.058484 
4 8.68 8.75  0.648 0.718 0.6381644 0.60794 
5 8.31 7.88 8.032 0.278 -0.152 0.8247335 1.111109 
        
     Average 1.0433717 1.239724 
     SD 0.4365805 0.716862 









∆∆Ct mvd control mvd 
1 7.81 8.16  -0.184 0.166 1.1360293 0.89131 
2 8.02 7.59  0.026 -0.404 0.9821396 1.323171 
3 8.26 8.15  0.266 0.156 0.8316221 0.89751 
4 8.15 8.27  0.156 0.276 0.8975101 0.825878 
5 7.73 7.83 7.994 -0.264 -0.164 1.2008034 1.120389 
1 6.93 7.84  -0.68 0.23 1.6021398 0.852635 
2 7.78 8.12  0.17 0.51 0.8888427 0.702222 
3 7.82 7.95  0.21 0.34 0.8645372 0.790041 
4 7.62 8 7.61 0.01 0.39 0.9930925 0.76313 
1 7.24 7.33  -0.0633333 0.026666667 1.0448772 0.981686 
2 7.18 6.85  -0.1233333 -0.45333333 1.0892487 1.3692 
3 7.82 7.55 7.303333 0.51666667 0.246666667 0.698985 0.842842 
4 7.61 6.96  0.30666667 -0.34333333 0.8085077 1.268684 
        
     Average 1.0029488 0.971438 
     SD 0.2311068 0.215187 









∆∆Ct fdps control fdps 
1 6.04 5.52  0.128 -0.392 0.9150992 1.312211 
2 6.41 5.51  0.498 -0.402 0.7080877 1.321338 
3 6.04 5.81  0.128 -0.102 0.9150992 1.07326 
4 5.12 5.08  -0.792 -0.832 1.7314731 1.780151 
5 5.95 5.53 5.912 0.038 -0.382 0.9740043 1.303147 
1 5.78 5.07  0.176 -0.534 0.8851538 1.447938 
2 5.71 4.81  0.106 -0.794 0.9291607 1.733875 
3 5.83 4.86  0.226 -0.744 0.8550022 1.674813 
4 5.71 5.15 5.604 0.106 -0.454 0.9291607 1.369833 
1 5.86 4.24  0.65 -0.97 0.6372803 1.958841 
2 5.05 4.92  -0.16 -0.29 1.1172871 1.22264 
3 4.87 4.5  -0.34 -0.71 1.2657566 1.635804 
4 5.58 5.1 5.21 0.37 -0.11 0.7737825 1.079228 
5 5.69 4.29  0.48 -0.92 0.7169776 1.892115 
        
     Average 0.9538089 1.486085 













∆∆Ct fdft control fdft 
1 5.77 5.82  -0.046 0.004 1.0323985 0.997231 
2 6.67 5.82  0.854 0.004 0.5532487 0.997231 
3 5.94 5.84  0.124 0.024 0.9176399 0.983502 
4 5.62 5.32 5.816 -0.196 -0.496 1.1455179 1.410298 
1 5.81 5.41  0.422 0.022 0.7463892 0.984866 
2 4.86 4.75  -0.528 -0.638 1.4419289 1.55617 
3 5.38 5.13  -0.008 -0.258 1.0055606 1.19582 
4 5.42 5.61  0.032 0.222 0.9780635 0.857376 
5 5.47 5.19 5.388 0.082 -0.198 0.944747 1.147107 
1 5.59 4.96  -0.3733333 -1.00333333 1.2953423 2.004626 
2 6.08 5.73  0.11666667 -0.23333333 0.9223162 1.175548 
3 5.96 5.81  -0.0033333 -0.15333333 1.0023132 1.112136 
4 5.65 5.74  -0.3133333 -0.22333333 1.2425753 1.167428 
5 6.2 4.99 5.963333 0.23666667 -0.97333333 0.848704 1.963372 
        
     Average 1.0054818 1.253765 
     SD 0.2309202 0.305977 
     SE 0.061716 0.081776 









∆∆Ct sqle control sqle 
1 6.23 5.87  0.012 -0.348 0.9917167 1.272795 
2 6.48 6.05  0.262 -0.168 0.833931 1.1235 
3 6.55 6.2  0.332 -0.018 0.7944344 1.012555 
4 5.63 5.7  -0.588 -0.518 1.5031615 1.431969 
5 6.2 6.21 6.218 -0.018 -0.008 1.0125548 1.005561 
1 6.24 5.85  -0.016 -0.406 1.0111521 1.325007 
2 6.26 7.09  0.004 0.834 0.9972313 0.560972 
3 6.3 5.3  0.044 -0.956 0.9699619 1.939924 
4 5.99 5.22 6.256 -0.266 -1.036 1.2024692 2.050534 
1 6.46 5.78  -0.6416667 -1.32166667 1.5601305 2.499547 
2 6.47 3.07 7.101667 -0.6316667 -4.03166667 1.5493538 16.35508 
3 6.24 5.13  -0.8616667 -1.97166667 1.8171363 3.92221 
        
     Average 1.1869361 2.874971 
     SD 0.282119 4.53592 









∆∆Ct lss control lss 
1 7.79 7.55  -0.202 -0.442 1.1502919 1.358486 
2 8.52 7.91  0.528 -0.082 0.6935155 1.058484 




4 7.49 7.45  -0.502 -0.542 1.4161754 1.45599 
5 8.23 8.17 7.992 0.238 0.178 0.84792 0.883928 
1 8.07 7.87  0.192 -0.008 0.8753913 1.005561 
2 8.23 8.34  0.352 0.462 0.7834972 0.725979 
3 8.17 8.59  0.292 0.712 0.816769 0.610473 
4 7.04 6.83 7.878 -0.838 -1.048 1.7875703 2.067661 
1 9.63 7.14  -0.0283333 -2.51833333 1.0198333 5.729199 
2 9.19 7.22 9.658333 -0.4683333 -2.43833333 1.3835103 5.420152 
        
     Average 1.0743987 1.951473 
     SD 0.3354105 1.507482 




Table B-26: Quantification of qRT-PCR test by 2-∆∆ method for MEF WT (control) 













1 6.83 6.51  -0.334 -0.654 1.2605034 1.573525 
2 6.96 6.73  -0.204 -0.434 1.1518876 1.350974 
3 7.34 7.44  0.176 0.276 0.8851538 0.825878 
4 7.25 6.38  0.086 -0.784 0.9421313 1.721898 
5 7.44 6.93 7.164 0.276 -0.234 0.8258777 1.176091 
        
     Average 1.0131107 1.329673 
     SD 0.1850199 0.350412 













1 5.53 5.35  -0.316 -0.496 1.2448742 1.410298 
2 6.09 5.88  0.244 0.034 0.8444009 0.976709 
3 5.72 6.18  -0.126 0.334 1.0912639 0.793334 
4 5.88 5.71  0.034 -0.136 0.9767085 1.098854 
5 6.01 5.82 5.846 0.164 -0.026 0.892547 1.018185 
        
     Average 1.0099589 1.059476 
     SD 0.1613198 0.225839 










∆∆Ct scap control scap 




2 7.81 7.05  0.084 -0.676 0.9434383 1.597704 
3 7.78 7.04  0.054 -0.686 0.9632619 1.608817 
4 7.63 6.97  -0.096 -0.756 1.068806 1.688802 
5 7.73 7.77 7.726 0.004 0.044 0.9972313 0.969962 
        
     Average 1.0010272 1.420312 
     SD 0.0508312 0.306502 
     SE 0.0227324 0.137072 













1 5.74 6.22  -0.416 0.064 1.3342232 0.956608 
2 6.57 6.22  0.414 0.064 0.7505395 0.956608 
3 6.12 6.73  -0.036 0.574 1.0252672 0.671752 
4 6.03 5.88  -0.126 -0.276 1.0912639 1.210833 
5 6.32 6.25 6.156 0.164 0.094 0.892547 0.936921 
        
     Average 1.0187682 0.946545 
     SD 0.2194813 0.190824 
     SE 0.098155 0.085339 









∆∆Ct s1p control s1p 
1 6.78 6.14  -0.17 -0.81 1.1250585 1.753211 
2 7.01 6.55  0.06 -0.4 0.9592641 1.319508 
3 6.97 6.71  0.02 -0.24 0.9862327 1.180993 
4 6.88 6.29  -0.07 -0.66 1.0497167 1.580083 
5 7.11 6.51 6.95 0.16 -0.44 0.8950251 1.356604 
        
     Average 1.0030594 1.43808 
     SD 0.0879393 0.227082 
     SE 0.0393276 0.101554 
 
Table B-27: Quantification of qRT-PCR test by 2-∆∆ method for MEF WT (control) 










∆∆Ct srebf1 control srebf1 
1 5.99 5.27  -0.5016667 -1.22166667 1.4158483 2.33216 
2 6.6 6.35  0.10833333 -0.14166667 0.9276591 1.103179 
3 6.71 6.26  0.21833333 -0.23166667 0.8595579 1.174191 
4 6.52 5.62  0.02833333 -0.87166667 0.9805524 1.829776 
5 6.66 6.12  0.16833333 -0.37166667 0.8898701 1.293847 
6 6.47 5.87 6.491667 -0.0216667 -0.62166667 1.0151315 1.538652 




     Average 1.0147699 1.545301 
     SD 0.2046039 0.468304 










∆∆Ct srebf2 control srebf2 
1 4.37 4.73  -0.7033333 -0.34333333 1.6282625 1.268684 
2 5.28 5.92  0.20666667 0.846666667 0.866537 0.556068 
3 5.07 5.56  -0.0033333 0.486666667 1.0023132 0.713672 
4 5.08 5.13  0.00666667 0.056666667 0.9953897 0.961483 
5 5.11 5.64  0.03666667 0.566666667 0.9749049 0.675175 
6 5.53 5.65 5.073333 0.45666667 0.576666667 0.7286679 0.670511 
        
     Average 1.0326792 0.807599 
     SD 0.3099665 0.262564 










∆∆Ct scap control scap 
1 7.56 7.59  -0.02 0.01 1.0139595 0.993092 
2 7.7 7.81  0.12 0.23 0.9201877 0.852635 
3 7.37 8.02  -0.21 0.44 1.1566882 0.737135 
4 7.59 7.87  0.01 0.29 0.9930925 0.817902 
5 7.76 7.81  0.18 0.23 0.882703 0.852635 
6 7.5 8.22 7.58 -0.08 0.64 1.057018 0.641713 
        
     Average 1.0039415 0.815852 
     SD 0.0980614 0.118866 










∆∆Ct insig1 control insig1 
1 5.59 6.8  -0.2866667 0.923333333 1.2198186 0.527289 
2 5.95 6.74  0.07333333 0.863333333 0.9504395 0.549681 
3 5.73 6.57  -0.1466667 0.693333333 1.1070088 0.618423 
4 5.88 6.75  0.00333333 0.873333333 0.9976922 0.545884 
5 6.15 6.74  0.27333333 0.863333333 0.8274056 0.549681 
6 5.96 6.64 5.876667 0.08333333 0.763333333 0.9438743 0.589134 
        
     Average 1.0077065 0.563349 
     SD 0.1377064 0.033696 









∆∆Ct s1p control s1p 
1 6.28 6.32  -0.35 -0.31 1.2745606 1.239708 
2 6.75 7.51  0.12 0.88 0.9201877 0.543367 
3 6.91 7.28  0.28 0.65 0.823591 0.63728 




5 6.53 7.1  -0.1 0.47 1.0717735 0.721965 
6 6.86 7.01 6.63 0.23 0.38 0.8526349 0.768438 
        
     Average 1.0126053 0.843243 
     SD 0.1768877 0.28395 
     SE 0.0722141 0.115922 
 
 
Table B-28: Quantification of qRT-PCR test by 2-∆∆ method for MEF PS1 rescue 













1 6.02 7.43  -0.266 1.144 1.2024692 0.452503 
2 6.19 6.91  -0.096 0.624 1.068806 0.648869 
3 6.23 6.97  -0.056 0.684 1.0395794 0.622437 
4 6.74 7.05  0.454 0.764 0.730016 0.588861 
5 6.25 7.17 6.286 -0.036 0.884 1.0252672 0.541863 
        
     Average 1.0132276 0.570907 
     SD 0.1731687 0.077329 













1 6.17 6.26  -0.396 -0.306 1.3158545 1.236275 
2 6.49 6.29  -0.076 -0.276 1.0540914 1.210833 
3 6.4 6.2  -0.166 -0.366 1.1219435 1.288775 
4 6.93 6.28  0.364 -0.286 0.7770073 1.219255 
5 6.84 6.28 6.566 0.274 -0.286 0.8270234 1.219255 
        
     Average 1.019184 1.234879 
     SD 0.2210015 0.031516 













1 7.95 8.26  -0.296 0.014 1.2277357 0.990343 
2 8.9 8.25  0.654 0.004 0.6355158 0.997231 
3 7.75 7.37  -0.496 -0.876 1.410298 1.83528 
4 8.46 8.44  0.214 0.194 0.8621435 0.874179 
5 8.17 8.88  -0.076 0.634 1.0540914 0.644387 
6   8.246     
     Average 1.0379569 1.068284 
     SD 0.3032257 0.451877 
















1 7.67 6.43  -0.096 -1.336 1.068806 2.524504 
2 7.85 6.4  0.084 -1.366 0.9434383 2.577549 
3 7.47 5.38  -0.296 -2.386 1.2277357 5.227061 
4 8.16 6.51  0.394 -1.256 0.7610167 2.388326 
5 7.68 6.83 7.766 -0.086 -0.936 1.0614232 1.913216 
        
     Average 1.012484 2.926131 
     SD 0.1731355 1.312662 












1 7.2 7.64  0.04 0.48 0.9726549 0.716978 
2 7.15 5.81  -0.01 -1.35 1.0069556 2.549121 
3 7 7.66  -0.16 0.5 1.1172871 0.707107 
4 7.16 7.33  0 0.17 1 0.888843 
5 7.29 7.01 7.16 0.13 -0.15 0.9138315 1.109569 
        
     Average 1.0021458 1.194324 
     SD 0.0740851 0.774793 
     SE 0.0331319 0.346498 
 
Statistical Analysis 
Normality test was performed before applying T-test by employing SPSS 25 software. 
Normally distributed data were tested by T-test while, Mann-Whitney U test was 
performed to non-normally distributed data.  
 
Table B-29: Normality test of MEF WT (control) and MEF APP ∆ CT 15 (sample) 
cells. 
 
Kolmogorov-Smirnova Shapiro-Wilk  
Statistic df Sig. Statistic df Sig. Sig. Test 
Hmgcs1-control .134 14 .200* .952 14 .594 
T. test 
Hmgcs1-sample .183 14 .200* .887 14 .074 
Hmgcs2-control .273 14 .006 .698 14 .000 
Mann-Whitney U test 
Hmgcs2-sample .114 14 .200* .957 14 .680 
Hmgcr-control .149 15 .200* .969 15 .840 
Mann-Whitney U test 
Hmgcr-sample .323 15 .000 .595 15 .000 
Mvk-control .166 14 .200* .954 14 .632 
T. test 
Mvk-sample .181 14 .200* .902 14 .119 




Pmvk-sample .165 14 .200* .959 14 .700 
Mvd-control .140 14 .200* .912 14 .169 
T. test 
Mvd-sample .176 14 .200* .943 14 .463 
Fdps-control .118 15 .200* .976 15 .930 
T. test 
Fdps-sample .184 15 .185 .931 15 .283 
Fdft-control .215 13 .101 .921 13 .256 
T. test 
Fdft-sample .123 13 .200* .957 13 .709 
Sqle-control .120 13 .200* .971 13 .908 
T. test 
sqle-sample .170 13 .200* .950 13 .599 
Lss-control .188 14 .194 .951 14 .575 
T. test 






Table B-30: Statistical significance (T.Test) of cholesterol genes in MEF APP ∆ CT 
15 cells. 
Levene's Test for Equality of 
Variances 
t-test for Equality of Means 















35.297 .000 -.916- 26 .368 -.07228- .07888 -.23443- .08987 
Equal variances 
not assumed 




8.713 .007 -2.075- 26 .048 -.17640- .08502 -.35117- -.00163- 
Equal variances 
not assumed 




1.716 .202 3.616 26 .001 .39109 .10815 .16879 .61340 
Equal variances 
not assumed 







5.693 .025 2.893 26 .008 .26407 .09129 .07643 .45171 
Equal variances 
not assumed 




.320 .576 4.790 28 .000 .34467 .07196 .19727 .49206 
Equal variances 
not assumed 




3.372 .079 -2.259- 24 .033 -.25382- .11238 -.48575- -.02189- 
Equal variances 
not assumed 




2.789 .108 -1.907- 24 .069 -.28107- .14737 -.58524- .02309 
Equal variances 
not assumed 




4.453 .045 .167 26 .869 .01973 .11806 -.22295- .26241 
Equal variances 
not assumed 
  .167 18.920 .869 .01973 .11806 -.22745- .26691 
 
Table B-31: Statistical significance (Mann-Whitney U test) of cholesterol genes in 
MEF APP ∆ CT 15 cells. 
 hmgcs2 hmgcr 
Mann-Whitney U 13.000 18.000 
Wilcoxon W 118.000 138.000 
Z -3.906- -3.920- 
Asymp. Sig. (2-tailed) .000 .000 









Table B-32: Normality test of MEF WT (control) and MEF APP-APLP2 -/- (sample) 
cells. 
 
Kolmogorov-Smirnova Shapiro-Wilk  
Statistic df Sig. Statistic df Sig. Sig. Test 
Hmgcs1-control .145 16 .200* .852 16 .015 
Mann-Whitney U test 
Hmgcs1-sample .223 16 .033 .872 16 .029 
Hmgcs2-control .110 13 .200* .951 13 .620 
T.test 
Hmgcs2-sample .173 13 .200* .916 13 .221 
Hmgcr-control .176 16 .200 .919 16 .161 
T.test 
Hmgcr-sample .158 16 .200* .921 16 .174 
Mvk-control .216 14 .075 .932 14 .323 
T.test 
Mvk-sample .184 14 .200* .912 14 .171 
Pmvk-control .178 13 .200* .943 13 .494 
Mann-Whitney U test 
Pmvk-sample .219 13 .088 .858 13 .036 
Mvd-control .155 16 .200* .919 16 .161 
Mann-Whitney U test 
Mvd-sample .236 16 .018 .790 16 .002 
Fdps-control .144 15 .200* .971 15 .867 
Mann-Whitney U test 
Fdps-sample .288 15 .002 .811 15 .005 
Fdft-control .210 13 .122 .943 13 .504 
T.test 
Fdft-sample .180 13 .200* .905 13 .159 
Sqle-control .139 13 .200* .927 13 .310 
Mann-Whitney U test 
sqle-sample .303 13 .002 .752 13 .002 
Lss-control .183 14 .200* .933 14 .341 
Mann-Whitney U test 
Lss-sample .214 14 .081 .809 14 .006 
 
Table B-33: Statistical significance (Mann-Whitney U test) of cholesterol genes in 
MEF APP/APLP2 -/- cells. 
 
 hmgcs1 pmvk mvk Fdps sqle Lss 
Mann-Whitney U 62.000 18.000 26.000 50.000 60.000 55.000 
Wilcoxon W 198.000 109.000 162.000 170.000 151.000 160.500 
Z -2.488- -3.413- -3.844- -2.592- -1.256- -1.953- 
Asymp. Sig. (2-tailed) .013 .001 .000 .010 .209 .051 








Table B-34: Statistical significance (T. test)) of cholesterol genes in MEF 
APP/APLP2 -/- cells. 
Levene's Test for Equality of 
Variances 
t-test for Equality of Means 











































1.052 20.611 .305 .11429 .10868 -.11198- .34055 
 
 
Table B-35: Normality test of MEF PS1 rescue (control) and MEF PS1/2 -/- (sample) 
cells. 
 
Kolmogorov-Smirnova Shapiro-Wilk  
Statistic df Sig. Statistic df Sig. Sig. Test 
Hmgcs1-control .243 14 .025 .781 14 .003 
Mann-Whitney U test 
Hmgcs1-sample .199 14 .137 .884 14 .066 
Hmgcs2-control .162 12 .200* .950 12 .635 
Mann-Whitney U test 
Hmgcs2-sample .371 12 .000 .775 12 .005 




Hmgcr-sample .205 14 .114 .901 14 .117 
Mvk-control .350 13 .000 .704 13 .001 
Mann-Whitney U test 
Mvk-sample .162 13 .200* .961 13 .777 
Pmvk-control .155 13 .200* .941 13 .469 
T.test 
Pmvk-sample .164 13 .200* .887 13 .089 
Mvd-control .139 13 .200* .891 13 .102 
T. test 
Mvd-sample .244 13 .033 .873 13 .058 
Fdps-control .257 14 .013 .824 14 .010 
Mann-Whitney U test 
Fdps-sample .155 14 .200* .940 14 .415 
Fdft-control .167 14 .200* .973 14 .917 
Mann-Whitney U test 
Fdft-sample .279 14 .004 .825 14 .010 
Sqle-control .302 11 .006 .858 11 .054 
T.test 
sqle-sample .229 11 .113 .862 11 .062 
Lss-control .199 10 .200* .867 10 .093 
T.test 
Lss-sample .149 10 .200* .946 10 .617 
 
 
Table B-36: Statistical significance (Mann-Whitney U test) of cholesterol genes in 
MEF PS1/2 -/- cells. 
      
 hmgcs1 hmgcs2 hmgcr mvk fdps fdft 
Mann-Whitney U 8.000 70.000 17.000 56.000 15.000 56.000 
Wilcoxon W 113.000 148.000 122.000 147.000 120.000 161.000 
Z -4.136- -.115- -3.722- -1.462- -3.815- -1.930- 
Asymp. Sig. (2-tailed) .000 .908 .000 .144 .000 .054 
Exact Sig. [2*(1-tailed Sig.)] .000b .932 .000 .153 .000 .056 
a. Grouping Variable: Grouping      













Table B-37: Statistical significance (T.Test) of cholesterol genes in MEF PS1/2 -/- 
cells. 
Levene's Test for Equality of 
Variances 
t-test for Equality of Means 















2.884 .102 -.843- 24 .407 -.19635- .23279 -.67681- .28411 
Equal variances 
not assumed 




.182 .673 .354 24 .726 .03151 .08892 -.15202- .21504 
Equal variances 
not assumed 




5.382 .031 -1.661- 20 .112 -.49552- .29841 -1.1179- .12695 
Equal variances 
not assumed 




.467 .503 -.743- 18 .467 -.12655- .17040 -.48454- .23144 
Equal variances 
not assumed 
  -.743- 17.132 .468 -.12655- .17040 -.48584- .23274 
 




Kolmogorov-Smirnova Shapiro-Wilk  
Statistic df Sig. Statistic df Sig. Sig. Test 
Srebf1-control .249 5 .200* .911 5 .475 
T. test 
Srebf1-sample .157 5 .200* .973 5 .897 
Srebf1-control .182 5 .200* .948 5 .723 
T. test 
Srebf2-sample .231 5 .200* .947 5 .716 
Scap-control .171 5 .200* .968 5 .861 
T. test 




Insig1-control .171 5 .200* .986 5 .964 
T. test 
Insig1-sample .280 5 .200* .905 5 .438 
S1p-control .176 5 .200* .987 5 .968 
T. test 




Table B-39: Statistical significance (T.Test) of SREBP-1 genes in MEF APP ∆ CT 15 
cells. 
Levene's Test for Equality of 
Variances 
t-test for Equality of Means 























































Table B-40: Normality test of MEF WT (control) and MEF APP/APLP2 -/- (sample) 
cells (SREBP-1). 
 
Kolmogorov-Smirnova Shapiro-Wilk  
Statistic df Sig. Statistic df Sig. Sig. Test 
Srebf1-control .333 6 .037 .755 6 .022 
Mann-Whitney U test 
Srebf1-sample .204 6 .200* .904 6 .400 
Srebf1-control .372 6 .009 .796 6 .054 
T. test 
Srebf2-sample .306 6 .082 .856 6 .177 
Scap-control .137 6 .200* .974 6 .919 
T. test 
Scap-sample .212 6 .200* .967 6 .874 
Insig1-control .196 6 .200* .964 6 .847 
T. test 
Insig1-sample .324 6 .048 .881 6 .276 
S1p-control .199 6 .200* .933 6 .602 
T. test 
S1p-sample .271 6 .193 .879 6 .266 
 
Table B-41: Statistical significance (Mann-Whitney U test) of SREBP-1 genes in 
MEF APP/APLP2 -/- cells. 
 Srebf1 
Mann-Whitney U 3.000 
Wilcoxon W 24.000 
Z -2.402- 
Asymp. Sig. (2-tailed) .016 




Table B-42: Statistical significance (T. test) of SREBP-1 genes in MEF APP/APLP2 -
/- cells. 
Levene's Test for Equality of 
Variances 
t-test for Equality of Means 














































1.240 8.373 .249 .16936 .13658 -.14316- .48188 
 
 
Table B-43: Normality test of MEF PS1 rescue (control) and MEF PS1/2 -/- (sample) 
cells (SREBP-1). 
 
Kolmogorov-Smirnova Shapiro-Wilk  
Statistic df Sig. Statistic df Sig. Sig. Test 
Srebf1-control .328 5 .084 .878 5 .300 
T. test 
Srebf1-sample .192 5 .200* .940 5 .667 
Srebf1-control .208 5 .200* .943 5 .690 
T. test 
Srebf2-sample .290 5 .197 .787 5 .063 
Scap-control .134 5 .200* .989 5 .977 
T. test 
Scap-sample .362 5 .031 .826 5 .129 
Insig1-control .211 5 .200* .967 5 .854 
Mann-Whitney U test 
Insig1-sample .405 5 .007 .733 5 .021 
S1p-control .274 5 .200* .938 5 .652 
Mann-Whitney U test 











Table B-44: Statistical significance (T.Test) of SREBP-1 genes in MEF PS1/2 -/- 
cells. 
Levene's Test for Equality of 
Variances 
t-test for Equality of Means 



































2.990 9.651 .014 .18809 .06291 .04723 .32895 
 
 
Table B-45: Statistical significance (Mann-Whitney U test) of SREBP-1 genes in 








Effect of cholesterol on IDE gene expression 
N2a cells were used in the experiments. Untreated N2a cells were used as control, 
while cholesterol treated cells were used as a sample. Cholesterol concentration was 
100 µM. Two housekeeping genes were used, β-actin and Polr2.  
 
 Insig1 S1p 
Mann-Whitney U .000 9.000 
Wilcoxon W 15.000 24.000 
Z -2.449- -.731- 
Asymp. Sig. (2-tailed) .014 .465 





Table B-46: Quantification of gene expression for IDE gene on 04.10.2016 (first 
experiment). 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 2218.23 
Baseline range start: 3    




Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty n2a sample actin beta 16.92 
A02-Ch5 SYBR Empty n2a sample actin beta 16.94 
A03-Ch5 SYBR Empty n2a sample actin beta 16.98 
A04-Ch5 SYBR Empty n2a sample actin beta 17.36 
A05-Ch5 SYBR Empty n2a sample actin beta 16.96 
A06-Ch5 SYBR Empty n2a sample actin beta 15.98 
A07-Ch5 SYBR Empty n2a sample actin beta 16.65 
A08-Ch5 SYBR Empty n2a control actin beta 16.73 
A09-Ch5 SYBR Empty n2a control actin beta 16.49 
A10-Ch5 SYBR Empty n2a control actin beta 16.72 
A11-Ch5 SYBR Empty n2a control actin beta 16.25 
A12-Ch5 SYBR Empty n2a control actin beta 16.69 
A13-Ch5 [none] [none]   n. def. 
A14-Ch5 [none] [none]   n. def. 
A15-Ch5 [none] [none]   n. def. 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty n2a sample polr2 22.54 




B03-Ch5 SYBR Empty n2a sample polr2 22.68 
B04-Ch5 SYBR Empty n2a sample polr2 22.62 
B05-Ch5 SYBR Empty n2a sample polr2 22.58 
B06-Ch5 SYBR Empty n2a sample polr2 22.32 
B07-Ch5 SYBR Empty n2a sample polr2 22.28 
B08-Ch5 SYBR Empty n2a control polr2 22.1 
B09-Ch5 SYBR Empty n2a control polr2 21.92 
B10-Ch5 SYBR Empty n2a control polr2 22.15 
B11-Ch5 SYBR Empty n2a control polr2 21.95 
B12-Ch5 SYBR Empty n2a control polr2 22.56 
B13-Ch5 [none] [none]   n. def. 
B14-Ch5 [none] [none]   n. def. 
B15-Ch5 [none] [none]   n. def. 
B16-Ch5 [none] [none]   n. def. 
C01-Ch5 SYBR Empty n2a sample ide 59 21.94 
C02-Ch5 SYBR Empty n2a sample ide 59 22.02 
C03-Ch5 SYBR Empty n2a sample ide 59 21.96 
C04-Ch5 SYBR Empty n2a sample ide 59 22.01 
C05-Ch5 SYBR Empty n2a sample ide 59 21.69 
C06-Ch5 SYBR Empty n2a sample ide 59 21.69 
C07-Ch5 SYBR Empty n2a sample ide 59 21.93 
C08-Ch5 SYBR Empty n2a control ide 59 21.9 
C09-Ch5 SYBR Empty n2a control ide 59 21.77 
C10-Ch5 SYBR Empty n2a control ide 59 22.01 
C11-Ch5 SYBR Empty n2a control ide 59 21.37 
C12-Ch5 SYBR Empty n2a control ide 59 21.66 
 
 
Table B-47: Quantification of gene expression for IDE gene on 12.10.2016 (second 
experiment). 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 1573.2 
Baseline range start: 3    







Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty control Actin Beta 16.4 
A02-Ch5 SYBR Empty control Actin Beta 15.92 
A03-Ch5 SYBR Empty control Actin Beta 16.23 
A04-Ch5 SYBR Empty control Actin Beta 15.82 
A05-Ch5 SYBR Empty control Actin Beta 16.01 
A06-Ch5 SYBR Empty control Actin Beta 15.95 
A07-Ch5 SYBR Empty sample Actin Beta 16.05 
A08-Ch5 SYBR Empty sample Actin Beta 16.27 
A09-Ch5 SYBR Empty sample Actin Beta 16.1 
A10-Ch5 SYBR Empty sample Actin Beta 16 
A11-Ch5 SYBR Empty sample Actin Beta 15.92 
A12-Ch5 [none] [none]   n. def. 
A13-Ch5 [none] [none]   n. def. 
A14-Ch5 [none] [none]   n. def. 
A15-Ch5 [none] [none]   n. def. 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty control Polr2 22.04 
B02-Ch5 SYBR Empty control Polr2 21.74 
B03-Ch5 SYBR Empty control Polr2 21.94 
B04-Ch5 SYBR Empty control Polr2 21.77 
B05-Ch5 SYBR Empty control Polr2 21.91 
B06-Ch5 SYBR Empty control Polr2 21.7 
B07-Ch5 SYBR Empty sample Polr2 21.63 
B08-Ch5 SYBR Empty sample Polr2 21.92 
B09-Ch5 SYBR Empty sample Polr2 21.98 
B10-Ch5 SYBR Empty sample Polr2 21.71 
B11-Ch5 SYBR Empty sample Polr2 21.47 
B12-Ch5 [none] [none]   n. def. 
B13-Ch5 [none] [none]   n. def. 
B14-Ch5 [none] [none]   n. def. 
B15-Ch5 [none] [none]   n. def. 




C01-Ch5 SYBR Empty control IDE 59 21.82 
C02-Ch5 SYBR Empty control IDE 59 21.56 
C03-Ch5 SYBR Empty control IDE 59 21.77 
C04-Ch5 SYBR Empty control IDE 59 21.71 
C05-Ch5 SYBR Empty control IDE 59 21.59 
C06-Ch5 SYBR Empty control IDE 59 21.42 
C07-Ch5 SYBR Empty sample IDE 59 21.48 
C08-Ch5 SYBR Empty sample IDE 59 21.52 
C09-Ch5 SYBR Empty sample IDE 59 21.84 
C10-Ch5 SYBR Empty sample IDE 59 21.36 




Table B-48: Quantification of gene expression for IDE gene on 22.02.2017 (third 
experiment). 
Data step: 4  Show channel: Thresholds: 
Sample Group: Default Ch 1 No  
Method: Threshold Ch 2 No  
Smoothing: ON Ch 3 No  
Smoothing window: 5 Ch 4 No  
Baseline: Trend Ch 5 Yes 1368.19 
Baseline range start: 3    




Well Fluorophore Sample Type Sample Name Target Cq 
A01-Ch5 SYBR Empty control Actin Beta 15.59 
A02-Ch5 SYBR Empty control Actin Beta 15.55 
A03-Ch5 SYBR Empty control Actin Beta 15.71 




A05-Ch5 SYBR Empty control Actin Beta 15.47 
A06-Ch5 SYBR Empty control Actin Beta 15.16 
A07-Ch5 SYBR Empty sample Actin Beta 15.53 
A08-Ch5 SYBR Empty sample Actin Beta 15.11 
A09-Ch5 SYBR Empty sample Actin Beta n. def. 
A10-Ch5 SYBR Empty sample Actin Beta 15.18 
A11-Ch5 SYBR Empty sample Actin Beta 15.03 
A12-Ch5 SYBR Empty sample Actin Beta 15.25 
A13-Ch5 [none] [none]   n. def. 
A14-Ch5 [none] [none]   n. def. 
A15-Ch5 [none] [none]   n. def. 
A16-Ch5 [none] [none]   n. def. 
B01-Ch5 SYBR Empty control polr2 21.7 
B02-Ch5 SYBR Empty control polr2 21.91 
B03-Ch5 SYBR Empty control polr2 22.14 
B04-Ch5 SYBR Empty control polr2 21.76 
B05-Ch5 SYBR Empty control polr2 22.04 
B06-Ch5 SYBR Empty control polr2 21.49 
B07-Ch5 SYBR Empty sample polr2 21.48 
B08-Ch5 SYBR Empty sample polr2 21.29 
B09-Ch5 SYBR Empty sample polr2 38.75 
B10-Ch5 SYBR Empty sample polr2 20.68 
B11-Ch5 SYBR Empty sample polr2 21.37 
B12-Ch5 SYBR Empty sample polr2 21.32 
B13-Ch5 [none] [none]   n. def. 
B14-Ch5 [none] [none]   n. def. 
B15-Ch5 [none] [none]   n. def. 
B16-Ch5 [none] [none]   n. def. 
C01-Ch5 SYBR Empty control IDE 21.63 
C02-Ch5 SYBR Empty control IDE 21.54 
C03-Ch5 SYBR Empty control IDE 21.14 
C04-Ch5 SYBR Empty control IDE 21.54 
C05-Ch5 SYBR Empty control IDE 21.41 
C06-Ch5 SYBR Empty control IDE 20.92 
C07-Ch5 SYBR Empty sample IDE 21.33 
C08-Ch5 SYBR Empty sample IDE 21.11 
C09-Ch5 SYBR Empty sample IDE 21.17 
C10-Ch5 SYBR Empty sample IDE 20.91 
C11-Ch5 SYBR Empty sample IDE 20.93 
















∆∆Ct IDE control IDE 
1 5.17 5.02   0.004 -0.146 0.9972313 1.106497 
2 5.28 5.08   0.114 -0.086 0.9240226 1.061423 
3 5.29 4.98   0.124 -0.186 0.9176399 1.137605 
4 5.12 4.65   -0.046 -0.516 1.0323985 1.429985 
5 4.97 4.73 5.166 -0.196 -0.436 1.1455179 1.352848 
6 5.42 5.43  -0.194 -0.184 1.143931 1.136029 
7 5.64 5.25  0.026 -0.364 0.9821396 1.286989 
8 5.54 5.74  -0.074 0.126 1.0526312 0.916369 
9 5.89 5.36  0.276 -0.254 0.8258777 1.192509 
10 5.58 5.35 5.614 -0.034 -0.264 1.0238469 1.200803 
11 6.04 5.8   0.138 -0.102 0.9087781 1.07326 
12 5.99 6   0.088 0.098 0.9408261 0.934327 
13 5.78 5.73   -0.122 -0.172 1.0882424 1.126619 
14 5.94 5.9   0.038 -0.002 0.9740043 1.001387 
15 5.76 5.2 5.902 -0.142 -0.702 1.1034337 1.626758 
        
     Avg, 1.0040347 1.172227 
     Std. 0.0926671 0.189414 
     SE 0.0239266 0.048906 
 
 









∆∆Ct IDE control IDE 
1 -0.2 -0.6   0.194 -0.206 0.8741786 1.153486 
2 -0.15 -0.8   0.244 -0.406 0.8444009 1.325007 
3 -0.14 -0.72   0.254 -0.326 0.8385682 1.253533 
4 -0.58 -0.61   -0.186 -0.216 1.1376052 1.161509 
5 -0.9 -0.89 -0.394 -0.506 -0.496 1.4201074 1.410298 
6 -0.22 -0.15  -0.03 0.04 1.0210121 0.972655 
7 -0.18 -0.4  0.01 -0.21 0.9930925 1.156688 
8 -0.17 -0.14  0.02 0.05 0.9862327 0.965936 
9 -0.06 -0.35  0.13 -0.16 0.9138315 1.117287 
10 -0.32 -0.2 -0.19 -0.13 -0.01 1.0942937 1.006956 
11 -0.37 -0.18   0.002 0.192 0.9986147 0.875391 
12 -0.63 -0.44   -0.258 -0.068 1.1958198 1.048262 
13 -0.57 -0.87 -0.372 -0.198 -0.498 1.147107 1.412254 
        
     Avg, 1.0357588 1.14302 
     Std. 0.1637802 0.170797 






Table B.51: Normality test of IDE gene expression experiments. 
 
Kolmogorov-Smirnova Shapiro-Wilk  
Statistic df Sig. Statistic df Sig. Sig. Test 
Srebf1-control 0.086 15 0.2 0.971 15 0.871 
T. test 
Srebf1-sample 0.173 15 0.2 0.934 15 0.317 
Srebf1-control 0.151 13 0.2 0.926 13 0.299 
T. test 




Table B-52: Significance test (T. test) of IDE gene expression experiments with two 
housekeeping genes, β-actin and Polr2. 
Levene's Test for Equality of 
Variances 
t-test for Equality of Means 















3.797 0.061 -3.089 28 0.004 -0.16819 0.05445 -0.27972 -0.05667 
Equal variances 
not assumed 




0.049 0.827 -1.634 24 .115 -.10726 .06563 -.24272 .02819 
Equal variances 
not assumed 



















Results of western blot experiments 
 




















                                 
 







 Gel 1 Gel2 
Ln Area Name AU AU-BG AU AU-BG 
1 Control 1439198 117324.73 1255429 100418.5 
2 Sample 1427673 115246.37 1374739 87774.95 
3 Control 1604975 156830.82 1328147 105682.31 
4 Sample 1489224 118341.89 1117720 73002.73 
5 Control 1420658 118232.35 1235122 68953.93 




      Table C.2: Results of gel analysis by Image gauge, date of experiment 26.06.2016. 








1 control 5587406 758865.1 sample 5009953 425863.6 
2 sample 5307325 467291.4 control 5165016 543389.2 
3 control 6234141 575775.9 sample 5603951 609008.5 
4 sample 4630562 475210.3 control 5550052 635950.8 
5 control 4499575 527447.5 sample 6010676 675323.2 
6 sample 7406998 753780.9 control 6803584 790098.3 
 
 
                            
 











       Table C.3: Results of gel analysis by Image gauge, date of experiment 27.06.2016. 




AU AU-BG AU AU-BG 
1 Control 1157456 85608.5 1209656 87349.69 
2 Sample 1155463 65002.16 1072515 53589.15 
3 Control 1070402 66621.12 1098202 72040.7 
4 Sample 1092584 70821.29 1063912 64246.09 
5 Control 1073482 79173.7 1100330 81272.19 
6 Sample 1036097 51241.76 1066814 54938.38 
 
  
     Table C 4: Data analysis of Aβ degradation in N2a living cells.   





117324.7 115246.4 116285.6 89.65 90.45115 88.84885 
156830.8 118341.9 137586.4  102.1895 77.11048 
118232.4 96761.55 107497  98.60308 80.69692 
100418.5 87774.95 94096.73  95.67303 83.62697 
105682.3 73002.73 89342.52 *Control×factor 106.046 73.25398 
68953.93 51679.81 60316.87 Area 102.4874 76.81259 
85608.5 65002.16 75305.33  101.9158 77.38421 
66621.12 70821.29 68721.21 **Sample×factor 86.91034 92.38966 
79173.7 51241.76 65207.73 Area 108.8509 70.44907 
87349.69 53589.15 70469.42  111.1248 68.17521 
72040.7 64246.09 68143.4  94.77733 84.52267 
81272.19 54938.38 68105.29  106.9822 72.31782 
753780.9 527447.5 640614.2  105.487 73.81301 
543389.2 425863.6 484626.4  100.5204 78.77959 
635950.8 609008.5 622479.7  91.59013 87.70987 
790098.3 675323.2 732710.8  96.67159 82.62841 
n= 16 n= 16  Average 100.0175 79.28246 
   Std. Dev. 6.950798 6.950798 









Statistic df Sig. Statistic df Sig. 
Control .108 16 .200* .977 16 .934 







Table C.6: Significance test (T. test) of Aβ degradation in N2a living cells. 
 
Figure C.4: Gel of Aβ degradation in N2a culture medium on 22.07.2016 (test). 
 
 















for Equality of 
Variances 
 t-test for Equality of Means 
































1 5 Po. Ctrl. 2422135.05 1587921 ------- 100 36 -----
- 
0.59 
1 4 30h 1248697.43 535212.4 ------- 100 31 ------- 0.52 
1 3 8h 1669695.01 799803.9 ------- 100 21 -----
- 
0.36 
1 2 24h 1314550.19 544132.1 ------- 100 21 -----
- 
0.31 




control 8h 12h 24h 30h MBV Factor 
1587921 799803.9 675714.2 544132.1 535212.37 828556.7 52.18 
       





           








        


















1 1 Control 665551 275493 ------- 100 29 ------ 0.49 
1 2 Sample 551600 185533.6 ------- 100 28 ------- 0.47 
1 3 Control 568755 227877.9 ------- 100 31 ------ 0.53 
1 4 Sample 436929 142111.8 ------- 100 30 ------ 0.51 
1 5 Control 528936 207464 ------- 100 27 ------ 0.46 
1 6 Sample 409305 115733 ------- 100 29 ------ 0.49 






























1 1 Control 1644177 375184 ------- 100 42 ------ 0.5 
1 2 Sample 1366264 379722.1 ------- 100 38 ------- 0.45 
1 3 Control 1399059 452008 ------- 100 41 ------ 0.49 
1 4 Sample 1311806 377304 ------- 100 36 ------ 0.43 
1 5 Control 1549441 505586 ------- 100 38 ------ 0.45 
1 6 Sample 1401487 434421.2 ------- 100 37 ------ 0.44 
1 7 Pos. Ctrl. 1572990 619443.4 ------- 100 33 ------ 0.39 
1 8 Control 1032179 387231.3 ------- 100 50 ------ 0.44 
1 9 Sample 1271509 477675 ------- 100 45 ------ 0.39 
1 10 Control 1289560 480904 ------- 100 44 ------ 0.39 
1 11 Sample 1417251 511439.4 ------- 100 42 ------ 0.37 























Figure C.7: Gel of Aβ degradation in N2a culture medium on 15.08.2016. 
 
Table C.11: Data analysis of Aβ degradation in N2a culture medium by Image gauge 
on 15.08.2016. 
 
      Table C 12: Data analysis of Aβ degradation in N2a culture medium.   





275493.23 185533.59 230513.41 90.3  107.920136 72.67986351 
227877.85 142111.82 184994.835  111.232132 69.36786828 
207464.2 115733.12 161598.66  115.929286 64.67071408 
321769.51 298625.07 310197.29  93.6687318 86.93126823 
416260.31 318671.48 367465.895 *Control×factor 102.290598 78.30940241 













1 1 Control 1191096 504710 ------- 100 63 ------ 0.51 
1 2 Sample 1152896 475437.8 ------- 100 58 ------- 0.47 
1 3 Control 1115939 475912 ------- 100 52 ------ 0.42 
1 4 Sample 1006545 378708.4 ------- 100 49 ------ 0.4 
1 5 Control 1000149 353512 ------- 100 46 ------ 0.37 
1 6 Sample 838334 300666 ------- 100 47 ------ 0.38 
1 7 Pos. Ctrl. 1389879 601135 ------- 100 55 ------ 0.44 
1 8 Control 1306717 472502.7 ------- 100 58 ------ 0.5 
1 9 Sample 1002967 289481.9 ------- 100 57 ------ 0.49 
1 10 Control 1294801 424910 ------- 100 57 ------ 0.49 
1 11 Sample 1111520 341102 ------- 100 55 ------ 0.47 




358854.67 420161.2 389507.935  83.193624 97.40637597 
405289.5 451102.67 428196.085 **Sample×factor 85.4693519 95.13064815 
504710.43 475437.83 490074.13 Mean 92.996853 87.603147 
475912.46 378708.39 427310.425  100.570669 80.02933141 
353512.47 300665.76 327089.115  97.5947367 83.00526335 
472502.71 289481.94 380992.325  111.989119 68.61088129 
424909.84 341101.89 383005.865  100.179559 80.42044126 
      
n= 13 n= 13  Average 100.0175 79.28246 
   Std. Dev. 6.950798 6.950798 












Table C.14: Significance test (T. test) of Aβ degradation in N2a culture medium. 
Levene's Test for Equality of 
Variances 
t-test for Equality of Means 






















Statistic df Sig. Statistic df Sig. 
Control .102 13 .200* .967 13 .861 




                            
Figure C.8: Gel of Aβ degradation in N2a IDE knock down living cells on 07.07.2016. 
 
 
Table C.15: Data analysis of Aβ degradation in N2a IDE knock-down living cells by 
















1 1 Control 990292 524566.11 ----- 100 57 ------ 0.47 
1 2 Sample 1365796 771508.88 ----- 100 60 ------- 0.5 
1 3 Control 1402848 795290.69 ----- 100 55 ------ 0.46 
1 4 Sample 1460101 857778.28 ----- 100 42 ------ 0.35 
1 5 Control 1412384 817909.94 ----- 100 54 ------ 0.45 
1 6 Sample 1043021 556937.18 ----- 100 56 ------ 0.47 
1 7 Control 1322214 579899.12 ----- 100 55 ------ 0.49 
1 8 Sample 1515306 672489.8 ----- 100 58 ------ 0.52 
1 9 Control 1582087 717753.38 ----- 100 51 ------ 0.46 
1 10 Sample 1592724 771843.76 ----- 100 50 ------ 0.45 
1 11 Control 1240434 585594.61 ----- 100 60 ------ 0.54 




                     
 




Table C.16: Data analysis of Aβ degradation in N2a IDE knock-down living cells by 















1 1 Control 1563580 459931.79 ----- 100 47 ------ 0.44 
1 2 Sample 1531823 395447.68 ----- 100 53 ------- 0.49 
1 3 Control 1566971 386060.69 ----- 100 61 ------ 0.56 
1 4 Sample 1572988 398463.39 ----- 100 57 ------ 0.53 
1 5 Control 1585782 419040.02 ----- 100 54 ------ 0.5 
1 6 Sample 1544350 398361.53 ----- 100 47 ------ 0.44 
1 7 Control 1436537 416346.1 ----- 100 51 ------ 0.47 
1 8 Sample 1491167 378900.7 ----- 100 47 ------ 0.44 
1 9 Control 1505112 332906.7 ----- 100 48 ------ 0.44 
1 10 Sample 1538252 414418.3 ----- 100 53 ------ 0.49 
1 11 Control 1583717 433353.3 ----- 100 53 ------ 0.49 




                
     Figure C.10: Gel of Aβ degradation in N2a knock down living cells on 14.12.2016. 
 
 
Table C.17: Data analysis of Aβ degradation in N2a IDE knock-down living cells by 

















1 1 Control 531837 299715.36 ----- 100 51 ------ 0.44 
1 2 Sample 537698 315162.35 ----- 100 53 ------- 0.46 
1 3 Control 623610 401214.12 ----- 100 45 ------ 0.39 
1 4 Sample 469937 292427.26 ----- 100 44 ------ 0.38 
1 5 Control 447225 266240.16 ----- 100 43 ------ 0.37 
1 6 Sample 378596 214336.48 ----- 100 40 ------ 0.34 
1 7 Control 426791 232883.37 ----- 100 51 ------ 0.41 
1 8 Sample 411479 210115.82 ----- 100 52 ------ 0.42 
1 9 Control 349445 189206.68 ----- 100 49 ------ 0.4 
1 10 Sample 384954 210789.87 ----- 100 58 ------ 0.47 
1 11 Control 384301 235899.66 ----- 100 61 ------ 0.49 




      Table C 18: Data analysis of Aβ degradation in N2a IDE knock down living cells. 





795290.69 771508.88 783399.785 97.4 
  
98.8783948 95.9216052 
817909.94 857778.28 837844.11 95.0826379 99.7173621 
579899.12 672489.8 626194.46  90.1990961 104.600904 
717753.38 771843.76 744798.57  93.8632028 100.936797 
585594.61 535338.9 560466.755 *Control×factor 101.766812 93.0331878 
459931.79 395447.68 427689.735 Mean 104.74265 90.0573497 
386060.69 398463.39 392262.04  95.8601837 98.9398163 
419040.02 398361.53 408700.775 **Sample×factor 99.8640092 94.9359908 
416346.11 378900.66 397623.385 Mean 101.986233 92.8137672 
433353.34 377432.73 405393.035  104.117761 90.6822385 
299715.36 315162.35 307438.855  94.9531121 99.8468879 
401214.12 292427.26 346820.69  112.675675 82.1243252 
266240.16 214336.48 240288.32  107.919484 86.8805157 
232883.37 210115.82 221499.595  102.405787 92.3942135 
189206.68 210789.87 199998.275  92.1444479 102.655552 
235899.66 201759.7 218829.68  104.997763 89.802237 
      
n= 16 n= 16  Average 100.091078 94.7089219 
   Std. Dev. 6.13206282 6.13206282 
   Std. Error 1.5330157 1.5330157 
   
Table C.19: Normality test of Aβ degradation in N2a IDE knock down living cells. 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Control .130 16 .200* .975 16 .909 
Cholesterol .130 16 .200* .975 16 .909 
 
Table C.20: Significance test (T. test) of Aβ degradation in N2a IDE knock down living 
cells. 
Levene's Test 
for Equality of 
Variances 
 t-test for Equality of Means 

























       





Table C.21: Data analysis of Aβ degradation in N2a IDE knock-down culture medium 


















1 1 Control 836235.46 271351 ----- 100 55 ------ 0.46 
1 2 Sample 1079152.43 438609.5 ----- 100 60 ------- 0.5 
1 3 Control 1219141.64 515873.8 ----- 100 55 ------ 0.46 
1 4 Sample 1299357.37 588597.1 ----- 100 43 ------ 0.42 
1 5 Control 1157699.76 454379.2 ----- 100 54 ------ 0.45 
1 6 Pos. ctrl. 1215394.9 525055.32 ----- 100 60 ------ 0.54 
1 7 Sample 903665.00 338911.49 ----- 100 55 ------ 0.49 
1 8 Control 928371.00 287963.07 ----- 100 58 ------ 0.52 
1 9 Sample 1041088.00 337942.14 ----- 100 51 ------ 0.46 
1 10 Control 1045749.00 335103.75 ----- 100 50 ------ 0.45 
1 11 Sample 1152047.00 448866.41 ----- 100 60 ------ 0.54 




                         




Table C.22: Data analysis of Aβ degradation in N2a IDE knock-down culture medium 



















1 1 Control 602047 436068.5 ----- 100 46 ------ 0.46 
1 2 Sample 685828 522977.1 ----- 100 40 ------- 0.4 
1 3 Control 600052 441892 ----- 100 37 ------ 0.37 
1 4 Sample 695801 557671.78 ----- 100 41 ------ 0.41 
1 5 Control 578717 451180.04 ----- 100 45 ------ 0.45 
1 6 Pos. ctrl. 893157 725671.64 ----- 100 52 ------ 0.52 
1 7 Sample 801280 570109.34 ----- 100 55 ------ 0.47 
1 8 Control 683845 490484.97 ----- 100 51 ------ 0.44 
1 9 Sample 758160 559059.67 ----- 100 47 ------ 0.41 
1 10 Control 595521 425572 ----- 100 53 ------ 0.46 
1 11 Sample 804564 611187.12 ----- 100 58 ------ 0.5 




                  
             Figure C.13: Gel of Aβ degradation in N2a culture medium on 22.12.2016. 
 
 
Table C.23: Data analysis of Aβ degradation in N2a IDE knock-down culture medium 


















1 1 Control 295849 176169.4 ----- 100 36 ------ 0.46 
1 2 Sample 402122 252506.8 ----- 100 30 ------- 0.38 
1 3 Control 358545 229148.69 ----- 100 32 ------ 0.41 
1 4 Sample 546564 369544.68 ----- 100 34 ------ 0.44 
1 5 Control 720619 528927.54 ----- 100 36 ------ 0.46 
1 6 Pos. ctrl. 929065 752009.67 ----- 100 33 ------ 0.42 
1 7 Sample 548470 369619.52 ----- 100 45 ------ 0.44 
1 8 Control 417388 239259.66 ----- 100 42 ------ 0.41 
1 9 Sample 452845 279887.29 ----- 100 48 ------ 0.47 
1 10 Control 388371 222755.44 ----- 100 49 ------ 0.48 
1 11 Sample 408780 271738.29 ----- 100 47 ------ 0.46 




   Table C.24: Data analysis of Aβ degradation in N2a IDE knock down culture 
medium. 









515873.78 588597.12 552235.45 107.334466 122.465534 
287963.07 337942.14 312952.605 105.725136 124.074864 
335103.75 448866.41 391985.08 *Control×factor 98.2267511 131.573249 
436068.48 522977.12 479522.8 Mean 104.487771 125.312229 
441892.04 557671.78 499781.91  101.591103 128.208897 
451180.04 570109.34 510644.69 **Sample×factor 101.519878 128.280122 
490484.97 559059.67 524772.32 Mean 107.392713 122.407287 
425572 611187.12 518379.56  94.3289948 135.471005 
176169.4 252506.75 214338.075  94.4389561 135.361044 
229148.69 369544.68 299346.685  87.9554904 141.84451 
239259.66 279887.29 259573.475  105.908105 123.891895 
222755.44 271738.29 247246.865  103.518401 126.281599 
      
n= 13 n= 13  Average 100.019895 129.780105 
   Std. Dev. 6.90937118 6.90937118 
   Std. Error 1.91631477 1.91631477 
 
Table C.25: Normality test of Aβ degradation in N2a IDE knock down culture medium. 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Control .201 13 .154 .879 13 .070 
Cholesterol .201 13 .154 .879 13 .070 
 
 




for Equality of 
Variances 
 t-test for Equality of Means 























                                           
                Figure C.14: Gel of intracellular IDE level experiment on 14.11.2016. 
 













1 1 Control 504865 220003.1 ----- 100 28 ------ 0.48 
1 2 Sample 534665 265261.4 ----- 100 28 ------- 0.48 
1 3 Control 455824 169778.4 ----- 100 22 ------ 0.38 
1 4 Sample 520694 234586.3 ----- 100 29 ------ 0.5 
1 5 Control 416955 158351 ----- 100 35 ------ 0.6 
1 6 Sample 436303 183488.6 ----- 100 31 ------ 0.53 
1 7 Control 346464 103522.4 ----- 100 36 ------ 0.56 
1 8 Sample 476908 184662.2 ----- 100 22 ------ 0.34 
1 9 Control 426424 142437.7 ----- 100 30 ------ 0.47 
1 10 Sample 719592 281510.5 ----- 100 29 ------ 0.45 
1 11 Control 516389 188146 ----- 100 31 ------ 0.48 




                               
                Figure C.15: Gel of extracellular IDE level experiment on 18.11.2016. 
 
 














1 1 Control 1609771 538131.6 ----- 100 68 ------ 0.46 
1 2 Sample 1441178 484345.3 ----- 100 73 ------- 0.49 
1 3 Control 1282271 413151.7 ----- 100 76 ------ 0.51 
1 4 Sample 898382 211983 ----- 100 66 ------ 0.45 
1 5 Control 1272527 367072.9 ----- 100 77 ------ 0.52 
1 6 Sample 1225284 354556.6 ----- 100 82 ------ 0.55 
1 7 Control 2464837 948945.9 ----- 100 53.57 ------ 0.43 
1 8 Sample 2347570 650705.4 ----- 100 64.48 ------ 0.52 
1 9 Control 2327348 760800.8 ----- 100 62.5 ------ 0.5 
1 10 Sample 1391520 325513 ----- 100 52.58 ------ 0.42 
1 11 Control 2403769 645972.1 ----- 100 68.45 ------ 0.55 




                                    
Figure C.16: Gel of intracellular (above) and extracellular (below) IDE level 
experiment on 28.11.2016. 
 
















1 1 Control 511963 365037.8 ----- 100 44 ------ 0.59 
1 2 Sample 493484 339787.3 ----- 100 43 ------- 0.58 
1 3 Control 535562 375865.9 ----- 100 45 ------ 0.61 
1 4 Sample 613624 447413.4 ----- 100 45 ------ 0.61 
1 5 Control 492618 341469.1 ----- 100 42 ------ 0.57 
1 6 Sample 560919 396887.9 ----- 100 46 ------ 0.62 
1 7 Control 644444 409930.7 ----- 100 46 ------ 0.49 
1 8 Sample 631546 386227.5 ----- 100 47 ------ 0.5 
1 9 Control 533024 346858.2 ----- 100 49 ------ 0.52 
1 10 Sample 654538 423788.6 ----- 100 50 ------ 0.53 
1 11 Control 544385 343837.2 ----- 100 51 ------ 0.54 




Table C.30: Data analysis of extracellular IDE level by Image gauge on 28.11.2016. 
 
                                   
Figure C.17: Gel of intracellular (above) and extracellular (below) IDE level 
experiment on 02.12.2016. 














1 1 Control 516768 281633.3 ----- 100 41 ------ 0.47 
1 2 Sample 490387 283608.9 ----- 100 50 ------- 0.57 
1 3 Control 211123 78622.21 ----- 100 41 ------ 0.47 
1 4 Sample 256100 114719.3 ----- 100 40 ------ 0.45 
1 5 Control 251969 117940.6 ----- 100 49 ------ 0.56 
1 6 Sample 394152 199744.4 ----- 100 53 ------ 0.6 
1 7 Control 474920.8 239786.1 ----- 100 52 ------ 0.58 
1 8 Sample 314185.5 172804.8 ----- 100 49 ------ 0.55 
1 9 Control 311114.1 177085.7 ----- 100 50 ------ 0.56 
1 10 Sample 300293.4 167792.6 ----- 100 48 ------ 0.54 
1 11 Control 342813 208784.5 ----- 100 51 ------ 0.57 




  Table C.31: Data analysis of intracellular IDE level by Image gauge on 02.12.2016. 
 
    Table C.32: Data analysis of extracellular IDE level by Image gauge on 02.12.2016. 
 













1 1 Control 902232.8 302674.6 ----- 100 53 ------ 0.62 
1 2 Sample 962881.6 281177.3 ----- 100 48 ------- 0.56 
 
1 3 Control 978921.2 352579.7 ----- 100 43 ------ 0.51 
1 4 Sample 1062623 419248.8 ----- 100 50 ------ 0.58 
1 5 Control 1242785 413519.1 ----- 100 49 ------ 0.57 
1 6 Sample 937629.5 334817.3 ----- 100 55 ------ 0.65 
1 7 Control 1165286 333506.3 ----- 100 53 ------ 0.62 
1 8 Sample 1007403 357442 ----- 100 45 ------ 0.53 
1 9 Control 1079120 409194 ----- 100 44 ------ 0.52 
1 10 Sample 1263176 441773.5 ----- 100 51 ------ 0.59 
1 11 Control 854582.1 253325.1 ----- 100 50 ------ 0.58 













1 1 Control 1280394.7 208755.2 ----- 100 68 ------ 0.46 
1 2 Sample 1151057.6 194224.8 ----- 100 73 ------- 0.49 
1 3 Control 1189151.6 320032.3 ----- 100 76 ------ 0.51 
1 4 Sample 858860.53 172461.5 ----- 100 66 ------ 0.45 
1 5 Control 1270240.4 364786.3 ----- 100 77 ------ 0.52 
1 6 Sample 1090289.4 219562.1 ----- 100 82 ------ 0.55 
1 7 Control 1825434.8 309543.8 ----- 100 53.57 ------ 0.43 
1 8 Sample 1980332.8 283468.2 ----- 100 64.48 ------ 0.52 
1 9 Control 1762816.5 196269.3 ----- 100 62.5 ------ 0.5 
1 10 Sample 1365797.9 299790.9 ----- 100 52.58 ------ 0.42 
1 11 Control 2051088.9 293292 ----- 100 68.45 ------ 0.55 
1 12 Sample 1942838.6 306183.1 ----- 100 54.56 ------ 0.44 









169778.39 234586.29 202182.34 91.5304695 126.46953 
158350.98 183488.6 170919.79 *Control×factor 100.984543 117.015457 
103522.35 184662.19 144092.27 Mean 78.3104892 139.689511 
142437.72 281510.48 211974.1  73.2434362 144.756564 
375865.93 447413.38 411639.655 **Sample×factor 99.5273071 118.472693 
341469.07 396887.89 369178.48 Mean 100.818793 117.181207 
409930.71 386227.46 398079.085  112.245152 105.754848 
346858.23 423788.59 385323.41  98.1189985 119.881002 





Table C.34: Normality test of intracellular IDE level experiments. 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Control .237 15 .023 .910 15 .136 
Cholesterol .237 15 .023 .910 15 .136 
 
Table C.35: Significance test (T. test) of intracellular IDE level experiments. 
 
 
Table C.36: Data analysis of extracellular IDE level experiments. 









367072.94 354556.64 360814.79 109.618869 105.881131 
645972.12 790785.55 718378.835 *Control×factor 96.8896807 118.610319 
650705.39 760800.75 705753.07 Mean 99.3456618 116.154338 
325513 948945.94 637229.47  55.041437 160.458563 
281633.28 283608.9 282621.09 **Sample×factor 107.373395 108.126605 
78622.21 114719.31 96670.76 Mean 87.6329422 127.867058 
117940.58 199744.36 158842.47  80.0044062 135.495594 
239786.1 172804.79 206295.445  125.242476 90.2575242 
177085.7 167792.6 172439.15  110.653434 104.846566 
208755.24 194224.8 201490.02  111.635192 103.864808 
302674.61 281177.34 291925.975  113.01335 104.98665 
352579.72 419248.83 385914.275  99.5847834 118.415217 
333506.27 357442.02 345474.145  105.224035 112.775965 
409193.97 441773.51 425483.74  104.826903 113.173097 
253325.14 270074.66 261699.9  105.511849 112.488151 
      
n= 15 n= 15  Average 100.027779 117.972221 
   Std. Dev. 11.9904916 11.9904916 
   Std. Error 3.09593161 3.09593161 
Levene's Test 
for Equality of 
Variances 
 t-test for Equality of Means 























309543.78 283468.17 296505.975  112.487926 103.012074 
196269.25 299790.9 248030.075  85.2639007 130.236099 
293292 306183.12 299737.56  105.432943 110.067057 
      
n= 14 n= 14  Average 100.002881 115.497119 
   Std. Dev. 17.9738068 17.9738068 
   Std. Error 4.80370192 4.80370192 
 
Table C.37: Normality test of extracellular IDE level experiments. 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Control .190 14 .183 .900 14 .112 
Cholesterol .190 14 .183 .900 14 .112 
 




for Equality of 
Variances 
 t-test for Equality of Means 
















































1 1 Control 467928 186286.3 ------
- 
100 59 ------ 0.61 
1 2 Sample 427552 154503.6 ------
- 
100 51 ------- 0.53 
1 3 Control 478562 186978.3 ------
- 
100 51 ------ 0.53 
1 4 Sample 527386 181624.2 ------
- 
100 55 ------ 0.57 
1 5 Control 520696 183593.5 ------
- 
100 47 ------ 0.49 
1 6 Sample 515330 175161.7 ------
- 




               
                Figure C.19: Gel of intracellular IDE stability experiment on 27.12.2016. 
      















1 1 Control 516216 94479.7 ------
- 
100 56 ------ 0.5 
1 2 Sample 1199879 330916.4 ------
- 
100 59 ------- 0.53 
1 3 Control 952195 252961 ------
- 
100 67 ------ 0.6 
1 4 Sample 891557 242337.9 ------
- 
100 64 ------ 0.57 
1 5 Control 600182 142775 ------
- 
100 55 ------ 0.49 
1 6 Sample 657027 191378.6 ------
- 
100 54 ------ 0.48 




100 55 ------ 0.47 




100 67 ------- 0.58 




100 62 ------ 0.53 




100 63 ------ 0.54 




100 62 ------ 0.53 








                           
          Figure C.20: Gel of intracellular IDE stability experiment on 21.01.2017. 
 















1 1 Control 357252 115833.9 ------
- 
100 50 ------ 0.5 
1 2 Sample 515614 184511.5 ------
- 
100 54 ------- 0.54 
1 3 Control 617602 221483 ------
- 
100 47 ------ 0.47 
1 4 Sample 1070386 440341 ------
- 
100 53 ------ 0.53 
1 5 Control 803044 274368 ------
- 
100 45 ------ 0.45 
1 6 Sample 874579 304551.1 ------
- 
100 44 ------ 0.44 




100 144 ------ 0.72 




100 132 ------- 0.66 




100 120 ------ 0.6 




100 100 ------ 0.5 




100 78 ------ 0.39 








Table C.42: Data analysis of intracellular IDE stability experiments. 





115833.89 184511.49 150172.69 114.6  88.3953254 140.804675 
221483.03 440341.01 330912.02   76.7030319 152.496968 
274367.99 304551.11 289459.55   108.625097 120.574903 
224048.5 428693.02 326370.76   78.6711349 150.528865 
212111.03 380517.63 296314.33   82.0342507 147.165749 
298716.89 263274.51 280995.7   121.827329 107.372671 
94479.7 330916.4 212698.05   50.9049031 178.295097 
252960.96 242337.92 247649.44   117.057911 112.142089 
142775.02 191378.56 167076.79   97.9311207 131.268879 
318778.65 357286.26 338032.455   108.072562 121.127438 
301111.4 314244.84 307678.12   112.154112 117.045888 
136623.46 180202.37 158412.915   98.8369447 130.363055 
186286.3 154503.56 170394.93   125.287824 103.912176 
186978.27 181624.24 184301.255   116.264589 112.935411 
183593.46 175161.67 179377.565   117.293434 111.906566 
n=15 n=15      
    Average 100.003971 129.196029 
    Std 20.9230332 20.9230332 
    SE 5.40230394 5.40230394 
 
Table C.43: Normality test of intracellular IDE stability experiments. 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Control .183 15 .186 .915 15 .162 
Cholesterol .183 15 .186 .915 15 .162 
 
 
Table C.44: Significance test (T. test) of intracellular IDE stability experiments. 
 
Levene's Test 
for Equality of 
Variances 
 t-test for Equality of Means 























                                    
          Figure C.21: Gel of extracellular IDE stability experiment on 26.12.2016. 
 














1 1 Control 461193 162439.25 ------
- 
100 37.00 ------ 0.42 
1 2 Sample 442811 147188.31 ------
- 
100 41.00 ------- 0.51 
1 3 Control 437486 138029.14 ------
- 
100 40.00 ------ 0.49 
1 4 Sample 479524 191199.24 ------
- 
100 38.00 ------ 0.47 
1 5 Control 489217 197539.94 ------
- 
100 35.00 ------ 0.53 
1 6 Sample 520155 214711.61 ------
- 




                        
          Figure C.22: Gel of extracellular IDE stability experiment on 27.12.2016. 
 













1 1 Control 239566.00 54848.29 ------
- 
100 35.00 ------ 0.47 
1 2 Sample 184602.00 37755.09 ------
- 
100 46.00 ------- 0.62 
1 3 Control 185399.00 44292.17 ------
- 
100 45.00 ------ 0.61 
1 4 Sample 269087.00 44164.62 ------
- 
100 37.00 ------ 0.50 
1 5 Control 440571.00 100253.92 ------
- 
100 40.00 ------ 0.54 
1 6 Sample 157036.00 25642.42 ------
- 
100 36.00 ------ 0.49 




100 37.00 ------ 0.50 




100 40.00 ------- 0.54 




100 44.00 ------ 0.59 




100 47.00 ------ 0.64 




100 43.00 ------ 0.58 








                               
          Figure C.23: Gel of extracellular IDE stability experiment on 23.01.2017. 
 
 




















1 2 Sample 858931.00 159322.10 ------
- 
100 45.00 ------- 0.51 
1 3 Control 439875.00 40363.10 ------
- 
100 53.00 ------ 0.60 
1 4 Sample 679251.00 118773.73 ------
- 
100 51.00 ------ 0.58 
1 5 Control 496841.00 45699.94 ------
- 
100 52.00 ------ 0.59 
1 6 Sample 626260.00 47043.55 ------
- 
100 35.00 ------ 0.40 




100 75.00 ------ 0.59 




100 81.00 ------- 0.63 




100 64.00 ------ 0.50 




100 53.00 ------ 0.41 




100 56.00 ------ 0.44 








Table C.48: Data analysis of extracellular IDE stability experiments. 





65425.2 159322.1 112373.7 115.2  67.07073 163.3293 
40363.1 118773.7 79568.42   58.43813 171.9619 
45699.94 47043.55 46371.75   113.5311 116.8689 
58272.84 81457.33 69865.09   96.08564 134.3144 
86077.42 59595.09 72836.26   136.1426 94.25738 
194393.1 127728.9 161061   139.041 91.35897 
162.439 147.18 154.8095   120.8774 109.5226 
138.029 191.199 164.614   96.59531 133.8047 
197.539 214.711 206.125   110.4014 119.9986 
37755.09 54848.29 46301.69   93.9358 136.4642 
44164.62 44292.17 44228.4   115.0339 115.3661 
25642.42 100253.9 62948.17   46.9276 183.4724 
38271.52 36987.49 37629.51   117.1655 113.2345 
32713.42 36303.28 34508.35   109.2079 121.1921 
37877.16 71177.98 54527.57   80.0228 150.3772 
n=15 n=15      
    Average 100.0318 130.3682 
    Std 27.06376 27.06376 
    SE 6.987834 6.987834 
 
Table C.49: Normality test of extracellular IDE stability experiments. 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Control .166 15 .200* .947 15 .472 









for Equality of 
Variances 
 t-test for Equality of Means 
























Results of IDE promoter assay experiments 
Table D.1: Results of IDE promoter assay on 03.02.2017 
Zeit: 13:18:43           
            
            
System    SAFIRE2        
Anwender    SAFIRE2\Safire       
Platte    Nunclon 96 Flat Bottom White Polystyrol LumiNunc FluoroNunc [NUN96fw_LumiNunc FluoroNunc.pdfx] 
Platten-ID (Stapler)           
            
            
Label: Label1           
Modus    Lumineszenz       
Abschwächung   AUTOMATIC        
Farbe für OD2 Abschwächung           
Integrationszeit   500 ms       
Ruhezeit    10 ms       
Bereich der Platte   D1-E12        
Startzeit: 03.02.2017 13:18:52          
            
 Temperatur: 22.5 °C          
<> 1 2 3 4 5 6 7 8 9 10 11 
Control 5059 6811 4871 257 1106034 429 63 35 43 37 49 
Sample 7085 5623 5129 97 269 95 43 43 25 19 41 
            
            
            




Datum: 03.02.2017           
Zeit: 12:54:42           
            
            
System    SAFIRE2        
Anwender    SAFIRE2\Safire       
Platte    
Nunclon 96 Flat Bottom White Polystyrol LumiNunc FluoroNunc [NUN96fw_LumiNunc 
FluoroNunc.pdfx] 
Platten-ID (Stapler)           
            
            
Label: Label1           
Modus    Lumineszenz       
Abschwächung   AUTOMATIC        
Farbe für OD2 Abschwächung           
Integrationszeit   500 ms       
Ruhezeit    10 ms       
Bereich der Platte   A1-B12        
Startzeit: 03.02.2017 12:54:51          
            
 Temperatur: 21.4 °C          
<> 1 2 3 4 5 6 7 8 9 10 11 
Control 272 402 306 194 5032 10 38 26 28 22 26 
Sample 266 200 166 148 5216 24 14 42 32 24 30 
            
            
            






Table D.2: Results of IDE promoter assay on 21.03.2017 
Programm: Tecan i-control   Tecan i-control , 1.9.17.0       
Gerät: infinite M1000Pro   Seriennummer: 1210001738      
Firmware: V_1.05_11/2011_S3LCE_ALPHA (Nov  
3 2011/09.27.24) MAI, V_1.05_11/2011_S3LCE_ALPHA (Nov  3 2011/09.27.24)    
            
Datum: 21.03.2017           
Zeit: 12:24:52           
System    SAFIRE2        
Anwender    SAFIRE2\Safire       
Platte    
Nunclon 96 Flat Bottom White Polystyrol LumiNunc FluoroNunc [NUN96fw_LumiNunc 
FluoroNunc.pdfx] 
Platten-ID (Stapler)           
Label: Label1           
Modus    Lumineszenz       
Abschwächung   AUTOMATIC        
Farbe für OD2 Abschwächung           
Integrationszeit   500 ms       
Ruhezeit    10 ms       
Bereich der Platte   A6-C12        
Startzeit: 21.03.2017 12:25:01          
 Temperatur: 22.4 °C          
<> 6 7 8 9 10 11 12     
Control 38865 25240 25329 31376 32480 54617 143940     
Sample 45812 43939 42861 36181 37849 44579 118296     
C 57 81 61 93 59 53 16563     







Programm: Tecan i-control   Tecan i-control , 1.9.17.0       
Gerät: infinite M1000Pro   Seriennummer: 1210001738      
Firmware: V_1.05_11/2011_S3LCE_ALPHA (Nov  
3 2011/09.27.24) MAI, V_1.05_11/2011_S3LCE_ALPHA (Nov  3 2011/09.27.24)    
            
Datum: 21.03.2017           
Zeit: 11:59:52           
            
            
System    SAFIRE2        
Anwender    SAFIRE2\Safire       
Platte    Nunclon 96 Flat Bottom White Polystyrol LumiNunc FluoroNunc [NUN96fw_LumiNunc FluoroNunc.pdfx] 
Platten-ID (Stapler)           
Label: Label1           
Modus    Lumineszenz       
Abschwächung   AUTOMATIC        
Farbe für OD2 Abschwächung           
Integrationszeit   500 ms       
Ruhezeit    10 ms       
Bereich der Platte   F1-G12        
Startzeit: 21.03.2017 12:00:01          
 Temperatur: 21.1 °C          
<> 1 2 3 4 5 6 7 8 9 10 11 
Control 60070 36432 37804 40125 44479 66831 48001 35 25 19 31 
Sample 50569 56896 54087 46733 54730 62817 36844 45 33 33 15 








Table D.3: Results of IDE promoter assay on 28.03.2017 
Programm: Tecan i-control   
Tecan i-control , 
1.9.17.0     
Gerät: infinite M1000Pro   Seriennummer: 1210001738    
Firmware: V_1.05_11/2011_S3LCE_ALPHA (Nov  3 
2011/09.27.24) MAI, V_1.05_11/2011_S3LCE_ALPHA (Nov  3 2011/09.27.24)  
          
Datum: 28.03.2017         
Zeit: 12:11:05         
System    SAFIRE2      
Anwender    SAFIRE2\Safire     
Platte    Corning 96 Flat Bottom Black Polystyrol  [COS96fb.pdfx]  
Platten-ID (Stapler)         
Label: Label1         
Modus    Lumineszenz     
Abschwächung   AUTOMATIC      
Farbe für OD2 Abschwächung         
Integrationszeit   500 ms     
Ruhezeit    0 ms     
Bereich der Platte   C1-D12      
Startzeit: 28.03.2017 12:11:15        
 Temperatur: 22.2 °C        
<> 1 2 3 4 5 6 7 8 12 
Control 3070 2682 3094 3110 3633 4869 270 170 64 
Sample 3158 3312 3144 3482 3817 5042 2472337 206 86 







Programm: Tecan i-control   
Tecan i-control , 
1.9.17.0    
Gerät: infinite M1000Pro   Seriennummer: 1210001738   
Firmware: V_1.05_11/2011_S3LCE_ALPHA (Nov  3 
2011/09.27.24) MAI, V_1.05_11/2011_S3LCE_ALPHA (Nov  3 2011/09.27.24) 
Datum: 28.03.2017        
Zeit: 11:54:54        
System    SAFIRE2     
Anwender    SAFIRE2\Safire    
Platte    Corning 96 Flat Bottom Black Polystyrol  [COS96fb.pdfx] 
Platten-ID (Stapler)        
Label: Label1        
Modus    Lumineszenz    
Abschwächung   AUTOMATIC     
Farbe für OD2 Abschwächung        
Integrationszeit   500 ms    
Ruhezeit    0 ms    
Bereich der Platte   A1-B12     
Startzeit: 28.03.2017 11:55:03       
 Temperatur: 21.4 °C       
<> 1 2 3 4 5 6 7 8 
A 9959 6392 8358 8134 8917 11792 56559 47 
B 8485 7902 7493 8595 9524 11149 25 55 
         
         
         




      Table D.4: Data analysis of IDE promoter assay experiments. 









16.94279 28.115 22.52889 84.15406 139.6459424 
15.9183 30.89759036 23.40795 76.09629 147.7037086 
0.646995 0.905930511 0.776463 *Control×factor 93.24176 130.5582428 
0.692798 0.772268701 0.732533 Mean 105.8301 117.9699118 
0.670008 0.792445504 0.731227  102.5317 121.2682981 
0.308264 0.372186211 0.340225 **Sample×factor 101.388 122.4120253 
0.419587 0.419134396 0.419361 Mean 111.9604 111.839617 
0.370184 0.419591619 0.394888  104.8997 118.9003203 
0.382346 0.405119255 0.393732  108.6638 115.1361564 
0.407424 0.400776984 0.404101  112.8203 110.9796801 
0.412907 0.452237869 0.432572  106.8129 116.9871454 
      
n= 12 n= 12  Average 100.035 123.7650371 
   Std. Dev. 11.38992 11.38991758 
 
Table D.5: Normality test of IDE promoter assay. 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Control .214 12 .135 .903 12 .172 












for Equality of 
Variances 
 t-test for Equality of Means 

























Results of IDE activity experiments 
 
Table E.1: Results of IDE activity experiment on 24.08.2016 with 150 µM PC 18:0.  
SAFIRE II;   Serial number: 506000019;   Firmware: V 2.10 12/2007 Safire2;   XFLUOR4SAFIREII 
Version: V 4.62n  
Date: 23/8/16       
Time: 11:57       
            
Measurement mode:   Fluorescence      
Excitation wavelength:   320 nm      
Emission wavelength:   405 nm      
Excitation bandwidth:   10 nm      
Emission bandwidth:   10 nm      
Gain (Manual):    100       
Number of reads: 10       
FlashMode: High sensitivity      
Integration time: 40 µs      
Lag time: 0 µs      
Plate definition file: COS96fb.pdf      
Part of the plate:    A1 - B7       
Z-Position (Calc. from Well A1):  5720 µm      
Number of kinetic cycles: 1000       
Kinetic interval (Minimal): 40 s      
Valid temperature range:   37 - 38 °C      
Shake duration (Orbital Medium): 10 s      
Shake duration between cycles (Orbital 
Medium): 30 s      
Target Temperature: 37 °C      
Current Temperature: 37.2 °C      
            






(°C) Ctr;l. Sample C S C S A7 Mean C 
Mean 
S 
1 0 37.0 1391 1109 1167 1143 1016 979 57 1191 1077 
2 40 37,1 1332 1159 1237 1139 1079 1080 57 1216 1126 
3 81 37.0 1554 1297 1436 1323 1253 1252 55 1414 1291 
4 121 37,1 1734 1419 1617 1516 1395 1385 54 1582 1440 
5 161 37,1 1910 1522 1750 1636 1559 1519 56 1740 1559 
6 201 37,1 2077 1609 1859 1757 1697 1621 56 1878 1662 
7 241 37.0 2186 1676 1993 1880 1806 1718 55 1995 1758 
8 281 37.0 2284 1741 2081 1983 1913 1780 58 2093 1835 
9 322 37,1 2375 1840 2168 2040 1982 1870 56 2175 1917 
10 362 37.0 2476 1879 2230 2097 2063 1936 54 2256 1971 
11 402 37,1 2542 1946 2298 2148 2149 1994 55 2330 2029 
12 442 37.0 2614 1971 2360 2198 2208 2034 56 2394 2068 
13 483 37,1 2658 2035 2407 2233 2239 2089 55 2435 2119 
14 523 37.0 2701 2056 2439 2247 2307 2145 54 2482 2149 
15 563 37,1 2745 2095 2484 2303 2333 2165 54 2521 2188 




17 644 37.0 2801 2164 2538 2372 2420 2256 55 2586 2264 
18 684 37,2 2857 2185 2569 2374 2425 2266 54 2617 2275 
19 724 37,1 2853 2209 2568 2383 2407 2297 55 2609 2296 
20 764 37,1 2878 2232 2587 2435 2453 2353 53 2639 2340 
21 804 37,1 2888 2264 2626 2482 2478 2374 52 2664 2373 
22 845 37.0 2937 2283 2661 2490 2501 2389 52 2700 2387 
23 885 37,2 2944 2319 2660 2539 2529 2428 57 2711 2429 
24 925 36,9 2952 2340 2657 2569 2527 2432 55 2712 2447 
25 965 37,1 2964 2356 2672 2580 2546 2446 59 2727 2461 
26 1005 37,1 2964 2358 2690 2610 2561 2479 55 2738 2482 
27 1046 36,9 3006 2394 2700 2627 2560 2489 56 2755 2503 
28 1086 37,2 3001 2402 2718 2649 2561 2498 55 2760 2516 
29 1126 37,1 3019 2406 2711 2666 2576 2534 54 2769 2535 
30 1166 37,1 2985 2441 2734 2700 2587 2531 55 2769 2557 
31 1206 37.0 3024 2434 2754 2741 2590 2549 55 2789 2575 
32 1246 36,9 3023 2437 2753 2770 2613 2582 55 2796 2596 
33 1287 37,2 2992 2437 2740 2758 2617 2568 56 2783 2588 
34 1327 37,1 3045 2463 2735 2771 2621 2577 54 2800 2604 
35 1367 36,9 3024 2466 2735 2746 2617 2601 56 2792 2604 
36 1407 37,2 3021 2466 2737 2797 2587 2603 54 2782 2622 
37 1447 37.0 3027 2463 2777 2799 2623 2605 55 2809 2622 
38 1487 37.0 3033 2506 2767 2825 2619 2638 54 2806 2656 
39 1528 37,2 3031 2499 2786 2834 2630 2650 53 2816 2661 
40 1568 37.0 3019 2522 2781 2830 2629 2671 55 2810 2674 
41 1608 36,9 3031 2531 2761 2848 2638 2656 55 2810 2678 
42 1648 37,1 3026 2551 2786 2862 2648 2716 58 2820 2710 
43 1688 36,9 3023 2534 2783 2872 2650 2685 55 2819 2697 
44 1728 37,2 3028 2535 2753 2861 2649 2723 55 2810 2706 
45 1768 37,1 3054 2542 2783 2920 2673 2755 55 2837 2739 
46 1809 37.0 3043 2564 2798 2980 2683 2777 57 2841 2774 
47 1849 37,3 3047 2570 2792 2932 2668 2749 56 2836 2750 
48 1889 36,9 3041 2563 2793 2985 2647 2761 53 2827 2770 
49 1929 37,1 3074 2603 2792 2981 2680 2774 53 2849 2786 
50 1970 37,1 3030 2585 2799 2990 2653 2786 57 2827 2787 
51 2010 37.0 3058 2605 2786 3040 2661 2773 58 2835 2806 
52 2050 37,2 3036 2632 2796 3009 2654 2803 54 2829 2815 
53 2090 37,1 3045 2631 2805 3044 2664 2809 54 2838 2828 
54 2130 37.0 3047 2657 2790 3052 2671 2840 52 2836 2850 
55 2170 37,2 3038 2627 2797 3046 2668 2845 57 2834 2839 
56 2211 36,9 3063 2679 2793 3025 2661 2848 56 2839 2851 
57 2251 37,1 3055 2644 2802 3011 2662 2874 55 2840 2843 
58 2291 37,1 3064 2657 2799 3029 2656 2885 53 2840 2857 
59 2331 36,9 3064 2647 2782 3025 2648 2901 56 2831 2858 
60 2371 37,2 3039 2660 2799 3033 2646 2898 56 2828 2864 
61 2411 37,1 3042 2680 2789 3029 2670 2928 52 2834 2879 
62 2451 37,1 3015 2698 2829 3029 2652 2901 57 2832 2876 
63 2492 37,1 3067 2686 2796 3018 2651 2897 51 2838 2867 
64 2532 37.0 3057 2670 2811 3051 2634 2880 57 2834 2867 
65 2572 37.0 3017 2697 2785 3001 2653 2887 53 2818 2862 
66 2612 37,1 3067 2670 2805 3030 2654 2917 55 2842 2872 
67 2652 37.0 3062 2702 2801 3020 2641 2886 57 2835 2869 




69 2733 37.0 3052 2698 2800 3053 2636 2934 53 2829 2895 
70 2773 37.0 3025 2682 2787 3050 2640 2960 57 2817 2897 
 
Slope 
0.461 0.498 0.437 0.630 0.455 0.601 
   
 
Table E.2: Test of normality of IDE activity exprement with 150 µM PC 18:0. 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Control .270 3 . .949 3 .565 
Cholesterol .270 3 . .949 3 .565 
 
 
Table E.3: Data analysis IDE activity with 150 µM PC 18:0 
 Control Sample mean Factor 
 0.461205 0.498868 0.480036 113.6 
 0.437001 0.630287 0.533644 113.6 
 0.455084 0.601608 0.528346 113.6 
 * **   
 109.1436 118.0564 * control × factor 
 93.02704 134.173 mean 
 97.84789 129.3521 ** Sample × Factor 
   mean 
Avg 100.0062 127.1938   
Std 8.272189 8.272189   
SE 4.77595 4.77595   
T.test  0.015795   
 
Table E.4: IDE activity 24.08.2016 without PC 
Time 
(s) 









0 221 374 284 408 251 369 252 384 32 21 
40 204 349 232 380 215 368 217 366 14 16 
81 206 379 225 416 230 397 220 397 13 19 
121 203 412 232 449 233 428 223 430 17 19 
161 206 430 228 482 232 455 222 456 14 26 
201 207 449 227 514 240 477 225 480 17 33 
241 206 474 223 542 232 504 220 507 13 34 
281 204 476 227 556 239 532 223 521 18 41 
322 206 496 228 580 235 555 223 544 15 43 
362 209 513 231 594 237 573 226 560 15 42 
402 205 513 228 605 234 588 222 569 15 49 
442 209 525 230 623 238 605 226 584 15 52 
483 209 522 227 637 238 611 225 590 15 60 
523 207 534 230 647 239 626 225 602 17 60 
563 207 544 228 651 246 646 227 614 20 60 
603 202 553 232 667 238 652 224 624 19 62 




684 204 553 234 679 242 653 227 628 20 67 
724 211 568 234 680 244 666 230 638 17 61 
764 207 568 234 680 238 667 226 638 17 61 
804 211 576 232 685 239 682 227 648 15 62 
845 212 567 232 688 235 680 226 645 13 68 
885 209 573 239 710 240 680 229 654 18 72 
925 210 579 232 702 234 691 225 657 13 68 
965 211 586 227 707 232 696 223 663 11 67 
1005 206 588 225 701 233 698 221 662 14 64 
1046 213 584 228 704 230 712 224 667 9 72 
1086 206 592 226 704 236 687 223 661 15 60 
1126 211 592 227 699 228 715 222 669 10 67 
1166 206 591 225 713 233 720 221 675 14 73 
1206 210 601 225 709 231 711 222 674 11 63 
1246 215 598 227 721 233 708 225 676 9 68 
1287 214 602 219 709 231 706 221 672 9 61 
1327 195 599 218 713 232 709 215 674 19 65 
1367 211 600 222 716 230 704 221 673 10 64 
1407 210 608 223 708 229 715 221 677 10 60 
1447 205 608 219 712 226 720 217 680 11 62 
1487 202 610 220 726 226 726 216 687 12 67 
1528 205 606 215 729 232 710 217 682 14 66 
1568 206 611 217 731 230 705 218 682 12 63 
1608 212 613 217 720 225 721 218 685 7 62 
1648 210 625 223 725 226 725 220 692 9 58 
1688 208 623 216 719 226 723 217 688 9 57 
1728 203 624 220 738 232 730 218 697 15 64 
1768 211 611 214 729 224 734 216 691 7 70 
1809 208 613 219 733 223 738 217 695 8 71 
1849 204 623 221 733 217 724 214 693 9 61 
1889 209 633 217 736 233 731 220 700 12 58 
1929 205 636 214 731 231 739 217 702 13 57 
1970 207 622 217 738 224 729 216 696 9 65 
2010 208 628 214 727 222 732 215 696 7 59 
2050 203 623 215 733 222 739 213 698 10 65 
2090 203 624 215 736 223 748 214 703 10 68 
2130 205 643 215 733 228 736 216 704 12 53 
2170 208 628 210 734 224 736 214 699 9 62 
2211 202 630 216 739 220 724 213 698 9 59 
2251 210 633 214 745 223 739 216 706 7 63 
2291 205 627 216 747 219 738 213 704 7 67 
2331 201 629 213 731 228 733 214 698 14 59 
2371 203 638 213 745 219 739 212 707 8 60 
2411 206 641 210 733 224 734 213 703 9 53 
2451 206 646 215 734 224 744 215 708 9 54 
2492 201 643 211 738 222 732 211 704 11 53 
2532 204 645 206 738 223 740 211 708 10 54 
2572 204 639 213 749 220 730 212 706 8 59 
2612 204 640 210 748 222 743 212 710 9 61 
2652 202 638 212 740 224 739 213 706 11 59 
2692 206 648 210 748 224 738 213 711 9 55 
2733 200 641 208 749 220 740 209 710 10 60 
2773 203 647 211 743 220 745 211 712 9 56 




Table E.5: Test of normality of IDE activity exprement without PC 18:0. 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Control .177 3 . 1.000 3 .966 
Cholesterol .177 3 . 1.000 3 .966 
 
 
Table E.6: Data analysis IDE activity without PC 18:0 
 Control Sample MBV Factor 
 0.001016893 0.087205 0.043094 785 
 0.010623266 0.103366 0.046372  
 0.007021257 0.115413 0.054196  
     
 18.5237793 1588.524   
 179.8355406 1749.836   
 101.699767 1671.7   
     
Avg 100.0196956 1670.02   
std 80.6690031 80.669   
SE 46.57427066 46.57427   
t.test  0.334703   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
